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Abstract 
DNA sequencing technologies have advanced rapidly in the 21st century and there 
are now an abundance of microbial genomes available to mine in search of novel 
biosynthetic gene clusters and the bioactive natural products they encode. Whilst an 
enormously exciting prospect, this abundance of genomic data presents a challenge 
in determining how to select clusters for further study. 
To address this issue, this project focusses on the biosynthesis of the β-lactone 
antibiotic obafluorin produced by the soil bacterium Pseudomonas fluorescens. β-
Lactones occur infrequently in nature but possess a variety of potent and valuable 
biological activities. They are commonly derived from β-hydroxy-α-amino acids, which 
are themselves privileged chiral building blocks in a variety of pharmacologically and 
agriculturally important natural products and medicines. 
I report the delineation of the entire obafluorin biosynthetic pathway using 
complementary mutagenesis and biochemical assay-based approaches. As part of 
this work I have been able to characterise ObaG, a novel PLP-dependent L-threonine 
transaldolase responsible for the biosynthesis of an unusual nonproteinogenic β-
hydroxy-α-amino acid precursor from which the β-lactone ring of obafluorin is derived. 
Phylogenetic analysis has shed light on the evolutionary origin of this rare enzyme 
family and has identified further gene clusters encoding putative L-threonine 
transaldolases. Furthermore, I have been able to biochemically assay an entire intact 
nonribosomal peptide synthetase that displays a noncanonical domain architecture 
and is responsible for obafluorin assembly and β-lactone ring formation. 
These studies allowed both mechanism- and redundancy-guided genome mining 
strategies to be developed that might allow the specific targeting of novel chemistry 
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α-OH-β-AA α-Hydroxy-β-amino acid 
β-OH-α-AA β-Hydroxy-α-amino acid 
2,3-DHBA 2,3-Dihydroxybenzoic acid 
2,4-DAPG  2,4-Diacetylphloroglucinol 
3-HBA  3-Hydroxybenzoic acid 
4-ABA  4-Aminobenzoic acid 
4-APA  4-Aminophenylalanine 
4-APP  4-Aminophenylpyruvate 
4-HBA  4-Hydroxybenzoic acid 
4-NPA  4-Nitrophenylacetaldehyde 
4-NPAA 4-Nitrophenylacetic acid 
4-NPE  4-Nitrophenylethanol 
4-NPP  4-Nitrophenylpyruvate 
AaRS  Aminoacyl-tRNA synthetase 
ADC  4-Amino-4-deoxychorismate 
ADH  Aldehyde dehydrogenase 
AHAB  (2S,3R)-2-Amino-3-hydroxy-4-(4’-aminophenyl)butanoate 
AHBAS 3-Amino-5-hydroxybenzoic acid synthase 
AHNB  (2S,3R)-2-Amino-3-hydroxy-4-(4’-nitrophenyl)butanoate 
AMP  Adenosine monophosphate 
ANA   Anthranilic acid 
ATP   Adenosine triphosphate 
BA   Benzoic acid 
BGC   Biosynthetic gene cluster 
CLP   Cyclic lipopeptide 
CoA   Coenzyme A 
DAHP   Deoxy-D-arabino-heptulosonate-7-phosphate 
DNA   Deoxyribonucleic acid 
DTT  DL-Dithiothreitol 
EDTA  Ethylenediaminetetraacetic acid 
FAS   Fatty acid synthase 
GCS   Glycine cleavage system 
GHMT  Glycine hydroxymethyltransferase 
GlyU  5′-C-glycyluridine 
HCN   Hydrogen cyanide 
HGT   Horizontal gene transfer 
HPLC  High-performance liquid chromatography 
HTS  High-throughput screening 
IAA   Indole-3-acetic acid 
IPM   Isopropylmalate 
IPMS   Isopropylmalate synthase 
IPP  Isopentenyl diphosphate 
LCMS  Liquid chromatography-mass spectrometry 
MGE   Mobile genetic element 
MIC   Minimum inhibitory concentration 
MS  Mass spectrometry 
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NAC  N-Acetylcysteamine 
NADH   Nicotinamide adenine dinucleotide (reduced) 
NMR  Nuclear magnetic resonance 
NP   Natural product 
NRP   Nonribosomal peptide 
NRPS   Nonribosomal peptide synthetase 
O/N  Overnight 
PCS   Protein coding sequence 
PK  Polyketide 
PKS  Polyketide synthase 
PLP   Pyridoxal-5’-phosphate 
PPant   Phosphopantetheine 
pPDC  Phenylpyruvate decarboxylase 
PPi  Inorganic pyrophosphate  
PQQ   Pyrroloquinolone quinone 
PQS   Pseudomonas quinolone signal 
PTM   Post-translational modification 
QS  Quorum sensing 
RiPP   Ribosomally synthesised and post-translationally modified peptide 
RNA  Ribonucleic acid 
SAL   Salicylic acid 
SAM   S-adenosyl methionine 
SHMT   Serine hydroxymethyltransferase 
TA   Threonine aldolase 
TEAB  Tetraethylammonium bicarbonate 
ThDP   Thiamine diphosphate 
THF   Tetrahydrofolate 
ThrRS  Threonyl-tRNA synthetase 





A   Adenylation 
ACP   Acyl carrier protein 
ArCP   Aryl carrier protein 
C   Condensation 
Cy   Cyclisation 
DH   Dehydratase 
E   Epimerisation 
ER   Enoyl reductase 
KR   Ketoreductase 
KS   Ketosynthase 
PCP   Peptidyl carrier protein 
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Chapter 1: Introduction 
 
1.1 Natural product discovery 
1.1.1 What are natural products? 
Natural products (NPs), or specialised metabolites, represent an extensive family of 
chemical compounds that possess a wide variety of valuable bioactivities. They are 
molecules of bacterial, fungal, plant and marine animal origin that, whilst not essential 
for survival under laboratory conditions, offer the producing organism some selective 
advantage in the specific environmental conditions in which they are produced. The 
source of their wide-ranging bioactivities lies in their incredible chemical diversity and 
complexity; NPs can range from hundreds to thousands of Da in size, can contain 
unusual chemical elements (e.g. halogens) and many comprise one or more 
stereospecific carbon centres. NP research today encompasses a broad range of 
disciplines and expertise, driven by the need for novel pharmaceuticals to treat 
infections and diseases, and agrochemicals to improve the growth and protection of 
major crops to nourish the world’s growing population. 
 
1.1.2 The rise of NP drug discovery 
Throughout the ages, humans have trusted in nature as a source of therapies for a 
whole range of infections and diseases. The oldest known record of natural medicines 
is the Egyptian “Ebers Papyrus” (ca. 1500 BCE) which documents over 700 drugs, 
mostly of plant origin (Borchardt, 2002). The major trigger in terms of modern NP 
discovery efforts was the serendipitous discovery of penicillin by Sir Alexander 
Fleming in 1928 (Fleming, 1929). It engendered Selman Waksman, a soil 
microbiologist at Rutgers University, to shift the efforts of his laboratory to search for 
natural compounds capable of killing bacteria known to cause human disease. By 
streaking bacteria and fungi isolated from the soil at right angles to pathogenic 
species, his group could observe the inhibition of pathogen growth by material 
diffusing from the producing organism (Figure 1.1), much as Fleming did. Waksman’s 
systematic phenotypic screening efforts led to the discovery of Actinomycin (1940), 
Streptothricin (1941) and most notably Streptomycin (1943), the first compound active 
against Mycobacterium tuberculosis (Hopwood, 2007). Their successes prompted 
pharmaceutical companies and a small number of academic groups to begin their 
own strain isolation and screening programmes, and over the subsequent 30 years, 
a wealth of important NPs with antibacterial, antifungal, antiparasitic, anticancer and 









Figure 1.1. Example of an antibacterial bioassay plate. Saccharopolyspora sp. 
KY21 (centre) is grown on nutrient agar and overlaid with agar containing Bacillus 
subtilis, representing a slight variation on the screens employed by Waksman in the 
20th century. An antibacterial produced by the Saccharopolyspora strain is diffusing 
into the agar and inhibiting B. subtilis growth, creating a ‘halo’ of inhibition. This image 





 2000; Demain 2014). This fruitful period is widely known as the ‘Golden Age’ of 
antibiotic discovery and many of the NPs discovered during this time, or their next-
generation derivatives, are still in use today. These include, but are not limited to, the 
penicillins, cephalosporins, tetracyclines, aminoglycosides, polyenes, 
chloramphenicol, glycopeptides, macrolides and ansamycins. Infectious disease was 
the leading cause of death in humans in 1900, but over the course of the 20th century 
NPs revolutionised the practice of medicine, almost doubling the average human life 
span in the U.S. (Lederberg, 2000), a pertinent reflection of the impact of NPs 
discovered during the 1900s. 
 
1.1.3 The fall of NP drug discovery 
During the 1990s, combinatorial chemistry allowed for the rapid generation of 
thousands of unique synthetic compounds. With advanced robotics, target-based 
assays could be applied to screen entire libraries of these compounds numbering in 
the range of 5 x 105 to 4 x 106 – a process called high throughput screening (HTS) 
(Katz and Baltz, 2016).  Unfortunately, NPs were not amenable to HTS strategies: 
obtaining a pure molecule from a complex culture mixture is often not trivial 
(especially at suitable concentrations for screening), compounds may act 
synergistically with activity lost following purification, and structural characterisation 
following purification can also be challenging (Li and Vederas, 2009). Compound 
rediscovery was a particular issue, given the rapid development of resistance to in-
use antibiotics and the need to replace those becoming ineffective (Fischbach and 
Walsh, 2009; Davies and Davies, 2010). Advances in NMR and MS analyses could 
improve dereplication to a degree, but the volume and speed of HTS caused almost 
all pharmaceutical companies to abandon NP discovery programmes.  
 
1.1.4 The second coming of NP drug discovery – the genome mining era 
Despite initially being an irresistible prospect, HTS of large compound libraries failed 
to fulfil its potential in replacing NPs as a viable source of novel drug candidates. By 
2002, the number of new chemical entities reaching the market had fallen to a two-
decade minimum (Ortholand and Ganesan, 2004). A key limitation was the insufficient 
understanding of which areas of chemical space are best suited to interact with 
biological space. Compared to synthetic compounds, NPs cover a very distinct area 
of chemical space and normally comprise fewer nitrogen, halogen and sulphur atoms, 
contain more hydrogen bond donors and are considerably more oxygen rich. They 
also tend to possess more ring systems and a greater number of stereochemical 
features. NPs are the result of hundreds of millions of years of evolution, and their 
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complex chemical structures have been selected for precisely because of their ability 
to interact highly specifically with their biological targets. Furthermore, they also 
intrinsically possess the physiochemical properties necessary for gaining entry to 
cells, unlike many synthetic molecules (O’Shea and Moser, 2008). Their suitability as 
drugs is reflected in the fact that of the 1184 new chemical entities approved between 
1981 and June 2006, more than half (52%) were NPs or NP-derived (Newman and 
Cragg, 2007), even with the withdrawal of NP discovery and screening programmes.  
 
The understanding of the genetics and enzymology of NP biosynthesis thus continued 
to advance in the 1980s and 90s, stemming from pioneering work by Sir David 
Hopwood on the model NP-producing Actinomycete bacterium Streptomyces 
coelicolor (Hopwood, 2007). Rapid progress was also being made in the area of 
whole-genome sequencing, culminating in the first complete microbial genome for 
Haemophilus influenza Rd being published in 1995 (Fleischmann et al., 1995). This, 
combined with the crucial discovery that genes encoding entire biosynthetic pathways 
are found clustered together in the genomes of producing organisms (Malpartida and 
Hopwood, 1984), left NPs poised to make a return to the mainstage of drug discovery 
research efforts. 
 
The sequencing of the S. coelicolor A3(2) genome in 2001 (Bentley et al., 2002), in 
addition to microorganism genomes published subsequently (Ikeda et al., 2003; 
Oliynyk et al., 2007), led to a radical re-envisioning of the field of NP research. Not 
only could the known compounds produced by a particular microorganism be linked 
to their cognate biosynthetic gene cluster (BGC), but it was found that many more 
putative BGCs were encoded in their genomes beyond those for known compounds 
(Figure 1.2). Bacterial BGCs are rarely expressed constitutively as their products are 
energetically very costly to synthesise and are instead switched on in response to 
specific environmental cues or at different stages in microorganismal development 
(Bibb, 2005). Consequently, often only a fraction are expressed under standard 
laboratory culture conditions. As a result, as much as 90% of the chemical potential 
of these microorganisms had remained undiscovered by the traditional empirical 
screening strategies employed extensively during the 20th century.  
 
This revelation established genome mining as an extremely powerful approach in NP 
discovery and led to the development of a range of new strategies for activating 
orphan or cryptic BGCs identified in genomic data (Challis, 2008; Rutledge and 











conditions, co-culture experiments, introducing chemical elicitors and epigenetic 
modifiers into cultures, as well as interfering with global regulators of transcription and 
translation. BGC sequence data allow for in silico predictions of final product structure 
to be made and often research groups are concerned with only a single promising or 
unusual biosynthetic locus. In these cases, pathway-specific approaches can be 
employed such as the over-expression of cluster-associated activators (or deletion of 
pathway-specific repressors), heterologous expression or in vitro reconstitution of 
pathways. Major advances have also been made in the field of metabolomics, 
allowing for faster dereplication and structural elucidation of isolated NPs (Li and 
Vederas, 2009; Ito and Masubuchi, 2014). More recently, molecular networking using 
tandem MS/MS data has become an increasingly popular tool for analysing complex 
mixtures of molecules in crude extracts. This allows improved novel NP identification 
and the detection of biosynthetic intermediates present in trace quantities (Watrous 
et al., 2012; Hoffmann et al., 2014; Crone et al., 2016). Visualisation of the production 
of NPs in situ using Matrix Assisted Laser Desorption/Ionization (MALDI) – Imaging 
Mass Spectrometry (IMS) is also providing a greater understanding of the spatial and 
temporal distribution of NPs produced in different environmental and ecological 
contexts (Watrous and Dorrestein, 2011). 
 
In the past decade, significant advances have been made in both the speed and 
accuracy of DNA sequencing, and the cost of sequencing per nucleotide has steadily 
declined (Gomez-Escribano et al., 2016). To manage increasing amounts of genomic 
sequence data available, software and databases have been developed to automate 
BGC identification and annotation (Medema and Fischbach, 2015). One of the most 
widely used is antiSMASH (Blin et al., 2017a; 2017b), which identifies BGCs based 
on the presence of biosynthetic enzymes putatively involved in NP biosynthesis; 
although they represent enormous chemical diversity, NPs are derived from a 
relatively modest set of building blocks and the biosynthetic machineries for their 
assembly are highly conserved. antiSMASH can identify >40 different BGC types in 
this way, in addition to making structural predictions of cluster products and showing 
homology to clusters in other sequenced genomes. Other software and databases 
(Medema and Fischbach, 2015) have been developed to catalogue characterised 
clusters and compounds (Pence and Williams, 2010; Medema et al., 2015; Harborne, 
2015;), to predict biosynthetic enzyme substrate specificity (Anand et al., 2010; Röttig 
et al., 2011), to connect genomic and mass spectrometric data (Medema et al., 
2014a; Wang et al., 2016) and more recently, a retro-biosynthetic in silico analysis 
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platform has been created to further aid in NP discovery dereplication (Dejong et al., 
2016).  
 
There are now >960,000 putative BGC entries in the Integrated Microbial Genomes 
Atlas of Biosynthetic gene Clusters (IMG-ABC), curated by the Joint Genome Institute 
(JGI) (Hadjithomas et al., 2015; Ziemert et al., 2016). Recent estimates based on the 
genomic data from 830 actinomycete genomes suggest that over 106 bacterial NPs 
remain to be discovered, with 104-105 of these possessing novel scaffolds (Doroghazi 
et al., 2014). Given that >99% of bacteria are not readily culturable (Amann et al., 
1995), this number likely represents a considerable underestimate. The incredible 
wealth of chemical diversity potentially locked away in as yet uncultured organisms is 
reflected in the work of Piel and co-workers on Entotheonella factor, a sponge 
symbiont that produces a number of structurally distinct bioactive NPs (Wilson et al., 
2014). Advances in single-cell sequencing technologies and metagenomics 
approaches (Lasken, 2012; Wilson and Piel, 2013; Katz et al., 2016), in addition to 
the development of innovative cultivation methods such as that which recently led to 
the discovery of teixobactin (Ling et al., 2015), should make this uncharted chemical 
space increasingly accessible. Novel chemical structures are highly sought after as 
they may facilitate interaction with novel biological targets. In the antibiotic narrative, 
the inhibition of novel targets is critical in the battle against multi-drug resistant 
pathogenic bacteria. Considering the volume of genomic data now available, 
enriching for BGCs that give rise to novel chemical structures presents a key 
















1.2 Pseudomonas spp. as producers of NPs 
Historically, bacteria of the class Actinobacteria have been the principal source of NP 
derived-drugs (Bérdy, 2012), with more than half of all bacterial metabolites identified 
originating from members of the genus Streptomyces alone (Bérdy, 2005; Katz and 
Baltz, 2016). This is likely a reflection of their larger genome sizes encoding a greater 
average number of BGCs (5-10% of the genome) compared to other bacteria (Baltz, 
2008), and the relative ease with which they can be cultured and studied in the 
laboratory. The rest of the eubacteria seem to be relatively poor producers, 
accounting for only 16% of all microbial NPs. Exceptions include Burkholderia (Liu 
and Cheng, 2014) and Bacillus spp. (Sansinenea and Ortiz, 2011), and more recently 
the cyanobacteria and myxobacteria are also proving to be rich sources of interesting 
NPs, accounting for 3.7 and 1.8% of known microbial NPs respectively (Bérdy, 2012). 
The ability of members of the genus Pseudomonas to produce a wide range of 
bioactive molecules is also well documented (Gross and Loper, 2009). Since 
obafluorin, the focus of this work, is a P. fluorescens NP, subsequent sections 
introduce the basic biology and genomics of this genus, and illustrate the significance 
of NPs in determining their ecology. 
 
1.2.1 Overview of the pseudomonads and their genomes 
Pseudomonas is a very diverse genus of gamma-proteobacteria comprising over 200 
species (http://www.bacterio.net) that have evolved to occupy a diverse range of 
environments and niches (Figure 1.3). Many are saprophytic, playing important roles 
in the turnover of organic matter in the soil and are thus being investigated for their 
potential as bioremediators (Loh and Cao, 2008). Strains of P. fluorescens, P. putida 
and P. protegens colonise plants, where they support development through the 
biosynthesis of plant growth hormones and metabolites that suppress pathogens 
(Haas and Défago, 2005; Silby et al., 2011; Loper et al., 2012). Conversely, P. 
syringae strains are extremely successful plant pathogens, and can be assigned to 
one of over 50 pathovars based on host specificity (Buell et al., 2003). Pathogenicity 
is not limited to plants, reflecting the opportunistic nature of these bacteria; P. 
entomophila orally infects and kill the larvae of many insect species (Vodovar et al., 
2006). P. aeruginosa is a clinical pathogen of patients with predisposing conditions 
such as cystic fibrosis or severe burns, and infections are notoriously difficult to treat 
due to a high degree of antibiotic resistance in this species (Lister et al., 2009; 














Figure 1.3. The functional and environmental range of Pseudomonas spp. The 
Pseudomonas common ancestor has encountered a wide range of abiotic and biotic 
environments that has led to the evolution of a multitude of traits and lifestyles with 
significant overlap among species. Silby et al. (2011) - Adapted with permission from 








The incredible versatility and adaptability of Pseudomonas spp. is reflected in the 
enormous genetic diversity they exhibit. Only 25-35% of the core genome is shared 
by all members of the genus (Silby et al., 2009; 2011; Baltrus et al., 2011), and this 
typically comprises housekeeping genes and RNA genes essential for survival. Most 
genes are species-specific or shared by a particular sub-set of species, and make up 
what is known as the flexible genome. Compared to other bacteria pseudomonad 
genomes are large, typically 4.9-7.1 Mbp in size, which means there is a large 
proportion that is plastic and permissive to evolution. Genetic diversity is mediated in 
part by horizontal gene transfer (HGT) and the movement of mobile genetic elements 
(MGEs) such as phages, plasmids, transposons and genomic islands, that result in 
the acquisition or loss of genetic information. Whole-genome sequence alignments 
also show evidence of extensive intragenomic recombination events between repeat 
sequences. These are particularly abundant in Pseudomonas spp. and typically occur 
in the flexible genome, indicating a strong selection pressure for highly adaptive 
variable regions (Gross and Loper, 2009; Silby et al., 2009; 2011). The core and 
flexible regions display a mosaic pattern of conserved and lineage-specific genes as 
the result of both processes (Spencer et al., 2003; Linderberg et al., 2008; Mathee et 
al., 2008; Winstanley et al., 2009). 
 
The genomes of Pseudomonas spp. encode a large complement of genes that endow 
them with broad metabolic versatility, including complete sets for the pentose 
phosphate, Entner-Doudoroff and tricarboxylic acid central metabolic pathways 
(Stover et al., 2000; Nelson et al., 2002; Buell et al., 2003; Paulsen et al., 2005; 
Vodovar et al., 2006). A sub-set are also able to metabolise plant-derived 
carbohydrates such as maltose, sucrose, trehalose and xylose, and even more 
complex molecules such as aromatics, long-chain fatty acids and hydrocarbons 
(Jiménez et al., 2002; Martins dos Santos et al., 2004; Paulsen et al., 2005). 
Components for the catabolism of most amino acids are also present. Their genomes 
also encode numerous hydrolytic enzymes such as chitinases, proteases and lipases 
involved in the breakdown of soil polymers to liberate metabolic substrates (Loper et 
al., 2012). Many species biosynthesise surfactants, solubilising agents that further 
increase the bioavailability of small molecules (Noordman and Janssen, 2002; Doong 
and Lei, 2003). Intuitively, Pseudomonas genomes encode many transport genes for 
the uptake of a diverse range of different nutrient sources (Buell et al., 2003; Paulsen 
et al., 2005). Extensive sets of regulatory genes are also encoded, reflecting the 
importance of directing gene expression in response to a variety of different 
environmental conditions and nutrient sources (Llamas et al., 2014).  
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1.2.2 The roles of NPs in Pseudomonas ecology 
High metabolic versatility and genome plasticity has created the ideal platform for the 
evolution of very diverse specialised metabolomes, which have played a critical role 
in the ability of Pseudomonas spp. to adapt to their diverse ecological niches. Their 
NP repertoires exhibit great chemical diversity (Figure 1.4), allowing the interaction 
with a broad range of biological targets. Many have antibiotic and antifungal activities, 
providing defence against competitors and predators. 2,4-diacetylphloroglucinol (2,4-
DAPG) for example is produced by many plant-associated pseudomonads and is 
active against a wide range of plant-pathogenic fungi, most notably the take-all 
pathogen of wheat, Gaeumannomyces graminis var. tritici (Keel et al., 1992; 
Raaijmakers and Weller, 1998). It also exhibits antibacterial and anthelmintic 
properties and triggers the systemic resistance of plants against disease (Nowak-
Thompson et al., 1994; Rezzonico et al., 2007). Pyrrolnitrin, an inhibitor of fungal 
respiratory chains (Tripathi and Gottlieb, 1969), and hydrogen cyanide (HCN), an 
inhibitor of cytochrome C oxidase (Gross and Loper, 2009) are likewise commonly 
produced by plant growth-promoting species due to their disease suppressive 
activities. Some plant-associated species also produce phytohormones (Lindow et 
al., 1998). Indole-3-acetic acid (IAA) influences many aspects of plant development 
and is produced at low concentrations by rhizosphere-inhabiting species to promote 
plant growth (Patten and Glick, 2002). Its effects are concentration-dependent 
however, and several plant-pathogenic species produce IAA at high concentrations 
as a virulence factor, causing hyperplasia (Smidt and Kosuge, 1978; Glickmann et 
al., 1998; Spaepen et al., 2007).   
 
Pathogenic species produce many NP toxins and virulence factors to facilitate host 
infection. Phytotoxins such as tabtoxin and syringomycin from P. syringae cause 
chlorosis and necrosis symptoms in host plants for example (Bender et al., 1999). 
Coronatine is a pseudomonad virulence factor that facilitates pathogen entry into the 
plant by causing stomata to open and which has also been shown to inhibit salicylic 
acid (SAL)-dependent plant host defences (Brooks et al., 2005; Melotto et al., 2006; 
Uppalapati et al., 2007). Pederin is a highly cytotoxic agent produced by an as-yet 
uncultured symbiotic Pseudomonas spp. It was originally isolated from rove beetles 
of Paederus and Paederidus spp., the symbiont insect hosts, which use it as a 















NPs also play important physiological roles more akin to ‘primary’ metabolic functions. 
The phenazines produced by P. aeruginosa initially attracted attention for their broad-
spectrum antibacterial, antitumour and antiparasitic bioactivities (Thomashow and 
Weller, 1988; Mavrodi et al., 2006). However, their redox potentials are such that they 
can react extracellularly with higher-potential oxidants, effectively acting as electron 
shuttles between the cell and external substrates, allowing cells to continue to 
‘respire’ under hypoxic conditions (Hernandez and Newman, 2001; Price-Whelan et 
al., 2006). This is critical in biofilm formation where internal cells are likely to be 
starved of oxygen, and phenazine production is thus intrinsically linked to bacterial 
community morphogenesis (Dietrich et al., 2013; Okegbe et al., 2017). These redox-
active metabolites also play critical roles as intercellular signals and influence 
transcriptional regulation by upregulating genes involved in stress response (Dietrich 
et al., 2008). 
 
Iron is essential for numerous metabolic and signalling functions, and is also an 
important enzyme cofactor for redox reactions (Wandersman and Delepelaire, 2004). 
However, it is insoluble in its oxidised form and highly toxic in its reduced form, and 
though abundant, is largely inaccessible in many environments. To overcome this 
issue, many Pseudomonas spp. secrete siderophores such as pyochelin (Cox et al., 
1981), pyoverdines (Visca et al., 2006) and pseudomonine (Anthoni et al., 1995). 
These chelate and solubilise ferric iron for uptake back into the producing-organism, 
whilst simultaneously depriving competitors of the same limited resource.  
 
1.2.3 Biosynthesis of Pseudomonas NPs 
The ability to produce a diverse set of chemical structures clearly provide the 
pseudomonads unique selective advantages that have allowed them to adapt to a 
broad range of ecological niches, but how is this chemical diversity achieved? To 
provide appropriate background knowledge for subsequent Introduction sections and 
Chapters, the major classes of NPs and their biosynthesis are here introduced using 
pseudomonad examples, which are illustrated in Figure 1.4. Pseudomonas spp. 
share much in common with the actinomycetes in that they utilise many of the same 
NP building blocks and machineries for assembling them. However, they also employ 
numerous unusual biosynthetic mechanisms to generate novel chemical structures 






1.2.3.1 Nonribosomal peptides (NRPs)  
Amino acids represent one of the principle building blocks used by Pseudomonas 
spp. in NP biosynthesis. They produce a broad array of structurally-diverse bioactive 
peptides which are assembled by large multifunctional proteins called nonribosomal 
peptide synthetases (NRPSs) (Finking and Marahiel, 2004; Fischbach and Walsh, 
2006). These build peptides in a highly modular, assembly line-like fashion with each 
module responsible for catalysing the incorporation of a single specific amino acid 
into the growing peptide chain (Figure 1.5). The elongating peptide is shuttled from 
one module to the next, for the incorporation of each subsequent amino acid. 
Elongation modules comprise a minimal set of three domains: An adenylation (A) 
domain which recognises a specific amino acid substrate, activates it as an amino-
acyl adenylate and tethers it to a phosphopantetheine (PPant) prosthetic group on 
the adjacent peptidyl carrier protein domain (PCP) via a thioester bond. Finally, a 
condensation (C) domain is then able to catalyse peptide bond formation between 
the PCP-tethered amino acid on the same module and the peptidyl intermediate 
bound to the PCP on the preceding module (Figure 1.5b). The assembly line is 
completed by an initial loading module, comprising A and PCP domains only, that 
initiates peptide assembly, and a termination module comprising a thioesterase (TE) 
domain, which catalyses release, and often cyclisation, of the final peptide product. 
 
Chemical diversity in Pseudomonas peptide NPs is achieved by a multitude of 
different mechanisms. Beyond variation in peptide length and which amino acids are 
incorporated, independence from the ribosome has freed NRPSs to evolve to accept 
a broad range of nonproteinogenic amino acid and alternative acid substrates. The 
pyoverdines, for example, consist of a dihydroxyquinoline chromophore attached to 
a variable peptide chain of six to twelve amino acids, both of which comprise unusual 
acid substrates (Ravel and Cornelis, 2003 – Figure 1.6). Incorporation experiments 
revealed that 2,4-diaminobutyric acid is introduced by PvdL in chromophore assembly 
(Böckmann et al., 1997), and PvdIJD subsequently extend the peptide by eight 
residues, incorporating two ornithine residues in the process. Further diversification 
is achieved by the presence of additional domains beyond the C-A-PCP paradigm 
that can further modify the peptide backbone during chain elongation. Epimerisation 
(E) domains for example allow the incorporation of D-configured amino acids (Figure 
1.5c), and one D-tyrosine and a range of other D-configured residues are introduced 
into the P. aeruginosa PA01 pyoverdines by PvdL and PvdIJD E domains, 
respectively (Nowak-Thompson and Gould, 1994; Meyer, 2000; Ravel and Cornelis, 








actions of PvdA, an ornithine hydroxylase, and PvdF, a transfomylase, which perform 
the respective hydroxylation and formylation at N-5 of ornithine, highlighting the many 
mechanisms by which chemical diversity can be generated among NP peptides. 
 
Deviations from canonical NRP biosynthesis seem to be the rule rather than the 
exception for Pseudomonas NP peptides with many pathways involving additional 
NRPS domains and unusual organisations. Salicylic acid (SAL) derived from the 
shikimic acid pathway is incorporated as an atypical unit in the siderophores 
pseudomonine (Figure 1.7 - Mercado-Blanco et al., 2001; Sattely and Walsh, 2008) 
and pyochelin (Serino et al., 1997; Reimmann et al., 1998), two more siderophores 
that are both assembled by NRPSs. Both comprise NRPSs with cyclisation (Cy) 
domains (Figure 1.5d), which catalyse the formation of two oxazole rings from serine 
residues and one thiazole ring from a cysteine residue during pseudomonine and 
pyochelin biosynthesis respectively. PmsD in pseudomonine biosynthesis is an 
extremely unusual NRPS module that is composed solely of two Cy domains and one 
A domain (Mercado-Blanco et al., 2001; Sattely and Walsh, 2008). Cy2 transfers SAL 
to PmsG-tethered L-threonine, before Cy1 catalyses cyclodehydration to generate a 
salicylmethyloxazolinyl-PmsG acylenzyme intermediate (Figure 1.7). The A domain 
activates another unusual precursor, N-hydroxyhistamine, which acts as a 
nucleophilic substrate for the PmsG C domain to release an oxazoline hydroxamate 
condensation product. The unusual organisation of this module serves to highlight 
the inherent plasticity of NRPS systems. Their highly modular repetitive organisations 
facilitate recombination events to yield novel assembly line organisations and novel 
products, and domains can sometimes evolve novel biosynthetic roles because of 
this process. Further biosynthetic flexibility is achieved in the substrate promiscuity of 
many NRPS A domains. PmsDEG were shown in vitro to accept 2,3-
dihydroxybenzoic acid (2,3-DHBA) instead of SAL, or L-cysteine instead L-threonine, 
yielding the siderophores acinetobactin and anguibactin, respectively (Wuest et al., 
2009). 
 
1.2.3.2 Ribosomally synthesised and post-translationally modified peptides 
(RiPPs)  
Genome mining efforts of the 21st Century have revealed another major class of NP 
peptides - the ribosomally synthesised and post-translationally modified peptides 
(RIPPs) (Arnison et al., 2013). They are encoded by small, structural genes which 
make them extremely difficult to identify by homology-based searches. However, the 




Figure 1.6. Biosynthetic model for pyoverdine in P. aeruginosa PA01. ACL = 
acyl-CoA ligase domain, Dab = 2,4-diaminobutyric acid. Gross and Loper (2009) - 





Figure 1.7. Biosynthesis model and BGC for pseudomonine. Gross and Loper 
(2009) - Reproduced with permission from The Royal Society of Chemistry.  
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in generating chemical diversity in this class of NP peptides is improving our ability to 
identify RIPP BGCs. Few examples have been characterised in Pseudomonas spp., 
although recently, microcin B-like BGCs have been identified in P. syringae and P. 
putida (Severinov et al., 2007; Metelev et al., 2013). Microcins were originally 
identified in E. coli and are peptides less than 10 kDa in size that contain multiple 
oxazole and thiazole rings and are potent inhibitors of DNA gyrase (Yorgey et al., 
1994; Li et al., 1996; Duquesne et al., 2007). Whilst mcb-like operons were identified 
in several P. syringae pathovars, their products have so far only been detected 
following heterologous expression in E. coli (Metelev et al., 2013).  
 
Genes encoding proteins of unknown function in the BGC for methanobactin 
biosynthesis, have allowed the identification of a homologous BGC in P. fluorescens, 
but it is yet to be characterised (Kenney and Rosenzweig, 2013). Methanobactins are 
a family of copper-binding RIPPs initially identified in the methanotroph Methylosinus 
thrichosporium OB3b, which requires copper as a cofactor for methane metabolism 
(DiSpirito et al., 1998; Téllez et al., 1998; Kim et al., 2004). Advances in our 
understanding of RIPP biosynthesis will continue to inform genome mining strategies 
and will likely lead to the identification of novel pseudomonad RIPPs in the future. 
 
1.2.3.3 Other amino acid-derived NPs 
Phaseolotoxin, a phytotoxic tripeptide consisting of ornithine, alanine and homo-
arginine connected to a sulfodiaminophosphinyl moiety, has been assigned to a 28 
kb cluster devoid of NRPS genes (Peet et al., 1986; Zhang et al., 1993; Aguilera et 
al., 2007). These building blocks are thought to be assembled by the L-amino acid 
ligase PhtU, encoded in the P. syringae pv. phaseolicola 1448A phaseolotoxin cluster 
(Arai and Kino, 2008), rather than by a canonical NRPS-based route. Other methods 
of ribosome independent peptide bond formation in NP biosynthesis are known 
(Goswami and Van Lanen, 2015), but have for a long time gone undetected by 
software such as antiSMASH.  
 
The pseudomonads have evolved multiple routes to assemble amino acid building 
blocks in NPs, and several are even the result of a series of modifications of individual 
amino acids. The antifungal pyrrolnitrin is a chlorinated phenylpyrrole that is derived 
from multiple modifications of L-tryptophan, for example (Hammer et al., 1997; Kirner 
et al., 1998). It is the product of a four-gene locus prnABCD that catalyses two 
chlorinations, a decarboxylation (to form a phenylpyrrole from the indole) and an 
amino group N-oxygenation to install a nitro- functionality. IAA is also derived from  
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L-tryptophan and its biosynthesis can proceed via one of two different routes in 
Pseudomonas spp.: The indole-3-acetamide pathway (Costacurta and Vanderleyden, 
1995) and the indole-3-pyruvic acid pathway (Patten and Glick, 1996). Further 
important examples of modified amino acid NPs include HCN which is derived from 
glycine (Wissing, 1974; Laville et al., 1998; Blumer and Haas, 2000) and tabtoxin 
which has its origins in the L-lysine biosynthetic pathway (Unkefer et al., 1987; Roth 
et al., 1990; Liu and Shaw, 1997; Kinscherf and Willis, 2005). 
 
1.2.3.4 Polyketides (PKs) and fatty acid-derived NPs 
Acetyl-CoA and malonyl-CoA are also very common building blocks, used by 
pseudomonads and other microorganisms in the assembly of polyketide (PK) NPs. 
PKs are assembled by polyketide synthases (PKSs), which catalyse decarboxylative 
Claisen-like thioester condensation reactions to connect units together in an 
analogous manner to fatty acid synthases (FASs) (Staunton and Weissman, 2001; 
Fischbach and Walsh, 2006; Hertweck, 2009). Like NRPSs, PKSs are multifunctional 
proteins organised into modules, each responsible for the addition and modification 
of an extender unit to the growing PK chain (Figure 1.8a and b). PKS modules are 
also minimally composed of three domains: an acyltransferase (AT) domain selects 
an extender unit and tethers it to the PPant group of its cognate acyl carrier protein 
(ACP) domain via a covalent thioester bond. A ketosynthase (KS) domain then 
catalyses condensation between the extender unit and PK intermediate tethered to 
the preceding module ACP domain. Analogously to NRPSs, the loading module lacks 
a KS and the terminal domain on the terminal module is typically a TE domain for 
PKS product release.  
 
Key distinctions from FASs are that PKSs can accept a greater variety of substrates, 
display a greater range of final product chain lengths, and exhibit varying levels of 
reduction following each round of chain elongation, where FASs fully reduce every 
acyl unit. This is due to the presence of three additional catalytic domains that are 
invariably present in FASs but ‘optional’ in PKSs: Ketoreductase (KR) domains 
convert the β-ketoacyl-S-ACP arising from KS-mediated condensation to a β-
hydroxyacyl-S-ACP, dehydratase (DH) domains subsequently catalyse dehydration 
to form the α,β-enoyl-S-ACP, and finally enoylreductase (ER) domains reduce the 
conjugated olefin to the saturated acyl-S-ACP (Figure 1.8c). These additional 
domains are also able to alter NP stereochemistry. PKSs are categorised into three 
major types: type I are large modular proteins, type II consist of complexes of 









Figure 1.8. Illustration of PKS assembly line biosynthetic logic. (a) PK chain 
elongation on a hypothetical assembly line (b) The Claisen condensation catalysed 
by KS domains during PKS biosynthesis. Decarboxylation of the downstream 
(methyl)malonyl-S-ACP yields a nucleophilic thioester enolate, which attacks the 
upstream acyl-S-ACP thioester to form a C-C bond. (c) β-Carbon processing in PKSs. 
The β-ketoacyl-S-ACP condensation product is reduced by the KR domain to form a 
β-hydroxyacyl-S-ACP, subsequent dehydration by the DH domain yields an β-enoyl-






closely related to chalcone and stilbene synthases in plants. The latter comprise a 
single KS domain with an active site cysteine, responsible for performing all the 
functions of the essential domains of type I and II PKS systems (Shimizu et al., 2017).  
 
One of the best studied Pseudomonas PKs is mupirocin (pseudomonic acid A), which 
is marketed as a topical antibiotic (Bactroban) that is active against methicillin-
resistant Staphylococcus aureus (MRSA), and is an excellent example of how 
chemical diversity is generated in pseudomonad PK NPs. The pseudomonic acids A-
D are a mixture of antimicrobial compounds, produced by P. fluorescens NCIMB 
10586, that all possess a dehydroxylated tetrahydropyran ring bearing functionalised 
side chains in positions C-2 and C-5 (Figure 1.9). The BGC was first identified by 
Thomas et al. in 2003 (El-Sayed et al., 2003) and is one of the earliest examples of a 
trans-AT PKS system (Helfrich and Piel, 2016). These PKS modules lack AT 
domains, but genes encoding AT(s) are present elsewhere in the cluster and act 
iteratively in trans to supply extender units to the assembly line (Figure 1.9). trans-AT 
PKs exhibit greater structural diversity than cis-AT systems as discrete AT domains 
relieve restrictions imposed by colinearity, facilitating a greater propensity for 
evolution in a mosaic-like fashion by extensive HGT and recombination. This is 
exemplified by the pederin family of compounds (Piel, 2002; Piel et al., 2004; Fisch 
et al., 2008), and the products of the misakinolide, luminaolide and tolytoxin trans-AT 
PKS systems (Ueoka et al., 2015).  
 
Structural diversification in mupirocin biosynthesis is achieved via multiple during- 
and post-PKS tailoring reactions, required to install the carbon at C-15, and to 
generate epoxide and tetrahydropyran groups. The C-15 methyl group is derived from 
acetate and is installed by the hydroxymethylglutaryl-CoA synthase MupH of the 
‘MCS cassette’ (Wu et al., 2007), and the epoxide is the product of the 
KS/oxidoreductase mmpE (Gao et al., 2014). Biosynthesis of the tetrahydropyran ring 
remains to be completely dissected but candidate enzymes have been identified in 
MupC (NADH oxygenase), MupO (cytochrome P450), MupT (ferredoxin 
dioxygenase) and MupW (dioxygenase), with MupW representing the most likely 
candidate based on mutagenetic experiments (Cooper et al., 2005). Finally, the 
mupirocin biosynthetic pathway also exhibits the use of a non-canonical extender unit 
3-hydroxypropionate, which, in addition to three malonyl-CoA units, is incorporated 

















Figure 1.9. Biosynthesis model and BGC for mupirocin. * = inactive domain. 














2,4-DAPG (Figure 1.4) is also of PK origin, but is synthesised by a type III PKS 
(Bangera and Thomashow, 1999). The key enzyme for biosynthesis is PhlD which 
condenses three malonyl-CoA units to form activated 3,5-diketoheptanedioate. This 
is subsequently decarboxylated and cyclised in a Claisen condensation to yield 
phloroglucinol (Achkar et al., 2005; Zha et al., 2006), before PhlABC then install two 
acetyl groups at the C-2 and C-4 positions (Shanahan et al., 1993). Despite their 
structural resemblance to phloroglucinols, the 2,5-dialkylresorcinols are not 
assembled on a PKS, and are instead generated by multiple modifications of medium-
chain-length fatty acids derived from fatty acid metabolism (Nowak-Thompson et al., 
2003). These examples serve to highlight the multiple mechanisms by which building 
blocks derived from fatty acid biosynthesis can be assembled into NPs. 
 
1.2.3.5 Hybrid NRP-PK NPs 
The highly modular nature and analogous biosynthetic logic of NRPS and PKS 
systems, particularly their shared use of phosphopantetheinylated carrier protein 
domains to tether substrates, has allowed for the ready hybridisation of these systems 
to generate new NPs and further structural diversity. NRPS/PKS systems can roughly 
be divided into two classes: those in which an NRPS-bound peptidyl intermediate is 
elongated by a PKS module and vice versa (Du et al., 2001). In pyoluteorin 
biosynthesis, L-proline is the starting unit, and this amino acid is extended by addition 
of three malonyl-CoA units on a PKS. L-proline is introduced by discrete A and PCP 
domains which activate and tether it respectively, and is the source of the 
dichloropyrrolyl moiety to which the three malonyl-CoA units are subsequently added 
(Nowak-Thompson et al., 1997; 1999).  
 
The cyclic lipopeptides (CLPs) are a structurally diverse class of compounds that 
minimally comprise a fatty acyl residue, ranging from five to sixteen carbons in length, 
attached to a peptide chain of seven to twenty-five amino acids. Between four and 
fourteen of these undergo macrocyclisation to form a macrolactam ring, as illustrated 
by massetolide A and syringomycin in Figure 1.4. (Raaijmakers et al., 2006; Gross 
and Loper, 2009; Nguyen et al., 2016). Where the first module in pyoluteorin contains 
a KS domain for C-C bond formation between malonyl-CoA and proline to yield an 
amino-acyl-S-ACP starter unit for the PKS PltB, the converse occurs in CLP 
biosynthesis. The first module contains a C domain for C-N bond formation between 
an amino acid and fatty acyl residue to yield an acylamino-S-PCP. Unusual features 
common to the biosynthesis of all CLPs include the presence of dual C/E domains for 
conversion of L- to D- configured amino acids (Balibar et al., 2005), and tandem 
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terminal TE domains that fulfil product release, cyclisation and potentially proof-
reading functions (Scholz-Schroeder et al., 2003). Many CLPs occur as a mixture of 
analogues that differ in fatty acid and amino acid composition, again reflecting the 
relaxed substrate specificity of A and C domains in their biosynthetic pathways (Gross 
and Loper, 2009).  
 
1.2.3.6 Shikimic acid-derived NPs 
In addition to acting as noncanonical substrates to NRPS assembly lines, 
intermediates and derivatives of the shikimic acid pathway are themselves modified 
by biosynthetic enzymes to form important pseudomonad NPs. The phenazines, for 
example, are derived from chorismate, the major branch point in the pathways to 
aromatic amino acids (Knaggs, 2003). This precursor undergoes a series of 
modifications catalysed by products of the conserved phzA/BDEFG operon 
(Blankenfeldt et al., 2004; Parsons et al., 2004; Mavrodi et al., 2006; Ahuja et al., 
2008; Guttenberger et al., 2017). Chemical diversity is introduced among the 
phenazines through the activity of further genes either associated with the core 
operon, such as the S-adenosylmethionine (SAM)-dependent N-methyltransferase 
PhzM (Parsons et al., 2007), or which are located externally like PhzH, which converts 
carboxylic acids to carboxamides (Mavrodi et al., 2001). 
 
The quinolones are also derived from chorismate, and are small antibacterial 
alkaloids that have been identified as important signalling molecules; 2-heptyl-3-
hydroxy-4-quinolone was renamed Pseudomonas quinolone signal (PQS) due to its 
diverse regulon which includes genes encoding elastase, rhamnolipids, PA-IL lectin 
and pyocyanin, which play various important roles in biofilm formation and cellular 
fitness (Calfee et al., 2001; Bredenbruch et al., 2005; Gross and Loper, 2009). The 
biosynthetic locus comprises seven structural genes, pqsABDH and phnAB, that 
catalyse the formation of PQS from head-to-head condensation of anthranilate and 
β-keto-(do)decanoic acids to create a functional hybrid molecule (Gallagher et al., 
2002; Coleman et al., 2008; Schertzer et al., 2010; Drees and Fetzner, 2015; Drees 
et al., 2016). PhnA and PhnB are thought to synthesise anthranilate from chorismate, 
though in some P. aeruginosa strains, it can be generated by L-tryptophan 
degradation via the kynurenine pathway (Farrow and Pesci, 2007). 
 
1.2.4 Summary 
Pseudomonas spp. exhibit an extraordinary repertoire of structurally diverse NPs 
(Figure 1.4) that have allowed them to colonise a wide range of environments and 
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adapt to a variety of different lifestyles. The advancement of modern genomics has 
highlighted the importance of MGEs in driving the diversification of Pseudomonas 
NPs, mediated by HGT. Evidence of this process is apparent in the mosaic 
arrangement of core and flexible regions of pseudomonad genomes. It is also 
reflected in the distribution and conservation of BGCs like that of pyrrolnitrin, which is 
shared among different Pseudomonas spp., as well as other closely related 
proteobacteria (Hammer et al., 1999; Costa et al., 2009; Weissman and Müller, 2010). 
Chemical diversity is achieved in the variation of number and structural composition 
of domains in modular biosynthetic machineries and in their inherent plasticity, 
underlined by unusual domain organisations and the relaxed substrate specificities 
observed in many of these megaenzymes. Further sophistication and divergence 
from the model NRPS and PKS systems in Gram-negative bacteria is achieved 
through the functional combination of modular and dissociated PKS and NRPS 
machineries. The common occurrence of trans-AT PKS systems in this genus (Piel, 
2002; Brendel et al., 2007), which exhibit greater propensity for pathway 
rearrangement and product diversity than cis-PKS systems, is conspicuous. So too 
is the number of pathways comprising biosynthetic enzymes for the modification of 
primary metabolic products, particularly amino acids and shikimic acid-derived 
metabolites. 
 
Substantial changes in NP product structure can be achieved through the introduction 
of noncanonical building blocks, a common occurrence in pseudomonad NP 
biosynthesis. This can involve either the modification of canonical substrates during- 
and post-modular enzyme assembly, or the generation of noncanonical substrates de 
novo prior to incorporation into a larger molecule. This project concerns the antibiotic 
obafluorin produced by P. fluorescens (Figure 1.4 - Wells et al., 1984; Tymiak et al., 
1985), which likely represents an example of the latter in which an unusual 
nonproteinogenic β-hydroxy-α-amino acid (β-OH-α-AA) precursor is incorporated into 
the final molecule (Herbert and Knaggs, 1988; 1990; 1992a and b). This moiety is 
significant because it ultimately gives rise to a β-lactone ring, an infrequent but highly 
bioactive NP pharmacophore. The final section of this Chapter introduces obafluorin 
and its key structural features, in addition to describing previous experimental work 





From this point forward, a compound numbering system will be employed that applies 
to all text and figures. Any number highlighted in bold is in reference to the 
Compound Key (page vi).  
 
1.3 Obafluorin 
1.3.1 Discovery and characterisation  
In the course of screening for new β-lactam antibiotics, the metabolite obafluorin (1) 
was isolated from cultures of a plant-associated P. fluorescens strain in Princeton, 
New Jersey in 1984 (Wells et al., 1984; Tymiak et al., 1985). It comprises a β-lactone 
ring, a highly bioactive moiety, and a 4-nitrobenzyl group, both of which are relatively 
uncommon features in NPs. The β-lactone ring of 1 appears to be derived from a from 
a very unusual nonproteinogenic β-OH-α-AA, (2S,3R)-2-amino-3-hydroxy-4-(4’-
nitrophenyl)butanoate (AHNB (2) – highlighted in Figure 1.10), and the molecule also 
comprises a 2,3-dihydroxybenzamide moiety, a common constituent of bacterial 
siderophore NPs (May et al., 2001; Crosa and Walsh, 2002).  
 
Subsequent screening for bacteria from many different locations worldwide revealed 
the widespread occurrence of this molecule among Pseudomonas strains, which may 
indicate high selection for its production and dispersal by HGT. However, early 
bioassay experiments revealed only weak antibiotic activity against a range of 
bacteria using traditional disc diffusion assays and complementary results were 
obtained in MIC testing (Wells et al., 1984; Tymiak et al., 1985). This is likely due to 
the reactivity of the molecule; 1 was found to bind to paper and is readily hydrolysed 
in methanolic or basic solutions, which may have confounded these early experiments 
by limiting diffusion and in not accurately reflecting the amounts assayed. Despite its 
inherent lability, 1 was shown to protect mice challenged with Streptococcus 
pyogenes (ED50 = 50 mg/kg by systemic administration), and caused cell elongation 
of E. coli cells treated with sub-lethal doses. Taken together, these experimental 
observations indicate that 1 operates in a specific manner, rather than as a general 
acylating agent, in keeping with specific activities exhibited by other β-lactone NPs 
(Kluge and Petter, 2010; De Pascale, 2011).  
 
This aim of this project is to dissect the biosynthetic pathway to 1 at the molecular 
level, with a particular focus on characterising the formation of two key structural 
features. The first is the unusual β-OH-α-AA precursor 2, and the second is the β-
lactone ring, which is derived from 2, and which is associated with NPs that are known 
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to be potent and specific inhibitors of many important protein targets. The subsequent 
sections of this Chapter develop our interests in these two moieties further.     
 
1.3.2 β-OH-α-AAs 
Despite the great structural diversity of biologically important NP scaffolds, several 
‘privileged’ structural motifs occur within them with high frequency. β-OH-α-AAs 
represent one of these, and are constituents and intermediates in the biosynthesis of 
many agriculturally and medicinally valuable bioactive NPs, as illustrated in Figure 
1.10. These building blocks are considered privileged because they often comprise 
more than one chiral centre on which a wealth of chemical diversity can be built, and 
because hydroxyl groups can serve as handles for further chemical modifications that 
introduce further beneficial properties or bioactivities (Süssmuth and Mainz, 2017).  
 
1.3.2.1 Synthesis  
β-OH-α-AAs are thus extremely useful units for synthetic purposes and L-threo-3,4-
dihydroxyphenylserine is itself a (pro)drug (Droxidopa) used in the treatment of 
Parkinson’s disease (Goldstein, 2006). Although many synthetic methods have been 
reported for their synthesis – including methods based on enolates (Kobayashi et al., 
2004), glycinamides (Seiple et al., 2014), glycine Schiff’s base (Trost and Miege, 
2014), and the aminohydroxylation of olefins (Liu et al., 2013) amongst others – these 
elegant methodologies often suffer from insufficient stereoselectivity, expensive 
precursors and/or the need for stoichiometric amounts of chiral auxiliaries (Steinreiber 
et al., 2007a). The production of β-OH-α-AAs by enzymatic means is thus highly 
desirable as it allows two stereocentres to be set in one single reaction, that can be 
performed in a one-pot process, with minimal protection of substrates and under mild 
aqueous conditions.  
 
Consequently, considerable effort has been put into developing L- and D-threonine 
aldolases (TAs) as biosynthetic tools for the generation of β-OH-α-AAs. TAs use the 
cofactor pyridoxal-5’-phosphate (PLP) to catalyse the retro-aldol cleavage of 
threonine to generate glycine and acetaldehyde. These enzymes supplement the role 
of serine hydroxymethyltransferase (SHMT), a key enzyme in the generation of C1 
units (formaldehyde) for tetrahydrofolate (THF)-dependent reactions, which cleave L-
serine via an analogous mechanism (Figure 1.11 - Schirch et al., 1985). Due to the 
reversibility of the retro-aldol reaction, TAs have been studied as potential 





Figure 1.10. Examples of β-OH-α-AA-comprising NPs. Moieties derived from β-





Figure 1.11. Reactions catalysed by SHMTs and TAs.  
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aldehydes and glycine (Dückers et al., 2010; Fesko and Gruber-Khadjawi, 2013; 
Fesko, 2016). Whilst very selective in terms of their donor glycine substrate, most 
TAs will accept a range of aliphatic and aromatic aldehydes as acceptor substrates, 
making them promising versatile biocatalysts (Fesko et al., 2008). However, despite 
great progress in the development of these enzymes, their utility remains limited due 
to only modest diastereoselectivity (highly selective for the α-carbon) and low 
synthetic yields (Fesko, 2016). An NP biosynthetic enzyme that has evolved to 
generate these building blocks efficiently with high stereoselectivity would thus 
represent an ideal alternative to these inefficient aldolases. 
 
1.3.2.2 β-OH-α-AAs in NP biosynthesis 
In NP biosynthesis, many β-OH-α-AAs are formed via the β-hydroxylation of 
proteinogenic L-amino acids. The glycopeptide antibiotic vancomycin, for example, 
comprises two β-hydroxytyrosine units in its peptide backbone (the 2R,3R-3-OH 
diastereomer at the C-2 position, and the 2S,3R-3-OH isomer at position C-6 – Figure 
1.10). β-Hydroxylation of tyrosyl-S-ACP is catalysed by the cytochrome P450 OxyD, 
following the activation and tethering of L-tyrosine to the A-PCP didomain protein 
VcmD. The use of aminoacyl-S-PCP intermediates as the substrates for P450 
monoxygenase-catalysed β-hydroxylation is a common mechanism for β-OH-α-AA 
generation in NPs. Further examples include the formation of β-hydroxytyrosine in 
aminocoumarin-containing angucycline antibiotics such as novobiocin (Chen and 
Walsh, 2001), β-hydroxyhistidine in nikkomycin biosynthesis (Chen et al., 2002), and 
β-hydroxytryptophan in echinomycin biosynthesis (Zhang et al., 2013) (Figure 1.10). 
In chloramphenicol, a nonheme diiron monooxygenase CmlA performs the role, 
catalysing the β-hydroxylation of its PCP-bound substrate 4-aminophenylalanine (4-
APA; 3) (Makris et al., 2010).  
 
Another mechanism of β-OH-α-AA biosynthesis in the context of specialised 
metabolism that has been reported is the reaction catalysed by L-threonine 
transaldolases (L-TTA). These enzymes are extremely rare and there are currently 
only two characterised examples: fluorothreonine transaldolase (FTase) and 
members of the LipK family of L-threonine:uridine-5′-aldehyde transaldolases 
(Murphy et al., 2001; Barnard-Britson et al., 2012). Like L-TAs these are PLP-
dependent enzymes that catalyse the cleavage of L-threonine to generate glycine and 
acetaldehyde (Figure 1.10). However, they are unique in that they subsequently 
catalyse C-C bond formation between the enzyme-bound glycine unit and an 
aldehyde substrate to yield β-OH-α-AA products. This results in the generation of  
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L-fluorothreonine in the case of FTase and an unusual 5′-C-glycyluridine (GlyU) unit 
for LipK and its homologues.  
 
Based on the results of isotope labelling studies described later in this introduction, it 
is unlikely that the assembly of 2 during the biosynthesis 1 is the result of a 
cytochrome P450-catalysed oxidation. Instead a thiamine diphosphate (ThDP)-
dependent mechanism has been proposed (Herbert and Knaggs, 1990) that is 
described in section 1.3.4 and would also preclude an L-TTA-mediated mechanism. 
However, these enzymes are revisited and discussed in further detail in Chapters 5 
and 6. The pathway to 2 thus potentially represents a completely new mechanism of 
β-OH-α-AA biosynthesis. 
 
1.3.2.3 Project outlook 
Identifying the biosynthetic mechanism by which 2 is generated is of interest for two 
key reasons. The first is that an enzyme involved in the biosynthesis of 2 may 
represent a valuable query for genome mining. P450 oxygenases belong to an 
enormous superfamily of oxidative enzymes that play widespread tailoring functions 
in NP biosynthetic pathways (Podust and Sherman, 2012). They are therefore likely 
to be limited as queries for genome mining efforts to identify further β-OH-α-AA-
containing NP BGCs due to high chances of generating false positive hits. The 
enzyme responsible for the biosynthesis of 2 could therefore be an ideal alternative if 
it represents a far more specific mechanism, and could be applied for the identification 
of further BGCs in which β-OH-α-AAs are similarly biosynthesised. 
 
The second reason is that current biocatalysts for the preparation of β-OH-α-AAs are 
not particularly efficient or stereospecific. Given the significance of 2 in formation of 
the β-lactone ring of 1, it is likely that the enzyme responsible is stereospecific to 
avoid the production of inactive products. It may thus represent an ideal candidate for 
development as a biocatalyst for both synthetic and industrial applications. If the 
enzyme responsible for the biosynthesis of 2 is permissive to alternate substrates, it 
might be possible to generate completely novel β-OH-α-AA building blocks and 
provide access to brand new chemical space. Depending on the mechanism, 
characterisation of such an enzyme might also create opportunities to search for, or 







The β-lactone structural motif occurs infrequently in nature but is associated with 
molecules possessing potent and valuable biological activities (Figure 1.12) (Kluge 
and Petter, 2010). They are highly electrophilic ring systems, readily susceptible to 
attack by nucleophilic protein amino acid residues (Figure 1.13). This makes them 
powerful acylating agents and they exhibit enormous therapeutic potential as highly 
effective, specific inhibitors of many important enzyme targets (De Pascale et al., 
2011). Given the impressive bioactivity of these ring-strained systems, they have 
arisen from multiple biosynthetic origins in nature. Subsequent sections cover several 
of the better genetically and biochemically characterised examples of these 
molecules, describing their biological targets and diverse biosynthetic pathways, with 
a focus on the variety of proposed mechanisms of β-lactone formation. 
 
1.3.3.1 Ebelactones 
The ebelactones are produced by Streptomyces aburaviensis and have been shown 
to be inhibitors of several important protein targets including esterases (Umezawa et 
al., 1980), lipases (Nonaka et al., 1996), cutinases (Koller et al., 1990), homoserine 
transacetylase (De Pascale et al., 2011) and cathepsin A (Ostrowska et al., 2005). In 
the case of homoserine transacetylase, inhibition is mediated by covalent 
modification of an active site serine residue (De Pascale et al., 2011).  
 
This surprisingly broad range of enzyme targets triggered interest in this group of 
compounds and their biosynthesis, and the BGC was finally identified in 2013. The 
compound is assembled across a PKS composed of six modules, each with a KS 
domain for chain elongation. KR, DH and ER domains present are almost all correctly 
placed to perform the necessary processing of the growing chain to introduce β-
hydroxy, alkene and methylene groups (Wyatt et al., 2013 - Figure 1.14). Module 1 
comprises a characteristic KSQ domain which loads malonyl-CoA before 
decarboxylating the malonyl-enzyme product to yield an acetate starter unit (Bisang 
et al., 1999). All other AT domains have specificity for methylmalonyl-CoA, again 
consistent with the final structure. One noncanonical element of ebelactone 
biosynthesis is in the organisation and use of module 4. Its cognate domains are split 
across three genes ebeDEF and it is anticipated to be used twice. In the first round, 
only the KS is used, leaving the required ketone intact. In the second iteration, the KS 
is used again but the growing chain is now processed by the discrete DH EbeE and 












Figure 1.13. General mechanism of β-lactone acylation. An active site nucleophile 
(serine represented) attacks the β-lactone ring ester to generate a covalently bound 












Figure 1.14. Biosynthetic model and BGC for ebelactone. Shown are the putative 
genes for ebelactone biosynthesis and the corresponding PKS assembly line. 
Downstream genes of possible biosynthetic relevance are shown although their 
putative functions are not required in the final maturation of ebelactone. These include 
an A domain, a reductase (Re), and a hypothetical protein (Hyp). Tethered PK 
intermediates are shown on the ebelactone assembly-line. The proposed ebelactone 
release mechanism through β-hydroxy attack is illustrated. T = thiolation (ACP) 











Intriguingly, there is no terminal TE domain to catalyse β-lactone ring formation and 
product release (Figure 1.14), and the spontaneous cyclisation of the final β-ketoacyl-
S-ACP intermediate was proposed, though this reaction would be energetically 
disfavoured. Alternatively, a terminal KS domain could potentially perform a catalytic 
role, but was suggested instead to be an artefact of the ‘original’ NP PKS in which the 
remaining modules have been lost following derailment by chemical cyclisation 
(Wyatt et al., 2013). Recently however, the β-lactone synthetase OleC involved in 
olefin biosynthesis, was shown biochemically to catalyse the cyclisation of syn and 
anti-β-hydroxy acid substrates to yield cis- and trans-β-lactone olefin intermediates 
(Christenson et al., 2017- Figure 1.15a). An oleC homologue (46% identity), orf1, was 
identified immediately adjacent to the ebelactone BGC (Figure 1.15b) and currently 
represents the most likely candidate for β-lactone ring formation. 
 
1.3.3.2 Lipstatin 
Lipstatin, first isolated from Streptomyces toxitricini (Weibel et al., 1987), is a highly 
potent irreversible inhibitor of human pancreatic lipase. It comprises a 2,3-trans-
disubstituted β-propiolactone with two linear alkyl chains (α-site C-6, β-site C-13). 
Tetrahydrolipstatin (Orlistat), a saturated derivative of lipstatin, inhibits mammalian 
lipases via covalent binding to an active site serine residue (Hadváry et al., 1991). 
The β-lactone ring is critical for enzymatic inhibition, as opening it leads to the 
complete loss of lipase inhibitory activity (Stadler et al., 1992). Today, it remains the 
only currently available FDA-approved oral drug (Xenical) for long-term treatment of 
obesity, mediated via control of diabetes (Torgerson et al., 2004; Kang and Park, 
2012). It also exhibits antitumor activity via inhibition of FAS TE domains in tumour 
cells (Kridel et al., 2004). Other natural homologues include the panclicins (Yoshinari 
et al., 1994), valilactone (Kitahara et al., 1987) and esterastin (Umezawa et al., 1978; 
Kondo et al., 1978), which differ only in the structure of their side chains and the 
nature of their linked amino acids. 
 
In silico analysis of the putative lipstatin BGC combined with the results of stable 
isotope and deuterium labelling experiments allowed a hypothetical pathway to be 
proposed (Eisenreich et al., 1997; 2003; Goese et al., 2000; 2001; Schuhr et al., 2002; 
Bai et al., 2014 – Figure 1.16). In the first committed step, Claisen condensation 
between 3-hydroxytetradeca-5,8-dienoyl-CoA and hexyl-malonyl-CoA, both derived 
from linolenic acid, yields the C22 α-branched fatty acid backbone. Subsequent 
carboxylation by an unidentified acyl-CoA carboxylase, generates hexyl-malonyl-











Figure 1.15. Illustration of β-lactone ring formation catalysed by OleC. (a) 
Illustration of the ole BGC and enzymatic pathway. (b) Homologous OleC enzymes 
encoded in the ebelactone and lipstatin BGCs. Percent identity is based on amino 
acid sequences. Adapted with permission from Christenson et al. (2017) Biochemistry 

















Figure 1.16. Biosynthetic model for lipstatin. Bai et al., (2014) - Reproduced with 










LstAB, β-ketoacyl-ACP synthase III FabH homologues, are proposed to subsequently 
decarboxylate hexyl-malonyl-CoA and catalyse condensation with 3-
hydroxytetradeca-5,8-dienoyl-ACP to afford a 3-keto-5-hydroxy-C22-ACP 
intermediate. A monomodular NRPS LstE activates and tethers L-leucine which is 
formylated by the formyltransferase LstF. The LstE C domain is then thought to 
catalyse nucleophilic attack of the 5-hydroxyl group of the 3-keto-5-hydroxy-C22-ACP 
intermediate on the acyl carbon of formyl leucine-S-PCP, by an analogous 
mechanism to AT reactions. 
 
The β-lactone ring was initially proposed to form spontaneously by attack of the 3-
hydroxy group on the carbonyl of the resulting ACP-tethered intermediate, following 
LstD (a 3-hydroxysteroid dehydrogenase/isomerase homologue)-catalysed reduction 
of the 3-keto group. However, like ebelactone, an oleC homologue (lstC) was 
identified in the lst BGC (Christenson et al., 2017 – Figure 1.15b), indicating an 
energetically more favourable catalytic route to β-lactone ring formation, but in a 
completely different BGC context.  
 
1.3.3.3 Salinosporamides and analogues 
The γ-lactam-β-lactone NP family are highly potent inhibitors of the 20S proteasome, 
the key proteolytic component of the ubiquitin-mediated protein degradation pathway 
(Groll et al., 2005). They include the salinosporamides, cinnabaramides and 
omuralide, which all share an ortho-fused γ-lactam-β-lactone bicyclic ring system core 
structure, but differ in the groups attached at the C-2, C-3 and C-5 positions (Figure 
1.12). They all undergo the same initial reaction step with their target in which the N-
terminal threonine residue of the 20S proteasome catalytic β5-subunit attacks the β-
lactone ring, resulting in the formation of a covalent ester linkage (Groll et al., 2006a). 
Binding is made irreversible in the case of salinosporamide A by a subsequent 
reaction in which the β-lactone-derived C-3 hydroxyl group reacts with a chlorinated 
C-2 side chain leaving group. This yields a tetrahydrofuran adduct that is stable to 
water hydrolysis. Omuralide is only a slow reversible inhibitor, in which the 5-hydroxy 
group of the opened β-lactone ring acts to displace water from the active site and 
prevent it from re-entering (Shah et al., 2002). This highlights the importance of the 
rest of the molecule in determining β-lactone inhibitory specificity and efficacy. 
Salinosporamide A (Marizomib) thus has enhanced potency (IC50 value of 1.3 nM vs 
49 nM for omuralide) and is currently in phase I human clinical trials for the treatment 
of multiple myeloma (Feling et al., 2003; Harrison et al., 2016). Structurally similar 
NPs include vibralactone (Liu et al., 2006) and ostalactone (Kang and Kim, 2016) 
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from the basidiomycetes Boreostereum vibrans and Stereum ostrea respectively, 
though these lack the γ-lactam functionality in their 4/5 fused ring systems and appear 
to be more potent inhibitors of lipases. 
 
Salinosporamide A was discovered in 2003 from the marine actinomycete 
Salinospora tropica CNB-392, which was subsequently found to produce several 
other salinosporamide analogues (Feling et al., 2003). It is assembled by a mixed 
PKS/NRPS system that is focussed around two key megasynth(et)ase-encoding 
genes, salAB (Figure 1.17 - Udwary et al., 2007; Eustáquio et al., 2009). SalA is a 
dimodular PKS with an unusual domain organisation that comprises continuous 
loading and extender AT domains. The loading ATL domain is of the type that 
recognises monocarboxylic acid starter units and is proposed to use acetyl-CoA to 
form an ACP-bound intermediate. Phylogenetically, the AT1 domain is placed in the 
methylmalonyl-CoA accepting-group and contains a distinct signature motif that is 
consistent with it accepting an unreported extender unit. In salinosporamide A, this is 
chloroethylmalonyl-CoA which is the product of eight enzymatic steps catalysed by 
the products of salGHLMNQST (Eustáquio et al., 2008). However, the detection of 
analogues with different side chains at C-2 points to a degree of promiscuity in this 
AT domain (Liu et al., 2009). The SalA KS1 domain presumably catalyses Claisen 
condensation between the two tethered substrates before the terminal C2 domain 
catalyses peptide bond formation between their condensation product and 3-
cyclohex-2’-enylalanine, which is activated by and tethered to the A2-PCP didomain 
NRPS SalB (Figure 1.17).  
 
There is no OleC homologue associated with the sal BGC, indicating a completely 
different mechanism for β-lactone ring formation in this family of NPs. The discrete 
TE SalF would be a candidate to catalyse ring closure, as would its homologue cinE 
in biosynthesis of cinnabaramide (using a β-hydroxyacyl-enzyme substrate - Rachid 
et al., 2011), however it has been suggested that these TEs instead perform an 
editing role to remove stalled pathway intermediates. An alternate hypothesis is that 
a spontaneous tandem aldol-lactonisation leads to ring formation in salinosporamide 
A (Gulder and Moore, 2010), however no mechanism has been experimentally 
validated. 
 
1.3.3.4 Oxazolomycin and analogues 
Oxazolomycin A from Streptomyces albus JA3453 (Mori et al., 1985) also comprises 















Figure 1.17. Biosynthetic model and BGC for salinosporamide A. Genes 
putatively involved in the chloroethylmalonyl-CoA pathway (red), construction of the 
core γ-lactam-β-lactone ring system (grey), assembly of the nonproteinogenic amino 
acid L-3-cyclohex-2′-enylalanine (blue), regulation and resistance (yellow), unknown 
(white), and 2 partial transposases (black) are color-coded. Eustáquio et al., (2009) – 
Adapted with permission from the Proceedings of the National Academy of Sciences 











spiro-linked (Figure 1.12). The structure is also characterised by a 5-substituted 
oxazole ring, an (E, E)-diene, and a (Z, Z, E)-triene chain. The producing strain 
synthesises two other geometrical isomers B and C that differ only in the configuration 
of the triene moiety (E, E, E and Z, E, E respectively) (Kanzaki et al., 1998). Other 
family members include 16-methyloxazolomycins KSM-26908 and KSM20906 (Otani 
et al., 2000), triedimycins (curryomycins) A and B (Ikeda et al., 1991; Ogura et al., 
1985), inthomycins (phthoxazolins) A-C (Henckel and Zeeck, 1991; Shiomi et al., 
1995), neooxazolomycin (Takahashi et al., 1985), and the lajollamycins (Manam et 
al., 2005; Ko et al., 2014). This family of compounds, all derived from various 
Streptomyces sp. strains, have been shown to exhibit diverse antibacterial, antitumor, 
anti-HIV and even antiviral activities (Nakamura et al., 1994; Zhao et al., 2006; 
Bagwell et al., 2008). 
 
Isotope labelled feeding experiments established that oxazolomycin is derived from 
three glycine and nine acetate molecules, and that all five C-methyl groups, the O-
methyl group and the N-methyl group are derived from L-methionine (Zhao et al., 
2006). Biochemical and genetic analysis indicated that the C3-C4 unit is derived from 
a metabolic intermediate of the glycolytic pathway, which serves as a precursor of an 
unusual methoxymalonyl-ACP extender unit in the biosynthesis of several PK NPs 
(Wu et al., 2000; Ligon et al., 2002; Yu et al., 2002; Rascher et al., 2003; Li et al., 
2006). Using these experimental observations, the ozm BGC was identified (Zhao et 
al., 2010 - Figure 1.18), and features trans-AT PKSs (OzmJKMNQ), NRPSs (OzmO 
and L) and a hybrid NRPS-PKS megasynthase (OzmH). Biosynthesis is proposed to 
be initiated by OzmO, an NRPS loading module comprising canonical A and PCP 
domains, as well as an N-terminal formylation domain, to activate, tether and 
formylate glycine to generate formyl-glycyl-S-PCP. This moiety is later cyclised to 
form the oxazole ring. This intermediate is then hypothesised to be transferred 
sequentially to OzmQ, N, H, J, K and L, where condensation of five malonyl-CoAs, a 
glycine, three malonyl-CoAs, a methoxymalonyl-ACP, a malonyl CoA and an L-serine 
occurs, in addition to C- and N- methylation events.  
 
Oxazolomycin likely represents yet another mechanism of β-lactone ring formation. 
The final module of OzmL contains a terminal C domain that is proposed to be 
responsible for concomitant formation of the spiro-linked γ-lactam-β-lactone moiety 
and release of the final product, as a TE domain is absent from this termination 
module (Figure 1.18). This terminal C domain lacks a full catalytic triad for peptide 






Figure 1.18. Biosynthetic model and BGC for oxazolomycin. (a) OzmM consists 
of the cryptic AT1 and active AT2 domains that transfer two extender units (malonyl-
CoA and methoxymalonyl-ACP) onto corresponding ACPs (OzmC is also involved). 
(b) Proposed pathway for methoxymalonyl-ACP extender unit biosynthesis 
in ozm gene cluster. Zhao et al., (2010) - Reproduced with permission from the 





and Cy domains (Zhao et al., 2010). As described previously, the latter is responsible 
for the cyclisation of either cysteine, serine or threonine residues to generate 
thiazoline or oxazoline rings. This C domain is therefore hypothesised to catalyse 
cyclisation of the oxazolomycin serine side chain to form the β-lactone ring. 
 
1.3.3.5 Belactosins and cystargolides 
As a final example, the belactosins and cystargolides represent a family of β-lactones 
which, like the ortho-fused γ-lactam-β-lactones, are proteasome inhibitors that 
mediate their effects through covalent binding to the proteasome β5-subunit (Asai et 
al., 2000; Groll et al., 2006b). Both consist of an N-acylated dipeptide and a 2-
carboxy-3-alkyl β-lactone moiety, but slightly different dipeptide backbones (Figure 
1.12). However, sequencing of the cystargolide-producer Kitasatospora cystarginea 
NRRL B16505 genome by Wolf et al. (2017) did not reveal any NRPS BGCs of the 
predicted size and specificity. Feeding experiments with [13C5]-labelled L-valine 
revealed the incorporation of ten and fifteen carbons in cystargolides A and C 
respectively. Subsequent feeding with [1,2-13C2]-labelled acetate indicated the 
incorporation of five carbons from L-valine and two from acetate in the β-lactone 
moiety of both analogues, suggesting the product is the result of a condensation 
reaction between a valine metabolite and acetate. The BGC was finally identified 
based on the presence of two isopropylmalate synthases (IPMSs) present within the 
cluster. In L-leucine biosynthesis, these enzymes catalyse Claisen-type 
condensations between acetyl-CoA and α-ketoisovalerate, a degradation product of 
L-valine, to generate 2-isopropylmalate (2-IPM). The belactosin BGC was similarly 
identified in the genome sequence of its producer Streptomyces sp. UCK 14. 
 
Based on a combination of in silico and biochemical data, analogous 4-step routes to 
β-lactone ring formation in both NP biosynthetic pathways were proposed (Wolf et al., 
2017 - Figure 1.19). First, the IPMS homologue CysA generates 2-IPM as described 
above – in belactosin biosynthesis BelJ, also an IPMS homologue, uses 2-keto-3-
methylvalerate (an intermediate of isoleucine metabolism), instead of α-
ketoisovalerate, to generate 2-(sec-butyl)-2-hydroxysuccinic acid. In the cystargolide 
pathway 2-IPM is isomerised to 3-IPM, presumably by primary metabolic enzymes, 
where in belactosin, this function is suggested to be provided by BelF and/or BelG 
(isopropylmalate dehydratase homologues). Putative SAM-dependent 
methyltransferases CysG and BelR are then proposed to form methyl esters of 3-IPM 
and 3-(1-methylpropyl)malate respectively, thereby generating intermediates to 










Figure 1.19. Biosynthetic models for belactosin C and cystargolide A. Wolf et al. 










acyl-CoA ligases CysC and BelV could activate the appropriate carboxylic acids for 
lactonisation. Putative esterases CysE and BelR are then thought to be responsible 
for supporting intramolecular esterification and cyclisation (Wolf et al., 2017). The 
dipeptide backbones of both molecules are hypothesised to be assembled by ATP-
grasp ligases CysD and BelU. These enzymes have only recently been shown to be 
involved in amide bond formation in NP biosynthesis (Dawlaty et al., 2010; Noike et 
al., 2015; Ooya et al., 2015), traditionally playing roles in primary metabolism such as 
in fatty acid, glutathione and cell wall biosynthesis (Fawaz et al., 2011). 
 
1.3.3.6 Terpenoid β-lactones 
Given that β-lactones interact so readily and effectively with their protein targets, it is 
perhaps unsurprising that multiple biosynthetic routes to their generation have arisen 
in nature. Other NP examples not described here include the 3-hydroxy-3-
methylglutaryl-CoA synthase inhibitor hymeglusin (Greenspan et al., 1987; Skaff et 
al., 2012) and the Hsp70 inhibitor novolactone (Hassan et al., 2014), both of fungal 
origin, the rubesanolides (Zou et al., 2011; 2012) and veranisatin (Yin et al., 2012) 
from the plant species Isodon rubescens and Illicium simonsii respectively, and 
spongiolactone from the Mediterranean sponge Spongionella gracilis (Mayol et al., 
1987) (Figure 1.12). All but hymeglusin appear to be of terpenoid origin, derived from 
the C5 building block isopentenyl pyrophosphate (IPP), which indicates that further 
mechanisms of β-lactone ring formation remain to be characterised. However, these 
examples are yet to be studied biosynthetically. 
 
1.3.3.7 Potential of synthetic β-lactones 
Considerable effort has also been put into generating synthetic β-lactones either to 
improve potency of naturally occurring compounds, to improve drug-like 
characteristics, or for use as building blocks for the biosynthesis of other synthetic 
molecules (Soucy et al., 1999; Yang and Romo, 1999; Schneider, 2002). Stefan 
Sieber and his lab were able to employ the reactivity of the β-lactone ring in activity-
based protein profiling (ABPP) efforts to identify new therapeutic targets and to gain 
a deeper understanding of the molecular mechanisms governing pathogenesis 
(Böttcher and Sieber, 2012). By generating a synthetic library of β-lactones inspired 
by naturally occurring compounds, and comprising an alkyne tag, they could probe 
the proteomes of Gram-positive and Gram-negative strains related to pathogenic 
strains, and identified many interesting cellular targets (Böttcher and Sieber, 2008a; 
2008b). Among these was the virulence associated protease ClpP, known to control 
the regulation of many virulence factors including hemolysins, proteases and 
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DNAses, and to which their β-lactone probes were bound via an active site serine 
residue. Probes were shown to be potent ClpP inhibitors, leading to attenuated 
virulence determinant production in both S. aureus and L. monocytogenes, and could 
be made more potent by altering C-2 and C-3 side chain substituents (Böttcher and 
Sieber, 2008a; 2008b; 2009a; Gersch et al., 2013). This work illustrates the enormous 
potential of synthetic β-lactones for the inhibition of novel biological targets, and 
reiterates the significance of stereochemical configuration and side chain composition 
in determining their specificity and potency.  
 
1.3.3.8 Project outlook 
Identifying new enzymes and mechanisms for the biosynthesis of β-lactones has 
important implications for synthetic biology approaches to generate novel protein 
inhibitors. Characterisation of the mechanisms employed during the biosynthesis of 
1 may provide a novel route by which these biologically active moieties can be 
synthetically introduced into new metabolites. Furthermore, if unique, the mechanism 
might also provide a suitable query for genome mining efforts to identify further β-
lactone NPs. The bioactivity conferred upon 1 by comprising such a reactive 
electrophilic moiety, and the influence the aromatic side chains have on governing 
target specificity and bioactivity, are also of interest, particularly given the number and 
distribution of isolated 1-producers identified by Wells et al. (1984). Therefore, 
investigating the bioactivity and mechanism of action for 1 is also within the scope of 
this project. Nature has found multiple biosynthetic routes to incorporate these 
moieties into highly bioactive metabolites, indicating that the presence of a β-lactone 
ring in 1 is unlikely to be trivial. This is particularly so given that the pathway has 
evolved to utilise an unusual β-OH-α-AA to generate it. 
 
1.3.4 Preliminary investigations of obafluorin (1) biosynthesis 
The presence of such a bioactive moiety and its potentially unique biosynthetic origins 
prompted chemical investigations to determine the likely biosynthetic pathway to 1. 
Stable isotope feeding experiments performed on the 1-producing strain P. 
fluorescens ATCC 39502 in the late 1980s and early 1990s allowed the proposition 
of a likely pathway and form the foundations for the work described in this thesis 
(Herbert and Knaggs, 1988; 1990; 1992a; 1992b).  
 
Initial inspection of the structure of 1 indicated that the two aromatic rings, and at least 
some of the other C atoms, have their origins in the shikimic acid pathway (Knaggs, 
2003). The 2 moiety is analogous to that seen in chloramphenicol (Figure 1.10), 
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though its side chain is distinguished in comprising one additional C atom. 13C NMR 
analysis of initial experiments supplementing production cultures with D-[U-
13C]glucose, generated coupling constants for the two aromatic rings consistent with 
an origin in the shikimic acid pathway via chorismate (Herbert and Knaggs, 1992a - 
Figure 1.20). The pattern observed for C-3 through C-10 is that expected of 
biosynthesis from an aromatic amino acid such as 3, which is also a precursor in the 
biosynthesis of chloramphenicol and pristinamycins I and II (Blanc et al., 1997; He et 
al., 2001). Consistent with this, cultures fed L-[2,6-3H2]3 revealed it to be an excellent 
precursor for 1 (10.3% specific incorporation), whereas L-[2,6-3H2]4-
nitrophenylalanine and L-[2,6-3H2]4-phenylalanine were both poor precursors 
(Herbert and Knaggs, 1988). 1 production cultures were also found to accumulate 4-
nitrophenylethanol (4-NPE; 4) and 4-nitrophenylacetic acid (4-NPAA; 5) as co-
metabolites, suggesting they might be intermediates between 3 and 2. However, 
neither [2-2H2]4 nor [2-2H2]5 were incorporated into 1. The involvement of the CoA 
ester of 5 was also ruled out (Herbert and Knaggs, 1990). DL-[2,3-2H3]3 was also an 
excellent precursor to 1, but loss of deuterium at the C-2 position indicated that this 
carbon originates from an alternative source. 
 
Glycine was identified as a prime candidate to provide the C-1 and C-2 carbons 
(Herbert and Knaggs, 1990). Using ‘resting’ P. fluorescens cells in MES buffer, 
supplementation with the precursors 2,3-DHBA (6), 3 and [2-13C]glycine showed the 
expected enhancement of the C-2 signal in 13C NMR experiments and no product 
was observed in the absence of any of the precursors. However, enhancement of the 
signal for the C-1 unit was also detected and both C-1 and C-2 units had doublets 
associated with them. A small amount of enrichment was also detected for the C-3 
and C-4 units (Herbert and Knaggs, 1990). Whilst the use of ‘resting cells’ was applied 
to minimise the effect of precursor channelling into primary metabolism, these results 
can be explained by the use of glycine as a growth source via the glyoxylate and 
tartronic semialdehyde pathways: the incorporation of two 13C units into tartronic 
semialdehyde given the levels of [2-13C]glycine supplemented would be likely, and 
glyoxylate subsequently generated from acetyl-CoA in the glyoxylate pathway  would 
be doubly labelled as a result (Figure 1.21). Similarly, labelled C-3 and C-4 signals 
would arise from doubly labelled phosphoenolpyruvate, the substrate of deoxy-D-
arabino-heptulosonate-7-phosphate (DAHP) synthase which is the first enzyme in the 











Figure 1.20. Illustration of interpreted results from D-[U-13C]glucose and L-[2,6-
3H2]4-aminophenylalanine feeding experiments conducted by Herbert and 









Figure 1.21. The tartronic semialdehyde pathway. 13C atoms are labelled to 
illustrate how they can be introduced at both the C-1 and C-2 positions in glyoxylate 
in P. fluorescens cultures fed [2-13C]glycine, consistent with the 13C NMR results 





Figure 1.22. Decarboxylative ThDP-dependent mechanism for the biosynthesis 




Based on their experimental data, Herbert and Knaggs proposed a mechanism for 
the biosynthesis of 2 involving a ThDP-mediated condensation to catalyse C-C bond 
formation between glyoxylate and either 4-aminophenylpyruvic acid (4-APP; 7) or 4-
nitrophenylpyruvic acid (4-NPP; 8), the transamination product of 3 (Figure 1.22 - 
Herbert and Knaggs, 1990). This mechanism was favoured based on the observation 
of deuterium loss from the C-2 of deuterated 3, and the existence of analogous ThDP-
catalysed condensations in yeast and Ephedra gerardiana (Grue-Sørensen & 
Spenser, 1988; 1989; Shin and Rogers, 1995). The product of this anticipated ThDP-
dependent condensation reaction would be an acyloin intermediate that would need 
to undergo further tautomerisation and transamination to generate 2 (Figure 1.22). 
(2S,3R)-2-amino-3-hydroxy-4-(4’-aminophenyl)butanoate (AHAB; 9) could also be 
the product depending on when the nitro group of 1 is introduced. Alternative 
schemes proposed by Herbert and Knaggs involved 4-aminophenylacetaldehyde as 
the substrate instead of 7, or the ThDP-derivative of glyoxylate reacting with either 4-
aminophenylacetaldehyde or 5, but these schemes lack supporting analogies. 
 
1.3.4.1 Project outlook 
The ThDP-dependent mechanism proposed by Herbert and Knaggs makes a 
mechanism-guided genome mining strategy particularly appealing because it would 
represent a novel pathway to β-OH-α-AAs. ThDP-dependent enzyme and 
transaminase queries, coupled with a query for peptide assembly (e.g. NRPS), might 
provide a ‘fingerprint’ for the identification of further NP BGCs encoding unusual 
nonproteinogenic amino acid precursors and novel chemistry.  
 
Furthermore, in the absence of tautomerisation (or using a transaminase that has α-
hydroxy-β-keto acyloin tautomer substrate specificity), a similar mechanism could be 
envisaged for the biosynthesis of α-hydroxy-β-amino acids (α-OH-β-AAs), expanding 
the potential chemical space accessible using a mechanism-guided approach. These 
building blocks are rarer in nature but when present are also associated with bioactive 
NPs, such as the anticancer agents bleomycin and taxol, and the cytotoxin 
microcystin (Kudo et al., 2014). In addition to introducing multiple stereocentres, α-
OH-β-AAs offer greater stability to peptides that comprise them as they are less often 
recognised by protease-type hydrolases. The aminopeptidase inhibitors amastatin 
(Aoyagi et al., 1978) and bestatin (Ubenimex) (Umezawa et al., 1976) represent ideal 
candidate NPs to validate a mechanism-guided genome mining approach, as both 
comprise α-OH-β-AA moieties (Figure 1.23), but neither have been characterised at 



















Figure 1.23. Structures of amastatin and bestatin. α-OH-β-AA moieties are 


















might be able to better explore the chemical space locked away in the genomes of 
microorganisms in a directed manner, enriching for NPs that likely comprise novel 
chemistry and thus may interact with novel biological targets. By discovering more of 
these biosynthetic enzymes, and identifying appropriate transaminase partners, a 
significant contribution can be made to the synthetic toolbox for the preparation of 
highly privileged nonproteinogenic amino acid building blocks. 
 
1.4 Project objectives 
 
1. Delineate the biosynthetic pathway of 1 at the molecular level  
2. Biochemically characterise the biosynthetic enzyme(s) responsible for the 
biosynthesis of 2 and assess its potential utility as a biocatalyst 
3. Biochemically characterise the mechanism of β-lactone ring formation 
4. Identify the biological target of 1 and characterise its mechanism of interaction 
5. Explore the potential for mechanism-guided genome mining/characterise α-






















Chapter 2: Materials and methods 
 
2.1 General materials 
Reagents and chemicals were purchased from Alfa-Aesar, Sigma-Aldrich, Santa 
Cruz Biotechnology Inc., Amatek Chemical Co., Ltd., and BD Biosciences, and were 
used without further purification. All solvents used for HPLC were obtained from 
Fisher Scientific (at least of HPLC grade) and were filtered before use. 
 
Commercially available enzymes, reagents, DNA purification kits and size markers 
for DNA and protein work used in this study are listed in Table 2.1. 
 
Supplier Enzymes and kits 
Invitrogen™ (Thermo Fisher Scientific), Paisley, UK DNA polymerase I, Large (Klenow) fragment 
New England Biolabs®, Ipswich, UK 1 kb DNA ladder 
Colour Prestained Protein Standard, Broad 
Range (11-245 kDa) 
Gibson Assembly® Master Mix 
Q5® High-Fidelity DNA polymerase 
T4 DNA ligase 
Promega, Southampton, UK GoTaq® G2 Green Master Mix 
RNAse ONE™ Ribonuclease 
Wizard® SV Gel and PCR product Clean-Up 
System 
Wizard® Plus SV Minipreps DNA purification 
System 
Roche, Burgess Hill, UK Deoxynucleoside Triphosphate (dNTPs) Set 
PCR Grade 
rAPid Alkaline Phosphatase 
Table 2.1. Lab consumables used in this work 
 
2.2 Bacterial strains, plasmids and oligonucleotides 
2.2.1 Bacterial strains 
Bacterial strains used in this study are listed in Table 2.2. All strains were maintained 




Plasmids used and constructed in this study are listed in Table 2.3. 
 
2.2.3 Oligonucleotides and primers  





Strain Description/Genotype Reference 
B. subtilis EC 1524 Bioassay strain; trpC2, Subtilin BGC 
deleted 
O'Rourke et al., 
2017 
E. coli ATCC 25922 Bioassay strain; WT ATCC, USA 
E. coli ATCC 25922 pJH10TS-
obaO 
 
ATCC 29522 carrying a WT copy of the 
obaO gene as a BmtI-KpnI fragment 




E. coli DH5α 
 
Cloning strain; Fˉ, endA1, glnV44, thi-1, 
recA1, relA1, gyrA96, deoR, nupG, 
ϕ80dlacΔ(lacZ)M15, Δ(lacIZYA-
argF)U169, hsdR17(rK- mK+), λ– 
Hanahan, 1983 
 
E. coli NiCo21(DE3):pLysS 
 
Expression strain; can::CBD, fhuA2, [lon] 
ompT, gal (λ DE3) [dcm] arnA::CBD, 
slyD::CBD, glmS6Ala, ΔhsdS λ DE3 = λ 
sBamHIo ΔEcoRI-B int::(lacI::PlacUV5::T7 









NiCo21(DE3):pLysS carrying a WT copy 
of the obaC gene as an NdeI-XhoI 
fragment for production of the ObaC 
protein with an N-terminal hexahistidine 







NiCo21(DE3):pLysS carrying a WT copy 
of the obaG gene as an NdeI-XhoI 
fragment for production of the ObaG 
protein with an N-terminal hexahistidine 







NiCo21(DE3):pLysS carrying a WT copy 
of the obaH gene as an NdeI-XhoI 
fragment for production of the ObaH 
protein with an N-terminal hexahistidine 







NiCo21(DE3):pLysS carrying a WT copy 
of the obaI gene as an NdeI-XhoI fragment 
for production of the ObaI protein with an 







NiCo21(DE3):pLysS carrying a copy of the 
obaI gene with a C1141A substitution as 
an NdeI-XhoI fragment for production of 
the ObaI C1141A protein with an N-






NiCo21(DE3):pLysS carrying a WT copy 
of the obaK gene as an NdeI-XhoI 
fragment for production of the ObaK 
protein with an N-terminal hexahistidine 







NiCo21(DE3):pLysS carrying a WT copy 
of the E. coli thrRS gene as an NdeI-XhoI 
fragment for production of the ThrRS 
protein with an N-terminal hexahistidine 






NiCo21(DE3):pLysS carrying a copy of the 
E. coli thrRS gene with a C480V 
substitution as an NdeI-XhoI fragment for 
production of the ThrRS C480V protein 
with an N-terminal hexahistidine tag in 
pET28a(+) 
This work 
E. coli NR698 
 
Bioassay strain; MC4100 (F- araD139 
Δ(argF-lac)U169, rpsL150, relA1, 
flbB5301, deoC1, ptsF25, rbsR), imp4213 
Ruiz et al., 2005 
 
E. coli NR698:pJH10TS-obaO 
 
NR698 carrying a WT copy of the obaO 
gene as a BmtI-KpnI fragment cloned into 





E. coli S17-1 λ(pir) 
 
Conjugation strain; recA, thi, pro, hsd(R- 
M+)RP4: 2- Tc::Mu- Km::Tn7 λpir SMR TpR    
Simon et al., 1983 
 
P. fluorescens ATCC 39502 Obafluorin-producing strain, WT ATCC, USA 
P. fluorescens ΔobaC ATCC 39502 with an in-frame truncation in 






ΔobaC strain carrying a WT copy of the 
obaC gene as a BmtI-KpnI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
 
P. fluorescens ΔobaF 
 
ATCC 39502 with an in-frame truncation in 
the obaF gene 
This work 




ΔobaF strain carrying a WT copy of the 
obaF gene as a BmtI-KpnI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
 
P. fluorescens ΔobaG 
 
ATCC 39502 with an in-frame truncation in 






ΔobaG strain carrying a WT copy of the 
obaG gene as a BmtI-KpnI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
 
P. fluorescens ΔobaH ATCC 39502 with an in-frame truncation in 





ΔobaH strain carrying a WT copy of the 
obaH gene as a BmtI-XbaI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
 
P. fluorescens ΔobaI 
 
ATCC 39502 with an in-frame truncation in 
the obaI gene 
This work 
 
P. fluorescens  
ΔobaI:pJH10TS-obaI 
 
ΔobaI strain carrying a WT copy of the 
obaI gene as a BmtI-XbaI fragment cloned 
into pJH10TS for complementation by 
expression in trans 
This work 
 
P. fluorescens ΔobaJ 
 
ATCC 39502 with an in-frame truncation in 





ΔobaJ strain carrying a WT copy of the 
obaJ gene as a BmtI-KpnI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
 
P. fluorescens ΔobaK 
 
ATCC 39502 with an in-frame truncation in 






ΔobaK strain carrying a WT copy of the 
obaK gene as a BmtI-KpnI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
 
P. fluorescens ΔobaL 
 
ATCC 39502 with an in-frame truncation in 
the obaL gene 
This work 
 
P. fluorescens  
ΔobaL:pJH10TS-obaL 
 
ΔobaL strain carrying a WT copy of the 
obaL gene as a BmtI-XbaI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
P. fluorescens ΔobaM 
 
ATCC 39502 with an in-frame truncation in 







ΔobaM strain carrying a WT copy of the 
obaM gene as a BmtI-XbaI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
 
P. fluorescens ΔobaO 
 
ATCC 39502 with an in-frame truncation in 






ΔobaO strain carrying a WT copy of the 
obaO gene as a BmtI-KpnI fragment 
cloned into pJH10TS for complementation 
by expression in trans  
This work 
 
Table 2.2. Strains used in this work 
 
Plasmid Genotype/description Reference 
pET28a(+) 
 
Expression vector; KanR, the transcription of the cloned gene 
is driven by the T7 RNA polymerase and controlled by the 
LacI repressor, ColE1 replicon 
Novagen 
 
pME3087 Suicide vector; ColE1 replicon, IncP-1, Mob; TcR Voisard et al., 1994 
pTS1 
 
pME3087 modified with a sacB gene for counter-selection 




Vector for complementation studies by in trans expression in 
P. fluorescens ATCC 39502 Δ strains; pOLE1 with IncC1 
deleted, EcoRI-SacI polycloning site, TcR from pDM1.2 
El-Sayed et al., 2003 
pJH10TS pJH10 modified with an expanded cloning site This work 
pLysS Vector for basal expression from the T7 promoter by 
producing T7 lysozyme; p15A replicon, CmR 
Novagen 
Table 2.3. Plasmids used in this work 
 
2.3 Culture media, buffers and solutions 
2.3.1 Culture media 
Where solid equivalents of media were used, agar 10 g/L was additionally added to 
the recipes presented below.  
 
Luria Bertani (LB)  
Difco™ Bacto tryptone 10 g/L 
Difco™ yeast extract  10 g/L 
NaCl      5 g/L 
Glucose     1 g/L 
 
Luria Bertani (LB) 7% sucrose 
Difco™ Bacto tryptone 10 g/L 
Difco™ yeast extract  10 g/L 
NaCl      5 g/L 
Glucose     1 g/L 




Müller Hinton (MH) broth 
Beef infusion solids    2 g/L 
Casein hydrolysate          17.5 g/L 
Starch              1.5 g/L 
 
Terrific broth (TB)  
Difco™ Bacto tryptone 12 g/L 
Difco™ yeast extract  24 g/L 
Glycerol             4 mL/L 
 
1 production medium (OPM) 
Difco™ yeast extract    5 g/L 
D-Glucose     5 g/L 
FeSO4              0.1 g/L 
MgSO4             0.1 g/L  
 
SOC medium 
Tryptone   20 g/L 
Yeast extract     5 g/L 
NaCl            0.58 g/L 
KCl            0.19 g/L 
MgCl2      2 g/L 
MgSO4                               2.5 g/L 
 
Soft Nutrient Agar (SNA) 
Difco™ Nutrient Broth    8 g/L 
Agar      7 g/L 
 
 
2.3.2 Buffers and solutions 
4-(2-pyridylazo)-resorcinol (PAR) solution 
PAR           7.1 mg/L   30 μM 







Chrome azurol S (CAS) assay solution 
Prepared as described by Alexander and Zuberer (1990). 21.9 mg HDTMA (601 μM 
final conc.) was dissolved in 25 mL ddH2O while stirring constantly over low heat. 1.5 
mL of 1 mM FeCl3·6H2O (15μM final conc., dissolved in 10 mM HCl) was mixed with 
7.5 mL of 2 mM CAS (150 μM final conc.). The resulting solution was gradually added 
to the HDTMA with stirring. 9.76 g MES (500 mM final conc.) was dissolved in 50 mL 
ddH2O pH 5.6 (adjusted with 50% KOH) and applied to the dye solution. ddH2O was 
added to a final volume of 100 mL. 
 
E. coli threonyl-tRNA synthetase (ThrRS) purification buffer 
HEPES/HCl (pH 7.8)    6 g/L  25 mM 
NaCl            17.5 g/L           300 mM 
MgCl2          952 mg/L  10 mM 
Glycerol         100 mL/L        10 % (v/v) 
Imidazole*    17 g/L           250 mM 
 
Loading dye for DNA samples (6× concentrated) 
Bromophenol blue            2.5 g/L            3.7 mM 
Xylene cyanol FF            2.5 g/L            4.6 mM 
Glycerol         165 mL/L         33% (v/v) 
 
Loading dye for protein samples (4× concentrated) 
Tris/HCl (pH 8.0)  29 g/L           240 mM 
SDS (25%)   80 g/L           8% (v/v) 
Bromophenol blue            0.4 g/L     0.04% (w/v) 
β-mercaptoethanol          40 mL/L           4% (v/v) 
EDTA            14.6 g/L  50 mM 
Glycerol        400 mL/L        40% (v/v) 
 
ObaG buffer 
HEPES/HCl (pH 7.8)    6 g/L  25 mM 
NaCl            17.5 g/L           300 mM 
MgCl2          952 mg/L  10 mM 
PLP          100 mg/L            0.4 mM 
Glycerol         100 mL/L        10 % (v/v) 





HEPES/HCl (pH 7.8)    6 g/L  25 mM 
NaCl            17.5 g/L           300 mM 
MgCl2          952 mg/L  10 mM 
ThDP          230 mg/L            0.5 mM 
Glycerol         100 mL/L        10 % (v/v) 
Imidazole*    17 g/L           250 mM 
 
ObaCIK purification buffer 
Tris/HCL (pH 7.8)    6 g/L 
NaCl            17.5 g/L           300 mM 
MgCl2          952 mg/L  10 mM 
Glycerol         100 mL/L        10 % (v/v) 
Imidazole*    17 g/L           250 mM 
 
PLP-dependence assay buffer 
HEPES/HCl (pH 7.8)     6 g/L  25 mM 
NaCl             17.5 g/L           300 mM 
MgCl2           952 mg/L  10 mM 
 
Running buffer for SDS-PAGE 
Tris/HCl (pH 8.0)     3 g/L  25 mM 
Glycine            14.4 g/L           192 mM 
SDS (25%)      1 g/L       0.1% (w/v) 
 
Tris-Borate-EDTA (TBE) buffer, pH 8.3 
Trizma base            10.8 g/L  89 mM 
Boric acid   5.5 g/L  89 mM 
EDTA           930 mg/L    3 mM 
 
Tris-EDTA (TE) buffer, pH 8 
Tris/HCl (pH 8.0)  1.2 g/L  10 mM 
EDTA           292 mg/L    1 mM 
 
*Imidazole only included in buffer for elution during Ni affinity chromatography 
(Section 2.6.1). Purified proteins were subsequently exchanged into their respective 




The stock and working concentrations of antibiotics used in this study are listed in 
Table 2.4. 
 




Carbenicillin Cb ddH2O 100 100 
Chloramphenicol Cm Ethanol 25 25 
Kanamycin Kan ddH2O 50 50 
Nitrofurantoin N DMSO 50 100 
Tetracycline Tc Ethanol 50 25 
Streptomycin Sm H2O 100 100 
Table 2.4. Stock and working concentrations of antibiotics used in this work. 
 
2.4 Cloning, screening and transformations  
2.4.1 Preparation of P. fluorescens ATCC 39502 genomic DNA  
10 mL LB cultures were inoculated from a -80°C 40% glycerol stock and were 
incubated O/N at 28°C, 250 rpm. 2 mL of culture were pelleted at 13,200 rpm for 2 
min in a 2 mL eppendorf and the supernatant was subsequently discarded. Cells were 
re-suspended in 600 μL 3 M guanidinium thiocyanate/10 mM EDTA (pH 7.0) and 
incubated at 85°C for 5 min, before being allowed to cool back down to room 
temperature. 1 μL RNAse ONE™ and 60 μL of the corresponding 10× buffer were 
then added and inverted 25 times to mix, before incubation at 37°C for 15 min. 200 
μL of 10 M ammonium acetate (pH 7.0) solution was then applied and mixed by 
thorough inversion, before centrifugation at 13,200 rpm for 3 min. 600 μL of 
supernatant were then removed and 600 μL isopropanol were introduced. Eppendorfs 
were then inverted 50 times to precipitate the DNA, before centrifugation at 13,200 
rpm for 1 min and removal of supernatant. 400 μL of 70% ethanol were then added 
to wash the DNA by inversion. Supernatant was removed as before and the ethanol 
wash was repeated once more. Supernatant was removed following centrifugation 
and samples were left to air dry to remove residual ethanol. Genomic DNA was then 
re-suspended in TE buffer by incubation at 65°C with intermittent flicking for 5 h. 
Genomic DNA samples were aliquoted and stored either at -20 or 4°C. 
 
2.4.2 Polymerase chain reaction (PCR) 
All PCR reactions were performed in a T100™ Thermal Cycler (Bio-Rad). PCR 
products for cloning and/or sequencing were generated using the high-fidelity Q5 
polymerase in 25 μL reaction volumes, following the manufacturer’s instructions 
(Table 2.5). P. fluorescens ATCC 39502 genomic DNA was used as template. Colony 
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PCR to screen colonies for introduced gene deletions or to verify constructs was 
performed using GoTaq polymerase in 10 μL reaction volumes (Table 2.6). A 
toothpick was used to apply cells to 50 μL dH2O which was used as template. PCR 
products were purified using a Wizard® SV Gel and PCR product Clean-Up System 
(Promega). 
 
High-fidelity PCR reaction mix 
Component Volume (μL) Final concentration 
5× Q5 reaction buffer 5 1× 
Forward primer 1.25 0.5 μM 
Reverse primer 1.25 0.5 μM 
DMSO 0.75 0.03% 
dNTPs 0.5 200 μM 
DNA template 0.5 ~50 ng 
Q5 polymerase 0.25 0.5 U 
 
Q5 PCR programme 
Cycle Temperature (°C) Time Repeat (×) 
Initial denaturation 98 3 min 1 
Denaturation 98 30 s 
30 Annealing 55-65 30 s 
Elongation 72 30 s/kb 
Final elongation 72 10 min 1 
Cooling 12 1 min 1 
Table 2.5. High-fidelity PCR reaction mix and programme  
 
 
Colony PCR reaction mix 
Component Volume (μL) Final concentration 
GoTaq G2 Master Mix 5 1× 
Forward primer 0.5 1.0 μM 
Reverse primer 0.5 1.0 μM 
DMSO 0.5 1% 
DNA template 3.5 Cell solution 
 
Colony PCR programme 
Cycle Temperature (°C) Time Repeat (×) 
Initial denaturation 95 5 min 1 
Denaturation 95 30 s 
30 Annealing 55-65 30 s 
Elongation 72 1 min/kb 
Final elongation 72 10 min 1 
Cooling 12 1 min 1 
Table 2.6. Colony PCR reaction mix and programme  
 
 
2.4.3 Agarose gel electrophoresis 
Agarose gels were prepared by adding agarose to TBE buffer to a final concentration 
between 0.8 and 1.2%, depending on the size of DNA fragments for analysis. 10 
μg/mL ethidium bromide was added before pouring for subsequent visualisation 
under ultraviolet (UV) light. DNA was prepared by addition of loading dye before gel 
63 
 
application. 1 kb ladder (NEB) was applied in parallel for analysis. Gel electrophoresis 
was performed in TBE buffer using a PowerPac™ Universal Power Supply (Bio-Rad) 
run between 80-120 V, until DNA fragments were deemed to be sufficiently 
separated. Gel visualisation was performed using a UV Transilluminator and Gel 
Documentation System (UVP). 
 
2.4.4 Cloning of DNA fragments 
Cloning was performed following standard molecular biology procedures. Vector DNA 
or PCR amplified DNA fragments were cut with the appropriate restriction 
endonucleases according to the manufacturer’s instructions. Restriction digest mixes 
were performed in 50 μL reaction volumes (20 μL for analytical digests) and were 
incubated at 37°C for 2 h. Vector digests were subsequently treated with alkaline 
phosphatase (addition of 1 μL alkaline phosphatase, 6 μL alkaline phosphatase buffer 
and 3 μL ddH2O) and incubated for a further 45 min at 37°C. Digests were either 
purified directly, or from size-separated gel fragments following electrophoresis, using 
a Wizard® SV Gel and PCR product Clean-Up System. Ligations were performed 
O/N at 8°C using 17 μL digested DNA, 1 μL T4 ligase and 2 μL 10× T4 ligase buffer. 
Ligation mixes were directly used for transformation of chemically competent E. coli 
DH5α cells. 
 
2.4.5 Restriction site removal 
To remove an unwanted NdeI site from the pTS1 suicide vector, a digest of the vector 
with NdeI was performed as above but incubation was at 37°C for 30 min only. Singly 
cut plasmid was gel-purified before the subsequent reaction was set up and incubated 
at room temperature for 20 min to ‘fill in’ the unwanted restriction site: 
 
4 μL  React buffer 10× (Invitrogen™) 
1.5 μL  dNTPs (10 mM final conc.) 
1.5 μL   DNA polymerase I (Klenow) (Invitrogen™) (10 U final conc.) 
20 μL  Partially digested pTS1 
13 μL  ddH2O 
 
A standard ligation as described previously was then performed to re-circularise blunt-
ended vector and ligation mixes were directly used for transformation of chemically 
competent E. coli DH5α cells. An analytical digest was performed to identify clones 




2.4.6 Gibson Assembly 
In order to create an ObaI expression construct with a C1141A substitution 
(TGC→GCC) Gibson Assembly® (Gibson et al., 2009) was used as it allowed the 
introduction of base substitutions in overlapping sequences. The ObaI gene was 
cloned as two overlapping fragments, that overlapped in the region where C1141 was 
encoded (Appendix 1 - Supplementary Table 1). This allowed identical double bp 
substitutions to be introduced in the primer sequences for each fragment in this 
region, which were introduced following the ligation of both fragments together along 
with the pET28a(+) backbone (also amplified as a PCR fragment with which both 
fragments’ primers overlap). A similar approach was applied for C480V substitutions 
in E. coli threonyl-tRNA (ThrRS) synthetase constructs. Primers were designed using 
NEBuilder® Assembly Tool (NEB) and PCR was performed with Q5 polymerase as 
described previously. PCR products were purified using a Wizard® SV Gel and PCR 
product Clean-Up System (Promega) and product concentrations were calculated 
using a NanoDrop-1000 (Thermo Fisher Scientific). Reactions were assembled 
following manufacturer’s instructions in containing 10 μL of 2×Gibson Assembly 
Master Mix (NEB) and a suitable ratio of PCR products, made up with ddH2O to a 
final reaction volume of 20 μL. Samples were then incubated at 50°C for 15 min, 
before transformation of the ligation mix into chemically-competent E. coli. 
 
2.4.7 Preparation and transformation of chemically competent E. coli  
A 5 mL LB culture was established for the E. coli strain to be transformed, grown O/N 
at 37°C, 250 rpm. 500 μL was used to inoculate a 100 mL LB culture which was grown 
at 37°C, 250 rpm until OD600 nm = 0.3-0.4. Cells were centrifuged at 4,500 rpm for 10 
min at 4°C, before gentle resuspension in 12.5 mL of ice-cold 100 mM MgCl2. The 
resulting cell suspension was centrifuged for 10 min at 4,000 rpm, 4°C. Cells were 
then re-suspended in 25 mL ice-cold 100 mM CaCl2 and incubated on ice for ~1 h. 
Cell suspensions were then pelleted at 4,000 rpm for 10 min at 4°C, before re-
suspension in 1 mL ice-cold 100 mM CaCl2 in 20% glycerol (v/v). 200 μL aliquots were 
made and snap-frozen with liquid nitrogen for storage at -80°C. 
 
To transform chemically competent cells, they were first thawed on ice. 50 μL cells 
were mixed with either 5 μL of ligation mix, 2 μL Gibson Assembly mix or 0.5 μL of 
vector DNA and incubated on ice for 30 min. Cells were then heat shocked at 42°C 
for 25 s before returning to ice for a further 3 min. 950 μL of SOC medium were then 
added to the transformed cells and recovery was performed at 37°C, 250 rpm for ~1 
h. Cells were finally plated on LB agar with appropriate selection and incubated O/N 
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at 37°C. Resulting colonies were screened by colony PCR to identify successful 
colonies. 
 
2.4.8 Plasmid purification and sequencing 
5 mL E. coli LB cultures with appropriate selection were established from single 
colonies on plates following cloning or from -80°C 40% glycerol stocks, and were 
grown O/N at 37°C, 250 rpm. Plasmid DNA was purified using a Wizard® Plus SV 
Minipreps DNA purification System (Promega). All constructs (and PCR products 
where necessary) generated during this project were sequenced by Sanger 
sequencing (Eurofins Genomics). 
 
2.5 Mutagenesis and complementation experiments 
2.5.1 pTS1 and pJH10TS construct design  
For pTS1-mediated knockout constructs, primers were designed to amplify 800-1,200 
bp flanking regions of a selected oba PCS for deletion, for cloning as XbaI-AvrII and 
AvrII-BmtI fragments into pTS1. Flanking regions were designed to contain 10-50 
PCS codons at either end of the oba locus for disruption to minimise possible polar 
effects. This would create a truncated copy of the oba PCS with an in-frame deletion 
and internal AvrII site, an artefact from ligation of the two flanking fragments. This 
would then be used to replace the WT chromosomal copy of the gene by double 
homologous recombination. To complement mutations, WT copies of oba PCSs were 
cloned from start to stop codon as BmtI-KpnI/XbaI fragments into pJH10TS, for 
introduction and ectopic expression in the relevant mutant background. 
 
2.5.2 Conjugation of constructs into P. fluorescens ATCC 39502 
Constructs were first transformed into E. coli S17-1, using empty vector constructs as 
negative controls. 5 mL O/N LB cultures with appropriate selection were prepared for 
the E. coli S17-1 donor and P. fluorescens. Cultures were centrifuged at 13,200 rpm, 
supernatant was discarded, and the pellets were washed twice in sterile LB medium, 
pre-warmed to 50°C. Pellets were ultimately re-suspended in 1.5 mL LB and were 
heat shocked for 15 min (E. coli - 37°C, P. fluorescens - 45°C). Conjugation 
suspensions were then prepared by mixing 700 μL of P. fluorescens cells with 300 
μL E. coli S17-1 donor cells. Suspensions were re-suspended in 50 μL sterile LB, 
following centrifugation at 13,200 rpm for 1 min, and pipetted to the centre of a 0.22 
μM GSTF mixed cellulose ester filter (Merck) placed on an LB agar plate. Plates were 
incubated at 28°C for 5 h. Cells were then re-suspended in 2 mL phosphate buffered 
saline (PBS) and were plated onto LB Tc25 N100 (to select for the construct and against 
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E. coli respectively), following serial dilution. Colonies were then subsequently 
screened by PCR, and ultimately by Sanger sequencing. 
 
2.5.3 pTS1 mutagenesis 
Following conjugation, selection on LB Tc25 N100 identified single crossover mutants 
in which the entire pTS1 construct vector backbone is integrated into the P. 
fluorescens chromosome because pTS1 is not a self-replicating vector. Colony PCR 
was used to identify candidate single crossover mutants and these were used to 
inoculate O/N LB cultures without antibiotics, grown at 28°C, 250 rpm. O/N cultures 
were serially diluted and plated on LB 7% sucrose N100 agar plates to select for a 
second crossover event. Resulting colonies were picked and patched onto LB 7% 
sucrose N100 plates with and without Tc25 to identify sensitive colonies that represent 
WT revertant or genuine Δoba strains. Colony PCR was then performed to verify 
Δoba strains and these were confirmed by Sanger sequencing of deletion PCR 
products. 40% glycerol stocks for three separate verified clones per gene deletion 
were prepared and stored at -80°C. 
 
2.5.4 Genetic and chemical complementation of Δoba strains 
pJH10TS complementation constructs were introduced into the relevant Δ 
backgrounds using the conjugation protocol described previously (2.5.2). Chemical 
complementation was achieved where possible by exogenous introduction of 
compounds when production cultures were established. Compounds were introduced 
prior to culture initiation and were dissolved in either dH2O or DMSO where 
appropriate. Concentrations used for each compound fed are specified within the 
relevant Chapters. 
 
2.5.5 Sample preparation for analysis of metabolite production 
WT and recombinant P. fluorescens ATCC 39502 strains were grown in OPM. A 
toothpick was used to inoculate 100 ml of OPM seed culture (250 ml Erlenmeyer 
flask) from a 40% glycerol stock (stored at -80°C), with subsequent growth for 24 h at 
25°C, 300 rpm. 1 ml of this culture was used to inoculate a 100 ml (500 ml flask) OPM 
production culture which was incubated under the same conditions for 14 h. Samples 
were prepared for HPLC/LCMS analyses by extracting 1 ml of culture broth with an 
equal volume of ethyl acetate with mixing at 1,400 rpm for 15 min. Samples were then 
centrifuged (13,200 rpm for 15 min), and the organic phase was collected and 
evaporated. The resulting extract was dissolved in 500 μL MeCN and centrifuged at 
13,200 rpm for 20 min to remove any remaining cell debris.  
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2.6 Expression and purification of recombinant proteins 
2.6.1 Protein expression and purification 
E. coli NiCo21(DE3):pLysS strains carrying pET28a(+)-obaC, pET28a(+)-obaG, 
pET28a(+)-obaH, pET28a(+)-obaI and pET28a(+)-obaK were cultivated in TB 
medium at 28°C and 250 rpm on a rotary shaker until A600 nm ~ 0.5. Protein expression 
was induced by addition of 0.1 mM IPTG and incubation continued at 18°C and 200 
rpm for 18 h. Cells were pelleted at 6,000 rpm and 4°C, and were subsequently re-
suspended in their respective purification buffers. After disruption with an EmulsiFlex-
B15 high pressure homogeniser (Avestin, Inc.), cells were pelleted at 15,000 rpm and 
4°C for 30 min. The lysed supernatant was incubated with chitin resin (NEB) with 
gentle mixing for 30 min to remove any endogenous E. coli metal-binding proteins. 
Eluted samples were loaded onto a HisTrap excel (GE Healthcare) Ni-NTA column 
using an ÄKTA pure (GE Healthcare) system. Proteins were washed in 5 CV of their 
respective buffers containing 10, 20, 30 and 50 mM imidazole concentrations (His6-
ObaI washed up to 30 mM imidazole only). His6-ObaI was eluted with 20 CV of 50 
mM imidazole, and His6-ObaC/G/H and K were eluted in 20 CV of 250 mM imidazole, 
collected in 2 ml fractions. Oba protein-containing fractions were combined and 
applied to Amicon columns (30 kDa MWCO) and diluted >1,000× to remove 
imidazole, before being concentrated. The His6-ObaI sample was further purified by 
size exclusion over a HiLoad 16/600 Superdex 200 pg column (GE Healthcare). 
Eluted His6-ObaI-containing fractions were combined and concentrated in an Amicon 
column (30 kDa MWCO). Protein samples were stored at 4°C for in vitro assays and 
long-term storage was at -80°C in their respective buffers supplemented with 20% 
glycerol.  
 
2.6.2 Protein concentration quantification  
Coomassie Brilliant Blue G-250 will shift from red colour under acidic conditions to 
blue when bound to cationic or non-polar, hydrophobic amino acid residues. This shift 
in absorbance can be used to quantify protein concentration using a simple 
colorimetric assay (Bradford, 1976). Bovine serum albumin (BSA) was used for 
calibration at a range of final concentrations between 1-20 μg/mL. 10 μL aliquots of 
purified protein sample and dilutions of BSA, were mixed with 200 μL of Protein Assay 
Dye Reagent (Bio-Rad) and were incubated for 5 min in the dark. The absorption at 
A595 nm was determined by comparison with a protein-free control. Protein 





2.6.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Proteins were analysed by size-separation under denaturing conditions with SDS-
PAGE. Protein samples were prepared by adding loading buffer to protein samples 
in a 1:3 ratio, up to 20 μL final volume, and heat-denaturing them at 100°C for 3 min. 
Samples were then loaded onto a 12% RunBlue (Expedeon Ltd.) polyacrylamide gel, 
along with 6 μL of Color Prestained Protein Standard (NEB) for comparison. 
Electrophoresis was performed at 100-180 V in SDS-PAGE running buffer using an 
XCell SureLock™ Mini-Cell electrophoresis system (Thermo Fisher Scientific). Gels 
were subsequently stained using InstantBlue (Expedeon Ltd.) for 1 h, followed by de-
staining in H2O for 1 h.  
 
2.6.4 Confirmation of protein identity by gel purification, trypsin digest and 
MALDI-TOF/TOF analysis 
Following SDS-PAGE, protein bands were cut out and prepared for trypsin digestion.  
Gel fragments were first de-stained by washing in 30% ethanol at 65°C for 15 min. 
Washes were repeated until gel fragments appeared clear. Ethanol was then 
removed and fragments were subsequently washed with 50% MeCN/50 mM TEAB 
for 15 min. Fragments were then incubated in 10 mM DTT/50 mM TEAB solution for 
30 min at 55°C. DTT/TEAB solution was then removed and gel fragments were 
incubated with 30 mM iodoacetamide/50 mM TEAB solution in the dark for 30 min 
following a brief vortex. Iodoacetamide/TEAB was subsequently removed and the 
fragments were washed with 50% MeCN/50 mM TEAB for 15 min. One final wash 
step was performed with 50 mM TEAB before gel fragments were sliced into cubes 
roughly 1 mm3 in size. Gel cubes were placed into a low-bind Eppendorf tube and 
washed as before with 50% MeCN/50 mM TEAB. Gel cubes were then washed with 
100% MeCN, causing gel fragments to shrink and become white. Residual MeCN 
was removed and gel slices were supplied to Dr. Gerhard Saalbach for trypsin 
digestion according to standard procedures adapted from Shevchenko et al. (1996).  
The tryptic digest peptide fragments were analysed by mass spectrometry to further 
confirm protein identity, using an autoflex Speed MALDI-TOF/TOF mass 
spectrometer (Bruker Daltonics GmbH).  
 
2.7 In vitro Oba enzyme assays 
2.7.1 His6-ObaH decarboxylase activity assay 
Reactions were performed in 100 μL reaction volumes comprising 50 mM His6-ObaH 
and 10 mM 4-NPP (8) or phenylpyruvate, all in ObaH buffer. Reactions were initiated 
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by introduction of the enzyme and were incubated at 27°C with 700 rpm for 5 min. A 
boiled enzyme sample was used as a negative control. Reactions were terminated 
by addition of ice-cold MeOH (100 μL) and were incubated at -20°C for 1 h to ensure 
full enzyme precipitation. Precipitated enzyme was pelleted at 13,200 rpm for 30 min 
before analysis by HR-LCMS and HPLC.  
 
2.7.2 His6-ObaG transaldolase activity assays, time course and kinetic analysis 
Reactions were performed in 100 μL reaction volumes comprising 50 mM His6-ObaG, 
10 mM glycine/L-serine/L-threonine or [U-13C4,15N]L-threonine (98% isotopic purity) 
(for subsequent NMR experiments), and 10 mM 4-NPA (11), all in ObaG buffer. 
Reactions were initiated by introduction of the enzyme and were incubated at 27°C 
and 700 rpm for 2 h. A boiled enzyme sample was used as a negative control. 
Reactions were terminated as described previously. HPLC and HR-LCMS analysis 
was performed as for the His6-ObaH decarboxylase activity assay. Time course data 
were similarly collected by terminating the reaction at a range of time points up to 5 h 
and all time points were assayed in triplicate.  
 
The amenability of His6-ObaG to alternative substrates was explored by performing 
the assay described above but using 10 mM of either benzaldehyde or 
phenylacetaldehyde instead of 11 as a co-substrate with L-threonine. The reverse 
reaction to generate 11 and L-threonine using AHNB (2) with and without 
acetaldehyde as substrates with His6-ObaG was also performed as above but using 
20 mM concentrations of starting substrates. Single-substrate kinetic analysis was 
carried out by performing the transaldolase activity assay with varying concentrations 
of L-threonine (1–200 mM). Reactions were performed using 25 mM enzyme and 
were incubated at 27°C, 700 rpm for 4 min, before quenching, sample processing and 
HPLC analysis. Five replicates were performed for each concentration of L-threonine 
assayed, and data were fitted to the Michaelis-Menten equation using GraphPad 
Prism 5.04 (GraphPad Software, Inc., La Jolla, USA). 
 
2.7.3 Coupled His6-ObaH and His6-ObaG activity assay 
His6-ObaG was first exchanged into His6-ObaH buffer using an Amicon column (30 
kDa MWCO) to avoid reaction of 8 with unbound PLP. Reactions were performed in 
100 μL reaction volumes comprising 50 mM His6-ObaG, 50 mM His6-ObaH, 10 mM 8 
and 10 mM L-threonine, all in His6-ObaH buffer. Reactions were initiated by 
introduction of the enzyme and were incubated at 27°C and 700 rpm for 2 h. Control 
reactions were also performed in which one or both of His6-ObaG and His6-ObaH 
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were boiled before the reaction. Reactions were terminated as described previously. 
HPLC and HR-LCMS analysis was performed as for the His6-ObaH decarboxylase 
activity assay. 
 
2.7.4 His6-ObaG L-penicillamine competition assay 
Recombinant His6-ObaG was incubated with L-penicillamine as described previously 
for serine palmitoyltransferase by Lowther et al. (2012). Excess PLP was removed 
from His6-ObaG samples by exchanging into PLP-dependence assay buffer using an 
Amicon column (30 kDa MWCO). Reactions were performed in 600 μL reaction 
volumes comprising 20 mM His6-ObaG and were initiated by addition of L-
penicillamine (dissolved in reaction buffer) to a final concentration of 10 mM. UV 
spectra were recorded over 30 min using a Lambda 35 UV/Visible Spectrophotometer 
(PerkinElmer). 
 
2.7.5 His6-ObaG sodium borohydride reduction assay 
His6-ObaG samples in which excess PLP was removed, were treated with NaBH4 to 
reduce the His6-ObaG-PLP aldimine to form an amine adduct (Chen and Frey, 2001). 
Reactions were performed on ice for 15 min in 600 μL volumes comprising 20 mM 
His6-ObaG and were initiated by addition of NaBH4 (dissolved in reaction buffer) to a 
final concentration of 1 mM. Samples were analysed by UV/Visible 
spectrophotometry as described before. 
 
2.7.6 His6-ObaI hydroxylamine-trapping assay  
Reactions were performed as described by Kadi and Challis (2009). Reaction 
mixtures comprised 8.5 mM His6-ObaI, 50 mM Tris/HCl pH 8.0, ATP (2.25 mM), 150 
mM hydroxylamine, 5 mM acid substrate and 15 mM MgCl2 in a final volume of 300 
μL, and were allowed to proceed at 28°C for 5 h. Boiled enzyme and no substrate 
reactions were performed as negative controls. Following reaction termination by 
addition of quenching solution (10% FeCl3 6H2O and 3.3% trichloroacetic acid made 
up in 0.7 M HCl), and centrifugation to pellet precipitated protein at 13,200 rpm for 15 
min, samples were transferred to cuvettes and were measured at A540 nm on a 
Spectronic Biomate 3 (Thermo Fisher Scientific). 
 
2.7.7 E. coli threonyl-tRNA synthetase (ThrRS) obafluorin (1)-binding assay 
His6-ThrRS, or its C480V variant, was first exchanged with MES buffer (pH 6.0) using 
an Amicon column (30 kDa MWCO). Reactions were performed in 100 μL volumes 
and were initiated by the addition of 95 μL of 10.5 μM His6-ThrRS (10 μM final conc.) 
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to 5 μL of 2 mM obafluorin (1) dissolved in 100% MeCN (0.1 mM final conc.). 100% 
MeCN was used as a negative control and reactions were incubated at 28°C for 15 
min, before analysis by UPLC-HRMS.  
 
2.8 Metal-binding assays 
2.8.1. Chrome azurol S (CAS) assay 
500 μL volumes of CAS assay solution and 25 μM 1 (dissolved in 100% MeCN) were 
mixed in an Eppendorf tube. The CAS assay solution contains an iron-dye complex, 
which is disrupted by the presence of a strong iron-binding ligand, releasing the dye 
to produce a distinct colour change from blue through pink to orange (Schwyn and 
Neilands, 1987; Alexander and Zuberer, 1991). 
 
2.8.2 4-(2-pyridylazo)-resorcinol (PAR) assay 
1 μL 10 mM ZnSO4 was added to a cuvette with 98 μL PAR assay solution. A serial 
dilution of 1 (dissolved in 100% MeCN) was performed and 1 μL was added to 
ZnSO4/PAR to give final concentrations of 1 of 1-50 μM. Solutions were mixed by 
pipetting before measuring spectra between 200-900 nm with a Lambda 35 
UV/Visible Spectrophotometer (PerkinElmer). 1 μL 100% MeCN was applied as a 
negative control. The Zn(PAR)2 complex has a characteristic absorbance at 493 nm 
which is lost when ligands are introduced which compete for zinc-binding (Bandara 
et al., 2009).  
 
2.9 Antibacterial activity assays 
2.9.1 Broth microdilution assay 
MIC values were determined by broth microdilution in 96-well microtitre plates in 
duplicate, following approved standards of the Clinical and Laboratory Standards 
Institute and European Committee on Antimicrobial Susceptibility Testing (Kahlmeter 
et al., 2006; Wiegand et al., 2008), with some modifications. A stock solution of 2000 
μg/mL 1 was prepared in MeCN diluted 1:10 in MH broth and a dilution series was 
prepared down to 0.125 µg/mL. 50 µL of each dilution was then added to appropriate 
test wells (final conc. 0.0625-1000 μg/mL). Positive control wells contained 50 μL of 
200 μg/mL carbenicillin or 100 µg/mL kanamycin (100 and 50 μg/mL final 
concentrations, respectively). Negative control and sterility control wells contained 50 
μL and 100 µL of sterile MH broth, respectively. Test strains were grown O/N in 5 mL 
LB cultures with appropriate selection at 37°C with 250 rpm. Cultures were 
standardised by dilution with LB against 0.5 McFarland standard solution to ~1.5 × 
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108 CFU/mL, before subsequent dilution by 1:150 to 1 × 106 CFU/mL. 50µL of cell 
culture was then added to all microtitre plate wells (except for the sterility control) to 
a final inoculum concentration of 5 × 105 CFU/mL in 100 μL reaction volumes. 
Microtitre plates were incubated at 37°C for ~16-18 h. The lowest concentration that 
showed no bacterial growth (no colour change or no turbidity) was recorded as the 
MIC. 
 
2.9.2 Disc and agar diffusion assays 
Test strains were grown O/N in 5 mL LB cultures containing appropriate selection. 50 
μL of each culture was used to inoculate 50mL LB cultures, which were incubated at 
37°C with 250 rpm until OD600 ~ 0.4-0.5. Cultures were used to inoculate molten SNA 
at 1% the final volume, before pouring into appropriately sized petri dishes to set. 1 
was serially diluted from 2000-0.015 μg/mL in 100% MeCN. 5 μL of each dilution of 
1 was spotted onto 5 mm Whatman filter discs (for disc diffusion method) or directly 
onto the SNA surface (for agar diffusion method). Kanamycin (50 μg/mL final conc.) 
and carbenicillin (100 μg/mL final conc.) were used as positive controls, and 100% 
MeCN was applied as a negative control.  Plates were incubated at 37°C for ~16-18 
h. The minimum inhibitory concentration (MIC) was defined as the lowest 
concentration of 1 that inhibited visible growth of the tested strains.  
 
2.10 Chemical methods 
2.10.1 Chemical synthesis and isolation of substrates 
2.10.1.1 Obafluorin (1)  
For the isolation of 1, the supernatant from 6 L of culture broth was subjected to liquid–
liquid partition using an equal volume of ethyl acetate. The organic fraction was 
concentrated under reduced pressure and the residue dissolved in MeCN. This was 
subjected to preparative reversed-phase HPLC using a Gemini® NX-C18 3u 110 Å 
150 mm × 4.6 mm column (Phenomenex); A: water; B: MeCN; gradient 0-5 min 10% 
B (v/v), 5-35 min, 10-100% B (v/v), 35–40 min 100% B (v/v), 40–41 min 100–10% B 
(v/v), 41–45 min, 10% B (v/v); flow rate was 20 ml/min; monitored at 254 nm). 1: Pale 
yellow solid, (13 mg). 1H NMR (400MHz, MeCN-d3) d 8.23 (1H, d, J = 8.8 Hz), 8.10 
(2H, d, J = 8.8 Hz), 7.45 (2H, d, J = 8.8 Hz), 7.20 (1H, dd, J1 = 8.2 Hz, J2= 1.27 Hz), 
7.04 (1H, dd, J1 = 7.9 Hz, J2 = 1.2 Hz), 6.82 (1H, t, J = 7.96 Hz), 5.75 (1H, dd, J1 = 
8.5 Hz, J2 = 6.2 Hz), 5.05 (1H, m), 3.38 (1H, dd, J1 = 15.1 Hz, J2 = 5.1 Hz), 3.21 (1H, 
dd, J1= 15.1 Hz, J2 = 5.1 Hz); 13C NMR (100 MHz, MeCN-d3) δ 171.47, 169.11, 
150.43, 148.08, 147.02, 145.41, 131.20, 124.64, 120.50, 120.07, 118.68, 114.86, 
78.50, 59.87, 36.16 ppm HRMS (m/z): [M+H]+ calculated for C17H14N2O7, 359.0874, 
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found, 359.0872, Diff. (ppm) = -0.56. The NMR data is consistent with published 
values (Pu et al., 1994).  
 
2.10.1.2 Ethyl 5-(4-nitrobenzyl)-4,5-dihydrooxazole-4-carboxylate 
Ethyl 5-(4-nitrobenzyl)-4,5-dihydrooxazole-4-carboxylate was synthesized according 
to a literature procedure (Rao et al., 1991) using 11 (990 mg, 6 mmol) and ethyl 
isocyanoacetate (750 mg, 6.6 mmol) to yield 910 mg of the racemic trans-
diastereoisomer. Yield: 55%. 1H NMR (400 MHz, CDCl3) δ 8.08 (2H, d, J = 8.8 Hz), 
7.36 (2H, d, J = 8.8 Hz), 6.87 (1H, d, J = 9.4 Hz), 4.72 (1H, dd, J1 = 9.4 Hz, J2 = 2.0 
Hz), 4.41-4.36 (1H, m), 4.22–4.13 (2H, m), 2.92-2.78 (2H, m), 1.23 (3H, t, J = 7.2 Hz); 
13C NMR (100 MHz, CDCl3) d 170.1, 161.8, 146.8, 145.3, 130.3, 123.6, 72.1, 62.2, 
54.6, 40.1, 14.0 ppm; HRMS (m/z): [M+H]+ calculated for: C13H15N2O5, 279.0975; 
found, 279.0978, Diff. (ppm) = 1.07. 
 
2.10.1.3 (2SR,3RS)-2-amino-3-hydroxy-4-(4’-nitrophenyl)butanoic acid (AHNB; 
2) 
2 was synthesized according to a literature procedure (Rao et al., 1991). Starting from 
720 mg of ethyl 5-(4-nitrobenzyl)-4,5-dihydrooxazole-4-carboxylate we obtained 570 
mg of 2. Yield: 92%. 1H NMR (400 MHz, D2O) δ 8.31 (2H, d, J = 8.5 Hz), 7.63 (2H, d, 
J = 8.5 Hz), 4.44 (1H, m), 3.84 (1H, m), 3.27 (1H, dd, J1 = 14.0 Hz, J2 = 3.2 Hz), 3.05 
(1H, dd, J1 = 14.0 Hz, J2 = 1.6 Hz); 13C NMR (100 MHz, D2O) δ 172.5, 146.6, 145.9, 
130.5, 123.9, 70.3, 59.2, 39.8 ppm HRMS (m/z): [M+H]+ calculated for: C10H13N2O5, 
241.0819; found: 241.0801, Diff. (ppm) = -7.47. NMR data are in agreement with 
published values for the (2S,3R)-enantiomer. 
 
The enzymatic synthesis of 2 was achieved by scaling up (to 2 ml) the analytical 
conditions for the ObaG discontinuous assay described above (2.7.1). The reaction 
was quenched after 2 h by the addition of MeOH (2 ml) and the solution was 
concentrated under reduced pressure. The resulting crude product was repeatedly 
subjected to solid-phase extraction for further purification and to remove excess 
buffer. Elution with 25% MeOH yielded 2 (1.8 mg, 38%). NMR data were consistent 
with those of the synthetic reference standard. [α]D + 48°, (c = 0.18, H2O) (Pu et al., 






2.10.1.4 (2SR,3RS)-2-amino-3-hydroxy-4-(4’-aminophenyl)butanoic acid 
(AHAB; 9) 
9 was synthesized according to a literature procedure (Herbert et al., 1994). Starting 
from 25 mg of 2 we obtained 7 mg of 10 as a yellow solid. 1H NMR (400MHz, D2O) δ 
7.37 (2H, d, J = 8.4 Hz,), 7.28 (2H, d, J = 8.1 Hz), 4.39 (m, 1H), 4.05 (1H, d, J = 4.0 
Hz), 3.01 (1H, dd, J1 = 14.1 Hz, J2 = 4.3 Hz), 2.82 (1H, dd, J1 = 9.9 Hz, J2 = 14.2 Hz); 
13C NMR (100MHz, D2O) δ 170.35, 138.28, 130.86, 128.44, 123.17, 69.71, 57.16, 
38.77 ppm HRMS (m/z): [M+H]+ calculated for: C10H15N2O3, 211.1077 [M+H]+; found, 
211.1082, Diff. (ppm) = -2.37. 
 
2.10.2 Analytical methods and instrumentation 
I performed HR-LCMS and HPLC analysis of extracts from mutational analysis and 
biochemical experiments. Dr. Daniel Heine performed His6-ObaG transaldolase 
assay NMR experiments, isolated enzymatically synthesised compounds and 
synthesised substrates. Prof. Barrie Wilkinson also helped synthesise substrates. Dr. 
Daniel Heine and Dr. Gerhard Saalbach performed analyses of ThrRS 1-binding 
experiments. Dr. Zhiwei Qin Isolated 1 and carried out NMR analysis. 
 
NMR spectra were recorded on a Bruker AVANCE III 400 MHz spectrometer. 
Chemical shifts are reported in parts per million (ppm) relative to the solvent residual 
peak of chloroform-d1 (1H: 7.24 ppm, singlet; 13C: 77.00 ppm, triplet), methanol-d4 (1H: 
3.30 ppm, quintet; 13C: 49.00 ppm, septet) or water-d2 (1H: 4.79 ppm).  
 
Semi-preparative and analytical HPLC was performed using an 1100 system (Agilent 
Technologies). Extracted samples from mutagenesis and complementation 
experiments were analysed using a Gemini® NX-C18 3u 110 Å, 150 mm × 4.6 mm 
column (Phenomenex) with a gradient elution: MeCN/0.1% (v/v) TFA (H2O) - gradient 
from 10/90 to 100/0 0–15 min, 100/0 for 15–16 min, gradient to 10/90 16–16.50 min 
and 10/90 for 16.50–23 min; flow rate 1 ml/min; injection volume 10 μL.  
 
Biochemical assays were analysed using a Synergi 4 mm Fusion-RP 80 Å LC column 
250 × 4.6 mm (Phenomenex) with a gradient elution: MeOH/0.1% (v/v) TFA (H2O) - 
gradient from 10/90 to 100/0 0–14 min, 100/0 for 14–18 min, gradient to 10/90 18–
18.50 min and 10/90 for 18.50–23 min; flow rate 1 ml/min; injection volume 5 μL (15 




UPLC-MS measurements were performed on a Nexera X2 liquid chromatograph (LC-
30AD) LCMS system (Shimadzu) connected to an autosampler (SIL-30AC), a 
Prominence column oven (CTO-20AC) and a Prominence photo diode array detector 
(SPD-M20A). A Kinetex 2.6 mm C18 100 Å, 100 2.1 mm column (Phenomenex) was 
used for LCMS. The UPLC-System was connected to a LCMS-IT-TOF Liquid 
Chromatograph mass spectrometer (Shimadzu).  
 
UPLC-HRMS data for ThrRS 1-binding experiments were acquired with an Acquity 
UPLC system connected to a Synapt G2-Si high resolution mass spectrometer 
(Waters). Analytical UPLC was performed using an Aeris widepore 3.6 µm C4, 
50 × 2.1 mm column (Phenomenex) with a gradient elution: 0.1% (v/v) formic acid 
(MeCN)/0.1% (v/v) formic acid (H2O) - 95/5 for 0-1 min, gradient to 10/90 2-6 min, 
10/90 for 6-7 min, gradient to 90/10 7-7.1 min, 90/10 for 7.1-9 min, gradient to 10/90 
for 9-14 min, gradient to 95/5 for 14-14.1 min, 95/5 for 14.1-16 min; flow rate 400 
μL/min; injection volume 5 μL. MS spectra were acquired with a scan time of 1 s in 
the range of m/z = 100 - 2000 in positive MS resolution mode. The following 
parameters were used: capillary voltage of 3 kV, sampling Cone 40 V, source offset: 
80 V, source temperature of 120 °C, desolvation temperature of 350 °C, cone gas 
flow of 10 L/h, desolvation gas flow of 900 L/h and a nebulizer pressure of 6 bar. A 
solution of sodium formate was used for calibration and a solution of leucine 
encephalin (H2O/MeOH/formic acid: 49.95/49.95/0.1) was used as lock mass, which 
was injected every 15 s. The lock mass was acquired with a scan time of 0.3 s and 3 
scans to average. The lock mass (556.2766) was applied during data acquisition. 
 
ThrRS 1-binding assays were further analysed following tryptic digest. Reaction 
mixtures were first denatured with sodium deoxycholate, treated with DTT and 
digested with trypsin according to standard procedures. For LC-MS/MS analysis of 
peptide fragments from, an Orbitrap-Fusion™ mass spectrometer (Thermo Fisher 
Scientific) equipped with an UltiMate™ 3000 RSLCnano System using an Acclaim 
PepMap C18 column (2 µm, 75 µm x 500 mm, Thermo Fisher Scientific) was used. 
Aliquots of the tryptic digests were loaded and trapped using a pre-column which was 
then switched in-line to the analytical column for separation. Peptides were eluted 
with a gradient of 5-40% MeCN in ddH2O/0.1% HCOOH at a rate of 0.5%/min. The 
column was connected to a 10 µm SilicaTip™ nanospray emitter (New Objective) for 
infusion into the mass spectrometer. Data dependent analysis was performed using 
parallel HCD/CID fragmentation using a top20 method with following parameters: 
positive ion mode, orbitrap MS resolution = 120k, mass range (quadrupole) = 300-
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1800 m/z, MS/MS isolation window 1.6 Da, threshold 2.5e4, AGC target 1e4, max. 
injection time 35 ms, dynamic exclusion 2 counts, 30 s exclusion, exclusion mass 
window ±7 ppm. MS scans were saved in profile mode while MS/MS scans were 
saved in centroid mode. Raw files from the Orbitrap were processed with MaxQuant 
(version 1.6.0.1) to generate re-calibrated peaklist-files which were used for database 
searches using an in-house Mascot Server (version 2.4). The searches were 
performed on a custom database containing the sequence of interest and on a 
common contaminants database using trypsin/P with 2 missed cleavages, 
carbamidomethylation (C), oxidation (M), acetylation (protein N-terminus), and 1 
(Cysteine, +358.0801 Da) as variable modifications. Mass tolerances were 6 ppm for 
precursor ions and 0.6 Da for fragment ions. Mascot search results were imported 
and evaluated in Scaffold 4.4.1.1 (proteomsoftware.com) with thresholds of 99% and 
95% for proteins and peptides.  
 
Solid phase extraction was carried out using Discovery DSC-18 SPE Tubes, filled 
with 1,000 mg of octadecyl-modified, endcapped silica gel (Supelco). The specific 
optical rotation of compounds was measured with a Model 341 Polarimeter 
(PerkinElmer, Inc.).  
 
2.11 Phylogenetic analysis 
Amino acid sequences of L-TAs and SHMTs were obtained from a previous 
phylogenetic study (Liu et al., 2015) and were combined with additional L-TA and 
SHMT sequences for enzymes which have been characterized or described in the 
literature, and were obtained from the National Centre for Biotechnology Information 
(NCBI) GenBank database (Clark et al., 2016) and the Protein Data Bank (PDB) 
(Berman et al., 2000). Blastp (Basic Local Alignment Search Tool – Altschul et al., 
1990) searches for L-TAs or SHMTs involved in NP biosynthesis were performed to 
identify enzymes from these families associated with specialized metabolism. A 
selection of 10 amino acid sequences for 3-amino-5-hydroxybenzoic acid synthases 
(AHBASs) described in the literature were obtained to function as an outgroup for 
phylogenetic analysis as they have been shown to share a recent common ancestor 
of L-TAs and SHMTs (Contestabile et al., 2001) (Source organisms and amino acid 
sequence GenBank accession numbers used are reported in Appendix 1 - 
Supplementary Table 2). Sequences were initially aligned (all alignments performed 
with default settings) using ClustalX2 (Larkin et al., 2007), before manual trimming of 
sequences at N- and C-termini to remove aberrant sequences (e.g. histidine tags) 
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that might interfere with the alignment. Trimmed sequences for the phylogeny 
illustrated in Figure 6.1 are reported in Supplementary Sequence Data 1 (Appendix 
2). Several iterations of alignment and trimming were repeated with different degrees 
of trimming to ensure that the final tree was relatively consistent and robust. MUSCLE 
(Edgar, 2004), in addition to ClustalX2, was trialled for initial alignment before 
trimming. Trimmed sequences were finally re-aligned with T-Coffee (Notredame et 
al., 2000), and phylogenetic tree inference was performed using maximum 
likelihood/rapid bootstrapping under the Generalised Time-Reversible (GTR) model 
using RAxML-HPC BlackBox (8.2.8) (Stamatakis, 2014) via the CIPRES Science 
Gateway portal (Miller et al., 2010). The JTT Protein Substitution Matrix was used 
and all other parameters were set to default values. 
 
2.12 Software 
Software used for in silico analyses are listed in Table 2.7 
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Rutherford et al., 2000 
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ChemDraw (v16.0) Property 
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Miller et al., 2010 




Larkin et al., 2007 
DNAPlotter (v1.11) Genome 
visualisation 
Carver et al., 2009 
ExPASy Compute pI/Mw Tool 
(http://web.expasy.org/compute_pi/) 
Calculate protein 
pI and Mw 
Gasteiger et al., 2005 
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MaxQuant (v1.6.0.1)  
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Cox and Mann, 2008 
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In addition to the discovery of novel NP scaffolds, access to entire genomes has 
allowed NP researchers to revisit a wealth of previously published molecules. Their 
structure and biosynthesis had only been characterised using chemistry-based 
approaches, but with advances in molecular approaches and genome sequencing, 
their biosynthesis can now be dissected at the genetic and biochemical levels. Of 
particular interest are NPs that possess unusual structural features which might 
endow a novel mode of action, and/or allow the discovery of unusual biosynthetic 
enzymes for synthetic applications. The structure of a NP and its breakdown 
products/co-metabolites allow a retrobiosynthetic approach to be used to predict the 
likely biosynthetic steps in its pathway. In the case of the biosynthesis of obafluorin 
(1), additional data are available from stable isotope labelling experiments which were 
described in detail in Chapter 1 (Herbert and Knaggs, 1988; 1990; 1992a; 1992b). 
Based on their results, Herbert and Knaggs identified 4-APP (7) or 4-NPA (8) and 
glyoxylate as the likely precursors of the unusual β-OH-α-AA AHNB (2) (Figure 3.1), 
which when condensed with 2,3-DHBA (6), form a pseudo-dipeptide precursor to 1. 
This proposal for the biosynthesis of 1 provided the starting point for this work. 
 
In this Chapter, the sequencing and in silico analysis of the P. fluorescens ATCC 
39502 genome are described. Comparative genomics approaches were first applied 
to highlight any unusual features in the ATCC 39502 genome.  Putative BGCs were 
then investigated in order to identify the likely BGC for 1 based on anticipated 
homology to previously characterised biosynthetic pathways and data from previous 
feeding studies. Biosynthetic predictions are made about the timing and functions of 
enzymes in the pathway.  
 
3.2 Sequencing and annotation of the P. fluorescens ATCC 39502 
genome 
A PCR was performed with degenerate primers F27 and R1492 (Weisburg et al., 
1991; Heuer et al., 1998) to amplify the 16S rRNA gene from the ATCC 39502 strain. 
This was sequenced and shared 99% query cover and identity at the nucleotide level 
to P. fluorescens SBW25. High molecular weight genomic DNA was subsequently 

















submitted to The Earlham Institute (formerly The Genome Analysis Centre) for 
sequencing using SMRT technology on the Pacific Biosciences (PacBio) RSII 
platform, and assembly using the HGAP2 pipeline. Given the highly repetitive nature 
of modular NRPSs and PKSs, shorter sequence read lengths can result in assembly 
issues. PacBio was therefore preferred over other sequencing technologies (Gomez-
Escribano et al., 2016) as it is capable of achieving average read lengths in excess 
of 20 kb (http://www.pacb.com/smrt-science/smrt-sequencing/read-lengths/). In 
comparison, Illumina’s HiSeq typically generates average read lengths of ~500 bp. In 
total, 110,545 sequence reads (mean read length, 5,700 bp) were used to assemble 
a single contig circular genome of just over 6.15 Mbp (GC content, 60.3%) with 115× 
coverage (80× required for 99.99% accuracy) (Figure 3.2). This contig was submitted 
to the Prodigal server (Hyatt et al., 2010) for identification of protein coding sequences 
(PCSs) and initial putative gene functions were assigned using the RAST server 
(Overbeek et al., 2014).  
 
3.3 Preliminary analysis of the P. fluorescens ATCC 39502 genome 
P. fluorescens spp. are known to have highly variable genomes, to the extent that 
they have been re-branded as a complex rather than as an individual species (Silby 
et al., 2009; 2011). The ATCC 39502 genome comprised specific marker genes 
identifying it as belonging to the P. fluorescens phylogroup of the P. fluorescens 
complex (Garrido-Sanz et al., 2017). Comparative genomic analyses were performed 
to compare the ATCC 39502 sequenced genome against those of three other fully-
sequenced model P. fluorescens strains to identify any unusual features. A basic 
comparison of general genomic characteristics revealed that all four strains are 
relatively similar: 6-7 Mbp in size, 87-89% coding density, 60-61% GC content and 
comparable numbers of tRNA and rRNA genes (Table 3.1).  
 
3431 PCSs are conserved between all four strains, representing a ‘core’ genome 
comprising 56-65% of total PCSs in each genome: this is in accordance with a similar 
comparison of P. fluorescens genomes conducted previously (Silby et al., 2009). In 
order to identify the location of ‘core’ PCSs within the genome, a pairwise tblastx 
comparison was performed by Dr. Govind Chandra, comparing the SBW25, Pf0-1 
and F113 genomes against that of ATCC 39502. Comparisons were visualised using 
the Act Comparison Tool (Carver et al., 2005) which revealed that ATCC 39502 
shares greatest synteny with SBW25 (Figure 3.3), and that the majority of 
homologous PCSs shared between strains are located close to the origins of 









Figure 3.2. Illustration of the P. fluorescens ATCC 39502 genome. The outer 
scale designates coordinates in base pairs (bp), with the origin of replication located 
at 0 bp. The first (outermost) track shows predicted PCSs on the + strand and the 
second shows predicted PCSs on the - strand. The third track comprises BGCs 
predicted by antiSMASH 4.0 (Blin et al., 2017), as described in the main text. The 
fourth track shows tRNA genes and the fifth track shows rRNA genes. The sixth track 
is a representation of GC plot and the seventh (innermost) track represents GC skew. 
Structures of NPs encoded in the genome are illustrated and linked to their respective 
BGCs. The predicted structure of a poeamide-like CLP has been illustrated with the 
predicted isoleucine (highlighted in orange), rather than the leucine residue present 









Figure 3.3. Assessment of genome synteny between P. fluorescens 
ATCC 39502 and three fully-sequenced model P. fluorescens strains. The 
top genome in each of the three panels represents ATCC 39502 and the 
bottom genome belongs to (a) SBW25; (b) Pf0-1; and (c) F113. P. fluorescens 
genomes are circular and the origins of replication for each strain are located 
at the first bp in the genome (i.e. at the start and end of the genomes 
represented here). Red bars between genomes represent individual tblastx 
matches and inverted matches are blue.  
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2009). The SBW25, Pf0-1 and F113 genomes were also submitted to RAST, which 
allocates general functions to PCSs. Comparison of allocated gene functions across 
the four genomes revealed that they share an extremely similar distribution in the 
function of their PCSs (Figure 3.4), with amino acid, protein and carbohydrate 
metabolism predominating, and high numbers of PCSs dedicated to membrane 
transport, iron acquisition and metabolism, and stress response, perhaps reflecting 
the ability of this species to adapt to a broad range of environments. ATCC 39502 
thus displays typical, characteristic genomic features of members of the P. 
fluorescens complex. 
 
General characteristics of  P. fluorescens genomes 
 
P. fluorescens strain ATCC 39502 SBW25 Pf0-1 F113 
Number of bp 6,148,190 6,722,539 6,438,405 6,845,832 
Number of PCSs 5,336 5,976 5,707 6,055 
Coding % 87.3 87.3 88.5 87.1 
%GC 60.3 60.5 60.5 60.8 
tRNA genes 69 66 73 66 
rRNA genes 19 16 19 16 
Predicted BGCs* (CF) 17 (49) 9 (54) 10 (45) 10 (54) 
Table 3.1. Comparison of P. fluorescens ATCC 39502 genomic characteristics 
with those of other sequenced model P. fluorescens strains. * refers to the 
number of putative BGCs identified by antiSMASH 4.0 (Blin et al., 2017), and the 
number identified when the ClusterFinder algorithm was applied is given in brackets.  
 
 
3.4 Identifying BGCs in the P. fluorescens ATCC 39502 genome  
The ATCC 39502 genome sequence was submitted to antiSMASH 4.0 (Blin et al., 
2017) and, using the ClusterFinder algorithm (Cimermancic et al., 2014), 49 putative 
gene clusters were identified, with 17 assigned to a specific NP class (Table 3.2). This 
is above average compared to other P. fluorescens strains in which nine or ten BGCs 
were identified by antiSMASH (Table 3.1). Each putative BGC was analysed manually 
using BLAST (Altschul et al., 1990) and Pfam (Finn et al., 2016) searches to 
determine their likely products. All ATCC 39502 BGCs assigned to a specific NP class 
or product are illustrated in Figure 3.2, along with their genomic location. Putative 
BGCs are concentrated in the more variable region of the genome, away from the 











Figure 3.4. Functional assignment of PCSs in the genomes of four fully-
sequenced P. fluorescens strains by the RAST server. (a) ATCC 39502 
(52%); (b) SBW25 (53%); (c) Pf0-1 (53%); and (d) F113 (52%). Percentages 
represent the PCSs identified by RAST that could be assigned a function. Pie 
chart segments reflect the relative number of those PCSs assigned to each 
functional group. The ‘cofactors, vitamins, prosthetic groups, pigments’ 
segment has been pulled out as a point of reference, with subsequent 









BGC composition observed between P. fluorescens strains and the common 
transmission of BGCs via MGEs.  
 
Table 3.2. Summary of P. fluorescens ATCC 39502 antiSMASH output. 
 
 
Surprisingly, only two BGCs contained elements of PK biosynthesis, despite the large 
number of  known pseudomonad PKS and hybrid NRPS-PKS biosynthetic pathways 
(Gross and Loper, 2009). One was a type I PKS with no homology to any known 
BGCs, and the other was a putative arylpolyene-encoding BGC. Arylpolyenes are 
pigmented compounds that have been recently recognised as being broadly 
distributed among the proteobacteria, in which they are proposed to play important 
roles in mitigating oxidative stress through their ability to effectively quench reactive 
oxygen species (Cimermancic et al., 2014; Schöner et al., 2016). Other assigned 
BGCs include a single thiopeptide cluster and a siderophore biosynthesis cluster, the 
latter comprising an iucA/iucC-like siderophore synthetase gene similar to that 
involved in aerobactin biosynthesis (De Lorenzo et al., 1986). Both of these BGCs 
have numerous homologues in other Pseudomonas spp., but neither have been 
previously characterised. A saccharide cluster was found to share 37% homology to 
the pseudopyronine BGC (Bauer et al., 2015), however no pseudopyronine synthase 
gene was found in the ATCC 39502 genome, indicating this cluster is probably 
inactive, or may perform an alternate role. 
antiSMASH 
Cluster No. 
BGC type Position BGCs of compounds with 
highest similarity (%) 
From To 
1 Other 108144 151521 Mangotoxin (57%) 
2 Arylpolyene 488265 531840 APE_Vf (40%) 
3 Bacteriocin 1500434 1511309 - 
4 T1pks-Resorcinol 2009855 2059104 - 
5 Nrps 2879189 2927378 - 
6 Nrps 2939150 2990150 Pseudomonine (100%) 
7 Terpene 3042675 3064894 - 
8 Thiopeptide 3209903 3235479 Lipopolysaccheride (5%) 
9 Nrps 3400040 3465917 Tawaichelin (11%) 
10 Bacteriocin 3491452 3502288 - 
11 Nrps 3531661 3599079 Poeamide (71%) 
12 Nrps 3886949 3933221 Poeamide (100%) 
13 Nrps 4189378 4242289 Pyoverdine (9%) 
14 Siderophore 4339809 4351734 - 
15 Cf_fatty_acid-Nrps 4354109 4424976 WS9326 (7%) 
16 Homoserine 
lactone-NRPS 
4762163 4815888 Lipopeptide_8D1-1 (6%) 
17 Bacteriocin 6104950 6115795 - 
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So far neither terpenoid metabolites, nor terpene synthases, have been reported from 
Pseudomonas spp. in the literature. Terpenes represent one of the largest NP classes 
and encompass the greatest chemical diversity of all NPs. They originate from the C5 
substrates dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP), 
where one or more IPP units are condensed with DMAPP in a head-to-tail fashion to 
form the basic terpenoid scaffolds geranyl diphosphate (GPP - C10), farnesyl 
diphosphate (FPP - C15), or geranylgeranyl diphosphate (GGPP - C20) (Oldfield and 
Lin, 2012). These units can be further condensed together to form larger terpene 
scaffolds, before subsequent cyclisation and/or any number of other post-
translational modifications (PTMs). Intriguingly, antiSMASH 4.0 identified a BGC 
comprised of 11 PCSs, including a dimodular terpene synthase/cytochrome P450 
enzyme, IPP isomerase and class I SAM methyltransferase. Whilst the cluster has a 
number of homologues in other Pseudomonas spp., it could not be linked to any 
known terpene BGCs. A terpene-NRPS BGC is identified by antiSMASH in the 
genome of P. fluorescens Pf0-1 genome, but the NRPS element corresponds to 
homologues of pvdGIJ in pyoverdine biosynthesis (described below) and the terpene 
element refers to a terpene synthase enzyme located just under 3 kb upstream, which 
does not appear to be involved in a specialised metabolite BGC context. 
 
BLAST searches were performed to try and identify PCSs for other well-characterised 
specialised metabolites from P. fluorescens such as pyoluteorin, pyrrolnitrin, 2,4-
DAPG and HCN (Gross and Loper, 2009), but no homologues could be found in P. 
fluorescens ATCC 39502. 32 of the putative BGCs predicted by the ClusterFinder 
algorithm were either classed as saccharides or were not assigned to a specific NP 
class and their likely functions, if any, were very difficult to determine. Amongst them, 
primary metabolite BGCs for biotin, pyrroloquinolone quinone (PQQ) and alginate 
biosynthesis were identified, in addition to loci encoding factors of polymyxin 
resistance and a cluster of flagellar-related PCSs (Figure 3.2). 
 
By far the most abundant NP BGC class in P. fluorescens ATCC 39502 is the NRPs, 
with eight candidate clusters comprising NRPS-like genes. Among them, six showed 
homology to known NRP BGCs. The entire BGC for the siderophore pseudomonine 
(Sattely and Walsh, 2008) is present (100% of genes show similarity), in addition to 
two BGCs which appear to be involved in the biosynthesis of pyoverdine. The first 
comprises homologues of pvdSGL, with PvdL being the NRPS responsible for 
assembling scaffold for the characteristic tripeptide chromophore moiety (Böckmann 
et al., 1997). The second BGC comprises two NRPSs, one of which is a homologue 
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of pvdD, the product of which is the terminal enzyme in the assembly of the variable 
peptidic chain in the pyoverdines. Based on the number of modules comprised by 
these two NRPSs, the peptidic side chain is likely to comprise seven amino acids. 
pvd loci for pyoverdine modification, regulation, export, siderophore detection and 
uptake are also found located elsewhere in the genome.   
 
An incomplete cluster comprising mgoABC homologues (60-70% amino acid 
sequence similarity – mgoD missing) involved in the biosynthesis of the P. syringae 
antimetabolite mangotoxin is also present (Arrebola et al., 2012). The mboABCDEF 
operon, which is only found in mangotoxin-producing strains and has been shown to 
be essential for production (Carrión et al., 2012), is absent however, so the function 
of mgo homologues in the ATCC 39502 genome is unclear. Two unlinked clusters 
comprising three NRPSs between them share extremely high homology to CLP 
clusters of the orfamide family, with 80-90% shared amino acid identity with poaABC 
in the poeamide-producer P. poea RE*1-1-14 (Zachow et al., 2015) – the key 
difference is that the A domain in module 4 of the poaB homologue in P. fluorescens 
ATCC 39502 appears to encode isoleucine specificity, as opposed to leucine.  
 
Based on the findings described in section 3.1, predictions could be made about 
PCSs anticipated in a putative oba BGC. These include PCSs involved in the 
biosynthesis of 4-APA (3) and 6, and one encoding a ThDP-dependent enzyme 
proposed by Herbert and Knaggs to catalyse a C-C bond forming reaction between 
glyoxylate and 7(or 8 depending on when the nitro group is introduced) to generate 
the acyloin precursor to 2 (Figure 3.1 - Herbert and Knaggs, 1990). A transaminase 
should also be present in a putative 1 BGC for the introduction of the α-amino group 
on 2. Pseudomonas spp. are known to produce many structurally diverse NP peptides 
(Gross and Loper, 2009), and given that many are derived from NRPSs, it is 
reasonable to hypothesise that 1 is similarly assembled using 2 and 6. Based on the 
biosynthetic logic of these multienzyme complexes, a dimodular NRPS should be 
sufficient to catalyse peptide bond formation between 2 and 6, with at least one A 
domain with substrate specificity for 6. Given the nonproteinogenic nature of 2, it 
would be unlikely that A domain substrate specificity predicting software would be 
able to identify the correct substrate for the second A domain in an oba BGC NRPS. 
Finally, an N-oxygenase similar to that observed in pyrrolnitrin biosynthesis (Lee et 





One designated NRPS BGC stood out in particular as being the likely candidate for 
the biosynthesis of 1 and is described in the subsequent sections.  
 
3.5 in silico analysis of the obafluorin (1) BGC 
The minimal oba BGC, is approximately 19 kbp in length. PCSs upstream of the 
cluster (orf12345678) could also play roles in precursor supply and export, potentially 
extending the cluster to 30 kbp (Figure 3.5). PCSs are reported in Table 3.3. Domains 
identified within each PCS by BLAST and Pfam are also stated. In the following 
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Transcriptional regulator ACT domain; PAS 
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Glycine cleavage system 
H-protein 
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Threonine tRNA ligase TGS domain; tRNA SAD 
domain; HMG-box DNA-
binding domain; threonyl-
tRNA synthetase class II 
























4e-4s single cluster 




















domain; WD40-like beta 











Table 3.3. PCSs identified in, and flanking, the putative obafluorin (1) BGC. 
Genes are annotated in accordance with Figure 3.5. 
 
 
3.5.1 Biosynthesis of 2,3-DHBA (6)  
Bioinformatic analysis of the oba BGC, suggested that three PCSs encode for the 
well understood pathway to 6 from chorismate (Figure 3.6a), a major branch point in 
the shikimic acid pathway to proteinogenic aromatic amino acids (Knaggs, 2003). 
obaN encodes an isochorismate synthase, which would act first to convert chorismate 
to isochorismate. The subsequent activities of obaJ, an isochorismatase, and obaL, 
a 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase, should then be sufficient to 
produce 6 (Figures 3.5 and 3.6a). 6 is a common constituent of bacterial siderophores 
(Hider and Kong, 2009) due to the ability of its deprotonated catechol group to 
coordinate metal ions. Homologues of obaJLN have previously been identified in the 
biosynthesis of enterobactin (Walsh et al., 1990), bacillibactin (May et al., 2001) and 
vibriobactin (Keating et al., 2000), which all comprise three catechol moieties for the 
coordination of ferric iron (Figure 3.6b). 
 
3.5.2 Biosynthesis of 4-APP (7) 
obaDEF also encode previously characterised functions in the chloramphenicol (He 
et al., 2001) and pristinamycin (Blanc et al., 1997) pathways, and should be 
necessary for the production of 7, another chorismate-derived intermediate (Figures 
3.5 and 3.7). 7 (or 8 derived from 7) is the proposed substrate of a ThDP-dependent 
enzyme during the biosynthesis of 2 (Figure 3.1). obaD and E are homologues of 
pabA/trpG (49% and 45% shared amino acid identity respectively) and pabB/trpE 
(31% and 28%) (Slock et al., 1990), which in primary metabolism, encode the two 
components of a 4-amino-4-deoxychorismate (ADC) synthase. This enzyme converts 








Figure 3.6. Proposed biosynthesis of 2,3-DHBA (6) and catechol-comprising 
NPs. (a) The proposed biosynthetic pathway to 6 catalysed by the products of 
obaJLN. Homologues in the enterobactin biosynthetic pathway are also depicted. (b) 
Examples of NP siderophores that incorporate 6 during their biosynthesis. 6 moieties 
are highlighted in orange, consistent with Figure 3.5.  
 
 
Figure 3.7. Proposed biosynthesis of 4-APP (7) and NPs with 4-APP-derived 
moieties. (a) The proposed biosynthetic pathway to 7 catalysed by the products of 
obaDEF. Homologues in the chloramphenicol (Cml) and pristinamycin IA (Pap) 
biosynthetic pathways are also depicted. (b) Examples of NPs that incorporate 7-
derived moieties - highlighted in turquoise, consistent with Figure 3.5. 
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to generate 4-aminobenzoic acid (4-ABA) for incorporation into folic acids. In 
chloramphenicol and pristinamycin biosynthesis, the two ADC synthase components 
are fused as a single enzyme encoded by cmlB and papA respectively (Figure 3.7a). 
In these specialised metabolic contexts ADC is not converted to 4-ABA, but is instead 
converted to 4-amino-4-deoxyprephrenate by an ADC mutase, before final 
conversion to 7 by a 4-aminoprephrenate dehydrogenase. These functions are 
encoded in the bifunctional product of obaF (Figure 3.5 and 3.7a), and in the discrete 
genes cmlD/papB and cmlC/papC in the chloramphenicol and pristinamycin BGCs. 
 
3.5.3 Biosynthesis of AHNB (2) 
In accordance with Herbert and Knaggs’ hypothesis for the biosynthesis of 2 (Herbert 
and Knaggs, 1990), a ThDP-dependent enzyme is encoded in the proposed oba BGC 
by obaH, which is annotated as a phenylpyruvate decarboxylase (pPDC). This type 
of activity was proposed to be responsible for catalysing C-C bond formation between 
7 (or 8) and glyoxylate to generate an acyloin intermediate of 2 (Figure 3.1). The obaH 
encoded amino acid sequence was submitted for analysis using the Phyre2 server 
(Kelley et al., 2015), and the highest structural match was to a pyruvate oxidase from 
E. coli with 95% coverage and 100% confidence. Intriguingly, there is no 
transaminase for acyloin transamination encoded in close proximity to the oba BGC 
cluster (Figure 3.5), which would imply that a background enzyme is able to fulfil the 
function of introducing the α-amino group of 2, if the previous proposal was correct 
(Herbert and Knaggs, 1990). In both chloramphenicol and pristinamycin biosynthesis 
(Blanc et al., 1997; He et al., 2001), the transaminase required for introducing the 
aminophenyl group of 3 is also not encoded in either BGC.  
 
3.5.4 Obafluorin (1) dipeptide assembly 
At the centre of the oba BGC is the dimodular NRPS-encoding gene obaI (Figure 
3.5), the product of which was predicted to catalyse formation of the amide bond 
between 2 and 6. The thioesterase (TE) domain of ObaI is unusually located between 
the peptide carrier protein (PCP2) domain and first adenylation (A1) domain, which 
could catalyse release of the resulting enzyme bound pseudo-dipeptide with 
concomitant formation of the β-lactone moiety to yield 1. This was proposed because 
no oleC homologue (Christenson et al., 2017) is present in the 1 BGC. Analysis of 
the A-domain sequences of ObaI using NRPSpredictor2 (Röttig et al., 2011) identified 
6 as the likely substrate of A1, whereas L-threonine was predicted to be the substrate 




The domain architecture of ObaI is further unusual as the putative A1-domain is 
located at the C-terminus of the enzyme, rather than towards the N-terminus as would 
be expected. Moreover, A1 is adjacent to an embedded MbtH-like protein domain. 
MbtH-like proteins are auxiliary proteins required for the activity of many NRPS A 
domains (Quadri et al., 1998a; Felnagel et al., 2010; Baltz, 2011). Some A domains 
require MbtH-like proteins for their functional expression, suggesting MbtH-like 
proteins may have a chaperone-like function (Heemstra et al., 2009). Embedded 
MbtH-like domains like that observed in the product of ObaI are rare, and discrete 
MbtH-like proteins are more commonly observed. Embedded MbtH-like domains in 
NRPSs have been reported for only two other BGCs: those responsible for the 
biosynthesis of nikkomycin (Chen et al., 2002) and streptolydigin (Herbst et al., 2013). 
During streptolydigin biosynthesis, an A-MbtH-like didomain protein is involved in the 
activation of 3-methylaspartate. Whilst the amino acid residues critical for inter-
domain interaction between these fused domains are well characterised at the 
structural level, no biochemical data exists to verify that in cis domains are functionally 
essential in vivo. The exact role of MbtH-like proteins in NRPS catalysis is also yet to 
be determined.  
 
ObaI also contains only a single PCP2 domain where two such domains would be 
expected for its correct function. Further analysis of the BGC suggested that obaK 
encodes the ‘missing’ discrete aryl carrier protein (ArCP1). The presence of an ArCP 
is anticipated as this protein function would be required for the tethering of 6 (following 
activation by the A1-domain) to participate in amide bond formation. Despite, their 
unusual organisation, all of the domains necessary for the assembly of 1 are 
accounted for by ObaIK (Figure 3.5). 
 
3.5.5 Nitro group formation 
The gene obaC encodes a putative non-heme di-iron monooxygenase related to the 
arylamine oxygenases AurF from the aureothin pathway (73% query cover, 25% 
identity) (He and Hertweck, 2001; Choi et al,. 2008) and ClmL from the 
chloramphenicol pathway (72% query cover, 19% identity) (Lu et al., 2012; Knoot et 
al., 2016). This enzyme was predicted to install the nitro group of 1. Although the 
timing of N-oxygenation during the biosynthesis of 1 cannot be determined based on 
in silico data alone, both AurF and CmlL catalyse the conversion of an aromatic amine 
to a nitro group at intermediate stages in their respective biosynthetic pathways 
(Figure 3.8a and b), so ObaC activity is illustrated at an earlier stage of 1 biosynthesis 







Figure 3.8. N-oxygenation during NP biosynthesis. (a) N-oxygenation of 4-ABA 
catalysed by AurF during aureothin biosynthesis. (b) N-oxygenation of 4-amino-β-
hydroxyphenylalanyl-S-PCP by CmlL during chloramphenicol biosynthesis. (c) 






specific substrate, as illustrated in Figure 3.8c, and experimental work will be required 
to confirm which it the true substrate. 
 
3.5.6 Precursor supply 
With all the biosynthetic functions necessary for 1 production seemingly accounted 
for, several unassigned PCSs in the oba BGC remained that could potentially be 
involved in supplying important precursors to biosynthetic enzymes in the 1 pathway 
(Figure 3.5). obaM for example, encodes a putative type II DAHP synthase, the first 
enzyme in the shikimic acid pathway (Figure 3.9). Homologues of this gene have 
been observed in a number of bacterial BGCs (Blanc et al., 1997; He et al., 2001; 
Gulder and Moore, 2010), where their products are believed to mitigate the aromatic 
amino acid-based negative feedback of primary metabolic type I DAHP synthases 
(Knaggs, 2003), and drive flux into specialised metabolism. This indicates a likely role 
for ObaM in chorismate supply for the biosynthesis of both 2 and 6. 
 
ObaG encodes a putative SHMT, a ubiquitous PLP-dependent enzyme that catalyses 
the interconversion of L-serine and glycine (Figure 1.11), using tetrahydrofolate (THF) 
as a C1 group acceptor (Schirch et al., 1985). Given that Herbert and Knaggs 
demonstrated that glycine (via glyoxylate) is the likely source of the C-1 and C-2 in 2 
(1990; 1992b), it seemed possible that this additional copy of SHMT was involved in 
driving flux through the ObaH-catalysed reaction by supplying an excess of 
glyoxylate. ObaM would work in parallel, supplying chorismate for the biosynthesis of 
6 and 7, the other substrate of the proposed ObaH-catalysed reaction. The presence 
of an intact glycine cleavage system (GCS) encoded by orf2345 upstream of the main 
oba cluster made a role for ObaG in precursor supply more convincing, because it 
too can operate reversibly to generate glycine from CO2, NH4+ and 5,10-methylene-
THF (Kikuci et al., 2008), potentially operating in tandem with ObaG to supply ObaH 
with glycine (glyoxylate) (Figure 3.10). 
 
3.5.7 Regulation of obafluorin (1) biosynthesis 
obaA and obaB encode LuxR and LuxI homologues respectively, indicating that the 
biosynthesis of 1 is regulated in a quorum sensing (QS)-dependent manner. Bacteria 
are able to synchronise gene expression and particular behaviours as a function of 
population density via the release of small signalling molecules called autoinducers 
(Camilli and Bassler, 2006). These alter gene expression when they are detected 
above a minimum threshold stimulatory concentration. In Gram-negative bacteria, the 







Figure 3.9. Role of DAHP synthase in the shikimic acid pathway to aromatic amino acids. DAHP synthases catalyse the stereospecific 







Figure 3.10. Illustration of the reactions catalysed by the glycine cleavage 
system (GCS). The glycine cleavage system catalyses the following reversible 
reaction: glycine + THF + NAD+ ⇌ 5,10-methylene-THF + CO2 + NH3 + NADH. The 
H-protein, modified with lipoic acid, functions to shuttle intermediates between the P-
protein (a glycine dehydrogenase), the T-protein, (and aminomethyltransferase) and 
the L-protein (a dihydrolipoyl dehydrogenase). It is an important part of the glycine 





and are the product of autoinducer synthases of the LuxI family, named after the first 
characterised member from the bioluminescent bacterium Vibrio fischeri. AHLs all 
share a common homoserine lactone moiety, but comprise distinct acyl side chains. 
These side chains are recognised by specific LuxR-type receptor enzymes, the acyl-
binding pockets of which exclusively accommodate the acyl-chain of their cognate 
AHL signal. LuxR-AHL complexes bind DNA promoter regions and activate the 
transcription of QS-controlled genes. QS is employed by bacteria to regulate 
processes that require the combined contribution of numbers of cells to be productive, 
including bioluminescence, biofilm formation, antibiotic production and virulence 
factor expression as examples (Camilli and Bassler, 2006). Whilst not within the 
scope of this project, experiments to investigate the regulation of the biosynthesis of 
1 are discussed in Chapter 9. 
 
3.5.8 Unassigned PCSs  
Several PCSs within the 30 kbp putative oba BGC could not be assigned direct roles 
in 1 production. Orf6 encodes a cold shock protein, thought to counteract the harmful 
effects of rapid drops in temperature. They are proposed to act as nucleic acid 
chaperones, preventing secondary structure formation in mRNA and maintaining 
normal levels of translation initiation (Jiang et al., 1997). Orf7 encodes a predicted 
transmembrane protein belonging to the RDD family, so-called because they contain 
one highly conserved arginine and two highly conserved aspartate residues. Orf7 
could possibly be involved in 1 export but the roles of RDD family proteins have not 
been well characterised. Orf8 encodes a quinolinate synthase, an iron-sulphur 
enzyme responsible for the biosynthesis of quinolinate, the precursor of the 
ubiquitous cofactor nicotinamide adenine dinucleotide (NAD) (Ollagnier-de Choudens 
et al., 2005). NAD is involved in numerous redox reactions through hydride transfer, 
and the products of both obaF and obaL comprise a Rossman fold that could bind it 
as a cofactor for catalysis. However, a role in cofactor supply is unlikely given there 
are no enzymes involved in ThDP or PLP biosynthesis associated with the cluster 
and cofactor biosynthetic genes are not typically found in NP BGCs. Finally, orf1 
encodes a σ-54 transcriptional regulator homologous to the multidomain TyrR protein, 
a regulator of aromatic amino acid biosynthesis and transport (Pittard et al., 2005). 
The presence of a DAHP synthase gene obaM in the cluster indicates that chorismate 
supply from the shikimic acid biosynthetic pathway is tightly coordinated in the 
biosynthesis of 1, and whilst its presence could be purely coincidental, it is not 
unreasonable to wonder whether a tyrR-like gene might also contribute to the 
regulation of chorismate supply. 
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 3.5.9 Identifying oba BGC boundaries 
Upstream of orf1 are PCSs encoding products involved in arginine and ornithine 
metabolism including a carbamate kinase, ornithine transcarbamylase, arginine 
deaminase and two arginine/ornithine antiporters. Downstream of obaN are two 
PCSs followed by a lysine tRNA gene, which has been identified as a common site 
of integration for genomic islands in Pseudomonas spp. (Williams, 2002; Mavrodi et 
al., 2009), and could well indicate the true downstream boundary of the oba cluster. 
The two PCSs encode a threonyl-tRNA synthetase (ThrRS), responsible for ligating 
L-threonine to the nucleotide triplet of its cognate tRNA (Sankaranarayanan et al., 
1999), and a PK cyclase, enzymes typically responsible for the aromatisation of PKs. 
Intriguingly, the PK cyclase PCS product shares 59% amino acid sequence identity 
with MgoD, the missing PCS from the incomplete mangotoxin BGC encoded 
elsewhere in the P. fluorescens ATCC 39502 genome. It is unlikely that these PCSs 
play any role in the production of 1, are more likely present by chance, falling within 
the lysine tRNA recombination site boundary. 
 
3.6 Discussion 
High molecular weight genomic DNA was prepared and submitted for sequencing 
using the PacBio SMRT platform. A single contig representing a single circular 
chromosome for the strain was obtained and was found to closely resemble the 
architecture and composition of other representative P. fluorescens strains. ATCC 
39502 was identified as a more ‘talented’ producer of NPs with 17 BGCs identified, 
compared to around ten in other strains. NRP BGCs were well represented with eight 
being identified and amongst those the likely oba cluster was readily identified (Figure 
3.5). 
 
Whilst several of the putative BGCs identified in the ATCC 39502 genome were 
assigned to known NPs such as pseudomonine and pyoverdine, the majority are 
orphan clusters for which the product has not been identified. Predictions were also 
possible for two poeamide-like BGCs. Perhaps the most unusual putative BGC was 
a cluster comprising a dimodular class I terpene synthase/cytochrome P450 enzyme, 
a class I SAM methyltransferase and an IPP isomerase. While around 50,000 
terpenoid metabolites representing nearly 400 distinct families have been isolated 
from plants and fungi, only a minor fraction have been identified in prokaryotes 
(Yamada et al., 2015). Their discovery and characterisation is challenging because 
bacterial terpene synthases share low amino acid sequence similarity to fungal and 
plant enzymes, and typically show low levels of mutual sequence similarity. Neither 
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terpenoid NPs nor terpene synthases have been described in the pseudomonads, 
but these three clustered genes appear to be highly conserved among a number of 
Pseudomonas spp. and perhaps warrant further investigation. Blastp analysis of the 
terpene synthase domain identified that all the conserved residues for substrate 
binding and for chelation of 3Mg2+ ions, responsible for ionisation of DMAPP (Oldfield 
and Lin, 2012), are present. In order to determine whether this cluster (minimally 3.6 
kbp) is functional and does produce a terpenoid NP, it could be cloned for expression 
in a heterologous host such as P. putida, which is known for its metabolic versatility 
and which does not contain the cluster (Loeschcke and Thies, 2015).  
  
The proposed oba BGC comprises PCSs encoding products for the biosynthesis of 6 
(obaJLN) and 7 (obaDEF) from chorismate. These have previously been well 
characterised in the biosynthetic pathways to several siderophore NPs, and to 
chloramphenicol and pristinamycin I and II respectively. Central to this project is the 
presence of a ThDP-dependent pPDC, obaH, proposed by Herbert and Knaggs to 
catalyse an C-C bond forming reaction between glyoxylate and 7 to generate 2 
(Figure 3.1).  
 
obaI and obaK, encode an NRPS and discrete ArCP respectively, which between 
them comprise all the domains deemed necessary to assemble 1 from 2 and 6, and 
form the β-lactone ring of the final product. The unusual organisation and MbtH-like 
domain in the product of obaI is intriguing. On the basis of these analyses one might 
hypothesise that the noncanonical positioning of A-domains within the assembly line 
provides them both access to the embedded MbtH-like domain, a potential 
prerequisite for efficient catalysis. This organisation likely precludes functional 
interaction of the A1 domain and the condensation (C2) domain, a consequence of 
which is the requirement for a discrete, and therefore mobile, ArCP1 (ObaK). This 
would enable both interaction with the A1 domain for acylation with 6, and subsequent 
interaction with the C2-domain for peptide bond formation. It would be important to 
query this possibility as obaK appears to have evolved by the splitting of an ancestral 
entB-like gene, which usually encode for didomain proteins involved in the 
biosynthesis of 6 (Walsh et al., 1990; Drake et al., 2006). Indeed, the adjacent obaJ 
gene corresponds to the N-terminal isochorismatase domain of EntB (Gehring et al., 
1997) and is required for production of 6.  
 
The final gene that could be assigned a biosynthetic function was obaC, which 
encodes an N-oxygenase likely to be responsible for oxygenation of the 1 
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phenylamino group to a nitro group. However, on what intermediate this N-
oxygentation occurs is unclear. The cluster also encodes several products which 
could play roles in driving flux through the biosynthetic pathway via the supply of 
important precursor molecules – chorismate in the case of obaM and glyoxylate from 
glycine in the case of obaG and orf2345. Finally, the biosynthesis of 1 appears to be 
regulated in a QS-dependent manner, due to the presence of luxI and R homologues 
obaA and B, but no experimental work was performed in this project to explore the 
regulation.  
 
Whilst the in silico data described above allow for a hypothesis for the biosynthesis 
of 1 to be made, experimental validation was required to confirm the involvement of 
PCSs described and to provide further information about the temporal organisation of 
biosynthesis (e.g. timing of N-oxygenation). Critically, it would allow the role of the 
obaH product in the pathway to be characterised and the mechanism proposed by 



















Chapter 4: Mutational analysis of the oba BGC 
 
4.1 Introduction 
In order to characterise NP biosynthesis at the molecular level, a range of different 
approaches can be used. The majority of methods employ comparative metabolic 
profiling to detect the presence or absence of NPs and their intermediates under 
different experimental conditions, often following the disruption of biosynthetic loci 
(Zerikly and Challis, 2008). For genetically intractable organisms, the cloning and 
expression of entire BGCs in heterologous hosts can link an NP to its BGC, through 
the detection of non-native metabolites in the host background (Zhang et al., 2016). 
To this end, ‘super-hosts’ have been developed in which highly expressed native NP 
BGCs are removed to aid the identification compounds biosynthesised from 
introduced BGCs (Gomez-Escribano and Bibb, 2011). Removal of native BGCs has 
the added benefit of increasing the availability of primary metabolites for biosynthesis 
in the heterologous host. A similar result has recently been achieved by deleting hfq 
in Photorhabdus and Xenorhabdus spp., which causes the majority of native NP BGC 
to become post-transcriptionally ‘silent’ (Tobias et al., 2017). In vitro reconstitution of 
biosynthetic pathways mitigates the need for a host all together and removes the 
restrictions of regulatory mechanisms. However, problems can be encountered in 
achieving the expression of multiple soluble biosynthetic proteins, and in obtaining 
complex precursors required as substrates.  
 
Genetic tools for P. fluorescens are reasonably well established, allowing for the 
comparison of WT and Δoba strains to identify genes responsible for production 
based on the presence or absence of particular metabolites. Given the assembly-line 
paradigm of NP biosynthesis, in some instances it is possible to detect the immediate 
substrate of a disrupted biosynthetic enzyme, which accumulates because it is no 
longer utilised. In this way, a top-down approach can be used to dissect biosynthetic 
pathways based on the accumulation of pathway intermediates. Many intermediates 
are often unstable or recycled by primary metabolic pathways and so are not 
detectable, which can limit this approach.  
 
This chapter describes the use of mutagenesis to dissect the biosynthetic pathway 
for obafluorin (1). First, suitable 1 production conditions and analytical methods to 
define a measurable ‘phenotype’ were established and pure 1 was obtained for use 
as a reference in experiments. Suicide and complementation vectors were 
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constructed/modified to facilitate gene disruption and complementation of oba PCSs, 
and a series of mutagenetic experiments were then performed to disrupt different 
elements of the biosynthesis of 1. Mutagenesis of genes suspected to be involved in 
precursor supply was also performed to evaluate their necessity for production. 
Where possible, mutants were also complemented chemically to identify likely 
pathway products. Based on the accumulation of shunt metabolites and 
intermediates, predictions are made about the function and timing of different 
biosynthetic enzymes during the biosynthesis of 1.  
 
4.2 Analysis of obafluorin (1) production 
P. fluorescens was grown according to reported production conditions (Wells et al., 
1984), though soil extract was omitted from the OPM recipe and dH2O was used 
instead. LCMS/MS allowed the identification of the corresponding UV peak for 1. 
Cultures were then scaled up and 13 mg of 1 were purified (Materials and Methods 
section 2.10.1). Dr. Zhiwei Qin, a postdoctoral researcher in the group, subsequently 
subjected the purified sample to HPLC, HR-LCMS and NMR analyses, and all data 
matched published values (Tymiak et al., 1985). An analytical reverse-phase HPLC 
method was then established to allow facile detection of 1 production from small-scale 
100 mL cultures (Materials and methods section 2.10.2). 1 appears as a dominant 
peak when chromatograms are generated for absorbance at 270 nm (absorption 
maxima at 215 nm and 260 nm) with a retention time of ~10 min, along with five minor 
peaks that elute at slightly lower organic solvent concentrations (Figure 4.1). 10 
represents the hydrolysed ring-open form of 1 that is always present in reference 
samples due to the ease with which the β-lactone ring is hydrolysed, and this was 
verified by HR-LCMS.  Two of the peaks were identified as 4-NPE (4) and 4-NPAA 
(5) based on detection of exact masses by HR-LCMS and HPLC comparison with 
authentic standards. These compounds were also detected by Herbert and Knaggs 
(1988, 1990). Synthetic standards for AHNB (2), 4-APA (3), 2,3-DHBA (6), 4-NPP (8), 
AHAB (9) and 4-ABA were acquired or synthesised, but did not account for peaks A 
and B. These peaks could also not be isolated or detected by HR-LCMS. Synthetic 
standards of both 2 and 9 were prepared by Prof. Barrie Wilkinson and Dr. Daniel 
Heine in the group (see Materials and Methods 2.10.1). At this point the production 
phenotype for 1 was sufficiently characterised, with reference material for 1 and a 
broad range of plausible pathway intermediates and break down products acquired 





Figure 4.1. HPLC profile for a WT obafluorin (1) production culture extract at 270 nm. Verified peak identities are linked to the molecule 






4.3 Construction of vectors for mutational analysis 
4.3.1 pTS1 suicide vector construction 
To generate gene disruptions in predicted oba PCSs, Dr. Jacob Malone (JIC) kindly 
provided the ColE1-based suicide vector pME3087 (Voisard et al., 1994), for 
performing knockouts in Pseudomonas spp. This vector works by double homologous 
recombination using flanking regions of the gene for disruption. The first homologous 
recombination event that integrates the vector into the host genome is selected for 
with tetracycline, as a TcR cassette is encoded in the pME3087 backbone. Following 
a PCR-based screen for positive colonies, selected clones are grown through several 
generations in the absence of antibiotic to allow for a second recombination event to 
occur to excise the vector backbone, resulting in either a) a disrupted copy of the 
target gene; b) a revertant to the WT sequence; or c) the single-cross over condition 
being retained. Growth of cells that have lost the vector backbone is arrested by 
addition of a bacteriostatic concentration of tetracycline, and those that retain the 
backbone and continue to replicate due to the possession of the TcR cassette are 
subsequently killed by applying phosphomycin and piperacillin. Colonies that grow 
when subsequently plated can then be screened for tetracycline sensitivity and loss 
of the vector backbone. In a side project investigating a potential virulence target in 
P. aeruginosa PA01, the antibiotic enrichment for double recombinant strains was not 
very efficient and >100 colonies had to be screened in order to identify a bona fide 
deletion colony. A counter-selectable marker was therefore introduced into pME3087 
to improve selection efficiency. pME3087 was first sequenced de novo by primer 
walking (submitted the sequence to GenBank under the accession no. KX931446) to 
facilitate cloning of an appropriate marker gene.  
The Bacillus subtilis sacB gene, which encodes a levansucrase, is a popular marker 
for counterselection in Gram-negative bacteria, as strains carrying this gene die when 
grown on media containing sucrose (Gay et al., 1985). The mechanism of toxicity is 
not entirely understood but the accumulation of levans, high molecular weight fructose 
polymer products of SacB, in the periplasm of Gram-negative bacteria is thought to 
be responsible. Whilst a putative levansucrase is encoded in the P. fluorescens ATCC 
39502 genome, it did not appear to impede growth when the strain was grown on 7% 
sucrose LB agar. The sacB gene was therefore cloned as a 2,009 bp EcoRI fragment 
from the site-specific excision vector pFLP2 (Huoang et al., 1998) into pME3087, and 
successful clones were confirmed by colony PCR. Only clones possessing the sacB 
fragment oriented in which the direction of transcription was away from the pME3087 
multiple cloning site (MCS) were selected to prevent unwanted read-through. An NdeI 
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site introduced in the EcoRI fragment containing sacB was then removed by partial 
digestion and religation following treatment with Klenow DNA Polymerase (Materials 
and methods section 2.4.5), leaving a single NdeI site in the MCS. 
  
This vector was further tailored by introduction of an expanded MCS. Sense and 
antisense oligonucleotides (Appendix 1 – Supplementary Table 1) comprising six 
additional restriction sites (AvrII-MfeI-NcoI-BmtI-XhoI-NdeI) were ligated together and 
cloned into the pME3087 HindIII site, which was regenerated upstream of the new 
MCS. Intended modifications of the vector were confirmed by Sanger sequencing. 
XbaI, AvrII and BmtI do not cut within the oba BGC and so could be used for cloning 
oba PCS flanking regions for knockouts. The use of three restriction enzymes for all 
knockout constructs facilitates subcloning between them to create different 
combinations of flanking sequences. This new pME3087-derived suicide vector was 
named pTS1 (Figure 4.2a) and its sequence was also submitted to GenBank 
(accession no. KX931445). Figure 4.3 illustrates the efficiency of pTS1-mediated 
double crossover for selected oba PCS disruptions. Following the second 
recombination step all colonies tested were sensitive to tetracycline, indicative of 
successful loss of the vector backbone and the generation of WT revertant or genuine 
deletion colonies. Design of flanking regions for oba locus disruptions using this 
vector are described in the Materials and methods (section 2.5.1).  
 
4.3.2 pJH10TS complementation vector construction 
To ensure that effects of a particular gene disruption were non-polar, Prof. 
Christopher Thomas (University of Birmingham) generously supplied pJH10 (El-
Sayed et al., 2003), a self-replicating, broad range IncQ expression vector with an 
IPTG-inducible promoter that is constitutively expressed in P. fluorescens (Mattheus 
et al., 2010). This vector, and its derivatives, have been used extensively in his lab to 
complement mutants in the mupirocin biosynthetic pathway (El-Sayed et al., 2003; 
Hothersall et al., 2007). The MCS was expanded by ligating sense and antisense 
oligonucleotides (Appendix 1 - Supplementary Table 1) comprising five additional 
restriction sites (MfeI-PacI-BmtI-XhoI-NdeI) together and cloning them into the pJH10 
EcoRI site (regenerated upstream of the expanded MCS). The resulting 
complementation vector was named pJH10TS (Figure 4.2b). All alterations were 





Figure 4.2. Vector maps for the suicide and complementation vectors 
constructed in this work. (a) pTS1 and (b) pJH10TS. Maps generated using Vector 
NTI®. Restriction sites in red represent unique sites within the vector. 
 
 
Figure 4.3. Examples of pick and patch plates to test for tetracycline sensitivity 
following pTS1-mediated gene disruption. Colonies were patched on to LB 7% 
sucrose N100 agar ± Tc50 (- are blue and on the left in each pair, + are red and on the 
right). (a) Potential ΔobaK mutants (ArCP = aryl carrier protein), (b) Potential ΔobaF 
mutants (CM/PD = chorismate mutase/prephrenate dehydrogenase), (c) Potential 
ΔobaJ mutants (IC = isochorismatase) and (d) Potential Δorf2345 mutants (GCS = 
glycine cleavage system). 
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4.4 Mutational analysis of oba loci 
Gene inactivation experiments were performed by generating in frame deletions using 
pTS1 and all resulting mutants were verified by PCR and Sanger sequencing. At least 
three independent mutants were checked for each gene deletion. All mutants were 
functionally confirmed and checked for the lack of polar effects by genetic 
complementation through ectopic expression of the deleted gene using pJH10TS. As 
required, chemical complementation with putative pathway intermediates was carried 
out in parallel by the addition of exogenous material to growing cultures. All strains 
and their complemented derivatives were grown in triplicate under 1-producing 
conditions (alongside the wild type (WT) strain), extracted with ethyl acetate and the 
extracts subjected to HPLC and HPLC-MS analysis (see Materials and Methods 
sections 2.5.5 and 2.10.2). Results in this chapter are described using HPLC profile 
data only, but HR-LCMS data were also acquired for confirmation of identified peaks. 
A revised biosynthetic pathway based on mutagenesis data presented in subsequent 
sections is illustrated in Figure 4.4. 
 
4.4.1 Disrupting the biosynthesis of 2,3-DHBA (6) 
Bioinformatic analysis suggested that obaJLN encode for proteins involved in the well 
understood pathway to 6 from chorismate (Figures 3.6 and 4.4). Deletion of either 
obaJ (an isochorismatase) (Figure 4.5) or obaL (a 2,3-dihydro-2,3-dihydroxybenzoate 
dehydrogenase) (Figure 4.6) led to the loss of 1 production and four to five-fold 
elevated levels of 4 and 5, which are proposed shunt metabolites of the biosynthesis 
of 2 (Herbert and Knaggs, 1988). The addition of exogenous 6 (0.2 mM final conc.) 
was sufficient to restore the biosynthesis of 1 to 71% and 68% of WT titres for ΔobaJ 
and ΔobaL, respectively. Ectopic expression of the deleted gene in their respective 
deletion backgrounds also restored 1 production, to 73% (obaJ) and 85% (obaL) of 
WT titres. By abolishing production of 6 (and therefore the pathway endpoint 1), it 
was anticipated that the predicted pathway intermediate 2 would accumulate (Figure. 
4.4). However, after exhaustive LCMS analysis and comparison with synthetic 
references, accumulation of 2 was not detected, nor was the potentially related 
pathway intermediate 9 (might accumulate if N-oxygenation is the final biosynthetic 
step). One further intriguing observation was the fact that the unusual purple colour 
of WT production cultures is lost in both ΔobaJ (Figure 4.7a) and ΔobaL strains. This 
phenotype was rescued in both genetically and chemically complemented strains 
where production of 1 had successfully been restored. This observation was made 
for all other Δoba strains in this chapter, and the significance of this colour change is 






Figure 4.5. HPLC profiles for obaJ mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 




Figure 4.6. HPLC profiles for obaL mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 




4.4.2 Disrupting the biosynthesis of 4-APP (7) 
obaDEF appear sufficient to encode for the production of 7 (Figures 3.7 and 4.4), the 
biosynthesis of which is well understood from previous genetic studies on 
chloramphenicol (He et al., 2001) and pristinamycin (Blanc et al., 1997) biosynthesis. 
Consistent with these predictions, deletion of the bifunctional gene obaF (a 
bifunctional 4-aminochorismate mutase/4-aminoprephenate dehydrogenase) led to 
the loss of 1, 4 and 5 production (Figure 4.8), which further indicated that these two 
shunt metabolites originate from some element of 2 biosynthesis. Addition of 
exogenous 3 (1 mM final conc.) was sufficient to restore production of 1 to between 
68%-71% of WT titres, as was the ectopic expression of obaF which restored 
production to between 73%-90% of WT titres. 3 is presumably converted to 7 by 
transamination in vivo to restore production. As with ΔobaJ and ΔobaL, the purple-
brown colour associated with 1 production is lost in ΔobaF, but is restored by genetic 
and chemical complementation (Figure 4.7b). Surprisingly, no accumulation of the 
pathway intermediate 6 could be observed in the obaF mutant.  
 
4.4.3 Disrupting the biosynthesis of AHNB (2) 
Mutation of obaH, which encodes a putative ThDP-dependent pPDC thought to be 
responsible for the biosynthesis of 2 (Figures 3.1 and 3.5), led to the abolition of 1 
production (Figure 4.9). 4, 5 and 6 did not accumulate in the ΔobaH strain, mirroring 
the ΔobaF phenotype. Ectopic expression of obaH led to the recovery of 1 production, 
albeit at lower titres of around 29% of WT production levels. This is reflected in the 
incomplete regeneration of the WT production culture colour phenotype (Figure 4.7c). 
Unfortunately, the addition of exogenous synthetic 2 or 9 (0.2-1 mM final conc.), the 
anticipated products of ObaH, did not recover 1 production in these mutants. One 
possible explanation for this is simply that they fail to penetrate the Pseudomonas cell 
membrane. Whilst it is clear that ObaH is important for the biosynthesis of 1, its exact 
function could not be determined by mutational analysis alone.  
 
4.4.4 Disrupting obafluorin (1) dipeptide assembly 
Deletion of obaI, which encodes a putative dimodular NRPS, abolished production of 
1, which was recovered to 79% of WT levels following ectopic complementation 
(Figure 4.10). The ΔobaI mutant accumulated the shunt metabolites 4 and 5 at similar 
levels to the WT strain, but, once again, exhaustive analysis of the fermentation 
extracts did not show any accumulation of 2 or 6, the putative substrates of ObaI. 
Deletion of the discrete ArCP obaK gave similar results to the ΔobaI mutant as 
expected, with 1 production abolished, and this was recovered by ectopic expression  
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Figure 4.7. Production culture flasks for WT, Δ and genetically complemented 
Δ strains. Left = WT; Middle = Δ strain; and right = genetically complemented Δ strain. 
(a) ΔobaJ (‘IC’ = isochorismatase); (b) ΔobaF (‘CM/PD’ = chorismate 
mutase/prephrenate dehydrogenase); (c) ΔobaH (‘PDC’ = phenylpyruvate 
decarboxylase); and (d) ΔobaC (‘NOx’ = N-oxygenase). 
Figure 4.8. HPLC profiles for obaF mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 
metabolites identified in Figure 4.4. 
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Figure 4.9. HPLC profiles for obaH mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 





Figure 4.10. HPLC profiles for obaI mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 
metabolites identified in Figure 4.4. 
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of obaK to 77% of the WT level (Figure 4.11). The titres of 4 and 5 also increased 
significantly (approx. four-fold) but again neither 2 nor 6 accumulated. Exogenous 
supply of 6 did not lead to production of 1 confirming that this phenotype is not linked 
to a lack of 6 biosynthesis. This possibility was queried because obaK appears to 
have evolved from the splitting of an ancestral entB-like gene, which usually encode 
for didomain proteins involved in the biosynthesis of 6 (Walsh et al., 1990; Drake et 
al., 2006). PCR and Sanger sequencing confirmed that obaK and obaJ represent 
independent PCSs. Both ΔobaI and ΔobaK, and their complemented mutants, 
displayed identical phenotypes in production cultures to their equivalents for obaJ as 
illustrated in Figure 4.7a. 
 
4.4.5 Disrupting nitro group formation 
The gene obaC encodes a putative non-heme di-iron monooxygenase expected to 
oxidise the 1 aromatic amino group derived from 7. This was predicted to utilise one 
of several pathway intermediates as its substrate (Figure 3.8c), but the precise 
substrate could not be identified by in silico analysis alone. Deletion of obaC 
abolished production of 1, 4 and 5 (Figure 4.12), and the biosynthesis of all three 
compounds was re-established after ectopic complementation with obaC to 81% of 
WT titres of 1. Surprisingly, only the addition of exogenous synthetic 8 (0.2 mM final 
conc.) to growing cultures of this mutant could restore the biosynthesis of 1 to 29% of 
WT titres, whereas addition of 2 did not. Furthermore, no shunt metabolites 
comprising an aminoaryl moiety were detected, consistent with ObaC functioning 
during precursor biosynthesis rather than as a final modification, likely preceding the 
activity of ObaH (Figure 4.4). N-oxygenase homologues AurF and CmlB, involved in 
aureothin and chloramphenicol biosynthesis respectively (He and Hertweck, 2001; 
Knoot et al., 2016), also function at an earlier stage in biosynthesis (Figures 3.8a and 
b). The characteristic colour of WT cultures is lost in ΔobaC and is replaced by a 
similar murky green colour to the ΔobaF strain (Figure 4.7d), perhaps offering further 
coincidental evidence that ObaC functions previous to ObaH. 
 
4.4.6 Disrupting precursor supply 
obaM, encoding a putative type II DAHP synthase, was predicted to be involved in 
ensuring a stable supply of chorismate for the biosynthesis of 2 and 6, mitigating the 
effects of negative feedback inhibition experienced by type I enzymes. However, 
whilst deletion of obaM led to the abolition of 1 production (Figure 4.13), it was 
surprising to observe the accumulation of 4 and 5 in this mutant, which indicated that 
the biosynthesis of 2 was proceeding normally. Moreover, exogenous supply of 6  
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Figure 4.11. HPLC profiles for obaK mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 





Figure 4.12. HPLC profiles for obaC mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 
metabolites identified in Figure 4.4. 
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(0.2 mM final conc.) alone was sufficient to restore production of 1 to 68–72% of WT 
titres, further indicating that biosynthesis of 2 is unperturbed by obaM deletion. 
Consistent with this, exogenous supply of 3 (transaminated to 7 - see 4.4.2) alone 
could not recover 1 production, but did lead to further elevated levels (five- to seven-
fold) of 4 and 5. Initial attempts to genetically complement this mutant by introducing 
pJH10TS-obaM failed, indicating possible polar effects of the mutation on genes 
involved in the biosynthesis of 6. The putative obaM methionine start codon for this 
gene was selected based on Prodigal PCS identification and homologous sequences 
returned in blastn database searches, however further analysis of the genome 
sequence revealed three alternate potential start codons. Cloning of the gene using 
each possible start codon in pJH10TS and their introduction into the ΔobaM 
background allowed the identification of the true start codon – a valine (GTG) forty-
one codons upstream of the predicted start site that overlaps with the PCS of obaL. 
The PCSs of obaJKLMN thus overlap to form a putative operon, perhaps reflecting 
the observed dependence of enzymes involved in 6 biosynthesis on ObaM function 
in chorismate supply. Ectopic expression of obaM using this alternate start codon 
recovered 1 production to 50–55% of WT titres, precluding the possibility of polar 
effects on obaJLN. For ΔobaM strains, the purple colour is lost in the mutant strain 
but is restored by genetic or chemical complementation (i.e. not when 3 is fed alone 
to ΔobaM), creating similar phenotypes as illustrated for ΔobaJ (Figure 4.7a). 
 
Initially we proposed that ObaG, a putative SHMT, in conjunction with the GCS 
encoded by orfs2345 (Figures 3.1 and 3.10), could function to supply glycine to drive 
flux through the ObaH-catalysed ThDP-dependent reaction to form 2. Given the pool 
of free glycine in the cell supplied via primary metabolism, one might expect a drop in 
1 titre as a result of disrupting either the orf2345-encoded GCS or ObaG. However, 
a deletion across orf2345 did not result in an observable decrease in 1 titre (or loss 
of purple colour), which could be explained by the richness of 1 production medium 
(OPM) obviating the need for additional mechanisms of glycine supply. Surprisingly, 
disruption of obaG resulted in the complete loss of 1 production, and the accumulation 
of 4 and 5 (Figure 4.14), as well as loss of purple colour from production cultures 
(ΔobaJ phenotype – Figure 4.3a). This indicated a potential biosynthetic role for 
ObaG; the accumulation of shunt metabolites 4 and 5 suggested their origin from an 
intermediate between ObaH and ObaG, placing ObaG as the enzyme directly 
responsible for the biosynthesis of 2. This strongly suggested that 4-
nitrophenylacetaldehyde (4-NPA; 11) might be the key intermediate, and Hebert and 











Figure 4.13. HPLC profiles for obaM mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 




















Figure 4.14. HPLC profiles for obaG mutagenesis and complementation 
experiments at 270 nm. Numbered peaks refer to key products and shunt 













4-aminophenylacetaldehyde, might be an alternative precursor in the biosynthesis of 
2 (Herbert and Knaggs, 1990; 1992b). Consistent with this hypothesis, the addition of 
exogenous 11 (0.2 mM final conc.) to growing cultures of the ΔobaG mutant did not 
restore 1 production, but did lead to elevated levels of 4 and 5. Ectopic expression of 
obaG in the deletion strain restored 1 production to 62% of WT titres (and purple 
culture colour as for obaJ – Figure 4.7a) but again, 2 and 9 failed to recover 1 
production as before, necessitating further experiments to ascertain the exact 
function of ObaG.  
 
4.5 Discussion 
Acquisition of the sequence data for the oba BGC allowed in vivo mutational 
experiments to be designed and performed. To this end, the suicide vector pTS1 was 
developed to create in-frame deletions in a number of proposed oba biosynthetic 
genes. To ensure individual deletions did not result in polar effects on other 
biosynthetic genes, the complementation vector pJH10TS was also developed for the 
ectopic expression of WT genes in their respective mutant strain backgrounds.  
 
All knockouts of proposed biosynthetic enzymes led to the abolition of 1 production, 
confirming that the identified BGC is responsible for the biosynthesis of 1. 
Furthermore, all genes disrupted could be complemented genetically, giving 
confidence that any observed alterations in metabolite production profiles were the 
result of an individual specific PCS disruption and not due to polar effects. 
 
Aside from the abolition of 1 production, the only other noticeable changes in 
metabolite profiles for Δoba strains was the accumulation of 4 and 5. These shunt 
metabolites were initially determined to originate from some intermediate in the 
biosynthesis of 2, given that they failed to accumulate in ΔobaC, ΔobaF and ΔobaH 
backgrounds. This result supported the hypothesis that ObaF was functioning 
analogously to CmlDC and PapBC in chloramphenicol and pristinamycin biosynthesis 
respectively, and was further supported by the return of 1 production with exogenous 
supply of 3. By association, it is reasonable to assume that ObaD and ObaE also 
function analogously to homologues in those pathways to convert chorismate to 7 
(Figure 3.7a). At no point were any metabolites comprising an aminoaryl group 
detected, indicating that ObaC functions early during the biosynthesis of 2, probably 
before the activity of ObaH (Figure 4.4). This was supported by the absence of 
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nitroaryl shunt metabolites 4 and 5 in ΔobaH production cultures, and the fact that 
addition of exogenous 8 restored 1 production in the ΔobaC mutant. 
 
ObaJLN are also assumed to function analogously to their homologues in 
enterobactin biosynthesis (Figure 3.6a), given that 1 production is abolished with 
concurrent accumulation of 4 and 5 in both ΔobaJ and ΔobaL. Recovery of production 
by addition of exogenous 6 indicated that it is indeed the product of these three 
enzymes. The suggested role in 1 assembly for the NRPS ObaI and ArCP ObaK was 
similarly supported by the abolition of 1 production and accumulation of 2-derived 
nitroaryl shunt metabolites in their respective mutant backgrounds. Given that obaK 
appears to have evolved from the splitting of an ancestral entB-like gene (didomain 
ArCP/isochorismatase), 6 was also exogenously fed to this mutant but did not result 
in 1 production, indicating that it represents a discrete enzyme that is not required for 
the biosynthesis of 6.  
 
One slightly confounding result was the finding that an ΔobaM deletion only impacted 
the biosynthesis of 6 – evidenced by the fact that both 4 and 5 accumulate in this 
mutant, which suggested that enzymes responsible for the biosynthesis of 2 are still 
functional. This observation was supported by the recovery of 1 production following 
exogenous supply of 6 alone, and the failure to restore production on addition of 3 
alone (which is readily transaminated to 7 in the cell, thereby supplying an 
intermediate in the biosynthesis of 2 – see 4.4.2). This is surprising because the 
proposed role of ObaM is in ensuring sufficient chorismate is supplied to the pathway 
which is required for the biosynthesis of both 1 precursor acid substrates (Figures 
3.10 and 4.4). The apparent impact on the biosynthesis of 6 is not completely without 
precedent however as a DAHP synthase in the vanchrobactin BGC was shown to be 
essential for the growth of Vibrio anguillarum under iron-limiting conditions (Balado et 
al., 2008). Vanchrobactin comprises a single 6-derived moiety, though the impact of 
type II DAHP synthase deletion on the biosynthesis of 6 in this case is also not 
understood. Furthermore, obaM is located in an operon with obaJKLN, perhaps 
reflecting a dependence of their products on the presence of ObaM. The differential 
effects of the ΔobaM mutation on the biosynthesis of 1 precursors are hard to 
rationalise but possible explanations might include the necessity for protein-protein 
interaction between ObaM and one or more of ObaJLN, or that the biosynthesis of 7 
can occur via an alternate mechanism to that proposed here for ObaDEF, perhaps 
from conversion of a metabolite downstream from chorismate. The latter suggestion 
is more likely given that homologues of obaJLN occur in BGCs that do not comprise 
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a type II DAHP synthase, e.g. enterobactin (Walsh et al., 1990). Deletions in obaD 
and obaE should be performed to confirm that these enzymes fulfil identical roles to 
their homologues in chloramphenicol and pristinamycin biosynthesis (Blanc et al., 
1997; He et al., 2001), and that 7 cannot be supplied via an alternate route. 
 
This left the biosynthesis of 2 as the remaining unknown, and the product of obaH to 
be functionally assigned. Its deletion led to the abolition of 1 production and nitroaryl 
shunt metabolites did not accumulate, implicating the involvement of ObaH in the 
biosynthesis of 2. Unfortunately, whilst genetic complementation was possible, the 
introduction of either synthetic 2 or 9 failed to restore 1 production. This is predicted 
to be due to the inability of these substrates to cross the P. fluorescens cell membrane 
and mutagenesis alone was thus not sufficient to demonstrate the exact function of 
ObaH in the biosynthesis of 2. However, the disruption of obaG also led to the 
abolition of 1 production, indicating an unforeseen biosynthetic role. The 
accumulation of both 4 and 5 in ΔobaG but not ΔobaH suggested that ObaG performs 
an additional step between ObaH and ObaIK-mediated assembly, and that 11 might 
be the key intermediate. 11 was confirmed as the source of 4 and 5 based on elevated 
levels of their accumulation when 11 was exogenously fed to ΔobaG. Feeding with 2 
or 9 failed to restore 1 production in the ΔobaG background, as for ObaH, and so 
again further experimental work was required to characterise the ObaG-catalysed 
reaction. This is the subject of Chapter 5. 
 
These observations led to the formulation of an alternative biosynthetic scheme for 2 
(Figure 4.15) in which ObaH is a ThDP-dependent decarboxylase that generates 11 
by decarboxylating 8 as a substrate for ObaG. ObaG might then act as a 
transaldolase rather than an SHMT, catalysing the retro-aldol cleavage of L-serine to 
generate a PLP-stabilised quinonoid intermediate and formaldehyde, before 
subsequently catalysing C-C bond formation between enzyme-bound glycine and 11 
to form 2. This hypothetical pathway has three advantages over an entirely ThDP-
dependent mechanism: 1) The use of 11 as an intermediate explains the absence of 
4 and 5 accumulation in ΔobaC, F and H mutants but their presence in the ΔobaG 
background; 2) the use of an amino acid substrate obviates the need for a 
transaminase (not present in the cluster) to install the α-amino group on 2; and 3) The 
C1 formaldehyde unit by-product of the reaction could then be recycled by the orf2345-
encoded GCS, to generate further L-serine from glycine and drive flux through the 









Figure 4.15. First proposed biosynthetic mechanism for the biosynthesis of AHNB (2) involving ObaG acting as a transaldolase. The 
initial hypothesis proposed by Herbert and Knaggs (1990) is re-illustrated below. Glycine imine (boxed) could also be a substrate for ObaH – 







(glyoxylate) to the ThDP-dependent reaction but could be operating in the reverse 
direction to generate serine as a substrate for a PLP-dependent mechanism (Figure 
3.10). Disruption across these four genes did not lead to 1 production loss and further 
experiments based on minimal conditions would be required to determine the role of 
orf2345 in the biosynthesis of 1, if any. Another possibility is that ObaG is an SHMT/L-
TA that has evolved to efficiently catalyse an aldol-type C-C bond formation reaction 
between glycine and 11, without initial amino acid cleavage. However, this seems 
unlikely given previous attempts to engineer these enzymes to catalyse aldol 
reactions (Fesko, 2016). 
 
The accumulation of pathway intermediates and shunt metabolites in oba locus 
mutants was limited to the breakdown products of 11. At no stage were any aminoaryl 
breakdown products, 2 or 6 detected, despite exhaustive searches for them. The 
former can be explained by the functioning of the N-oxygenase ObaC at an early 
stage in biosynthesis and the substrate specificities of subsequent enzymes requiring 
the presence of the nitroaryl group. Absence of 2 from ΔobaJ, L, K and I strains is 
likely due to the breakdown of this nonproteinogenic amino acid for recycling through 
primary metabolic pathways. Indeed, the L-threo stereochemistry of 2 (see Chapter 
5) would potentially make it a substrate for cleavage by an L-threonine aldolase (L-
TA), a primary metabolic enzyme that is able to cleave β-OH-α-AAs to generate 
glycine and an aldehyde by-product (Fesko, 2016). In this case the aldehyde product 
would be 11, which has been shown to be degraded to 4 and 5. The absence of 6 
can be explained by the observation that cultures of ΔobaJ and ΔobaL supplied 
exogenous 6 at concentrations above ~0.4 mM, both growth of P. fluorescens and 
biosynthesis of 1 are adversely affected, and thus it is likely prevented from 
accumulating in the cell. Taken together these combined data suggest that the 
biosynthetic pathway is tightly regulated to avoid the accumulation of intermediates 
deleterious to cell growth and survival. Strategies to avoid the accumulation of toxic 
intermediates in NP biosynthetic pathways are well reported. A recent example 
relevant to this work is found in ripostatin biosynthesis, in which the intermediary of 
free phenylacetaldehyde, a reactive aldehyde structurally similar to 11, is avoided via 
the activity of a pyruvate dehydrogenase-like complex. This complex functions to 
decarboxylate phenylpyruvate and then retain the phenylacetaldehyde product as a 
phenylacetyl-S-carrier protein species (Fu et al., 2017). Whilst not necessarily 
conducive to the elaboration of steps in a biosynthetic pathway, mechanisms of toxic 





Finally, whilst the lysine tRNA gene represents one likely boundary of the oba BGC, 
the boundary upstream of obaA remains to be defined. Possible roles for 
orfs12345678 were proposed in Chapter 3, and a simple experiment to determine 
their involvement in the biosynthesis of 1 would be to perform a large deletion across 
all 8 PCSs. If 1 production is affected, then subsequent smaller deletions can be 
performed to identify individual PCSs responsible. The PK cyclase encoded in the 
cluster has also not been studied, though this is likely to be an artefact of HGT that is 
inherited with the cluster by virtue of its position between 1 biosynthetic loci and the 
lysine tRNA gene. pTS1-mediated disruption of this gene should determine whether 
it is significant for the biosynthesis of 1 or not, but no biosynthetic role could be 
ascribed based on in silico analysis. The threonyl-tRNA synthetase (ThrRS) gene 
located between obaN and the lysine tRNA gene will be explored further in Chapter 
8. 
 
The mutagenesis and complementation experiments described here have confirmed 
the identity of the BGC necessary for 1 production and this was deposited in GenBank 
under the accession no. KX931446. Furthermore, the likely function of oba loci was 
determined, in addition to gaining further understanding of the order of biosynthetic 
steps (e.g. N-oxygenation). The absence of toxic precursors/shunt metabolites in 
Δoba strains, and the importance of obaM in the biosynthesis of 6, indicates that the 
1 biosynthetic pathway is subject to very tight regulation. Critically, whilst these 
experiments demonstrated the essentiality of obaH in 1 production, and identified that 
a potential biosynthetic role for obaG, failed chemical feeding experiments with 2 and 
9 left the exact function of these enzymes during the biosynthesis of 2 to be 
determined. In order to achieve this, an alternative approach described earlier, in vitro 
reconstitution, was applied to characterise the function of these two enzymes 
independently of the cell and potential interference from primary metabolic pathways. 

























Mutational analysis of oba biosynthetic loci revealed that the correct BGC for the 
biosynthesis of obafluorin (1) had been identified and, critically, that obaH, encoding 
a ThDP-dependent pPDC, is essential for its production. Furthermore, the absence 
of 4-NPE (4) and 4-NPAA (5) accumulation in the ΔobaH strain was consistent with 
a role in the biosynthesis of AHNB (2). 8 appeared to be a likely substrate of ObaH, 
which was proposed to introduce two further carbons to the side chain from 
glyoxylate, though this was not validated experimentally. ThDP-dependent enzymes 
are ubiquitous in nature and participate in numerous biosynthetic pathways, 
catalysing a wide range of reactions typically involving formation or cleavage of C-C 
bonds, making one an ideal candidate for this reaction (Jordan, 2003; Müller et al., 
2013). The first step common to all ThDP-dependent reactions is the formation of a 
ThDP ylide, resulting from protein-assisted deprotonation at its C-2 atom (Andrews 
and McLeish, 2013), typically mediated by a highly-conserved glutamic acid active 
site residue. This activates the cofactor, allowing the subsequent decarboxylation of 
an α-keto acid to generate an active aldehyde ‘acceptor’ intermediate with two free 
electrons to participate in subsequent C-C bond formation.  
 
In the context of 2 biosynthesis, Herbert and Knaggs (1990) proposed that either 7 or 
8 act as the α-keto acid donor that is decarboxylated for subsequent C-C bond 
formation with glyoxylate to generate an α-hydroxy-β-keto acyloin intermediate 
(Figures 1.22 and 3.1). This would then need to be tautomerised to form the β-
hydroxy-α-keto equivalent for subsequent transamination to 2. Tautomerisation could 
occur either enzymatically or spontaneously, and if a subsequent transaminase was 
specific for the β-hydroxy-α-keto substrate, it would represent the ideal mechanism to 
shift the equilibrium of the reaction in favour of the necessary tautomer for 2 formation 
by kinetic resolution. By this logic, a transaminase specific for the α-hydroxy-β-keto 
acyloin would create the opportunity to access α-hydroxy-β-amino acids and the 
enhanced proteolytic stability they afford, as alluded to in the introduction. ThDP-
dependent enzymes are known to accept an extremely diverse set of substrates, and 
an alternate route to 2 using glycine imine as a substrate was also considered (Figure 
4.15). In this case, neither tautomerisation nor transamination would be required to 
generate 2. However, this is unlikely given stable isotope feeding experiments by 
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Herbert and Knaggs that showed glycine to be an excellent donor for C-1 and C-2 in 
2 (Herbert and Knaggs, 1990). There is also no natural ThDP-dependent enzyme 
reported to date that uses an imine substrate, though this does not preclude the 
possibility that such an enzyme could evolve in a specialised metabolic context. The 
broad use of α-keto substrates by the ThDP-dependent enzyme family makes the 
scheme proposed by Herbert and Knaggs the most likely for a purely ThDP-mediated 
mechanism. 
 
Unexpectedly however, obaG was also implicated in the biosynthesis of 2, leading to 
abolition of 1 with concomitant accumulation of 4 and 5 when disrupted genetically. 
This led to the proposition of an alternative scheme (Figure. 4.15) for 2 biosynthesis 
that proceeds via a PLP-dependent mechanism. PLP-dependent enzymes also 
catalyse an extremely broad set of reactions including transaminations, 
decarboxylations and β-eliminations among others, almost all involving amino 
compound substrates (Schneider et al., 2000). PLP is very efficient at resonance 
stabilising α-carbanionic intermediates, formed by the removal of a proton, 
carboxylate or side chain from the substrate Cα atom. The resulting quinonoids are 
susceptible to attack by electrophilic substrates, resulting in the formation of new C-
C bonds with the Cα. The product of obaG was initially annotated as a putative SHMT, 
enzymes which, in the absence of THF, deprotonate L-serine to release formaldehyde 
and generate a glycine-bound quinonoid intermediate (Figure 1.11 - Schirch et al., 
1985). Glycine is subsequently released by hydrolysis. Based on mutagenetic data, 
a mechanism was proposed for ObaG by which it acts as a transaldolase, first 
catalysing L-serine cleavage to yield glycine, before performing a C-C bond forming 
reaction with 11 to release 2 (Figure 4.15). L-Threonine is also a possible substrate if 
ObaG is acting as an L-threonine transaldolase (L-TTA). The L-TTAs are a rare family 
of fold-type I PLP-dependent enzymes that perform an identical cleavage reaction to 
L-TAs, but which subsequently catalyse C-C bond formation between glycine and an 
aldehyde substrate (Murphy et al., 2001; Barnard-Britson et al., 2012). A final 
possibility is that ObaG is catalysing the aldol-type reaction with 11 and glycine to 
form 2, but this seems unlikely based on previous failed attempts to date to engineer 
SHMTs and L-TAs to perform such aldol-type reactions, where products are often 
generated in low yields and as a mixture of diastereoisomers (Fesko, 2016). However, 
one cannot rule out the possibility that an enzyme might evolve to perform this 




The failure of feeding experiments with either 2 or AHAB (9) left the exact roles of 
ObaH and ObaG in the biosynthesis of 1 to be defined. In this Chapter, the results of 
HPLC-based biochemical experiments are reported that dissect the individual and 
combined functions of ObaH and ObaG in the biosynthesis of 2. Specifically, ObaG 
is identified as the enzyme directly responsible for 2 production and further 
experiments are described to evaluate the kinetics of this enzyme and its utility in 
synthetic approaches for the preparation of new β-OH-α-AAs. 
 
5.2 Biochemical analysis of His6-ObaH activity 
ObaH was readily expressed as a soluble protein in a hexahistidine-tagged form in E. 
coli NiCo21(DE3):pLysS (Figure 5.1). Due to the original proposal of Herbert and 
Knaggs (1990) that a ThDP-dependent enzyme might produce an acyloin 
intermediate (Figure 3.1), ObaH was first assayed with 8 and glyoxylate as substrates 
(with ThDP and Mg2+ as cofactors) in a discontinuous format coupled to independent 
LCMS/MS and HPLC-UV assays (Materials and methods section 2.7.1). In none of 
my experiments was I able to detect the accumulation of an acyloin product, whereas 
11 accumulated whenever His6-ObaH was incubated with 8, clearly identifying it as 
an 8 decarboxylase (Figure 5.2a). Synthetic references were used for comparison. 
Trial experiments were attempted with phenylpyruvate instead of 8, but no 
decarboxylation product was detected, indicating the potential significance of the nitro 
group for ObaH substrate recognition. Unfortunately, the aminoaryl equivalent 7 is not 
commercially available and has not yet been synthesised in the lab to see whether it 
is accepted as a substrate by ObaH. 
 
5.3 Biochemical analysis of His6-ObaG activity 
To examine the involvement of the putative SHMT-like enzyme ObaG in 2 
biosynthesis, it too was expressed and purified as an N-terminally hexahistidine-
tagged protein (Figure 5.1). A similar assay format as for His6-ObaH was applied but 
using PLP rather than ThDP as cofactor, and using glycine and 11 as substrates 
(Materials and methods section 2.7.2), to first explore whether ObaG may catalyse 
an aldol-type reaction analogous to that of L-TAs in the formation of β-OH-α-AAs from 
glycine and an aldehyde.  However, the production of 2 under these conditions was 
not observed. The experiment was repeated using either L-serine or L-threonine as 
the amino acid substrate to see if ObaG could function as a transaldolase. 2 
production was only observed when L- threonine and 11 were present in the reaction 













Figure 5.1. 12 % SDS PAGE gel of His6-ObaG and His6-ObaH purification steps. 
1 = Cell lysate, 2 = Chitin wash eluent, 3 = Ni-affinity purified sample, and M = Colour 
Prestained Protein Standard, Broad Range (NEB). The expected molecular weights 



















Figure 5.2. Experimental characterisation of the biosynthesis of AHNB (2). (a) 
His6-ObaH decarboxylase activity assay HPLC profiles. (b) His6-ObaG transaldolase 
activity assay HPLC profiles. (c) Illustration of the biosynthesis of 2 in a two-step 
reaction catalysed by consecutive action of ObaH and G. The His6-ObaG 
transaldolase activity assay was also performed using [U-13C4,
15N]L-threonine, and 
terminated reactions were purified and analysed by NMR (Figure 5.3) to show 13C 
incorporation into 2. The result of this experiment is also illustrated here. (d) Coupled 
decarboxylase and transaldolase assay HPLC profiles. 8 was also found to be a poor 








In order to confirm the L-TTA activity of ObaG, the biochemical assay described was 
repeated but using [U-13C4,15N1]L- threonine as a co-substrate with 11. Dr. Daniel 
Heine analysed the samples (following C18 solid-phase extraction clean-up) using 
13C NMR spectroscopy and HR-LCMS/MS, and was able to demonstrate the 
regiospecific transfer of three heavy isotope atoms to the appropriate positions in the 
product 2 (Figures 5.2c and 5.3), with doublets observed for the C-1 and C-2 positions 
sharing a coupling constant of JC,C = 52.8 Hz. The coupling constant for the 13C and 
15N atoms at the C-2 position was also determined (JC,N = 6.2 Hz), indicating the 15N 
atom from [U-13C4,15N1]L-threonine was incorporated. The two acetal forms of glycerol 
and acetaldehyde (JC,C = 45.6 Hz) were also detected, which indicated the formation 
of [1,2-13C2]acetaldehyde occurred, identifying acetaldehyde as a by-product of the 
ObaG-catalysed reaction. The structure and stereochemistry (L-threo) of isolated 2 
was verified by comparison of its NMR spectra and optical rotation to those of 
previously synthesised material (Pu et al., 1994).  
 
To confirm the biosynthetic relevance of L-threonine in vivo, [U-13C4,15H1]L-threonine 
was added exogenously to WT production cultures of P. fluorescens ATCC 39502 to 
a final concentration of 2 mM. This resulted in the highly efficient site-specific 
incorporation of a 13C215N1 unit as anticipated, detected as a shift of 3 m/z using HR-
LCMS/MS in the final 1 product from m/z [M+H]+ = 359.0875 (Expected m/z for 
C17H14N2O7: 359.0874, Diff. (ppm) = 0.28) to 362.0913 (Expected m/z for C1513C2H-
14N15NO7: 362.0911, Diff. (ppm) = 0.55), compared to no change in a WT culture fed 
unlabelled L-threonine at the same concentration (Figure 5.4). Finally, again using the 
same assay format (using 20 mM of starting substrates), ObaG was shown to also 
catalyse the reverse transaldol reaction to generate 11 and L-threonine from 2 and 
acetaldehyde as substrates (Figure 5.5), however yields of 11 were particularly low. 
 
5.4 His6-ObaH/His6-ObaG coupled reaction experiment 
As a final experiment to confirm the precise involvement of ObaH and G in the 
biosynthesis of 2, both enzymes were incubated at equimolar concentrations with 8 
and L-threonine (Materials and methods section 2.7.3). Excess PLP was removed 
from His6-ObaG samples prior to the experiment to avoid unwanted side reactions 
with 8. Following 2 h incubation, both 11 and 2 could be detected in an active enzyme 
sample, demonstrating that ObaH decarboxylase and subsequent ObaG L-TTA 
activities are sufficient to produce 2 (Figure 5.2c and d). As negative controls, 
reactions in which either one or both of His6-ObaH and His6-ObaG were boiled were 










Figure 5.3. Characterisation of the biosynthesis of AHNB (2) by ObaG using 13C 
NMR. (a) 13C NMR spectrum of [U-13C4,
15N]L-threonine in methanol-d4. (b) 
13C NMR 
spectrum of the synthetic reference 2. (c) 13C NMR spectrum of enzymatically 
synthesised 2. Signals marked with X correspond to the two acetal forms of 
acetaldehyde and glycerol, being formed after release of acetaldehyde, and these are 
















Figure 5.4. LCMS profiles for in vivo [U-13C4,15N]L-threonine feeding 
experiments. WT production cultures fed (a) ddH2O (negative control); (b) 2 mM 












Figure 5.5. HPLC profiles for the His6-ObaG reverse transaldolase assay with 









Figure 5.6. Proposed products of the His6ObaG transaldolase reaction using 4-
NPP (8) and L-threonine as substrates. A fragment for a deformylated form of the 




results (8 only and 11 only detected respectively), but when ObaH alone was boiled, 
in addition to a peak matching the 8 reference, an additional peak (*) was detected 
(Figure 5.2d). HR-LCMS of this peak gave an accurate mass of m/z = 285.0718 
[M+H]+, consistent with it belonging to the ObaG transaldolation product of 8 (Figure 
5.6), indicating that ObaG is able to tolerate it as a substrate, albeit with very low 
affinity. 
 
5.5 Characterising the PLP-dependency of ObaG  
Given that examples of L-TTAs are rare in the literature, experiments were performed 
to further biochemically characterise ObaG by confirming its identity as a PLP-
dependent enzyme. An alignment was generated to compare amino acid sequences 
of authentic and putative SHMTs (Appendix 1 - Supplementary Figure 1). Despite 
initially being identified as a putative SHMT, ObaG shares only 25% sequence 
similarity to bona fide bacterial SHMTs, but does however comprise residues critical 
for PLP-dependent activity, most importantly the lysine residue necessary for internal 
aldimine formation (Schneider et al., 2000). The ObaG amino acid sequence was 
submitted to Phyre2 for structural prediction, and the top structural match was to 
mouse SHMT (PDB: 1EJI). This is annotated as a 4-aminobutyrate aminotransferase-
like family enzyme with a PLP-dependent transferase-like fold, and matched with 
100% confidence over 92% of the ObaG query. Based on the predicted structure, 
ObaG comprises the large and small domains characteristic of fold-type I PLP-
dependent enzymes (Schneider et al., 2000). The large domain consists of a 
characteristic seven-stranded β sheet and the small domain folds into a 3-stranded β 
sheet covered with helices on one side (Figure 5.7a). PLP would be covalently 
attached via its phosphate group to the ε-amino group of the active site lysine in the 
large domain, located at the N-terminus of a short helix following a β strand, and 
would present into the active site pocket (Figure 5.7b and c). Phyre2 investigational 
analyses revealed that the highest degree of structural conservation between ObaG 
and mouse SHMT is located around the active site of both proteins (Figure 5.7d and 
e), which potentially reflects the structural stringency required to accommodate PLP-
mediated biochemistry and would explain why the highest residue mutational 
sensitivities are observed in this region (Figure 5.8f). 
 
To confirm that ObaG does indeed utilise PLP as a cofactor experimentally, two 
spectrophotometric assays (Materials and methods sections 2.7.4 and 2.7.5) were 
performed using His6-ObaG samples in which excess PLP was removed. His6-ObaG 









Figure 5.7. Phyre2 investigator analysis results for mouse SHMT (PDB: 1EJI).  
(a) 1EJI model structure, rainbow colour = N→C terminus, L indicates large domain, 
S indicates small domain. (b) Catalytic sites based on data from the Catalytic Site 
Atlas. The conserved catalytic lysine is boxed in yellow. Red indicates identical 
residues between query and template, green indicates different residues at this 
position. (c) Pocket detection as detected by fpocket2 (red indicates largest pocket). 
(d) Alignment confidence. The scale represents good (red) to bad (purple) confidence 
levels (e) Conservation based on Jensen-Shannon divergence (Capra and Singh, 
2007). The scale represents high relative conservation (red) to low relative 
conservation (purple) (f) Mutation sensitivity as predicted by the SuSPect tool. The 








absorption maxima at 340 and 390 nm (blue traces - Figures 5.8a and b), 
corresponding to the equilibrium established between enolimine and ketoenamine 
forms of PLP respectively. The enzyme is unusual in that it also exhibits a distinct 
salmon pink colour in solution (Figure 5.8c), which creates an additional absorbance 
maximum at 512 nm (Figures 5.8a and b). Treatment of His6-ObaG with 10 mM L-
penicillamine resulted in the anticipated formation of a thiazolidine adduct (Figures 
5.9a and d), determined by UV absorbance at 340 nm, with concomitant loss of the 
ketoenamine peak at 390 nm. This is consistent with previous observations made for 
serine palmitoyltransferase (Lowther et al., 2012). 
 
In a further experiment, His6-ObaG was incubated with 1 mM NaBH4, resulting in the 
formation of a peak at 330 nm consistent with the formation of the reduced His6-
ObaG-PLP aldimine adduct (Chen and Frey, 2001 - Figures 5.8b and e), which occurs 
with concomitant loss of the ketoenamine peak. Finally, boiling His6-ObaG sample in 
which excess PLP had been removed led to the loss of the characteristic pink colour 
of this enzyme, and led to the formation of a light yellow/green solution containing 
precipitated protein (Figure 5.8c). This likely represents the release of enzyme-bound 
PLP which is a yellow-green colour in solution. In summary, all results are consistent 
with His6-ObaG having bound its PLP cofactor, prior to its chemical/physical removal. 
 
5.6 Exploring the potential of His6-ObaG for synthetic applications 
With the ObaG-catalysed reaction satisfactorily characterised, preliminary kinetic 
data were collected to assess its potential use as a synthetic biocatalyst for the 
production of β-OH-α-AAs. First, a time course was determined using standard 
transaldolase assay conditions and showed that equilibrium between L-threonine and 
11 is achieved within ~2 h following reaction initiation (Figure 5.9a). Based on these 
data, the reaction yields 55-60% product and as mentioned previously this is as a 
single stereoisomer (L-threo). Unfortunately, the UV/Vis spectrum of 11 overlaps with 
that of NADH, precluding the use of a continuous coupled assay using acetaldehyde 
dehydrogenase (ADH) to collect kinetic data for His6-ObaG.  ADH oxidises the 
acetaldehyde by-product, reducing its β-NAD+ cofactor to NADH in the process, and 
NADH has a characteristic absorbance that can be measured spectrophotometrically 
(Barnard-Britson et al., 2012). Discontinuous methods measuring product formation 
with respect to varying 11 were also confounded by its inherent reactivity. The best 
results were finally achieved by varying L-threonine concentration using a 
discontinuous HPLC-based approach (Materials and methods section 2.7.2). Single-















yielding kinetic constants of Km = 40.2 ± 3.8 mM and kcat = 62.9 ± 1.9 min-1 (Figure 
5.9b). 
 
Preliminary experiments were also performed to see whether His6-ObaG would 
accept alternative substrates. Given that the enzyme appears to be specific for L-
threonine, I used benzaldehyde and phenylacetaldehyde as surrogate aromatic 
aldehydes to 11, as the closely related L-TAs have been shown to accept a wide 
range of aliphatic and aromatic aldehyde substrates (Steinreiber et al., 2007a and b). 
Incubation with phenylacetaldehyde led to a single product in very respectable yield 
(~45% based on product depletion) whose LCMS profile was consistent with the 
expected product (2S)-amino-(3R)-hydroxy-4-phenylbutanoate (Figure 5.10a). The 
reaction with benzaldehyde was less efficient leading to two products in a 1:2 ratio 
and poor overall yield (<20%) (Figure 5.10b). The LCMS profile of these was 
consistent with the production of both L-threo and L-erythro-phenylserine, 




Mutagenetic analysis could not elucidate the roles of ObaG and ObaH in the 
biosynthesis of 2, which necessitated the use of biochemical approaches to 
characterise their respective functions. Biochemical assays performed with both 
enzymes revealed that the entirely ThDP-dependent route to its production predicted 
by Herbert and Knaggs (1990) was incorrect. ObaH failed to produce an acyloin 
intermediate when supplied with 8 and glyoxylate, instead acting solely as a 
decarboxylase to generate 11 as an intermediate to 2. Furthermore, phenylpyruvate 
was not accepted as an alternate substrate, supporting the hypothesis in Chapter 4 
that ObaC-catalysed N-oxygenation occurs prior to ObaH activity, likely following 
generation of 7 by ObaF (as illustrated in Figure 4.4). 
 
The missing biosynthetic link was shown to be ObaG, a PLP-dependent enzyme that 
produces 2 as a single isomer (L-threo) at very respectable yields (55-60%) using 11 
and L-threonine as substrates. These results were reinforced by NMR analysis 
following biochemical assays using [U-13C4,15H1]L-threonine, which showed that 
13C215N1 is incorporated at the C-1 and C-2 positions in 2. The two remaining 13C 
atoms are incorporated into acetaldehyde, a by-product of the ObaG-catalysed 
reaction. An alignment with bona fide and putative SHMTs, in addition to two 





Figure 5.9. Time course and kinetic analysis of His6-ObaG transaldolase 
activity. (a) Time course of the discontinuous L-TTA activity assay monitoring 
depletion of substrate 11 and generation of product 2. (b) Single-substrate kinetic 
analysis of the L-TTA reaction with 10 mM 11 and variable L-threonine (1-200 mM). 
All data are mean values of three (a) or five (b) independent experiments and error 
bars represent the s.e.m.  
 
 
Figure 5.10. HPLC profiles for His6-ObaG transaldolase assays with L-threonine 
and alternative aldehyde substrates. (a) His6-ObaG transaldolase activity assay 
with phenylacetaldehyde and L-threonine as substrates. (b) His6-ObaG transaldolase 
activity assay with benzaldehyde and L-threonine as substrates. Structures refer to 
the substrate and product references for each reaction. Reference material for (2S)-
amino-(3R)-hydroxy-4-phenylbutanoate was not obtained. 
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Combined, these results are consistent with ObaG acting as an L-TTA which, like L-
TA, initially catalyses the retro-aldol cleavage of L-threonine to generate PLP-bound 
glycine and acetaldehyde, the latter being released as a by-product. In L-TAs, glycine 
is also then released by hydrolysis, however in L-TTAs, a subsequent C-C bond 
forming reaction is catalysed: the glycine quinonoid intermediate undergoes an attack 
from an aldehyde co-substrate to generate a β-OH-α-AA product which is released to 
regenerate the holo-enzyme (Figure 5.11). The exact temporal nature of the ObaG-
catalysed reaction remains to be elucidated, particularly with regards to when the 
aldehyde substrate 11 is bound for the second step of the reaction. Future work will 
be to obtain crystal structures for ObaG and various enzyme-substrate complexes to 
determine the exact mechanism of reaction, and identify critical catalytic residues that 
govern aldehyde substrate binding and specificity.  
 
Herbert and Knaggs likely did not consider a PLP-dependent route for the 
biosynthesis of 2 because at the time of their work, no L-TTAs had been 
characterised, and so there was no precedent for such a mechanism. Their feeding 
experiments with [2-13C]-, [1-13C]- and [2-2H2]glycine, which showed excellent specific 
incorporation into 1 (Herbert and Knaggs, 1990; 1992b), can be explained by the 
activity of SHMTs and L-TAs. Both can catalyse aldol-type reactions between glycine 
and acetaldehyde that would ultimately introduce stable isotope-labelled atoms into 
L-threonine, the substrate of ObaG. Unfortunately, the observation that glycine is 
readily converted to glyoxylate in P. fluorescens ATCC 39502, confirmed by NMR 
(Herbert and Knaggs, 1990), may have caused them not to consider an alternate 
amino acid substrate further. 
 
L-TTAs are relatively rare and only recently have two other members of this family 
been described and biochemically characterised in the literature (Figure 5.12). The 
first to be discovered was fluorothreonine transaldolase (FTase) from S. cattleya 
(Murphy et al., 2001; Schaffrath et al., 2002; Deng et al., 2008) which produces the 
antibiotic 4-fluorothreonine from fluoroacetaldehyde and L-threonine via an identical 
mechanism to that proposed for ObaG (Figure 5.12). The second example are 
members of the LipK family of L-TTAs (Barnard-Britson et al., 2012), which use L-
threonine and uridine-5’-aldehyde as co-substrates to produce the unusual β-OH-α-
AA 5’-glycyluridine (GlyU) and acetaldehyde. Homologues of this enzyme function in 
a number of different biosynthetic pathways that encode lipopeptidyl nucleoside NP 
inhibitors of translocase I. These all incorporate GlyU as a building block, and include 




Figure 5.11. Proposed biochemical mechanism of ObaG L-TTA activity. Holo-ObaG (a) binds L-threonine (blue) to generate the external 
aldimine (b), and 11 (orange) to form a ternary complex. The bound L-threonine β-hydroxyl group is deprotonated by an enzyme base (c) before 




muraminomicin (Chi et al., 2013), muraymycins (Cheng et al., 2011), A-102395s, A-
500359s, A-503083s, (Cai et al., 2015), A-90289s (Barnard-Britson et al., 2012), and 
sphaerimicin (Funabashi et al., 2013) (Figure 5.13). Intriguingly, amino acid 
alignments of these representative L-TTAs with ObaG revealed relatively low shared 
sequence similarity, only 29% identity shared with FTase (N-terminal domain only – 
FTase is a didomain protein that also comprises a C-terminal phosphate binding 
domain) and 33% with LipK (Appendix 1 - Supplementary Figure 2). However, Phyre2 
predictions indicate that they are structurally similar, all matching mouse SHMT (PDB: 
1EJI) as a top hit (LipK – 100% confidence, 94% query cover; FTase – 100% 
confidence, 67% query cover – due to C-terminal phosphate binding domain). 
Convergent evolution is a common feature in the evolutionary history of PLP-
dependent enzymes and has resulted in members of similar structural fold families 
catalysing distinct reactions, and enzymes with very different structural folds 
catalysing very similar reactions (Mehta and Christen, 2000; Paiardini et al., 2003). It 
is possible that L-TTAs originated multiple times in the evolution of the fold-type I PLP-
dependent enzymes, which would explain the low shared sequence similarity, or that 
they arose at an early stage and have greatly diverged since. Chapter 6 explores the 
evolutionary history of these enzymes in greater depth. 
 
L- and D-TAs have previously been developed as biocatalysts for the generation of β-
OH-α-AAs. Despite displaying relatively relaxed substrate tolerance for the aldehyde 
acceptor substrate, they remain limited in their use by poor stereoselectivity and low 
yields, even when supplied with excess glycine to shift the equilibrium in favour of the 
aldol reaction (Fesko et al., 2016). Given that ObaG produces very respectable yields 
of a single optically pure stereoisomer after ~1 h under the experimental conditions 
used in this work, it represents a promising biosynthetic enzyme for synthetic use. 
However, despite exhibiting a reasonable kcat, 40 mM represents a relatively high Km, 
indicating that ObaG has a relatively low affinity for its L-threonine substrate. Multiple 
factors could have influenced this high value, including the fact that a discontinuous 
assay was used which will inherently introduce a greater chance of sampling errors 
(though relatively little standard error was observed between the five replicates at 
each time point), and that reaction conditions were not optimised for the enzyme from 
those used for analytical biochemical assays. There is also a possibility that a lower 
selection pressure on enzyme efficiency exists in a NP biosynthetic context (Firn and 
Jones, 2000), particularly for an enzyme that is not rate-limiting, compared to 
essential enzymes in primary metabolism that need to function with high fidelity. The 




Figure 5.12. L-TTA-catalysed reactions characterised in the literature and this 





Figure 5.13. NPs comprising GlyU moieties derived from LipK homologues. (a) 
A-90289A, Caprazamycin A, Liposidomycin A and Muraminomycin A; (b) A-500359, 
A-503083 and A-102395; (c) Spaerimicin A; and (d) Muraymycin A. The GlyU-derived 
moiety is highlighted in orange in each example. 
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kcat = 40 min-1 being reported for LipK, though these were obtained using an optimised 
continuous assay and with respect to varying aldehyde substrate concentration 
(Barnard-Britson et al., 2012).  
 
ObaG was also found to display a degree of substrate promiscuity with regard to its 
aldehyde substrate, synthesising diastereoisomers of phenylserine from 
benzaldehyde, and (2S)-amino-(3R)-hydroxy-4-phenylbutanoate from 
phenylacetaldehyde. The latter was produced in respectable yields of ~45% product, 
indicating ObaG might have use in generating congeners of 2 that are substituted at 
the aromatic end of the molecule. Further improvements in yield might be achieved 
by introducing excess L-threonine and aldehyde substrates to shift equilibrium further 
in the direction of the biosynthesis of 2. This reaction appears to be favoured under 
the experimental conditions used, based on attempts to demonstrate the reverse 
reaction to form 11 and L-threonine from 2 and acetaldehyde. Depletion of 
acetaldehyde by-product levels would also serve to drive flux through the 2-forming 
reaction, and this could be achieved by introducing glycerol to react with acetaldehyde 
and generate acetals, as observed in [U-13C4,15H1]L-threonine NMR analysis 
experiments, or by introduction of a suitable ADH to oxidise acetaldehyde to acetic 
acid. 
 
As a final comment, the cause of the pink colour of His6-ObaG remains unknown and 
is also present when the protein is expressed without a tag. Given that the colour is 
not significantly lost following L-penicillamine or NaBH4 treatment, it appears to not be 
associated with PLP in the active site, and may be the cause of some other structural 
element or the binding of a chromophore elsewhere on the protein, although there is 
no evidence for this at the sequence or predicted structural levels. 
 
Given that the SHMTs, L-TAs and L-TTAs perform analogous reactions with respect 
to L-amino acid cleavage to generate a PLP-bound glycine quinonoid intermediate, 
the next logical progression of this work was to understand how these different PLP-
dependent enzymes relate to one another in an evolutionary context. Specifically, to 
understand how the L-TTAs diverged from SHMTs and L-TAs to utilise an aldehyde 
substrate, as opposed to water, to release PLP-bound glycine and form 2. This might 
provide amino acid sequence-based or structural clues that allow the identification of 
further members of the L-TTA family. This would be highly desirable given the 









Phylogenetic analysis of 










Chapter 6: Phylogenetic analysis of SHMTs, L-TAs and L-TTAs 
 
6.1 Introduction 
PLP-dependent enzymes are thought to have originated very early in evolutionary 
history, before the divergence of the three biological domains of life ~1,500 million 
years ago. They comprise five structurally distinct fold-type families that each arose 
from separate evolutionary lineages (Mehta and Christen, 2000). SHMTs, L-TAs and 
L-TTAs belong to the fold-type I family of PLP-dependent enzymes that all act at the 
Cα position of their amino acid substrate, as discussed in Chapter 5. They all function 
as homodimers, forming two active sites at the dimer interfaces and with both 
monomers contributing residues to each site (Eliot and Kirsch, 2004). Although fold-
type I enzymes are all structurally similar, fold-type does not dictate reaction-type, 
and they have greatly diversified to catalyse a broad range of different reactions. This 
is facilitated by the catalytic promiscuity of the PLP cofactor, which, free in solution, 
can catalyse multiple reactions, including transamination, racemisation and α,β-
elimination, albeit at much slower rates compared to when it is acting as an enzyme 
cofactor. It is thus believed that ancestral enzymes could probably also catalyse a 
range of different reactions (Di Salvo et al., 2013), and gene duplications and natural 
selection have driven the diversification of function among different PLP-dependent 
enzymes, simultaneously narrowing their substrate and reaction specificities over 
time.  
 
SHMTs possess an especially broad reaction specificity. They can catalyse retro-
aldol cleavage, decarboxylation, transamination and racemisation reactions, with 
both natural and unnatural substrates (Di Salvo et al., 2013). Critically for this work, 
SHMTs, and the closely related L-TAs (Contestabile et al., 2001), have been 
investigated as synthetic tools for the asymmetric preparation of unnatural β-OH-α-
AAs, as both can catalyse an aldol-type reaction between glycine and an aldehyde 
(Figure 6.1). Whilst highly specific at the Cα of their amino acid substrates, these 
enzymes show relatively high aldehyde acceptor substrate promiscuity (Fesko, 
2016), making them attractive targets for development as biocatalysts. Although 
specific for glycine, some examples do exist of L-TAs that can accept D-alanine, D-
serine and D-cysteine (Fesko et al., 2010), further expanding the potential to generate 
new chemistries. As mentioned in Chapter 1 however, these enzymes are limited in 
their use for the synthesis of β-OH-α-AAs by poor stereoselectivity and low yields of 
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the aldol reaction, and equilibrium sits in favour of the opposite retro-aldol cleavage 
reaction (Figure 6.1). 
 
L-TTAs were initially identified as putative SHMT/L-TA-type enzymes, but have been 
shown to efficiently catalyse L-threonine β-substitutions via the sequential breaking 
and forming of Cα-Cβ bonds with aldehyde substrates, in Chapter 5 and elsewhere 
(Deng et al., 2008; Barnard-Britson et al., 2012). SHMTs, L-TAs and L-TTAs employ 
the same mechanism of amino acid substrate cleavage, but different selection 
pressures and thermodynamic arguments might explain how L-TTAs diverged to 
catalyse a subsequent C-C bond forming reaction (Figure 6.1). They also offer a 
possible explanation for the low yields and poor stereoselectivity exhibited by SHMTs 
and L-TAs in the reverse, aldol reaction to β-OH-α-AAs. 
 
SHMTs are ubiquitous, essential enzymes that are necessary in folate metabolism 
for the generation of C1 units for THF-dependent reactions, and subsequent use of 
those units likely drives flux through the retro-aldol cleavage reaction (Schirch et al., 
1985). The breakdown of a single substrate, L-serine, to two products, glycine and 
formaldehyde, is also entropically favourable (Figure 6.1). L-TA cleavage of L-
threonine to glycine and acetaldehyde would similarly be entropically preferential, and 
the reactivity of the acetaldehyde by-product would likely drive the reaction 
equilibrium further in favour of retro-aldol cleavage through its continuous depletion. 
L-threonine serves as the sole source of carbon and nitrogen for growth in a wide 
variety of organisms and L-TAs are thought to play a key role in its catabolism, 
supplementing SHMT function in glycine supply if it becomes blocked (Liu et al., 1998; 
Dückers et al., 2010). The ability to effectively catalyse retro-aldol cleavage is 
therefore of primary importance in both cases, but identifying a selective advantage 
to shifting equilibrium in favour of the non-physiological aldol-type reaction is less 
obvious. This is reflected in the poor yields and lack of stereospecificity observed at 
the second chiral centre in SHMT/L-TA-catalysed aldol reactions (Fesko, 2016).   
 
It is possible that L-TTAs evolved from the duplication of a gene encoding either an 
SHMT or an L-TA. Independent of the selective restrictions of primary metabolism, L-
TTAs have subsequently diverged to perform an additional C-C bond forming step 
following retro-aldol cleavage, leading to the formation of new products in specialised 
metabolic contexts. Indeed, in addition to obaG, there are two putative SHMTs and 
two putative L-TAs encoded elsewhere in the ATCC 39502 genome. The C-C bond-















Figure 6.1. Reactions catalysed by SHMTs, L-TAs and L-TTAs. Schemes 














to retro-aldol cleavage, rather than via evolutionary optimisation of the reverse aldol 
reaction catalysed by SHMTs and L-TAs (Figure 6.1), again reflecting the primary 
metabolic relevance of this reaction. In addition to generating β-OH-α-AA products in 
reasonable yields, L-TTA-catalysed reactions are stereospecific, perhaps highlighting 
the importance of stereochemistry for substrate recognition by downstream-acting 
proteins. In the case of obafluorin (1), changes in the stereochemistry of AHNB (2) 
could have substantial consequences for the formation and/or activity of 1.  
 
Given the close structural similarity and shared reaction mechanisms, the 
evolutionary relationship between SHMTs, L-TAs and L-TTAs was investigated 
further. D-TAs (TAs specific for D-threonine) have also been reported, and are 
enantio-complementary to L-TAs. However, they belong to the fold-type III family of 
PLP-dependent enzymes and represent an example of convergent evolution 
(Paiardini et al., 2003).  Previous phylogenetic approaches have been applied 
successfully to demonstrate that the L-TAs form two discrete evolutionary lineages 
that are phylogenetically distinct from the closely related SHMTs (Liu et al., 2015). 
Although all PLP-enzymes share very similar mechanistic features with regards to 
PLP-chemistry, and the reactions catalysed by SHMTs and L-TAs are very similar, 
there is clearly some basis at the sequence level that allows them to be distinguished 
phylogenetically. If this is also the case for the L-TTAs, it creates a clear opportunity 
to identify further members of the family, and expand the synthetic toolkit for the 
preparation of unusual β-OH-α-AA building blocks. In this Chapter, the construction 
of a phylogeny for the fold-type I PLP-dependent enzymes described is presented. 
The results replicate previous findings (Liu et al., 2015) and allow a hypothesis as to 
the likely evolutionary origins of the L-TTA family to be proposed. Furthermore, it is 
shown that phylogenetics may represent a powerful approach for the expansion of 
the L-TTA family and could aid in future genome mining efforts. 
 
6.2 Phylogenetic analysis of SHMTs, L-TAs and L-TTAs 
83 amino acid sequences of putative L-TAs and SHMTs were obtained from a 
previous study (Liu et al., 2015) and were combined with 81 additional sequences 
from both enzyme families for which the crystal structure has been solved or that have 
been characterised/described in the literature (see Appendix 1 - Supplementary Table 
2). These were collected from the GenBank database (Clark et al., 2016) and the 
Protein Data Bank (PDB) (Berman et al., 2000). A focussed search of the literature 
was also conducted to identify putative SHMTs, L-TAs or closely related enzymes 
(e.g. methylSHMTs) involved in NP biosynthesis. NP-associated enzymes are 
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discussed in subsequent sections. Blastp searches were performed using 
characterised L-TTAs as queries, and any hits sharing >30% amino acid sequence 
identity belonging to a published BGC were included. This cut-off was selected based 
on shared amino acid sequence identities between ObaG, FTase and LipK 
(Supplementary Figure 2) Finally, ten amino acid sequences for 3-amino-5-
hydroxybenzoic synthases (AHABSs) described in the literature were obtained to 
function as an outgroup for phylogenetic analysis, as the AHABS family shares a 
recent common ancestor with SHMTs and L-TAs (Contestabile et al., 2001). Selected 
sequences were first aligned with ClustalX2 (Larkin et al., 2007) before several 
iterations of manual sequence trimming to remove aberrant N- and C-terminal 
sequence data (Materials and methods section 2.11). The sequences were ultimately 
aligned with T-Coffee (Notredame et al., 2000), and phylogenetic tree inference was 
performed using maximum likelihood/rapid bootstrapping with RAxML-HPC BlackBox 
(8.2.8) (Stamatakis, 2014). The resulting phylogenetic tree is illustrated in Figure 6.2. 
Alternate trees created using slightly different alignments to ensure the final tree was 
consistent and robust are illustrated in Supplementary Figures 3 and 4 (Appendix 1). 
 
Consistent with previous reports, the L-TAs formed two discrete clades which, 
combined with data from a sequence similarity network analysis (Liu et al., 2015), 
indicates that these enzymes evolved independently following their divergence from 
a shared common ancestor. The SHMTs are monophyletic, diverging from a shared 
progenitor with the two L-TA clades. The L-TTAs share a common ancestor with the 
SHMTs and also form their own discrete evolutionary lineage. Although the 
evolutionary relationship between ObaG and FTase is not so easily determined when 
comparing different phylogenies (Appendix 1 - Supplementary Figures 3 and 4), they 
are clearly distinct from the L-threonine:uridine-5’-transaldolases of the LipK 
subfamily. Given the essential nature of SHMTs in folate metabolism, and their 
inherent catalytic promiscuity, it is reasonable to suggest that the earliest common 
ancestor of the SHMTs, L-TAs and L-TTAs likely used L-serine as a substrate. It 
appears that a substrate shift from L-serine to L-threonine occurred multiple times in 
the evolutionary history of the fold-type I PLP enzymes, giving rise to the L-TA and L-
TTA clades independently. An alternative interpretation is that the original ancestor 
of these enzymes used L-threonine as a substrate, and a duplication event gave rise 
to a descendant that diverged into the SHMT lineage, with a shift in substrate 
specificity to L-serine, and the L-TTAs, which diverged to accept an additional 
aldehyde substrate. However, the essential nature of SHMTs likely precludes this 











Intriguingly, among the amino acid sequences for NP-associated enzymes included 
in the analysis, one was consistently sorted into the L-TTA clade. This was the 
sequence for OrfA, identified as a putative glycine hydroxymethyltransferase (GHMT) 
involved in the biosynthesis of alanylclavam by S. clavuligerus NRRL 3585 (Zelyas et 
al., 2008). S. clavuligerus is known to produce numerous clavam metabolites 
(Jensen, 2012), but analysis by transposon-mutagenesis showed the orfA mutant to 
be specifically deficient in alanylclavam production. OrfA was predicted to be 
responsible for generating β-OH-α-AA intermediate 8-hydroxyalanylclavam by fusing 
glycine to an unusual aldehyde substrate (X in Figure 6.3), in an analogous aldol-
reaction to SHMTs and L-TAs. This was based on the observation that the amino acid 
sequence comprises the three residues necessary for glycine binding, but lacks five 
of the six amino acids involved in 5,10-methylene-THF binding. However, OrfA activity 
has never been investigated biochemically and the anticipated aldehyde substrate X 
(Figure 6.3) was never detected in ΔorfA cultures (Zelyas et al., 2008). Based on our 
own observations for 4-NPA (11), absence of X could be due to the rapid breakdown 
of what may be an unstable aldehyde intermediate. 
 
Further investigation of the literature revealed the presence of further OrfA-like 
proteins involved in the biosynthesis of two other clavam metabolites. In valclavam 
biosynthesis, hmt encodes an OrfA-homologue (68% shared amino acid sequence 
identity) proposed to perform a similar reaction to OrfA, but using a slightly different 
aldehyde substrate (includes an extra carbon in the side chain – Y in Figure 6.3) to 
produce a 9-hydroxyclavam intermediate (Z) (Nobary and Jensen, 2012). In 
clavamycin A biosynthesis, the same β-OH-α-AA moiety (derived from X) is present 
as for alanylclavam, indicating that an OrfA homologue catalyses an identical reaction 
before subsequent divergent modifications (Figure 6.3 - Jensen, 2012). Given that it 
is located in the L-TTA clade, it is possible that L-threonine may be the true substrate 
of OrfA and its homologues and, if so, then phylogenetics may represent a powerful 
tool for the expansion of the L-TTA family which currently comprises only three 
subfamilies. However, attempts to purify soluble OrfA using both native and codon 
optimised genes for expression in E. coli have so far been unsuccessful and this 
phylogenetic approach remains to be validated. 
 
Putative L-TAs have been identified in the biosynthetic pathways to several 
streptomycete uridyl peptide translocase I inhibitors. The products of these pathways 
share structural similarities to the capuramycin-like compounds described in Chapter 









Figure 6.4. Proposed reactions catalysed by putative SHMTs/L-TAs in NP 
biosynthetic pathways. (a) PacT in pacidamycin biosynthesis (Zhang et al., 2010); 
(b) VrtJ in viridicatumatoxin biosynthesis (Chooi et al., 2010); (c) FmoM and (d) FmoH 
from JBIR-34 and JBIR-35 biosynthesis (Muliandi et al., 2014). AmiS, a homologue 









LipK-like L-TTAs). These L-TAs include PacT (pacidamycins – Zhang et al., 2010a), 
02991 (mureidomycins – Jiang et al., 2015), NspJ (napsamycins – Kaysser et al., 
2011), and SsaT (sansanmycins – Li et al., 2013), and all are hypothesised to play a 
role in the generation of N-methyl-2,3-diaminobutyric acid (DABA) in their respective 
pathways (Figure 6.4a). Specifically, they are proposed to epimerise DABA from the 
(2S,3R) configuration to (2S,3S), though this has not been biochemically validated. 
These four homologues consistently grouped together in all phylogenies, forming 
their own subclade (with 100% support) within the ‘A’ L-TA cluster (Figure 6.2), 
indicating that they diverged during L-TA evolution. A putative L-TA has also been 
identified in the biosynthesis of the hybrid PK-isoprenoid viridicatumatoxin from 
Penicillium aethiopicum Frisvad, a rare example of fungal-derived tetracycline-like 
compound (Chooi et al., 2010). VrtJ has been identified as a 
decarboxylase/transaminase responsible for conversion of L-asparagine to the 
intermediate malonamate (Figure 6.4b), the proposed substrate of the acetoacetyl-
CoA synthetase VrtB, which generates the unusual PKS starter unit malonamoyl-
CoA. However, this hypothesis has not been experimentally validated and contrasts 
with acetate labelling results reported in the same publication. VrtJ also fell within the 
‘A’ L-TA cluster (Figure 6.1), sharing a recent common ancestor with other putative 
ascomycete L-TAs. The P. aethiopicum Frisvad genome contains another copy of an 
L-TA-like gene (PaTA0310), which shares higher identity to Pc12g01020 (92%), the 
only homologue in P. chrysogenum, than VrtJ (54%), which implies it is the primary 
L-TA and supports the evolution of VrtJ as an additional copy into a specialised 
metabolic role (Chooi et al., 2010). VrtJ could have originated either from the 
duplication and divergence of a primary metabolic L-TA encoded in the same genome 
or been acquired by HGT. 
 
The final putative L-TA identified in a NP biosynthetic context is FmoM, thought to act 
canonically in catalysing the retro-aldol cleavage with subsequent oxidation of the β-
OH-α-AA acid 3,6-dihydroxy-8-chloro-tryptophan during JBIR-34 and -35 
biosynthesis in Streptomyces sp. Sp080513GE-23 (Figure 6.4c - Muliandi et al., 
2014). Its product, 6-chloro-4-hydroxyindole-3-carboxylic acid, is then combined with 
α-methyl-L-serine in a condensation reaction catalysed by the NRPS FmoA3 Cy 
domain before further NRPS-catalysed extensions. A second fold-type I PLP-
dependent enzyme encoded in the pathway, FmoH, is implicated in the biosynthesis 
of α-methyl-L-serine (Figure 6.4d), and is annotated as a putative D-alanine/α-methyl-
L-serine hydroxymethyltransferase. Biochemical and stable isotope feeding 
experiments confirmed the role of FmoH the conversion of D-alanine and 
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formaldehyde to α-methyl-L-serine in an aldol-type reaction, allowing a similar 
function to be ascribed to a homologue in amicetin biosynthesis, AmiS (Figure 6.4d - 
Zhang et al., 2012). FmoM diverges very early in the L-TA ‘B’ cluster, and FmoH and 




Detailed phylogenetic analysis has shed light on the evolutionary origins of the L-TTA 
family, which appears to have diverged from a common ancestor with the SHMTs. 
This is perhaps not surprising given the inherent catalytic promiscuity associated with 
the SHMTs. The SHMTs and L-TAs in turn have evolved from a progenitor that also 
gave rise to the two L-TA clades that appear to have diverged independently from a 
shared common ancestor (Liu et al., 2015). Given the essential nature of SHMT in 
metabolism, it is assumed that the early ancestor of these enzymes likely used L-
serine as a substrate. In order to explore this hypothesis further, future work will 
include an ancestral state reconstruction to predict the specific amino acid substrate 
of the earliest common ancestor of the SHMTS, L-TAs and L-TTAs. Additionally, the 
construction of a species phylogeny will aid in distinguishing between duplication and 
divergence events, and examples in which genes encoding members of these fold-
type I PLP-dependent enzyme families have been acquired by HGT. Although the 
exact evolutionary relationship between FTase and ObaG in the L-TTA clade could 
not be determined, they are clearly distinct from members of the LipK family. OrfA 
appears to be more closely related to the LipK family, consistently branching from a 
shared recent common ancestor with these enzymes (Figure 6.2 and Supplementary 
Figures 3 and 4). 
 
The necessity to accommodate a second aldehyde substrate is likely to be the feature 
that differentiates the L-TTAs from the L-TAs and SHMTs at the amino acid sequence 
level. If so, it would make a phylogenetic approach ideal for the identification of novel 
members of this potentially useful enzyme family. OrfA, previously identified as a 
GHMT in alanylclavam biosynthesis (Zelyas et al., 2008), was consistently placed 
within the L-TTA clade, indicating that it might be a genuine L-TTA. Given that the 
anticipated substrate of OrfA, X, and product, 8-hydroxyalanylaclavam, have already 
been proposed (Figure 6.3 - Zelyas et al., 2008), this enzyme represents an ideal 
candidate to biochemically validate a phylogenetics-based mining approach for 
further L-TTAs. Unfortunately, efforts so far to purify soluble OrfA have failed with both 
native and codon-optimised sequences for expression in E. coli. The aldehyde 
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substrate has also proved difficult to isolate, and the biochemical assay necessary to 
validate a phylogenetic genome mining approach thus remains elusive.  
 
Dr. Esther Schmitt at Novartis is currently sequencing the clavamycin producing-stain 
S. hygroscopicus NRRL 15879. She has kindly agreed to share the genome 
sequence to allow the identification and cloning of the OrfA-like homologue in the 
pathway. The valclavam-producer S. antibioticus Tü1718 the genome of which 
encodes the OrfA homologue hmt has also kindly been gifted to us by Prof. Wolfgang 
Wohleben. Future work will thus involve obtaining soluble protein for one of these 
OrfA homologues, isolating the necessary substrates, and proving their function 
biochemically (Figure 6.5). We may also be able to use soluble homologues to 
generate non-native clavam aldehyde products (i.e. use Hmt to generate X - Figure 
6.3). This approach was applied to characterise the chorismate hydrolase activity of 
RapK and homologues FkbO506 and FkbO520 in the biosynthesis of the macrocyclic 
PKs rapamycin, FK506 and FK520 respectively (Andexer et al., 2011). If all 
homologues prove insoluble in E. coli, then expression in a Streptomyces 
heterologous host is also an option, where codon usage will be less of an issue and 
the proteins are more likely to be correctly folded. Expression vectors for use in 
Streptomyces spp. have already been developed in our department (Takano et al., 
1995), and an S. lividans TK24 strain has been optimised with an strR mutation 
equivalent to that which has been shown to increase levels of heterologous protein 
production in Bacillus (Prof. Mervyn Bibb, personal communication).  
 
Dunathan proposed that the specific reaction catalysed by a PLP-dependent enzyme 
is determined by the orientation of the cleavable bond to the plane of the PLP pyridine 
ring (Dunathan, 1966). However, this can only account for the reaction specificity of 
a PLP-dependent enzyme, and substrate specificity is determined by further active 
site structural features. Evolution to remodel the substrate binding pocket to 
accommodate an additional aldehyde substrate, whilst retaining the shape necessary 
for amino acid substrate cleavage, would have required significant structural 
alterations in the L-TTAs. Different aldehyde substrates will require distinct active site 
geometries and this would explain the arrangement of different subfamilies within the 
L-TTA clade.  Whilst aligning the amino acid sequences can provide clues as to 
potential key residues involved in determining substrate specificity, crystal structures 
of one or more of the L-TTAs, bound to PLP and their substrates, would allow the 
critical residues and structural motifs in these enzymes to be identified. It would also 












Figure 6.5. L-TTA-catalysed reactions characterised or proposed in the 











of substrate binding. A specific search of the databases could then be performed for 
PLP-dependent enzymes with the specific L-TTA ‘signature’. Blastp searches using 
LipK or OrfA queries allows homologues to be readily identified as they are the closest 
related matches, but below 50% identity return members of the other already known 
L-TTA classes. To identify L-TTAs with significantly different aldehyde substrates, and 
add new members to the family, an expansion of the phylogeny presented here could 
be performed using amino acid sequences for all annotated SHMTs, L-TAs and L-
TTAs available in the databases as an unbiased search for novel L-TTAs. The amino 
acid sequences for Hmt and the OrfA homologue involved in the biosynthesis of the 
clavamycins will also be added to see whether they clade with the L-TTAs. 
 
Whilst other NP biosynthesis-associated SHMTs and L-TAs were identified in this 
work, none of them was revealed by phylogenetics to belong to the L-TTA family of 
PLP-dependent enzymes. However, together with the L-TTAs, they serve to illustrate 
the impressive catalytic versatility of the PLP-cofactor and the broad range of 
functions it can bestow on enzymes. This is especially true in NP biosynthesis where 
there are many examples in which PLP-dependent enzymes have been acquired by 
BGCs and perform novel specific functions. These range from canonical 
transaminations, as observed for myxochelin (Silakowski et al., 2000) and zeamine 
biosynthesis (Masschelein et al., 2013), to far more unusual functions such as the 
PLP-dependent chain release mechanisms characterised for fumonisin biosynthesis 
in Fusarium verticillioides (Gerber et al., 2009), and proposed for prodigiosin 
biosynthesis in Serratia and Streptomyces spp. (Garneu-Tsodikova et al., 2006). 
Embedded PLP-dependent tailoring domains are widely distributed in modular PKSs 
and NRPSs (Milano et al., 2013), but few, such as the aminotransferase domain of 
MycA in mycosubtilin biosynthesis (Aron et al., 2005), have been characterised 
biochemically. Clearly, nature has realised the functional potential of PLP-dependent 
catalysis, and it is hoped that phylogenetics-based approaches might allow us to 
identify further unusual PLP-dependent biosynthetic enzymes and realise their 
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Chapter 7: Biochemical characterisation of obafluorin (1) 
assembly and β-lactone ring formation 
 
7.1 Introduction 
With the roles of ObaH and ObaG in the biosynthesis of AHNB (2) biochemically 
characterised, the focus of the project shifted to investigating how 2 is subsequently 
incorporated into obafluorin (1) (Figure 4.4). Mutagenesis experiments supported the 
initial hypothesis that both ObaI and ObaK fulfil this function, and together they 
comprise all the domains necessary to catalyse peptide bond formation between 2 
and 2,3-DHBA (6), before releasing 1. ObaI represents a particularly non-canonical 
domain organisation that could be due to the presence of an unusual embedded 
MbtH-like domain. It may have facilitated the recruitment of the 6-specific A1 domain 
to the C-terminus of ObaI to permit the MbtH-like domain to interact with both ObaI A 
domains. This organisation would explain the apparent domain splitting of an EntB-
like progenitor to generate discrete ArCP ObaK and isochorismatase ObaJ proteins, 
affording ObaK increased mobility to better interact with both the unusually located 
A1 domain and the C2 domain.  
 
As discussed in Chapter 3, MbtH-like proteins are traditionally auxiliary proteins that 
are required for the activity of many, but not all NRPS A domains. Genetic knockout 
experiments have demonstrated their importance for the efficient production of NRPs 
and in some cases they have been shown to be critical for A domain functional 
expression (Lautru et al., 2007; Wolpert et al., 2007; Heemstra et al., 2009), 
suggesting a chaperone like function. There is growing evidence that MbtH-like 
proteins could also be involved in allosteric regulation of A domains and so may 
influence catalytic properties (Herbst et al., 2013; Miller et al., 2016). Remarkably, 
MbtH-like protein paralogues can partially complement one another, and this 
phenomenon has also been observed in vitro for MbtH-like proteins from different 
species, even for A domains with different amino acid substrates (Wolpert et al., 2007; 
Zhang et al., 2010b; Boll et al., 2011). Whilst structural data and mutagenesis 
experiments have identified amino acid residues critical for interaction with A domains 
(Herbst et al., 2013; Miller et al., 2016), the exact mechanism of MbtH-like protein 
activity remains obscure. Given that an MbtH-like domain is embedded within ObaI, 
it is reasonable to assume that it is functionally significant for one or both A domains. 
If soluble and active protein can be obtained, ObaI may thus represent an ideal 
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system for further studying the role of MbtH-like proteins and domains in NRP 
biosynthesis.   
 
Beyond activation and assembly of 2 and 6, the formation of the β-lactone ring during 
1 biosynthesis also remains to be addressed. The electrophilic β-lactone moiety is a 
privileged structure among NPs, as it is susceptible to attack from nucleophilic amino 
acid residues in protein active sites (Figure 1.13), making these compounds potent 
and specific inhibitors of important protein targets (De Pascale et al., 2011). 
Identifying new enzymatic routes to the formation of these strained four-membered 
rings is thus highly desirable, particularly when considering the closely related β-
lactams, which themselves have served as a particularly rich source of marketed 
drugs and have opened up new areas of target-based drug discovery (Kluge and 
Petter, 2010).  
 
Considerable effort has been put into identifying and characterising the biosynthetic 
pathways to β-lactones as a platform to developing synthetic routes to novel 
molecules. However, in many cases the mechanisms of ring formation remain 
unclear, and no enzymatic domains have been experimentally linked to cyclisation in 
PKS or NRPS-derived examples. The β-lactone rings in lactacystin (Dick et al., 1996) 
and ebelactone (Wyatt et al., 2013) have been shown to form nonenzymatically at pH 
7 from β-hydroxythioesters, challenging the evolutionary need for enzyme-catalysed 
ring formation. However, 1 is readily hydrolysed to 10 under aqueous conditions, 
which could necessitate an enzymatic mechanism of β-lactone ring formation to 
ensure sufficient titres of the active metabolite are achieved. The β-lactone 
synthetase OleC in olefin biosynthesis remains the only characterised enzymatic 
route to these molecules, with further homologues identified in the ebelactone and 
lipstatin clusters (Christenson et al., 2017), though their role in catalysing ring 
formation in these latter pathways has not yet been characterised experimentally.  
 
An alternative enzymatic route to β-lactones is via NRPS C domains that lack the full 
catalytic triad for condensation (Cy domains), and which catalyse cyclisations to form 
heterocycles. Cy domains do this by catalysing intramolecular amide bond formation 
with cysteine, serine or threonine residues to form five-membered oxazoline and 
thiazoline rings. A Cy domain has been proposed to catalyse β-lactone ring formation 
from a serine residue in oxazolomycin biosynthesis, (Zhao et al., 2010) but this 




A putative PK cyclase is located downstream of obaN that belongs to the SRPBCC 
superfamily that includes the PYR/PYL/RCAR-like plant receptor proteins and 
aromatase/cyclase domain containing proteins, such as that involved in 
tetracenomycin biosynthesis (Caldara-Festin et al., 2015). However, the mechanism 
of cyclisation they employ does not apply in the context of 1 biosynthesis. Given that 
there is no OleC homologue associated with the oba BGC, and the ObaI C2 domain 
comprises the full complement of residues necessary for catalysing condensation 
reactions between 2 and 6, a TE-mediated mechanism was determined to the most 
likely route to ring closure during the biosynthesis of 1. 
 
In NRPS assembly lines, TE-domains typically mediate product release by hydrolysis 
or macrocyclization, and belong to the α/β-hydrolase superfamily which contain a 
conserved serine-histidine-aspartate catalytic triad (Nardini and Dijkstra, 1999). In 
canonical NRPS biosynthesis, when the linear peptide chain reaches its full length, it 
is transferred from the last PCP to the hydroxyl group of the TE active site serine 
residue to form a peptidyl ester (Du and Lou, 2010). Depending on the nature of the 
TE, the peptidyl-O-TE intermediate is then attacked either by 1) an external 
nucleophile, typically water, which leads to a linear hydrolysed product (e.g. 
vancomycin – Hubbard and Walsh, 2003); or 2) by an internal nucleophile, typically 
an amino or hydroxyl group on the intermediate that leads to macrolactam (e.g. 
tyrocidine – Trauger et al., 2000) or macrolactone (e.g. enterobactin – Frueh et al., 
2008) release respectively (Figure 7.1). For the biosynthesis of 1, the internal ObaI 
type I TE domain is proposed to catalyse β-lactone ring formation using the β-hydroxyl 
group of the 2-derived moiety as an internal nucleophile (Illustrated in Figure 4.4).  
 
In this Chapter, data are presented showing that soluble hexahistidine-tagged ObaI 
can be obtained and is functional in vitro, as determined by A domain substrate 
specificity assays. These experiments validate 2 as the preferred substrate for the 
ObaI A2 domain, in addition to revealing varying degrees of substrate promiscuity for 
both A1 and A2 domains. Experiments prepared to characterise ObaI TE-mediated β-
lactone ring formation and further work to reconstitute the biosynthesis of 1 in vitro 
are also described. Unfortunately, similar experiments were published during the 
course of the project and those results are also summarised here. This line of 








Figure 7.1. Thioesterase-mediated PK/NRP chain release mechanisms. The 
acyl-O-TE can either be hydrolysed by H2O to produce a linear product (a), or 
macrocyclised following intramolecular nucleophilic attack to generate a macrolactam 






Figure 7.2. 12 % SDS PAGE gel of His6-ObaI purification steps. 1 = Cell lysate, 2 
= Chitin wash eluent, 3 = Ni-affinity purified sample, 4 = Size exclusion purified 
sample, and M = Colour Prestained Protein Standard, Broad Range (NEB). The 




7.2 Investigating His6-ObaI A domain specificity 
Traditionally, individual catalytic domains from multi-modular NRPS and PKSs are 
purified for biochemical characterisation experiments as it can be challenging to 
achieve soluble protein for entire synth(et)ases, which are often several hundred kDa 
in size. Recently however, the monomodular NRPSs SrfA-C from surfactin 
biosynthesis, EntF from enterobactin biosynthesis and AB3403 from an 
uncharacterised pathway in Acineobacter baumannii, were successfully purified and 
crystallised (Drake et al., 2016). The entire obaI PCS was cloned as an NdeI-XhoI 
fragment into pET28a(+) and was expressed to generate soluble apo-His6-ObaI 
(211.5 kDa, ~2.5 g/L - Figure 7.2). Access to the full ObaI protein creates 
opportunities to study the dynamics between different domains and to reconstitute 1 
assembly in vitro.  
 
A domains catalyse the activation of amino or carboxylic acids in an ATP-dependent 
manner to form an (amino)acyl-AMP adenylate and PPi (Figure 7.2a). The local 
concentration of pantetheinyl thiolate is sufficient for an adjacent PCP domain to 
capture the (amino)acyl-AMP in the A domain active site, yielding aminoacyl-S-PCP 
(Fischbach and Walsh, 2006). In order to assess the A domain substrate specificity 
of soluble apo-His6-ObaI in vitro, a non-radioactive approach was used which 
employs the propensity of (amino)acyl-AMP intermediates to react with 
hydroxylamine to form hydroxamic acids (Materials and methods section 2.7.6 - Kadi 
and Challis, 2009). Hydroxamate adducts are easily measurable by 
spectrophotometry after addition of ferric iron (Figure 7.3b). In this experiment, 2 was 
tested against a panel of alternate L-amino and carboxylic acid substrates. 6 could 
not be used as a positive control because it chelates ferric iron directly and when 
tested led to saturated absorbance measurements. Benzoic acid (BA) and 3-
hydroxybenzoic acid (3-HBA) were used as surrogates for 6 due to successful results 
in mutasynthesis experiments (described in detail in Chapter 8). Whilst this approach 
would not allow the independent dissection of the activities of the two ObaI A 
domains, it did suggest that 2 is indeed the preferred substrate for the A2 domain, 
giving the highest absorbance measurement at 540 nm of any tested acid substrate 
(Figure 7.4). This domain appears to exhibit some degree of relaxed substrate 
specificity as significant absorbances were also observed for L-serine and L-
tryptophan. BA and 3-HBA gave significant signals, indicating that they are substrates 
for the A1 domain, and the difference in absorbance levels between them reflects their 







Figure 7.3. NRPS A domain-catalysed reaction mechanism and substrate specificity assay principle. (a) A domain-catalysed substrate 
activation. A domains first catalyse the Mg·ATP-dependent adenylation of carboxylic acid substrates. This generates an (amino)acyl-AMP 
intermediate that is subsequently loaded onto the cognate PCP PPant arm. Reactions illustrated are catalysed by the domain highlighted in red. 
(b) Hydroxylamine-trapping assay. Hydroxylamine intercepts aminoacyl-adenylates to form hydroxamic acids. These form complexes with 
ferric iron that can be detected spectrophotometrically at λ540 nm and is a thus a measure of (amino)acyl-AMP formation. This will only occur when 










Figure 7.4.  Hydroxylamine-trapping assay results. His6-ObaI adenylation domain 
specificity was assayed using a range of amino and carboxylic acid substrates. All 











concluded that the soluble His6-ObaI apo-enzyme was indeed correctly folded and 
functional in vivo, creating the possibility of studying the role of the MbtH-like domain 
further in the future with respect to both A domains. 
 
7.3 Characterising His6-ObaI TE-mediated β-lactone ring formation 
The ultimate objective in this line of investigation was to reconstitute the biosynthesis 
of 2 and the assembly of 1 in vitro. This would involve incubating 2 and 6 with holo- 
forms of ObaCGHI and K. To this end, ObaH and ObaG reactions were successfully 
coupled (Chapter 5), and ObaC and ObaK were purified as N-terminally hexahistidine 
tagged soluble proteins (Figure 7.5). 1 assembly would also require His6-ObaI to be 
phosphopantetheinylated to its holo-form to allow substrate tethering to PCP 
domains. Traditionally, this is performed using Sfp, the phosphopantetheinyl 
transferase from Bacillus subtilis (Quadri et al., 1998b). Whilst sourcing the sfp gene, 
experiments were prepared to confirm and characterise TE activity using apo-His6-
ObaI. 
 
A similar approach to that used to characterise the cyclisation activity of the TE 
domain from TycC in the tyrocidine biosynthetic pathway was selected (Trauger et 
al., 2000). Trauger et al. synthesised a synthetic peptide N-acetylcysteamine (NAC) 
thioester (peptide-SNAC), which was substituted for the terminal decapeptide-S-PCP 
to study TE domain activity (Trauger et al., 2000). NAC is structurally identical to the 
terminal portion of PPant and is thus an excellent mimic of the natural TE substrate 
(Aggarwal et al., 1995). Dr. Daniel Heine kindly converted 1 into the desired dipeptide-
SNAC (Figure 7.6), which was confirmed by HR-LCMS and NMR, to use as a 
substrate for apo-ObaI. As a negative control for the experiment, a copy of His6-ObaI 
in which the TE active site serine is mutated to an unreactive residue was required. 
To identify the correct residue, an alignment was performed of the ObaI TE domain 
against several NRPS TE domains described and/or characterised in the literature 
(Appendix 1 – Supplementary Figure 5). Intriguingly, the ObaI TE active site 
possesses a cysteine rather than a serine residue, presumably tethering the 1 
dipeptide via its thiol group, as illustrated in Figures 3.5 and 4.4. A His6-ObaI C1141A 
construct was generated to act as a negative control for the experiment using Gibson 
Assembly® (Gibson et al., 2009 - Materials and methods section 2.4.6). 
 
Unfortunately, a similar experiment was published in which TE-mediated 1 β-lactone 





Figure 7.5. 12 % SDS PAGE gel of His6-ObaC and His6-ObaK purification steps. 
1 = Cell lysate, 2 = Chitin wash eluent, 3 = 0 mM imidazole wash.  4 = 10 mM 
imidazole wash eluent, 5 = 20 mM imidazole wash eluent, 6 = 30 mM imidazole wash 
eluent, 7 = 50 mM imidazole wash eluent, 8 = 250 mM imidazole wash eluent, and M 
= Colour Prestained Protein Standard, Broad Range (NEB). The expected molecular 















This was achieved by incubating WT holo-ObaK and WT (C1141), C1141S and 
C1141A variants of holo-ObaI with 2, 6 and ATP. Only the WT form of ObaI could 
catalyse β-lactone ring formation. 10 was detected in experiments with the C1141 
copy, but was also detected following incubation of 2 and 6 with the C1141S ObaI 
variant. Neither 1 nor 10 were detected following the C1141A ObaI substitution, 
consistent with the TE being responsible for β-lactone ring formation. Schaffer et al. 
also biochemically characterised ObaC by introducing it into a combined reaction with 
ObaG and ObaH using 7 and L-threonine as substrates. These three enzymes were 
able catalyse the production of 2, providing further evidence that 7 is the true 
substrate of ObaC.  
 
7.4 Discussion 
The NRPS ObaI can be purified as a soluble N-terminally hexahistidine-tagged 
protein in its apo-form. Apo-His6-ObaI is active in vitro and could be used in a 
hydroxylamine-trapping assay for A domain substrate specificity. The assay revealed 
2 to be the preferred substrate for the A2 domain as expected. Intriguingly, L-serine 
and L-tryptophan were also accepted, though they generated significantly less signal 
than 2, indicating some degree of substrate promiscuity in the ObaI A2 domain. When 
comparing the ObaI A2 amino acid residues that determine substrate specificity 
(Stachelhaus et al., 1999) in ObaI A2 against those for L-phenylalanine and L-
threonine-specific A domains (structurally similar substrate and substrate predicted 
by NRPSpredictor2 for ObaI A2, respectively), the ObaI A2 domain contains several 
important differences (Schaffer et al., 2017 - Figure 7.7). Compared to phenylalanine-
activating domains, ObaI A2 contains a glycine, not a threonine, at position 278, which 
would extend the substrate pocket to accommodate the C4 side-chain of 2. When 
compared to threonine-activating A domains, isoleucine at position 299 is a cysteine 
in ObaI A2, possibly providing a hydrogen-bonding partner for the aromatic nitro group 
of 2, as well as facilitating interaction with the benzyl ring. Alanine is present instead 
of phenylalanine at position 236, creating space to accommodate the aromatic ring 
for 2 in place of the phenylalanine phenyl group. This unusual amino acid specificity 
conferring code could enhance future A domain substrate predictions based on the 
ten letter Stachelhaus code.  
BA and 3-HBA were tolerated as substrates for the A1 domain, complementing 
mutasynthetic results described in Chapter 8. In vitro A domain substrate promiscuity 
has been reported in several pseudomonad NRPS pathways (Gerard et al., 1997; 













Figure 7.7. Illustration of the ObaI A2 domain substrate-specifying residues. 
Residues that differ from L-phenylalanine- or L-threonine-specific A domains are 











allows NP-producers to generate novel structures from single pathways and respond 
to new environmental stimuli. In support of this, single point mutations are sufficient 
to completely alter the substrate specificity of NRPSs, as has been shown in the 
biosynthesis of novel analogues of calcium-dependent antibiotic (Thirlway et al., 
2012), luminmide (Bian et al., 2015) and gramicidin (Kries et al., 2014).  Despite 
apparent flexibility of both A domains in ObaI, no congeners of 1 were detected in WT 
P. fluorescens ATCC 39502 production cultures, although such molecules might be 
susceptible to proteolytic degradation. More likely however, is that the C2 domain 
exerts a ‘gatekeeper’ function with regards to the selection of substrates for carrier 
protein acylation and subsequent amide bond formation. This has been demonstrated 
for the cyanobacterial hepatotoxin microcystin, in which the downstream C domains 
are responsible for rendering modules monospecific for amino acid substrates rather 
than the A domains (Meyer et al., 2016).  
 
The MbtH-like domain could also be critical for determining substrate specificity of the 
ObaI domains. MbtH-like proteins/domains share a conserved fold comprising an α-
helix that packs onto a 3-stranded antiparallel β-sheet. Multiple sequence alignments 
have identified a sequence of 15 invariant, mostly hydrophobic, amino acids including 
three characteristic tryptophan residues that are common to all MbtH-like proteins 
(Baltz et al., 2011). Structural studies on SlgN1, an A-MbtH didomain protein involved 
in streptolydigin biosynthesis (Herbst et al., 2013), showed that these hydrophobic 
residues are mostly clustered on the face of its MbtH-like domain and pack against a 
small α-β docking motif on the A domain. This docking domain terminates in an 
alanine residue, the side chain of which projects into a hydrophobic cleft in the MbtH-
like domain. Given that ObaI can be purified in an active form and A domain activity 
can be assayed, future work will include generating point mutants in putative key 
MbtH-like domain residues to determine their impact on A domain activity both in vivo 
and in vitro. In parallel, we have begun a collaboration with the Prof. Changjiang Dong 
at the UEA to crystallise ObaI. If this is possible, it should allow the characterisation 
of A domain/MbtH-like interactions in ObaI at the structural level. 
 
During the preparation of experiments to characterise TE-mediated cyclisation and to 
reconstitute the biosynthetic pathway for 1 in vitro, another group achieved these 
results (Schaffer et al., 2017). Schaffer et al. showed that alteration of the holo-ObaI 
TE active site cysteine to a neutral alanine residue (C1141A) abolished the ability of 
ObaI and ObaK to assemble 1 in vitro. This is likely because the 1 dipeptide thioester 
is stalled on the PCP domain, as acyl transfer to the TE is no longer possible. 
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Intriguingly, a C1141S variant did not lead to 1 production, but low levels of 10 were 
detected, which indicates that this amino acid substitution converts ObaI to a classic 
hydrolase, leading to the release of a linear dipeptide product. The difference between 
the C1141 and C1141S variants is likely due to the relative weakness of the C-S bond 
of the thioester compared to the C-O bond of the oxo-ester, which is necessary in 
order to make strained β-lactone ring formation thermodynamically favourable 
(McGrath and Raines, 2011). The higher ground-state energy of the thioester is also 
predicted to increase the rate of alcohol addition to the carbonyl group, which is likely 
to be the rate-limiting step. These thermodynamic requirements presumably are not 
met by the oxo-ester (Schaffer et al., 2017). An active site cysteine residue was also 
recently reported in the SulM TE domain which could similarly be necessary for β-
lactam ring formation and product release during the biosynthesis of sulfazecin (Li et 
al., 2017). 
 
Given that 1 assembly by ObaIK, and the biosynthesis of 2 from 7 and L-threonine 
have both been reconstituted in vitro, further biochemical experiments regarding the 
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Chapter 8: Characterising the putative resistance gene and 
mode of action for obafluorin (1) 
 
8.1 Introduction 
NPs encompass an astonishing variety of chemical structures, which allow them to 
mediate specific interactions with biological targets. Though many different selective 
advantages have been shown to be conferred by NPs (Traxler and Kolter, 2015), the 
majority are believed to act as chemical weapons that allow the producer to out-
compete competitors in resource-limited environments. Bacterial and fungal NP 
targets are often sufficiently structurally different to their mammalian target 
equivalents that they will not interact with the latter, and so NPs have been employed 
extensively by humans as a source of antibiotics. Following hundreds of millions of 
years of evolution and diversification, it is perhaps unsurprising that for almost every 
known druggable target, there is at least one NP that targets it (Johnston et al., 2016), 
a factor which has contributed significantly to their re-emergence in the genome 
sequencing era as a promising source of novel drug leads. In excess of 50 distinct 
molecular targets have been identified for antibacterial NPs (Figure 8.1), and the 
majority of these are inhibitors of three essential cellular processes: 1) Cell wall 
biosynthesis; 2) protein synthesis; and 3) DNA replication and repair (Walsh, 2000).  
 
NP discovery today is driven by the rapid development of resistance to widely used 
antibiotics and the need to identify new ones to replace them. Antibiotics impose an 
extremely high selection pressure for the development of resistance, which is 
facilitated by the large number of bacteria involved in a given infection cycle, relatively 
high rates of intrinsic mutation, and the rapid spread of genes encoding resistance 
via MGEs and HGT (Walsh, 2000). Three principal mechanisms by which resistance 
is achieved are: 1) the use of drug efflux pump proteins to keep intracellular antibiotic 
concentration at ineffectual levels, as has been observed for tetracyclines and 
erythromycins (Ross et al., 1990; Paulsen et al., 1996); 2) the enzymatic modification 
of the antibiotic chemical structure to destroy its ‘warhead’. This is exemplified by β-
lactamases which cleave the pharmacophore β-lactam antibiotics before they can 
interact covalently with their PBP targets in the cytoplasmic membrane (Philippon et 
al., 1985); and 3) the modification of antibiotic target structure to prevent or minimise 
antibiotic interaction, as illustrated by the vanHAX genes in enterococcal bacteria. 
Their gene products lead to the incorporation of D-alanine-D-lactate units into 








a 1,000-fold drop in vancomycin binding affinity whilst having no detrimental impact 
on crosslinking efficiency (Bugg et al., 1991; Walsh et al., 1996). In order to mitigate 
the threat of antibiotic resistance, it is of critical importance to identify novel NPs with 
distinctly different modes of action to those of known antibiotics.  
 
As mentioned in the introduction, 1 displayed only weak antibiotic activity against a 
range of different bacteria in early bioactivity experiments, but results were likely to 
be confounded by the inherent lability of the molecule and propensity for the β-lactone 
ring to be hydrolysed (Wells et al., 1982; Tymiak et al., 1985). However, in live-animal 
models, 1 was shown to protect mice challenged with Streptococcus pyogenes (ED50 
= 50 mg/kg by systemic administration) and thus does display therapeutic potential. 
This, together with the observation that 1 also causes elongation of E. coli cells when 
administered at sub-lethal doses indicates that the molecule acts in a specific manner 
rather than as a general acylating agent. Given that β-lactone NPs are proven 
inhibitors of a diverse range of biological targets (De Pascale et al., 2011), the mode 
of action for 1 warranted further investigation. 
 
One fundamental condition of being able to synthesise a cytotoxic molecule is that a 
producing organism must have some mechanism of protecting itself from its own NP’s 
adverse effects. This means that mechanisms of resistance against each 
antimicrobial NP inevitably already exist in nature, and resistance has been shown to 
be an ancient phenomenon (D’Costa et al., 2011). As a result, loci encoding 
resistance determinants are commonly found adjacent to the biosynthetic genes 
required for the production of an antibiotic metabolite (Cundliffe and Demain, 2010), 
thereby facilitating their co-inheritance and utility in recipient cells (Osbourn, 2010). 
This property has been successfully employed in genome-mining efforts to identify 
novel glycopeptide antibiotic BGCs in actinomycete strains resistant to vancomycin 
(Thaker et al., 2013), and in this Chapter the application of similar logic to identify a 
putative resistance gene associated with the BGC for 1 is reported. Preliminary 
bioassay data collected by an MSc student under my supervision, Ms. Eposi Enjema 
Carine Solange (Carine), are also presented which validate the biological target of 1. 
Experiments Carine performed to explore the metal-binding capacity of 1 are also 
described. Novel congeners of 1 were generated by mutasynthesis and will form the 





8.2 Identifying the putative resistance gene in oba BGC  
When the project began, only one other 1-like BGC had been deposited in GenBank. 
This locus was found in the genome of Chitiniphilus shinanonensis DSM 23277 
(NZ_KB895358.1), an environmental chitin-degrading β-proteobacterium (Figure 
8.2). All oba genes have direct homologues in this cluster (except for obaA (luxI 
homologue) which is absent in C. shinanonensis) which all share between 60-99% 
identity at the amino acid level. obaD and obaE ADC synthase component 
homologues appear to be fused in one single gene in C. shinanonensis, analogously 
to cmlB and papA in the chloramphenicol and pristinamycin BGCs, respectively 
(Blanc et al., 1997; He et al., 2001). Genes flanking either cluster appear to be 
markedly different although a threonyl-tRNA synthetase (ThrRS) homologue is also 
present in both BGCs. The significance of this could not be determined given the low 
numbers of BGCs for comparison, uncertainty about how the obaB homologue in C. 
shinanonensis came to be located at the opposite end of the cluster compared to the 
ATCC 39502 BGC, and the lack of knowledge as to whether the BGC is even 
functional in this bacterium. 
 
During the course of the project, several other putative oba BGCs were identified in 
genome sequences deposited in GenBank, allowing a more robust comparison to be 
made (Figure 8.2). A number of Burkholderia spp. (B. diffusa - NZ_LOTC01000033.1, 
B. stagnalis - NZ_LPGD01000044.1, B. territorii - NZ_LOSY01000044.1, and B. 
ubonensis - NZ_CP013463.1) were identified as carrying oba-like BGCs, albeit in a 
slightly rearranged form. obaA and obaB homologues in Burkholderia spp. are 
situated at the opposite end of the BGC to ATCC 39502, and the obaM homologue is 
located adjacent to an obaC homologue. Intriguingly, the A domain for 6 is encoded 
independently of the rest of the NRPS machinery in these clusters and obaF is split 
into independent chorismate mutase and prephrenate dehydrogenase-encoding 
genes.  
 
Two further P. fluorescens strains were identified in an analysis of Pseudomonas 
genomic diversity in take-all infected wheat fields (Mauchline et al., 2015), which also 
comprise putative oba BGCs. These are 98-100% identical to that in ATCC 39502 at 
the amino acid level, and also comprise orfs12345678. They only share homology as 
far as the lysine tRNA gene downstream of obaA-N in ATCC 39502, however (Figure 
8.2). This is consistent with the lysine tRNA gene being the likely boundary of the oba 
BGC, having been previously identified as a hot-spot for genomic island integration 













Figure 8.2. Illustration of putative oba BGCs identified in genomic sequence 
data uploaded to GenBank. A key is provided above that is consistent with Figures 











1-producing P. fluorescens strains (34 E 7 - NZ_CVTX01000156.1; and 37 R 15 - 
NZ_CVTV01000010.1), and when grown in OPM both produce 1 and cultures go 
purple. 
 
Critically, in addition to characterised and predicted regulatory and biosynthetic 
genes, a PCS encoding a ThrRS was always found associated with putative oba 
BGCs, identifying it as the best candidate for a self-resistance gene. ThrRSs are class 
II aminoacyl-tRNA synthetases (aaRS) that are essential enzymes in protein 
synthesis that ligate L-threonine to its cognate tRNA molecule (Sankaranarayanan et 
al., 1999 – Figure 8.3). aaRSs are well-documented targets for antimicrobial NPs 
(Cochrane et al., 2016) and borrelidin is a known example of a NP ThrRS-inhibitor 
(Fang et al., 2015). Further in silico analysis identified an additional gene encoding a 
ThrRS located elsewhere in the ATCC 39502 genome (in addition to the putative oba 
cluster-associated ThrRS copy) which likely represents the essential primary 
housekeeping copy of the enzyme. The oba ThrRS copy should only be essential 
under 1-producing conditions, and is the likely result of a duplication of a primary 
enzyme which has evolved to be resistant to 1. C. shinanonensis DSM 23277, 
Burkholderia spp. encoding putative oba BGCs, and P. fluorescens sp. 37 E 15 also 
all encode only one other ‘primary’ ThrRS in their genomes in addition to obaO 
homologues. 
 
8.3 Experimental validation of obaO as a resistance determinant for 
obafluorin (1) 
8.3.1 Disruption of obaO 
obaO was disrupted using pTS1 and ΔobaO production culture samples were 
analysed by HPLC (Figure 8.4a). The obaO deletion led to the abolition of 1 
production and the loss of the characteristic purple phenotype (Figure 8.4b), 
consistent with a critical role in some element of 1 production. Unfortunately, initial 
attempts to complement this mutant genetically by introducing pJH10TS-obaO failed, 
however sequence data were consistent with a clean in-frame deletion that should 
not impede obaJKLMN transcription. Furthermore, characteristic shunt metabolites 4 
and 5 also did not accumulate in the ΔobaO background, where they did in 6 
biosynthesis mutants ΔobaJ (Figure 4.5) and ΔobaL (Figure 4.6), suggesting that the 
phenotype cannot be explained by polar effects of the deletion on 6 biosynthesis 
alone. However, further work is required to absolutely preclude possible polar effects 








Figure 8.3. Mechanism by which aminoacyl tRNA synthetases (aaRSs) ligate 
amino acids to their cognate tRNAs. The amino acid first attacks ATP to yield an 
aminoacyl-adenylate with concomitant release of pyrophosphate. The amino acid is 
then transferred to the 2’ (class I) or 3’ (class II) hydroxyl of the 3’ terminal adenosine 
residue of the cognate tRNA molecule to generate an aminoacyl-tRNA complex. 
Some aaRS enzymes are also capable of pre- or post-transfer editing. Cochrane et 
















Figure 8.4. Mutagenesis HPLC data for ΔobaO and image of the corresponding 
production cultures. (a) HPLC profiles for obaO mutagenesis and complementation 













8.3.2 Assaying obafluorin (1) antibacterial activity 
In order to determine whether obaO confers resistance to 1, thereby confirming 1 as 
a ThrRS inhibitor, antibacterial activity assays were conducted to determine the 
minimum inhibitory concentration (MIC) of 1 against three different bioassay strains: 
1) E. coli ATCC 25922, a strain traditionally used in antibiotic susceptibility 
experiments (Boyle et al., 1973); 2) E. coli NR698 (Ruiz et al., 2005), which carries 
an in-frame deletion in the imp4213 gene which is responsible of outer-membrane 
lipopolysaccharide assembly (Ruiz et al., 2006), thereby increasing antibiotic 
permeability into the cell; and 3) B. subtilis EC 1524 (O’Rourke et al., 2017), as a 
representative of Gram-positive bacteria. Given that 1 is a substrate for β-lactamases 
(Wells et al., 1984), Pseudomonas spp. were not assayed as the genomes of many 
encode one or more of these enzymes (Livermoore, 2002; Michaux et al., 2008); five 
putative β-lactamases are encoded in the ATCC 39502 genome. All antibiotic 
susceptibility assays described were performed by Carine and are described in 
Materials and methods section 2.9. 
 
8.3.2.1 Broth microdilution assays 
Initially, test strains were challenged with 1 over a range of concentrations between 
0.015-2000 μg/mL in a liquid culture, microtitre plate-based format. MICs were 
determined to be 2000 μg/mL for both E. coli ATCC 25922 and B. subtilis EC 1524, 
and 1000 μg/mL for E. coli NR698. No growth was observed in positive controls 
containing either 100 μg/mL carbenicillin or 50 μg/mL kanamycin. Whilst one would 
anticipate E. coli NR698 to be slightly more susceptible to 1 given the imp4213 
deletion, MIC values recorded were far in excess of what would be expected for a 
genuine antibiotic compound. However, these results were not consistent with 
previous MICs recorded from disc-diffusion based assays for 1 against several other 
E. coli strains (Table 8.1 - Wells et al., 1984; Tymiak et al., 1985). At concentrations 
where cell growth was unaffected, small films were observed at the bottom of the 
wells, suggesting possible biofilm formation. Many bacteria can encase themselves 
in matrices composed of polysaccharides and proteins known as biofilms, which limit 
antibiotic penetration and so confer resistance (Stewart and Costerton, 2001). To 
prevent cells from aggregating and forming biofilms, the experiment was repeated in 
a rotary shaker with 200 rpm agitation, but similar MIC values were recorded despite 





Organism SC strain no. Zone of inhibition (mm) 
(Obafluorin (1) – 10 μg) 
Staphylococcus aureus 1276 8.7 
2399 7.4 
2400 7.9 




Enterobacter cloacae 8236 9.3 
P. rettgeri 8479 7.7 
P. aeruginosa 9545 9.1 
Table 8.1. Obafluorin (1) disc diffusion assay results from Wells et al. (1982). In 
these experiments inoculum was adjusted with McFarland 0.5 turbidity standard and 
tested on K10 agar (pH 6.7). 2 mg/mL Obafluorin (1) was dissolved in MeCN and 5 
μL were applied to 6.3mm Whatmann #4 filter discs.  
 
 
8.3.2.2 Disc diffusion assays 
Given the unexpectedly high MIC values obtained in liquid culture, agar plate-based 
methods were subsequently employed to confirm the validity of these results. In initial 
experiments, 1 dissolved in 100% MeCN over the same range of concentrations as 
before, 5 μL was applied to paper discs before being placed on agar plates inoculated 
with one of the three WT test strains described. No measurable zone of bacterial 
growth inhibition was observed following incubation at any concentration of 1 tested, 
nor were they for the MeCN vehicle negative control. In contrast, halos of inhibition 
were clearly visible for 100 μg/mL carbenicillin and 50 μg/mL kanamycin positive 
controls. These data were consistent with the previous finding that 1 binds to paper 
discs, limiting its diffusion into agar (Tymiak et al., 1985).  
 
8.3.2.3 Agar diffusion assays 
Finally, assays were performed in which 5 μg/mL of 1 was pipetted directly onto the 
agar surface. Zones of clearing could be clearly observed following direct application, 
allowing new MIC values to be determined: B. subtilis EC 1524 = 0.125 μg/mL; E. coli 
ATCC 39502 = 32 μg/mL; and E. coli NR698 = 4 μg/mL (Table 8.2). A negative control 
in which MeCN alone was applied resulted in no observable impact on bacterial 
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growth. These results indicate that contrary to previous findings (Wells et al., 1984; 
Tymiak et al., 1985), 1 has potent antibacterial activity against both Gram-positive 
and -negative bacteria.  
 
Bioassay strain Obafluorin MIC (μg/mL) 
B. subtilis 1524  0.125 
E. coli ATCC 25922  32 
E. coli ATCC 25922 pJH10TS 32 
E. coli ATCC 25922 pJH10TS-obaO >2000 
E. coli NR698  4 
E. coli NR698 pJH10TS 0.5 
E. coli NR698 pJH10TS-obaO >2000 
Table 8.2. Preliminary obafluorin (1) agar diffusion assay results. 
 
 
pJH10TS and pJH10TS-obaO were subsequently transformed into both E. coli strains 
and the agar diffusion assay was repeated to determine whether any degree of 
resistance is conferred by the putative 1 resistance gene. Remarkably, in both strains 
the MICs were >2000 μg/mL, representing >60-fold and >4000-fold increases for 
ATCC 25922:pJH10TS-obaO and NR698:pJH10TS-obaO respectively, when 
compared to the same strains carrying the empty vector (Table 8.2). These results 
demonstrate that ObaO confers resistance to 1, identifying 1 as a genuine ThrRS 
inhibitor. Whilst these are preliminary data, they are consistent with observations 
made during the development of the assay. Bioassays with both E. coli strains at 
higher concentrations will also be performed to determine the exact MIC values as 
these were outside the range of 1 concentrations used in these preliminary 
experiments.  
 
8.4 Identifying the obafluorin (1) mechanism of ThrRS inhibition 
8.4.1 In silico comparison of putative obafluorin (1)- ‘sensitive’ and ‘resistant’ 
ThrRS amino acid sequences 
Given that the residues critical for ThrRS catalytic activity are well defined 
(Sankaranarayanan et al., 1999; 2000 – Figure 8.5), an alignment was performed in 
order to identify potential nucleophilic amino acid β-lactone targets. Amino acid 
sequences of putative 1 resistance genes were aligned against putative ‘sensitive’ 
ThrRSs from the same strains, in addition to those for which structures are available 
on the PDB database (Appendix 1 – Supplementary Figure 6). This included the 
Homo sapiens ThrRS which is known to bind another natural ThrRS inhibitor, 
borrelidin (Fang et al., 2015). Almost all key active site residues are highly conserved 
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across the different sequences except for an active site cysteine residue (position 480 
in E. coli – 1QF6), which in putative 1 resistance ThrRSs is consistently substituted 
by a valine residue. Cysteine is extremely nucleophilic by virtue of its thiol group, and 
would represent an ideal candidate residue for attack of the 1 β-lactone ring. If this 
residue were the target for 1, it would explain why a valine is present in putative 
resistance ThrRSs as it is a particularly non-polar amino acid. A lysine residue is 
present at this position in S. aureus and whilst not as nucleophilic as cysteine, could 
still conceivably attack the 1 β-lactone ring. Bioassays would determine whether 1 is 
active against S. aureus. 
 
8.4.2 In silico comparison of obaO with other putative ThrRS-inhibiting NP 
resistance determinants  
A putative ThrRS, OzmT, is also encoded in the oxazolomycin BGC, indicating that 
in addition to 1 and borrelidin, oxazolomycin might also be a ThrRS inhibitor (Zhao et 
al., 2010). An alignment of putative resistant ThrRSs for 1, borrelidin (BorO) and 
oxazolomycin (OzmT) revealed that the active site residues in each are highly 
conserved (Appendix 1 -Supplementary Figure 7). Like ObaO, both BorO and OzmT 
possess alternative amino acids to the C480 residue in E. coli ThrRS. Borrelidin is 
known to occupy the active site of human ThrRS by forming hydrogen bonds with a 
number of active site residues to exclude enzyme substrates. In BorO an alanine is 
in place of this cysteine residue, but this does not participate in borrelidin binding, 
indicating that variation at this position is not necessarily associated with resistance. 
In OzmT, the residue at this position is a lysine, which whilst not as nucleophilic as 
cysteine, could still plausibly attack the β-lactone ring, though β-lactones have so far 
only been reported to react with cysteine, serine or threonine enzyme active site 
residues (Böttcher and Sieber, 2012). This could indicate an alternate mode of action 
for oxazolomycin.  
 
The genome of B. subtilis, which was found to be highly sensitive to 1, encodes two 
ThrRS genes, thrS and thrZ (Putzer et al, 1990), which were included in the same 
alignment (Appendix 1 - Supplementary Figure 7). During vegetative growth, only the 
former is expressed, with thrZ expressed in response to decreases in intracellular 
ThrS concentration in a dose-compensatory manner (Putzer et al., 1992). ThrS and 
ThrZ only share 57% sequence identity and possess lysine and cysteine residues 
respectively at the position equivalent to C480 in E. coli ThrRS.  If both are expressed, 
1 would have to be able to inhibit both copies in order to have its antibiotic effects, 
raising the question how it would mediate specific interactions with both proteins.  
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Alignments using putative resistance genes for BorO, OzmT and redundant B. subtilis 
ThrRS copies did not provide further support for the hypothesis that the ThrRS active 
site cysteine residue is the target of 1. Biochemical experiments were performed to 
investigate interaction between 1 and ThrRS. 
 
8.4.3 E. coli ThrRS obafluorin (1)-binding assay 
In order to validate the hypothesis that 1 binds to C480 in native E. coli ThrRS, it was 
cloned for expression in pET28a(+) as an N-terminally hexahistidine-tagged protein 
(Figure 8.6). Once purified, His6-ThrRS was exchanged into MES buffer (pH 6.0) and 
incubated with 1 before subsequent analysis by UPLC-HRMS (Materials and 
methods sections 2.7.7 and 2.10.2). All metabolomic analyses performed for these 
experiments were conducted by Dr. Daniel Heine and Dr. Gerhard Saalbach. As a 
negative control, Gibson Assembly® (Gibson et al., 2009) was applied as for ObaI 
TE mutations to create a construct with a C480V (TGC→GTG) substitution, mimicking 
the alteration observed in putative 1 resistance gene products (Materials and methods 
section 2.4.6). Both WT and E. coli ThrRS C480V equivalents appeared to bind 1, as 
determined by a mass shifts of 358.2 and 358.6 Da for both proteins (1 = 358.1 Da), 
respectively, following incubation with 1 (Figure 8.7). Samples were subsequently 
subjected to trypsin digest to identify specific residues modified by 1. Analysis of these 
samples using Orbitrap Fusion (Thermo Fisher Scientific) and Synapt G2-Si (Waters) 
high-resolution mass spectrometers could not confirm the specific binding of 1 to the 
active site C480 residue, or to any other E. coli ThrRS active site residues. Further 
work is required to investigate 1 ThrRS-binding and is discussed in further detail in 
the discussion. 
 
8.5 Investigating the metal-binding properties of obafluorin (1) 
In addition to the β-lactone ring, 1 comprises two other structural elements, a catechol 
moiety and aromatic nitro group, both of which occur in a number of bioactive NPs 
(Crosa and Walsh, 2002; Winkler and Hertweck, 2007; Parry et al., 2011). Whilst the 
role of nitro groups in bioactivity is poorly understood, the role of the catechol moiety 
in the coordination of ferric iron has been well characterised in numerous siderophore 
NPs (Hider and Kong, 2009). ThrRS requires a Zn2+ cofactor to coordinate L-threonine 
in its active site through the formation of a pentacoordinate intermediate with both the 





Figure 8.5. The interaction network of the Thr-AMS molecule with the Zn2+ 
cofactor and the ThrRS active site residues. Adapted from Sankaranarayanan et 





Figure 8.6. 12 % SDS PAGE gel of E. coli His6-ThrRS and His6-ThrRS C480V 
purified protein sample serial dilutions. 1 = 1/20, 2 = 1/100, 3 = 1/200, and M = 
Colour Prestained Protein Standard, Broad Range (NEB). The expected molecular 










Figure 8.7. Mass spectra (74,000 – 79,000 m/z range) for E. coli ThrRS obafluorin 
(1)-binding assays. (a) E. coli His6-ThrRS and (b) E. coli His6-ThrRS C480V. Left = 
MeCN negative control, right = 1 test assay. The expected masses for E. coli WT and 
C480V His6-ThrRS variant proteins are 76,177.62 and 76,173.61 Da, respectively. 
Discrepancies between expected masses and observed masses could possibly be 
attributed to formylation of the N-terminal methionine (28.01 m/z) and/or the presence 








This raised the possibility that the 1 catechol might also participate in target 
interaction. The ability of 1 to bind Fe3+ and Zn2+ was therefore evaluated using two 
different assays and these experiments were also performed by Carine. 
 
8.5.1 Chrome azurol S (CAS) assay to determine obafluorin (1) iron-binding 
potential 
To explore the ability of 1 to bind ferric iron, a CAS assay was performed which 
assesses the ability of molecules to chelate Fe3+ bound to CAS, resulting in a colour 
change from blue through pink to orange (Schwyn and Neilands, 1987). Introduction 
of 1 to CAS-Fe3+ complex solution resulted in a colour change from blue to pink 
(Figure 8.8), indicating that 1 disrupts the complex to chelate iron and release the 
CAS dye. This was not observed in a negative control in which 100% MeCN was 
added instead, providing qualitative evidence that 1 is able to chelate ferric iron.  
 
8.5.2 4-(2-pyridylazo)-resorcinol (PAR) assay to determine obafluorin (1) zinc-
binding potential 
A PAR assay (Bandara et al., 2009) was performed to determine whether 1 could out-
compete PAR to bind Zn2+ in solution. Addition of varying concentrations of 1 between 
1 and 50 μM to PAR solution resulted in a decrease of the characteristic Zn(PAR)2 
complex absorbance peak at 493 nm (Figure 8.9), with greater decreases observed 
at higher concentrations of 1. This suggests that 1 does indeed out-compete PAR for 
Zn2+. However, a concomitant increase in absorbance at 410 nm corresponding to the 
accumulation of unbound PAR was not observed. This was shown to occur in a similar 
experiment with holomycin (Chan et al., 2017), and might suggest that PAR can react 
with another assay component, with 1 the most likely candidate as it is the variable 
component between our experiments and those previously published.  
 
8.6 Generation of congeners of obafluorin (1) by mutasynthesis 
To explore whether the catechol moiety is significant in the interaction of 1 with 
ThrRS, we desired access to congeners of 1 in which the catechol moiety was altered 
such that metal-binding affinity would be reduced or abolished. These congeners 
could be applied in bioassay and ThrRS-binding experiments to see whether such 
alterations impact the ability of the molecule to inhibit bacterial growth or to bind its 







Figure 8.8. Preliminary qualitative liquid CAS assay results. Left = CAS + MeCN 
negative control, Right = CAS + 1. The pink colour indicates that 1 is outcompeting 





Figure 8.9. Preliminary PAR assay spectrophotometric data. Red = PAR only, 
Pink = 1 dissolved in MeCN only, Green = MeCN vehicle negative control, Blue = 
Test assays with incremental (1 μM) increases between 1(light)-10(dark) μM 1 to 
Zn(PAR)2 complex solution, and Purple = Test assay with 50 μM 1 added to the 
Zn(PAR)2 complex solution. Higher concentrations of 1 cause greater reductions of 




To achieve this, ΔobaL strain production cultures were fed alternative benzyl 
carboxylic acids to see whether these would be accepted as alternative substrates to 
6, as illustrated in Figure 8.10. If successful, this would generate congeners with 
reduced metal-binding capacities which could be applied in both biochemical ThrRS-
binding experiments and bioassays to compare their antibiotic activities relative to 1. 
Benzoic acid (BA), salicylic acid (SAL), 3-hydroxybenzoic acid (3-HBA), 4-
hydroxybenzoic acid (4-HBA), 3,5-dihydroxybenzoic acid, 2,3,4-trihydroxybenzoic 
acid, gallic acid and anthranilic acid (ANA) were all fed exogenously to ΔobaL 
production cultures to a final concentration of 0.4 mM (ANA was fed to a final 
concentration of 1 mM). Whilst none of the ΔobaL cultures fed alternate benzyl 
carboxylic acids displayed the purple colour associated with 1 (Figure 8.11), HPLC 
analysis revealed the generation of novel peaks in cultures fed BA, SAL, 3-HBA and 
ANA (Figure 8.12), suggesting the successful production of novel 1 congeners. In all 
cases, 1 production was no longer observed, but shunt metabolites 4 and 5 are still 
seen to accumulate, indicating that 2 biosynthesis is unaffected. Titres of 4 and 5 
were very low in ANA and SAL-fed cultures, reflecting the fact that cultures grew 
poorly and titres simply did not reach observable levels. ANA was fed at lower 
concentrations (0.2-0.5 mM) but no change in peak areas were observed under these 
conditions, despite noticeably improved culture growth.  
 
Culture samples were further analysed by HR-LCMS and accurate masses were 
detected for each of the anticipated 1 congeners (Figures 8.13-8.15), in addition to 
their hydrolysed, ring-open equivalents, in all cases except for ANA, in which the 
corresponding congener masses could not be detected. This could be because the 
ANA congener ionises poorly, and/or because of poor growth of cultures and low 
metabolite titres. These results match with hydroxylamine-trapping assay data 
probing A-domain substrate specificity which showed that both BA and 3-HBA are 
accepted as substrates by the ObaI A(1) domain (Figure 7.3). In those experiments, 
BA appears to be better accepted relative to 3-HBA, and this reflected in the titres of 
their respective 1 congeners, based on integrated peak areas at 270 nm (Figures 
8.13 and 8.15).  Mutasynthesis experiments will be scaled up to generate sufficient 
material for NMR analysis to verify the structural identity of these congeners of 1, 
particularly as SAL and 3-HBA congeners have the same expected masses. Material 
generated can then be used in biochemical and bioassay experiments to elucidate 











Figure 8.11. Image of mutasynthesis experiment production cultures. Left-Right: WT fed DMSO, ΔobaL fed DMSO, ΔobaL fed 6 (0.2 mM), 










Figure 8.12. HPLC data for extracts of mutasynthesis experiment production 
cultures. Samples correspond to the cultures in Figure 8.11. Novel peaks can be 
seen in each of the test conditions indicating the biosynthesis of novel congeners of 
1. Benzyl carboxylic acids fed are indicated for each trace and colours used 
coordinate with Figure 8.11. Samples here were analysed on the Agilent 1100 series 
HPLC. Subsequent analysis (Figures 8.13-15) was performed on a Nexera X2 (LC-
30AD) system connected to a LCMS-IT-TOF Liquid Chromatograph mass 
spectrometer (Shimadzu) using an identical programme and column to collect MS 









Figure 8.13. HPLC and MS data for ΔobaL fed 0.4 mM benzoic acid (BA). (a) UV 
chromatogram for a ΔobaL production culture fed BA to a final concentration of 0.4 
mM. Extracted mass spectra for peaks identified in the BA-fed culture UV 
chromatogram with * are included above: Red = BA congener of 1 (Calculated for 
C17H14N2O5 [M+H]
+ - Pred. m/z: 327.0975, Meas. m/z: 327.0978, Diff. (ppm) = 0.92); 
Blue = Hydrolysed form of the BA congener of 1 (Calculated for C17H16N2O6[M+H]
+ - 
345.1081, Meas. m/z: 345.1082, Diff. (ppm) = 0.29). (b) UV chromatogram of a ΔobaL 






Figure 8.14. HPLC and MS data for ΔobaL fed 0.4 mM salicylic acid (SAL). (a) 
UV chromatogram for a ΔobaL production culture fed SAL to a final concentration of 
0.4 mM. Extracted mass spectra for peaks identified in the SAL-fed culture UV 
chromatogram with * are included above: Red = SAL congener of 1 (Calculated for 
C17H14N2O6 [M+H]
+, Pred. m/z: 343.0925, Meas. m/z: 343.0906, Diff. (ppm) = -5.54); 
Blue = Hydrolysed form of the SAL congener of 1 (Calculated for C17H16N2O7[M+H]
+, 
Pred. m/z: 361.1030, Meas. m/z: 361.1033, Diff. (ppm) = 0.83). (b) UV chromatogram 






Figure 8.15. HPLC and MS data for ΔobaL fed 0.4 mM 3-hydroxybenzoic acid (3-
HBA). (a) UV chromatogram for a ΔobaL production culture fed 3-HBA to a final 
concentration of 0.4 mM. Extracted mass spectra for peaks identified in the 3-HBA-
fed culture UV chromatogram with * are included above: Red = 3-HBA congener of 1 
(Calculated for C17H14N2O6 [M+H]
+, Pred. m/z: 343.0925, Meas. m/z: 343.0914, Diff. 
(ppm) = -3.21); Blue = Hydrolysed form of the 3-HBA congener of 1 (Calculated for 
C17H16N2O7[M+H]
+, Pred. m/z: 361.1030, Meas. m/z: 361.1035, Diff. (ppm) = 1.38). 





Access to genomic data for additional strains that contain putative oba BGCs allowed 
the identification of a putative resistance gene (obaO) for 1, based on a minimal set 
of genes that are common to all clusters. ObaO encodes a ThrRS, the enzyme 
essential for loading L-threonine onto its cognate tRNA for protein synthesis. Although 
aaRSs are ubiquitous in nature, divergence in their sequence and structure has 
created the opportunity for organisms to be able to biosynthesise NPs that selectively 
target the aaRSs of potential competitors (Cochrane et al., 2016). Self-resistance can 
also be achieved via the duplication and divergence of the target aaRS within the 
producer to create a resistant copy. This was the basis for the identification of obaO, 
which represents a second putative ThrRS encoded in the ATCC 39502 genome. 
This is also the case in the genomes of other bacteria that encode putative oba BGCs. 
Many other NP BGCs that encode inhibitors of aaRSs contain a resistant copy of the 
target aaRS, in addition to a primary copy encoded elsewhere in the genome. These 
include the mupirocin BGC which encodes a resistant isoleucyl-tRNA synthetase (El-
Sayed et al., 2003), the indolmycin BGC which encodes a resistant tryptophanyl-tRNA 
synthetase (Du et al., 2015) and the BGC for borrelidin, also a ThrRS inhibitor, which 
encodes a resistant ThrRS (Olano et al., 2004).  
 
Disruption of the obaO gene in P. fluorescens ATCC 39502 led to the abolition of 1 
production and loss of the characteristic purple phenotype in production cultures, 
indicating an intrinsic relationship between this locus and 1 production. Unfortunately, 
introduction of pJH10TS-obaO into the ΔobaO strain was unable to recover the WT 
production phenotype. This could be because overexpression of this gene disrupts 
the physiology of the cell (e.g. through L-threonine starvation), resulting in 
suppressors in which the gene is not expressed. A more likely explanation is that 
removal of obaO function leads to a suppressor mutation in a biosynthetic oba gene 
to abolish production and prevent self-harm. To circumvent this issue, in future work 
obaO will be introduced into the WT strain elsewhere in the genome, before 
subsequently disrupting the oba BGC cluster copy, thus preventing selection for 
biosynthesis mutants under 1-producing conditions. This could be performed using 
pUC18T-mini-Tn7-Gm, a vector which integrates DNA sequences flanked by Tn7R 
and Tn7L coding sequences in to Tn7 transposition sites. In the Pseudomonas 
chromosome, such an attTn7 transposition site is located downstream of a highly-
conserved glucosamine-6-phosphate synthetase (glmS) gene (Choi and Schweizer, 
2006). A pTS1-based knockout can then be performed to target the endogenous oba 
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BGC copy, which should allow the possibility of non-polar effects as a result of obaO 
disruption to be ruled out. 
 
Agar diffusion assays performed to identify the MIC of 1 against two E. coli strains 
showed that obaO increased the MIC by >60 fold for ATCC 25922, and >4000 fold 
for NR698, compared to empty vector controls. This indicated that obaO represents 
the 1 resistance gene and that 1 is an inhibitor of ThrRS. 1 was also shown to be 
active against B. subtilis, a Gram-positive bacterium, with an MIC of only 0.125 μg/mL. 
Further experiments are required to clone a codon-optimised copy of obaO in an 
appropriate expression vector into B. subtilis, in order to see whether it can also 
confer resistance in this bacterium. As a further control, the ‘primary’ metabolic ThrRS 
PCS from the ATCC 39502 strain could also be introduced in to bioassay strains to 
confirm that it does not confer resistance to 1. In the future, bioassays can be 
extended to investigate 1 antibiotic activity against ESKAPE (Rice, 2008) and other 
clinically significant pathogens to establish the spectrum of its activity. To provide 
additional support for 1’s role in ThrRS inhibition, future work will also include the use 
of reporter strains in which the promoters of genes known to be highly transcribed in 
response to different antimicrobial compounds have been fused to a luciferase 
reporter gene (Hutter et al., 2004). When challenged with 1, only strains with protein 
synthesis-associated gene promoters should express luciferase and display 
bioluminescence.  
 
Alignment of amino acid sequences for putative 1-‘sensitive’ and -‘resistant’ ThrRSs 
revealed that putative 1 resistant genes are substituted with a valine at a key ThrRS 
active site cysteine residue. Cysteine represents an ideal candidate nucleophilic 
residue for β-lactone ring attack, and would explain why putative resistance genes 
have evolved to encode a valine at this position to prevent reaction with 1. To test 
this, variants of E. coli ThrRS were purified and incubated with 1 before HR-LCMS 
analysis to determine whether mass shifts corresponding to 1-binding could be 
detected. Unfortunately, in both cases, a mass shift of ~358 Da was observed 
indicating that both variants bound 1, and in neither case was a cysteine residue 
found to be modified. Future work will be to perform the same experiment with purified 
obaO and a V481C variant to identify whether the result observed for E. coli ThrRS 
was due to of technical issues or whether 1 might possess an alternative mode of 
action for ThrRS inhibition. The other ThrRS encoded in the ATCC 39502 genome 
will similarly be investigated (C479V substitution). Constructs in which cysteine and 
valine residues have been switched and vice versa will also be introduced into 
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bioassay strains to determine the significance of that residue for antibiotic activity. 
Samples of purified 1 have been sent to Prof. Christopher Francklyn’s group at the 
University of Vermont, who specialise in the biochemistry of aaRSs, to perform kinetic 
analyses to further verify whether 1 is a true ThrRS-binder. 
 
Not only is 1 prone to hydrolysis under aqueous conditions at neutral and alkaline pH, 
but it was also found to be particularly reactive with other chemicals in solution. During 
the course of experimental optimisation for 1 ThrRS-binding assays, it was found that 
1 readily reacts with glycerol, in addition to a number of buffers including Tris and 
HEPES. Fortunately, MES buffer did not react with 1 and hydrolysis could be 
minimised at pH 6. This lability could explain several of the results observed in 
preliminary mode of action experiments; microtitre plate-based bioassays in MH broth 
might have failed if 1 reacts with any of the constituents in this medium for example. 
Instability of the molecule would also explain why relatively little experimental data on 
1 activity are available in the literature. β-lactam rings are seemingly more prevalent 
among NPs compared to β-lactones, which are relatively uncommon, and this 
observation could also be a reflection in nature of issues associated β-lactone 
instability. The major force driving the reactivity in both of these ring-strained systems 
is the high relief on ring strain following opening (95-130 kJ/mol – Roux et al., 1995; 
Kim et al., 2002), however, the amide bond of the azetidine-2-one ring (β-lactams) is 
more stable to hydrolysis than the oxetan-2-one (β-lactone) ester bond. Whilst this 
causes the β-lactam ring to be less reactive, it provides significant advantage in 
minimising unspecific reactivity that would hamper the utility of these molecules in 
nature, as exemplified by experimental difficulties encountered with 1.  
 
In addition to the β-lactone ring, 1 comprises a catechol moiety which is often found 
in siderophore NPs and is responsible for metal-ion chelation. ThrRSs require Zn2+ 
as a cofactor for activity, raising the possibility that the 1 catechol might also be 
important for mode of action through cofactor-binding. This raised two possible modes 
of action based on both β-lactone ring and catechol moieties: 1) The binding of the β-
lactone to the ThrRS active site cysteine residue is reversible, but is stabilised by 
catechol binding to the Zn2+ cofactor which acts to keep the β-lactone in close 
proximity to cysteine for subsequent reactions; and/or 2) Initial coordination of the 
Zn2+ cofactor is necessary to orient the β-lactone into the necessary position to 
facilitate attack of the ring by the active site cysteine residue. If coordination of the 
Zn2+ ThrRS cofactor is indeed necessary for 1-mediated inhibition, this would explain 
why the specific modification of the cysteine residue could not be detected following 
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tryptic digestion in biochemical assays with E. coli ThrRS, as 1-Zn2+ binding would be 
disrupted. However, it does not explain why 1-binding was detected in both WT and 
C480V ThrRS variant protein assays prior to tryptic digestion. 
 
Ability of 1 to chelate metal ions was assessed in preliminary CAS assay experiments, 
which indicated that 1 does indeed chelate Fe3+, as a colour change from blue to pink 
was observed, indicative of CAS-Fe3+ complex disruption by competing 1 to release 
CAS dye. However, potent ferric iron chelators cause the complete dissociation of the 
CAS-Fe3+ complex resulting in a distinct orange colour. In order to quantify 1 iron-
binding, this assay will be repeated in future experiments over a range of 
concentrations and resulting absorbance spectra will be collected to quantify iron 
chelation by calculating EC50 values for the decomplexation of CAS-Fe3+. A similar 
metal-binding competition assay was performed to assess the ability of 1 to 
outcompete PAR for Zn2+-binding. Whilst the characteristic Zn(PAR)2 complex 
absorbance peak at 493 nm clearly decreased with increasing 1 concentrations, no 
concomitant increase in absorbance at ~410 nm reflecting dissociated PAR was 
observed. One possibility is that 1 could react with PAR independently of Zn2+ and 
that is why an increase in absorbance at ~410 nm is not observed when 1 is 
introduced. The basic pyridine moiety of PAR could aid hydrolysis of 1 and the 
hydroxyl groups of the resorcinol moiety are also likely to be relatively nucleophilic, 
and attack of the β-lactone ring could also be an issue. For both metal-binding assays, 
LCMS analyses are required to determine whether 1 reacts with any reaction 
components other than the metal ions. This would also allow determination of the 
ratio of 1 to each metal ion in complex, permitting quantification of metal ion-binding 
through binding/dissociation constant calculations.  
 
An alternative possibility is that the catechol moiety is not at all involved in directing 1 
ThrRS-binding, and instead, could play a role in uptake. Metal ions are often limiting 
in natural environments and many microorganisms biosynthesise siderophores to 
mediate ion-uptake (Wandersman and Delepelaire, 2004). The notable antibiotic 
activity demonstrated by 1 makes it unlikely that it functions purely as a siderophore, 
however, its siderophore-like properties may provide 1 entry into target cells. Many 
microorganisms have evolved the ability to utilise non-native siderophores 
(xenosiderophores), conferring them with a special fitness advantage by placing the 
metabolic burden of biosynthesis and secretion on others. This phenomenon is well 
documented in many key bacterial species (Jin et al., 2006; Cornelis, 2010; Hammer 
and Skaar, 2011; Miethke et al., 2013; Endicott et al., 2017), and xenosiderophores 
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have also been successfully applied to promote the growth of uncultivated bacteria 
(D’Onofrio et al., 2010). As a counter-evolutionary strategy, some microorganisms 
have evolved the ability to synthesise antibiotic-siderophore NP conjugates 
(sideromycins) that are taken up via siderophore transport proteins to circumvent 
issues of cell membrane permeability and kill competitors (Klahn and Bröstrup, 2017). 
Albomycins, for example, are composed of the natural antibiotic SB-217452 
(Stefanska et al., 2000), a seryl-tRNA synthetase inhibitor, and a hydroxymate-type 
ferrichrome moiety, known to be utilised as a xenosiderophore by E. coli (Hartmann 
et al., 1979; Braun et al., 1994; Clarke et al., 2002), P. aeruginosa (Jurkevitch et al., 
1994; Hannauer et al., 2010), Streptococcus pneumoniae (Pramanik and Braun, 
2006) and Salmonella spp. (Ernst et al., 1978; Braun et al., 1983). Other natural 
examples include the salmycins (Vertesy et al., 1995), ferrimycins (Bickel et al., 
1965), danomycins (Tsukiura et al.,1964) and class IIb microcins (Duquesne et al., 
2007). 1 may then represent another example, in which the catechol moiety facilitates 
uptake into the target cell and the β-lactone mediates cell death. It is also possible 
that 1 export in ATCC 39502 is mediated by siderophore transporters, rather than by 
the RDD-domain protein encoded by orf7 as suggested in Chapter 3, particularly 
given that no RDD-family proteins have been documented in the NP literature. 
 
Future work in determining the mechanism of action for 1 will be aided by the 
mutasynthetic generation of four novel congeners of 1. In each of these, the catechol 
has been substituted with different benzyl carboxylic acid moieties which should have 
reduced metal-binding abilities. This can be confirmed using CAS and PAR assays. 
If appropriate conditions for 1-binding biochemical assay experiments can be 
established, congeners should be able to determine whether the catechol is 
necessary for ThrRS interaction, and thus distinguish between possible roles in 
uptake or ThrRS Zn2+ cofactor-binding for the 1 catechol moiety. Congeners of 1 can 
also be applied in in vivo experiments to determine how alterations in this moiety 
affect antibiotic activity. Production of 1 congeners will be scaled up so that sufficient 
material for each can be purified for NMR analysis and conformation of structure, and 
for use in biochemical and bioassay experiments. Whilst access to congeners of 1 
allow a far more comprehensive study of the significance of the catechol moiety of 1, 
a crystal structure for the 1-ThrRS complex would permit the absolute 
characterisation of 1 ThrRS-binding mechanism. 
 
A key phenotypic characteristic of 1 production cultures is the generation of a purple 
colouration (Figures 4.3 and 8.4). During in silico analysis of the ATCC 39502 
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genome, no BGCs for known potential candidate pigmented NPs, such as violacein 
(Lichstein and Vandesand, 1945) or prodiginines (e.g. prodigiosin, which gives 
Serratia marcescens its characteristic violet/red colour (Williamson et al., 2006)), 
were identified. The colour is lost or at least diminished in all 1 biosynthetic deletion 
strains (Figure 4.3), indicating that it is either a direct or indirect result of 1 production. 
The observation that purified 1 alone is in fact pale yellow colour, and that 1 congener 
production cultures do not retain the purple phenotype (Figure 8.11), suggested that 
colour might be the result of a 1-metal ion complex chromophore. Further work is 
required to elucidate the true origins of this intriguing production phenotype and will 
involve simple experiments incubating physiological concentrations of 1 with a range 
of metal ions in various concentrations to see if any colour develops. 
 
The significance of the aromatic nitro group of 1 has not been explored at all in this 
work. Nitro groups are rare moieties among NPs (Winkler and Hertweck, 2007; Parry 
et al., 2011), but have been shown to be critical to the bioactivity of several NPs 
including thaxtomin (King et al., 2001; Scheible et al., 2003), a phytotoxin that inhibits 
cellulose synthesis, and pyrrolnitrin, an antifungal inhibitor of electron transport 
(Lambowitz and Slayman, 1972; van Pée and Ligon, 2000). Currently, the best 
characterised involvement of a nitro group in NP bioactivity is from a structure of 
chloramphenicol in complex with the 70S ribosome from Thermus thermophilus 
(Bulkley et al., 2010). In this structure, the chloramphenicol 4-nitrobenzyl group 
participates in a π-stacking interaction with C2452 of the ribosomal 23S RNA. Given 
that our data suggest ObaC operates at an earlier stage during the biosynthesis of 1 
and that the nitro group appears to be significant for ObaH substrate recognition, it 
seems likely that nitro group incorporation has been specifically selected for. The 
strong electronegativity of the nitro group can delocalise the π-electrons of the 
benzene ring, providing a charge to the molecule which could be important for 
directing interactions with the ThrRS target (Ju and Parales, 2010). Unfortunately, the 
amino- congener of 1 does not accumulate in the ΔobaC mutant, and so cannot be 
compared to 1 in bioassay experiments. However, given that Schaffer et al., (2017) 
demonstrated 1 assembly in vitro by incubation of 2 and 6 with ObaI, ObaK and Sfp, 
a mutasynthesis approach could be employed using (2S)-amino-(3R)-hydroxy-4-
phenylbutanoate (prepared enzymatically using His6ObaG) in place of 2 to generate 
the corresponding congener of 1. This would only work provided the A2 domain (and 
downstream-acting domains) is sufficiently promiscuous and will accept these 
alternate substrates. The hydroxylamine-trapping assay can be used to determine 
whether this is a possibility. Alternatively, 1 congeners substituted at the 4-nitro 
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position can be prepared chemically using published total synthesis methods for 1 
(Lowe et al., 1992). As mentioned previously, a crystal structure of the 1-ThrRS 
complex will permit elucidation of the precise interactions that mediate 1-binding. 
 
Whilst the results presented here represent very preliminary data, they reveal that 1 
has very potent antibiotic activity against both Gram-positive and Gram-negative 
bacteria. Furthermore, they suggest that the β-lactone ring, with possible involvement 
of the catechol moiety, may represent a novel mechanism of inhibition for ThrRSs, 
and future work will be concerned with fully characterising the 1 mode of action, which 
will be aided by the generation of novel congeners of 1. If 1 does indeed have a 
completely novel mode of action, it would warrant further experiments to explore its 




















9.1 Summary of results  
In this project, mutational analyses were performed to dissect the biosynthetic 
pathway for obafluorin (1) using custom made suicide and complementation vectors. 
The precursors 2,3-DHBA (6) and 4-NPP (8) (via 4-APP (7)) were shown to be the 
products of gene sub-clusters (obaJLN and oba(C)DEF, respectively) in the pathway. 
8 is an intermediate in the biosynthesis of AHNB (2), and both 2 and 6 are activated 
and condensed by a dimodular NRPS (ObaI) in conjunction with the discrete ArCP 
(ObaK) to yield 1. Failure of 2 to complement biosynthetic mutants precluded the 
possibility of characterising the biosynthesis of 2 from 8 in vivo, necessitating further 
biochemical experiments. The ThDP-dependent enzyme ObaH was found to act as 
an 8 decarboxylase, responsible for generating the intermediate 4-NPA (11), which 
is the substrate of ObaG. This disproved the previous hypothesis that 2 is the direct 
product of a ThDP-dependent mechanism (Herbert and Knaggs, 1990; 1992b). 
Instead, ObaG, a PLP-dependent L-TTA, was shown to be responsible for the 
biosynthesis of 2 as a single stereoisomer in respectable yields from L-threonine and 
11, with acetaldehyde as a by-product. ObaG represents a third subfamily of the L-
TTAs, adding an additional member to join the FTase and LipK-like subfamilies. 
 
L-TTAs, SHMTs and L-TAs all catalyse the cleavage of β-OH-α-AA substrates to 
produce glycine and an aldehyde by-product, and a phylogenetic analysis was 
performed to gain insight into the evolutionary history of these fold-type I PLP-
dependent enzymes. All three enzyme families were determined to originate from an 
ancestor that probably used L-serine as a substrate and two separate substrate-
switching events led to L-TA and L-TTA lineages that use L-threonine. The phylogeny 
allowed the identification of a new candidate L-TTA family, homologues of which are 
involved in the biosynthesis of β-OH-α-AA intermediates in several clavam metabolite 
pathways. Phylogenetics may represent a powerful approach for the expansion of the 
L-TTA enzyme class, and may additionally allow the identification of lineages of PLP-
dependent enzymes that perform further unusual chemistries in NP biosynthetic 
pathways. 
 
Biochemical experiments were also performed on the dimodular NPRS ObaI, which 
is responsible for 1 assembly from 2 and 6. The offloading of the newly assembled 
pseudo-dipeptide occurs with concomitant β-lactone ring formation. A hydroxylamine-
trapping assay was performed to probe the substrate specificity of the ObaI A 
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domains, and identified 2 as the preferred substrate, although significant signals were 
recorded for L-serine, L-tryptophan, benzoic acid (BA) and 3-hydroxybenzoic acid (3-
HBA). This indicated some degree of substrate promiscuity in both A domains. The 
ObaI TE domain contains an active site cysteine residue that was shown by others 
(Schaffer et al., 2017) to be critical in creating thermodynamically favourable 
conditions for cyclisation and formation of the strained β-lactone ring in 1 to occur. 
With this data, the biosynthetic pathway to 1 from chorismate has been effectively 
delineated. 
 
Finally, in silico analysis of putative oba BGCs encoded in the genomes of bacteria 
uploaded to GenBank during the course of this project permitted the identification of 
obaO as the putative 1 resistance gene. It encodes a ThrRS, essential for ligating L-
threonine to its cognate tRNA during protein biosynthesis. Its role was confirmed by 
mutational analysis and agar diffusion assays, which showed that 1 has potent 
antibiotic activity against both Gram-positive and -negative bacteria, and that obaO is 
sufficient to confer high-level resistance upon sensitive strains. Alignments of ObaO 
homologues compared with those of putative primary metabolic ThrRSs revealed a 
C480V (E. coli numbering) substitution in ‘resistant’ copies. However, in vitro binding 
assays with WT and C480V copies of E. coli ThrRS have so far failed to shed light on 
the possibility that this is the nucleophilic residue that attacks the β-lactone ring to 
bind 1. Preliminary experiments were also performed to assess the metal-ion-binding 
capacity of 1, given that ThrRSs require a Zn2+ cofactor for catalytic activity and 1 
comprises a catechol moiety synonymous with a role in Fe3+ chelation in NP 
siderophores. CAS and PAR assays indicated that 1 binds both Fe3+ and Zn2+, but 
further work is required to dissect the mechanism of 1 ThrRS-binding. A 
mutasynthetic approach was applied by feeding alternate benzyl carboxylic acids to 
the ΔobaL strain and resulted in the generation of at least three novel congeners of 1 
in which one or both catechol hydroxyl groups are no longer present. These 
congeners will form the basis of further bioassay and metal-binding experiments to 
determine the significance of the catechol moiety in the antibiotic activity of 1.  
 
9.2 Future directions 
9.2.1 Regulation of the biosynthesis of obafluorin (1) 
Although the potential quorum-dependent regulatory roles of obaA and obaB (luxI 
and luxR homologues respectively) were discussed in Chapter 3, no experimental 
work was performed in this project to characterise their respective functions during 
the biosynthesis of 1. luxR homologues have been implicated in the regulation of 
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many pseudomonad NP biosynthetic pathways (Pierson III et al., 1995; El-Sayed et 
al., 2001; de Bruijn et al., 2008; Dubern et al., 2008), where, presumably, they ensure 
that a compound is only made when it can be produced in biologically significant 
concentrations. Logical initial experiments to explore the regulation of the 
biosynthesis of 1 would be to first define a production time course to identify when 
peak 1 production occurs and at what cell density. Experiments can then be 
performed to see whether peak production can be shifted to an earlier or later time 
point by introduction or removal of cell density. It would be interesting to see whether 
the purple colour that coincides with 1 production also develops earlier or later, as it 
remains unclear whether this colour is a direct or indirect consequence of the 
biosynthesis of 1. Additionally, disruption and/or overexpression of either obaA and/or 
obaB should result in either an increase or decrease in 1 titres relative to the WT, 
which would indicate whether these regulators are acting as repressors or activators. 
In addition to genetic complementation, co-culture experiments with ΔobaB might 
also be an option to recover 1 production in an ΔobaA strain, as the autoinducer 
synthesised by ObaA in the ΔobaB strain cells should diffuse in liquid culture, eliciting 
a response from ObaB in the ΔobaA cells, thus switching 1 production on (or off). 
Using concentrated extracts from spent ΔobaB (or biosynthetic mutant) culture 
medium should produce a similar result in the ΔobaA strain.  
 
In silico analysis of the oba BGC should allow the identification of putative Lux(Oba)-
boxes, 20 bp inverted repeat sequences located ~40 bp upstream of transcriptional 
start sites, to which LuxR homologues bind to mediate gene regulation (Devine et al., 
1989; Qin et al., 2007). Identified targets can be identified via several methods 
including reporter fusions and reverse transcriptional analysis to determine which 
genes are genuinely regulated by ObaB. The ultimate experiment to identify all the 
genes in the ObaB regulon would be to perform Chromatin Immunoprecipitation 
Sequencing (ChIP-seq) which, coupled with transcriptional organisation mapping, 
would identify regions of DNA to which ObaB is bound under particular growth 
conditions. With ObaB targets in hand, the N-acylhomoserinelactone molecule to 
which ObaB responds can be identified using a bioautography approach, as used by 
Thomas and co-workers in the study of quorum-sensing mediated regulation in 
mupirocin biosynthesis (El-Sayed et al., 2001). 
 
9.2.2 L-TTA directed evolution 
L-TTAs represent exciting tools for synthetic applications in the generation of β-OH-
α-AAs, far surpassing the aldol reaction catalysed by engineered SHMTs and L-TAs 
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in terms of both product yield and stereoselectivity. Whilst ObaG was shown to 
demonstrate some aldehyde substrate promiscuity (these enzymes are highly 
selective for their L-threonine amino acid donor), the only other characterised L-TTA 
family members, LipK and FTase, have not been explored for the generation of novel 
β-OH-α-AAs. This might be one direction for further study provided appropriate 
alternate aldehyde substrates can be prepared. Rational engineering by directed 
evolution of these enzymes, after solving their crystal structures, represents another 
possible strategy that might expand our access to new β-OH-α-AAs.  
 
Compared to their primary metabolic counterparts, specialised metabolic enzymes 
tend to be significantly less efficient, as illustrated by the relatively high Km values 
observed for ObaG and LipK. High efficiency is expected for central metabolic 
enzymes as the reactions they catalyse are intrinsically linked to growth rate and so 
strong selection pressures have been acting to optimise their catalytic activity over 
many millions of years (Bar-Even et al., 2011). This would explain why SHMTs and 
L-TAs have proven to be recalcitrant in efforts to engineer them for β-OH-α-AA 
biosynthesis (Fesko, 2016). In specialised metabolism, there appears to be significant 
selection for the maintenance of chemical diversity (Firn and Jones, 2000), and 
broader substrate specificity is selected for at the expense of catalytic efficiency, 
which also serves to avoid competition with essential primary metabolic pathways 
(Bar-Even and Tawfik, 2013). As a result, L-TTAs may be more amenable to 
manipulation for altered substrate specificity. 
 
In nature, specialised metabolic biosynthetic genes are thought to have evolved via 
a number of different routes including HGT, homologous recombination, gene fusion 
and gene duplication followed by divergence (Eisenbeis and Hocker, 2010). In the 
latter case, a duplicated primary metabolic enzyme is proposed to first diverge to 
become a substrate generalist, before evolving into a specialist enzyme optimised for 
the use of a new specific substrate in the context of NP biosynthesis (Firn and Jones, 
2000). A similar logic would be employed in a directed evolution approach with L-TTA 
enzymes, using rounds of gene-sequence level diversification followed by 
expression, screening and selection for alterations that lead to better acceptance of 
a desired alternate substrate (Denard et al., 2015). Once a new substrate is accepted, 
similar approaches can be used to select for improved yield and stereoselectivity to 
make the enzyme suitable for use as a biocatalyst. Optimisation of protein expression 
or thermostability for industrial use can also subsequently be considered. This work 
would be facilitated by a greater understanding of the reaction mechanism employed 
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by these enzymes and structural data for each of the L-TTAs, especially if they can 
be crystallised with their substrates bound. As mentioned in Chapter 6, this would 
allow the identification of key residues for modification in the active site that are 
necessary for substrate interaction and/or for creating the three-dimensional space 
necessary to accommodate new substrates.  
 
9.2.3 Strategies for future genome mining efforts 
One of the key broader questions this project hoped to address was how can we mine 
the wealth of available genomic data in a way that selects for discovering novel 
chemistry? Accessing new, diverse chemical structures is paramount to identifying 
NPs that interact with new biological targets, and will be critical in tackling the issue 
of multidrug resistant pathogenic bacteria. Initially, it was hoped that a ThDP-
dependent enzyme and transaminase, as previously hypothesised to be responsible 
for the biosynthesis of 2 (Figure 3.1), could be used as a ‘fingerprint’ to query the 
genomic sequence databases to identify BGCs that biosynthesise unusual β-OH-α-
AAs or α-OH-β-AAs. In this project however, 2 was proven to be the product of a PLP-
dependent L-TTA reaction. 
 
This finding does not prevent the development of alternate strategies to search for 
novel chemistries, as highlighted by the use of phylogenetics to identify further 
potential L-TTAs among clavam biosynthetic pathways. In collaboration with Dr. 
Govind Chandra, the phylogenetic study will be expanded to include more putative 
SHMTs, L-TAs and related PLP-dependent enzymes (e.g. methylSHMTs) available 
in the GenBank database. This may allow us to both identify further L-TTAs that have 
been incorrectly annotated, and identify additional clades of PLP-enzymes that have 
diverged from primary metabolic enzymes to fulfil roles in NP biosynthetic pathways. 
The clustering of PacT homologues, thought to be responsible for the biosynthesis of 
DABA in four different biosynthetic pathways (Zhang et al., 2010; Kaysser et al., 2011; 
Li et al., 2013; Jiang et al., 2015), indicates that this is possible. The PLP-cofactor is 
well known for its catalytic versatility (Contestabile et al., 2001) and so these enzymes 
represent ideal candidates for divergence into new functions in specialised 
metabolism. Indeed, many examples of PLP-dependent enzymes and domains have 
been reported in the NPs literature (highlighted in Chapter 6). Phylogenetics may 
therefore allow us to unlock a broader range of chemistries for PLP-dependent 




Given that the product of all L-TTAs is an amino acid, more refined genome mining 
attempts could be envisaged using characterised family members in coupled queries 
with NRPS domains/modules, as these represent the most common mechanism of 
amino acid assembly among NPs. ATP-grasp ligases could be similarly applied as 
these are also reported to introduce amino acids into NPs (Dawlaty et al., 2010; Noike 
et al., 2015; Ooya et al., 2015). For example, Lig is an ATP-grasp fold family protein 
encoded in the valclavam BGC that is proposed to ligate valine and a 9-
hydroxyclavam intermediate (Z in Figure 6.2 - Nobary and Jensen, 2012); this work 
suggests Z is the product of an L-TTA-catalysed reaction. However, biasing a query 
based on amino acid assembly would exclude the discovery of L-TTAs such as FTase 
(Murphy et al., 2001) or OrfA (Zelyas et al., 2008) in which the β-OH-α-AA alone forms 
the entire scaffold for the final product. Not only would crystal structures for L-TTA 
subfamily members aid in guiding directed evolution efforts to engineer these 
enzymes, but they would also facilitate more directed searches for additional L-TTA 
family members. The characterisation of key catalytic residues necessary for 
aldehyde substrate interaction in these enzymes would provide an L-TTA ‘signature’ 
for genome-mining efforts. 
 
ThDP-dependent enzymes also catalyse an incredibly diverse range of 
biotransformations in nature, including cleavage and formation of C-C, C-O, C-N and 
C-S bonds (Pohl et al., 2004; Duggleby, 2006). Diversity in substrate specificity and 
catalytic activity have been the result of the shuffling, rearrangement and fusion of 
domains, mutations and gene duplications, which has created a great breadth of 
ThDP-dependent enzymes (Vogel and Pleiss, 2014). Like PLP, ThDP is also able to 
catalyse reactions independently in solution, albeit at a much slower rates, indicating 
that early ThDP-dependent enzymes might have exhibited broad substrate 
specificities (Kluger and Tittmann, 2008). ThDP-dependent enzymes all share a 
common reaction mechanism in which a ThDP ylide is formed by protein-assisted 
deprotonation at its C-2 atom, which subsequently acts as a nucleophile adding to 
the α-carbon of a 2-keto substrate (Jordan, 2003). Pyrophosphate (PP) and 
pyrimidine (PYR) domains are always present and are necessary for binding and 
activating the cofactor. Perhaps unsurprisingly, these versatile catalysts have also 
diverged into NP biosynthetic contexts to utilise new unusual substrates (e.g. ObaH) 
and perform novel chemistries (Chen et al., 1998; Balskus and Walsh, 2008; Peng et 
al., 2012; Proschak et al., 2014; Su et al., 2016). However, the only phylogenetic 
study of these enzymes to date included just 17 different ThDP-dependent enzyme 
amino acid sequences (Costelloe et al., 2008), warranting a more expansive study to 
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further understand their evolutionary history. This might also allow the identification 
of lineages involved in NP biosynthesis. 
 
Phylogenetics might also be useful tool for the identification of further BGCs encoding 
β-lactone and β-lactam NPs. This would be extremely desirable given their 
reputations for being potent specific inhibitors of important biological targets. As 
mentioned earlier, Schaffer et al. (2017) demonstrated that β-lactone formation by 
ObaI is catalysed by an active site cysteine, rather than a canonical serine, residue. 
This switch makes the formation of the strained ring thermodynamically favourable. 
Schaffer et al. also showed that the ObaI TE domain and its homologues from putative 
1 BGCs identified in Chapter 8, form their own discrete lineage in a phylogeny of class 
I and II TEs from other NP biosynthetic pathways. Given the apparent necessity of 
the cysteine residue for cyclisation (substitution to serine resulted in the hydrolysis of 
a linear dipeptide product (10) – Schaffer et al., 2017), a phylogeny of all annotated 
TEs might allow the expansion of this clade with more distantly related domains that 
introduce β-lactone rings into different NPs. The recent example of sulfazecin 
biosynthesis in which the TE domain from SulM with an active site cysteine residue 
catalyses β-lactam ring formation (Li et al., 2017), creates the potential to also identify 
novel β-lactam NP BGCs. 
 
Gene duplication has played a key role in the evolution of NP biosynthetic pathways 
as additional gene copies have evolved to fulfil new functions in the context of 
specialised metabolism (Fischbach et al., 2008). In the biosynthetic pathway to 1, the 
L-TTA ObaG, and the ThrRS ObaO studied in this work are excellent examples of 
duplicated primary metabolic enzymes that have evolved to perform novel chemistry 
and resistance functions, respectively. During the evolution of bacterial genomes, if a 
duplicated gene does not provide some selective advantage, it will accumulate 
mutations, and its removal will be selected for due to the energy expenditure and 
lowered replication rates associated with the maintenance of additional DNA 
sequence (Sela et al., 2016). The large effective population sizes of prokaryotes, in 
addition to short generation times, enables them to maintain very compact genomes 
by this process of selection (Lynch, 2006). Consequently, bacterial genomes will often 
only encode a single copy of each essential housekeeping gene, which has allowed 
their identification by approaches such as transposon mutagenesis (Simon et al., 
1983). This phenomenon also formed part of the basis for identification of obaO as 
the putative 1 resistance gene, which exists as the only additional copy to a putative 
housekeeping ThrRS encoded in the ATCC 39502 genome. This is the case in all 
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strains encoding a putative oba BGC, whereas model P. fluorescens strains F113, 
Pf0-1 and SBW25, which do not encode a putative oba cluster, only encode only a 
single thrRS gene. These observations raise the possibility that genetic redundancy 
could be utilised during genome mining approaches, as a marker of NP BGC 
evolution. 
 
The essential housekeeping genes for many clinically relevant pathogenic bacteria 
have already been determined (Ackerley et al., 2001; Geoffroy et al., 2003; Garsin et 
al., 2004; Liberati et al., 2006). Essential genes for which a NP inhibitor is currently 
not known could be selected as queries, and a search of the genome sequence 
databases could be performed to identify strains which possess multiple copies of the 
selected essential gene target. Duplication of essential enzymes is known among 
bacteria (the B. subtilis genome encodes two ThrRSs (Putzer et al., 1990)) so a 
condition could be applied to the query that one of the multiple copies of the target 
gene in a given strain must be within a certain distance of a known NP biosynthetic 
gene (e.g. NRPS/PKS). This caveat capitalises on the natural tendency for NP 
biosynthetic genes to be clustered together (Fischbach and Walsh, 2006; Osbourn, 
2010). Hits would then have to be analysed manually to identify whether they do occur 
in plausible BGCs or not. False positives can be minimised by increasing the copy 
number threshold of a target gene, decreasing the maximum distance a target must 
be from a NP biosynthetic locus and by omitting species from the search in which 
redundancy of essential genes is particularly common.  
 
This redundancy-based approach is limited in that it will not identify NP BGCs which 
rely on efflux or target modification as resistance mechanisms, will only identify BGCs 
comprising genes known previously to be involved in NP biosynthesis (NRPSs etc.), 
and can only be used with complete genomic data sets. However, the possibility of 
identifying BGCs for NPs with pre-determined targets could be very powerful in 
tackling the issue of multidrug resistant bacterial pathogens. In the first instance, 
redundancy-based genome mining could be performed and refined with actinomycete 
bacterial genomes as these are known to encode among the highest numbers of 
BGCs (Bérdy, 2012). Given that NPs that target aaRSs commonly employ a 
duplicated copy of the target enzyme as a resistance mechanism (Cochrane et al., 
2016), they would make ideal initial queries to validate this genome mining strategy. 
 
Whilst developing this idea with Dr. Govind Chandra, a new web server called the 
Antibiotic Resistant Target Seeker (ARTS – Alanjary et al., 2017) became available 
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online which detects known and putative resistance genes present within a submitted 
DNA sequence query based on duplication, localisation within a BGC and evidence 
of HGT. This web tool was able to recognise duplications of genes encoding putative 
SHMTs, ThrRSs and GCS genes in the ATCC 39502 genome, however it did not 
identify any of these as belonging to a putative BGC. Nevertheless, this tool shows 
great potential and indicates that a refined redundancy-based approach could work. 
The ARTS server has the added benefit of not being limited to type of resistance 
mechanism, and is able to identify putative efflux resistance mechanisms and NP 
modifying enzymes, in addition to resistant NP target enzymes. 
 
Similar reasoning and database queries could conceivably be used to identify 
essential enzymes that have been acquired by NP biosynthetic pathways following 
duplication and have evolved to perform novel chemistry. This would also require 
queries to be coupled with known biosynthetic genes to reduce the numbers of hits 
located outside of NP BGCs. A recent phylogenomics-based approach designed to 
search for the expansion of central metabolic families among 230 actinobacteria 
strains was successful in identifying biosynthetic pathways to arseno-organic 
metabolites in S. coelicolor and S. lividans (Cruz-Morales et al., 2016). This work 
further validates a redundancy-based genome mining strategy, but with the added 
benefit of not limiting hits to BGCs that encode members of characterised NP families. 
However, the presence of a duplicated essential gene in a putative BGC is by no 
means a guarantee of novel chemistry and there is no way of knowing this until at 
least the NP structure has been characterised. 
 
9.2.4 Evolution of the oba BGC 
The ability to rapidly generate structural variety seems to be an especially important 
property of NP biosynthetic pathways and is reflected in the fact that many are known 
to be responsible for the production of multiple compounds that are variations on the 
same core structure. As an example, work in the Wilkinson group on the 
formicamycins produced by Streptomyces formicae revealed that a single type II PKS 
BGC was responsible for the production of 13 natural detectable analogues of these 
pentacyclic PKs (Qin et al., 2017). High-affinity, reversible, non-covalent interactions 
between a NP ligand and its protein target require the ligand to possess a highly 
specific configuration to interact with the specific 3D structure of its target, which is a 
rare property for any molecule to possess (Firn and Jones, 2000). This is reflected in 
the fact that different formicamycins vary greatly in their bioactivity against MRSA and 
VRE, and also in the failure of combinatorial chemistry and HTS in the late 1990s to 
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produce viable drug leads. However, the moderate, varied bioactivities exhibited by 
congeners provide sufficient selective advantage to favour the maintenance of 
chemical diversity in NP biosynthetic systems. In pathways for which the biosynthesis 
of a single product has been strongly selected for, BGCs remain sufficiently plastic 
that minor mutations or alterations can restore the ability to generate chemical 
diversity. This is illustrated by the tenellin biosynthetic pathway in the ascomycete 
fungus Beauveria bassiana, which was found to produce 18 new compounds 
following the silencing of individual genes by RNA interference or when epigenetic 
elicitors were introduced exogenously to production cultures (Yakasai et al., 2011). 
Microbes inhabit highly dynamic environments and the ability to generate chemical 
diversity presumably allows them to adapt to new environmental 
conditions/competitors very rapidly. 
 
The diversification of BGCs and the NPs they encode is facilitated by a number of 
different mechanisms, and evidence for several of these can be illustrated in the 1 
biosynthetic pathway. One mechanism is via alterations to individual genes that cause 
them to accept new substrates or to perform new chemistries. This has been 
described in this work for ObaG, which appears to have evolved from an SHMT-like 
progenitor to accept L-threonine (instead of L-serine) as a substrate. Furthermore, it 
also catalyses a subsequent C-C bond-forming reaction with an aldehyde following 
L-threonine cleavage to generate an unusual β-OH-α-AA building block (2). The 
evolutionary radiation of lanthipeptides in marine cyanobacteria to produce diverse 
families of cyclic peptides represents an example in which mutations in precursor 
substrate genes have generated enormous chemical diversity (Donia et al., 2006; 
Cubillos-Ruiz et al., 2017, Gu and Schmidt, 2017). In larger multi-modular 
biosynthetic genes, such as PKSs and NRPSs, mutation of individual domains can 
either render them inactive, as is commonly observed in PKS processing domains 
(Fischbach et al., 2008), or alter their substrate recognition. The ObaI A2 domain for 
example must have evolved from an A domain with specificity for one of the 20 
canonical amino acids to accept its nonproteinogenic substrate 2. Homologous 
recombination in these highly modular systems also represents a significant 
mechanism by which cluster and product variation is achieved (Fischbach et al., 
2008). 
 
NP BGCs can also diversify through the acquisition or loss of entire genes, which can 
occur both intra- and intergenically (via HGT). As mentioned previously, non-
functional genes are rapidly lost in bacterial genomes and this is no less true for NP 
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BGCs. Consequently, many are assembled from sub-clusters of genes which each 
encode their own small molecules that possess some degree of advantageous 
bioactivity, and so are maintained, available for incorporation into new biosynthetic 
contexts (Medema et al., 2014b). The catechol moiety of 1 is encoded by the sub-
cluster obaJLN and is an example of this phenomenon. 6 can act directly as a 
siderophore (López-Goñi et al., 1992), albeit not as effectively as 6-incoporating 
siderophores, the pathways of which might have evolved by recruiting the genes 
necessary to connect several 6 molecules together to augment Fe3+-binding capacity 
(Fischbach et al., 2008). We propose that the oba BGC was formed by the merging 
of a sub-cluster of genes necessary for the biosynthesis of 6, and a small cluster 
encoding a β-lactone NP. This would have been selected for because the 6-derived 
catechol either mediated specific interaction with a new target (ThrRS via Zn2+ 
cofactor-binding) and/or improved 1 uptake into target cells via siderophore 
transporters. The putative oba BGC identified in several Burkholderia spp. (Figure 
8.2) would represent an intermediate stage in the evolution of the BGC preceding the 
fusion of the A1 domain necessary for 6 activation to ObaI (possibly mediated by the 
embedded MbtH-like domain), but following the separation of an entB-like precursor 
to mobilise the cognate ArCP. We propose that a mobile ArCP is necessary to 
facilitate interaction with both the 6-specific A domain and ObaI homologue C domain. 
It is possible that the 2-derived moiety was introduced in a similar fashion, following 
the merging of a progenitor NRPS cluster with the obaCDEFGH sub-cluster, replacing 
the previous proteinogenic amino acid incorporated into the β-lactone NP following 
evolution of the necessary A domain to accept 2 as a substrate. It is likely that 
obaCDEFGH operated together to biosynthesise 2 prior to their forming a sub-cluster, 
but clustering was selected for to coordinate the regulation of these genes and 
facilitate their co-inheritance by HGT. The 2-derived moiety of 1 must also offer some 
selective advantage to have been maintained in all putative oba BGCs identified, 
possibly through mediating some other interaction in the ThrRS active site as 
mentioned previously. The nitro group of 1 could play an important role in this regard, 
as described in Chapter 8. 
 
1 was initially discovered as part of efforts to discover novel β-lactam NPs using a β-
lactamase induction assay (Wells et al., 1982; 1984), during the course of which 
several other β-lactones were isolated and characterised from Arthrobacter, Bacillus 
and Pseudomonas isolates. These all differ from 1 in the composition of their C-2 and 
C-3 side chains (Figure 9.1a). In terms of BGC evolution, this suggests that an 









Figure 9.1 Evolutionary origins of the oba BGC. (a) β-lactones isolated by Wells 
et al. (1982; 1984) as part of screening efforts for β-lactam antibiotics. R? = an 
unspecified R group (Wells et al. 1982); R’ and R’’ are variable groups that could be 
altered using synthetic chemistry and/or biology approaches to develop novel β-
lactones. (b) Hypothetical monomodular ObaI ancestor NRPS. Minimally this 
comprises of A and PCP domains for the activation and tethering of either of the 
proteinogenic β-OH-α-AAs L-serine or L-threonine, and a TE domain with an active 
site cysteine for β-lactone ring formation. A hypothetical primary metabolic AT is 









three domains: an A domain specific for activation of a proteinogenic β-OH-α-AA 
substrate (L-serine or L-threonine), a PCP domain to tether it, and a cysteine active 
site residue-bearing TE domain responsible for β-lactone ring formation (Figure 9.1b). 
Chemical diversity has been generated in this system by the acquisition of genes 
necessary for biosynthesis of alternate acid substrates and the corresponding 
recruitment/evolution of A domains able to accept them. Two of the other β-lactones 
isolated by Sykes et al. comprise a methyl group as the C-3 side chain, indicating that 
the A domain in their hypothetical NRPSs utilise L-threonine as a substrate (Wells et 
al., 1982). Initial in silico analysis of the ObaI A2 domain also identified L-threonine as 
its likely substrate, and it is conceivable that it evolved from being specific for L-
threonine to 2 following the acquisition of obaCDEFGH to the BGC.  
 
The C-2 side chain in several of the identified β-lactones appears to be derived from 
acetate, which is likely installed on the amino group by a background AT (SQ 26,517 
- Figure 9.1a and c). Due to their nucleophilicity, primary amino groups are often 
modified to avoid non-specific reactions. This is exemplified by the desosamine 
moiety in methymycin; when the N-methyltransferase desVI (responsible for 
methylation of the desosamine amino group) was knocked out, only N-acylated 
intermediates were detected (Zhao et al., 1998). If a C domain were also present on 
a monomodular NRPS ancestor, then the acetate group could alternatively be 
introduced via an acyl-S-ACP as observed in hybrid PKS/NRPS systems. 
 
I favour this hypothesis of cluster evolution over one in which the ObaI NRPS TE-
domain active site serine has been mutated to a cysteine residue after amino acid 
substrates have been fixed, because this would likely require the simultaneous 
substitution of two bp to avoid an inactive intermediate. Perhaps more importantly, 
the inherent reactivity of the ring-strained β-lactone would mean that any product 
generated from a minimal monomodular NRPS described would have some degree 
of bioactivity to be selected for, maintained, and subsequently ‘improved’ upon, 
similar to the 6 example described previously. The same is not as certain for a linear 
dipeptide product, and the occurrence of other β-lactones that vary in the composition 
of the same two side chains supports the former hypothesis. A candidate progenitor 
BGC in which the NRPS TE comprises an active site serine has also not yet been 
identified. 
 
An exciting future project would be to obtain the strains responsible for producing the 
other β-lactone molecules characterised by Sykes et al. (Wells et al., 1982) and to 
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sequence their genomes to identify and characterise the BGCs responsible for 
producing them. This would allow the above hypotheses to be evaluated and perhaps 
revised, and might provide further understanding of how these different β-lactone 
biosynthetic pathways have evolved. Coincidentally, they would also permit further 
validation (or not) for the use of a TE-based phylogenetics approach to identify further 
β-lactone clusters. It would be particularly exciting if these molecules interact with 
different targets to 1, as this might provide valuable insights into how different side 
chains have been selected for. 
 
9.2.5 Synthetic biological manipulations of the oba BGC 
A logical progression to the evolutionary work discussed would be to modify the C-2 
and C-3 side chains of 1 using synthetic biology approaches. The primary focus of 
this work would be on engineering the specificity of the ObaI (or analogous β-lactone 
synthesising NRPSs) A domains, as these will to a large extent determine the nature 
of the side chains, though the importance of downstream acting domains (C and TE) 
and the MbtH-like domain in substrate activation must also be considered (Meyer et 
al., 2016). Mutasynthetic approaches have already been applied in this work to alter 
the C-2 side-chain and hydroxylamine-trapping assay results suggest that there is 
some degree of promiscuity in the A2 domain as L-serine and L-tryptophan were both 
accepted as substrates. However, the latter of these does not possess the β-hydroxyl 
group necessary for β-lactone ring formation and a product without a C-3 side-chain 
(expected if L-serine used instead of 2) was never detected in production cultures. 
This does not preclude the possibility that 1 congeners are subject to proteolytic 
degradation in the cell, and in vitro mutasynthetic experiments might allow the 
generation of this anticipated product in addition to others. 
 
The modular nature of NRPSs has allowed for domains or even entire modules to be 
swapped to introduce new amino acids into the peptide backbone. A domain-
swapping strategy was successfully employed to generate novel pyoverdine 
analogues with modified peptide backbones in P. aeruginosa PA01 by swapping 
either A domains or C-A didomains (Calcott et al., 2014), for example. However, this 
strategy often encounters problems as even slight alterations to the modular NRPS 
structure can impact protein folding or the interactions between different domains, 
which is presumably why a previous attempt to alter the penultimate amino acid in 
pyoverdine failed (Ackerley and Lamont, 2004). This could prove detrimental in the 
ObaI system depending on how both A domains interact with the MbtH-like domain 




More subtle alterations of A domain specificity can be achieved through site-directed 
mutagenesis of Stachelhaus motif residues to alter substrate specificity (Stachelhaus 
et al., 1999). This approach has been applied to change A domain substrate 
specificity for both natural (Eppelmann et al., 2002) and non-natural amino acids 
(Thirlway et al., 2012) to generate novel NP analogues. However, binding pocket 
mutagenesis can be laborious and inappropriate for larger specificity changes and an 
alternate subdomain swapping strategy could also be considered. In silico analysis of 
the hormaomycin NRPS genes revealed that a natural recombination event between 
core subdomains comprising substrate determining active site residues likely 
occurred between A domains, significantly altering their substrate specificities. The 
identified subdomain of the HrmO-(β-Me)Phe3 A domain was replaced with those 
from other NRPS A domains in the pathway based on putative recombination points. 
All hybrid enzymes were active and recognised their cognate amino acid substrates 
to generate the anticipated products, though similar swaps with subdomains from the 
calcium-dependent antibiotic (CDA) biosynthesis were found to be inactive 
(Crüsemann et al, 2013). A similar logic was applied to the gramicidin biosynthetic 
pathway - out of nine chimeric constructs derived from the GrsA-A NRPS designed 
to alter the specificity of the phenylalanine-specific initiation module A domain, four 
activated their new anticipated amino acid substrate when assayed (Kries et al., 
2015). This method would avoid key residues identified as being important for MbtH-
like domain interaction (Herbst et al., 2013; Miller et al., 2016). A sensible proof of 
concept for either of these approaches would be to alter the A2 domain specificity to 
L-threonine, given that this was the amino acid substrate predicted by 
NRPSpredictor2 for this domain (Röttig et al., 2011). An A domain involved in the 
biosynthesis of other β-lactone NPs isolated by Wells et al. (1982) would also appear 
to activate and tether L-threonine for cyclisation, if indeed these NPs are assembled 
by an analogous NRPS to 1. If their producers’ genome sequences can be obtained, 
it would allow the identification of the necessary A subdomain for swapping in. 
  
If synthetic biology approaches can be applied successfully, it opens the door to 
efforts to design small molecule inhibitors of new enzyme targets. This potential is 
highlighted in the work of Sieber et al., who found that a series of synthetic trans-β-
lactone probes could specifically bind active site serine residues in caseinolytic 
protein proteases (ClpPs) (Böttcher and Sieber, 2008a). ClpP-binding led to 
attenuated extracellular virulence factor production in both S. aureus and L. 
monocytogenes (Böttcher and Sieber, 2008a; 2008b; 2009a; Gersch et al., 2013). β-
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Lactone-binding was found to be highly specific, and by altering the C-2 and C-3 side 
chains the inhibitors could be further structurally refined to produce more potent 
inhibitors (Böttcher and Sieber, 2009b; Weinandy et al., 2014). Computational 
modelling would allow for the rational design of new β-lactone molecules with the 
physiochemical properties necessary to interact with novel biological targets 
(Rodrigues et al., 2016); side chains could be selected that would best position the 
reactive β-lactone ring in close proximity to nucleophilic active site residues in the 
desired protein target. The use of a synthetic biological approach to generate new β-
lactones would not incur the same costs associated with low-yielding reactions, and 
expensive chemical substrates and reaction conditions associated with chemical 
syntheses. Aside from the tractability of the system to manipulation, the only other 
drawback is the prerequisite for a β-hydroxy acid substrate for β-lactone ring 
formation with a suitable Cα group to introduce variable C-2 side chains. 
 
9.3 Concluding remarks 
This study investigating the biosynthesis and bioactivity of the antibiotic 1 has led to 
the identification of a new subfamily of PLP-dependent enzymes, the L-TTAs. These 
rare enzymes have great potential for the preparation of L-threo-β-OH-α-AAs for 
synthetic biology and chemistry approaches. Characterisation of individual genes 
within the 1 BGC has led to the identification of new queries for future genome mining 
efforts applying both mechanism- and redundancy-guided approaches. These should 
allow the specific targeting of uncharted NP chemical space to identify novel 
structures with potentially novel functions, and the identification of NPs with desired 
bioactivities, respectively. The modular nature of the 1 biosynthetic pathway lends 
itself to the rational design of synthetic β-lactone inhibitors of important protein 
targets. 1 was itself shown to be a potent inhibitor of ThrRSs in both Gram positive- 
and -negative bacteria, and likely represents a novel inhibitory mode of action for this 
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PaGlyA1   1 MFSKHDQIRGYDDELLAAMDAEEARQEDHLELIASENYTSKRVMQAQGSGLTNKYAEGYP 
PfGlyA    1 MFSRDLTIAKYDADLFAAMEQEAVRQEEHIELIASENYTSPAVMEAQGSVLTNKYAEGYP 
1EQB_B    1 MLKREMNIADYDAELWQAMEQEKVRQEEHIELIASENYTSPRVMQAQGSQLTNKYAEGYP 
2VMV_A    1 ----MKYLPQQDPQVFAAIEQERKRQHAKIELIASENFVSRAVMEAQGSVLTNKYAEGYP 
ObaG      1 MSNVKQQTAQIVDWLSSTLGKDHQYREDSLSLTANENYPSALVRLTSGSTAGAFYHCSFP 
 
 
PaGlyA1  61 -----GKRYYGGCEHVDKVERLAIDRARQLFGADYANVQPHSGSSANAAVYLALLNAGDT 
PfGlyA   61 -----GKRYYGGCEYVDVVEQLAIDRAKELFGADYANVQPHAGSQANSAVYLALLQGGDT 
1EQB_B   61 -----GKRYFGGCEYVDIVEQLAIDRAKELFGADYANVQPHSGSQANFAVYTALLEPGDT 
2VMV_A   57 -----GRRYYGGCEYVDIVEELARERAKQLFGAEHANVQPHSGAQANMAVYFTVLEHGDT 
ObaG     61 FEVPAGEWHFPEPGHMNAIADQVRDLGKTLIGAQAFDWRPNGGSTAEQALMLAACKPGEG 
 
 
PaGlyA1 116 ILGMSLAHGGHLTHGAKVSSSGKLYNAVQYGLDTATGLIDYDEVERLAVEH-KPKMIVAG 
PfGlyA  116 ILGMSLAHGGHLTHGASVSSSGKLYNAVQYGID-ANGLIDYDEVERLAVEH-KPKMIVAG 
1EQB_B  116 VLGMNLAHGGHLTHGSPVNFSGKLYNIVPYGID-ATGHIDYADLEKQAKEH-KPKMIIGG 
2VMV_A  112 VLGMNLSHGGHLTHGSPVNFSGVQYNFVAYGVDPETHVIDYDDVREKARLH-RPKLIVAA 
ObaG    121 FVHFAHRDGGHFALESLAQKMG--IEIFHLPVNPTSLLIDVAKLDEMVRRNPHIRIVILD 
 
                                                                                     
PaGlyA1 175 FSAYSKTLDFPRFRAIADKVGALLFVDMAHVAGLVAAGLYPNPIPF-ADVVTTTTHKTLR 
PfGlyA  174 FSAYSQILDFPRFRAIADKVGAYLFVDMAHVAGLVAAGVYPNPVPY-ADVVTTTTHKTLR 
1EQB_B  174 FSAYSGVVDWAKMREIADSIGAYLFVDMAHVAGLVAAGVYPNPVPH-AHVVTTTTHKTLA 
2VMV_A  171 ASAYPRIIDFAKFREIADEVGAYLMVDMAHIAGLVAAGLHPNPVPY-AHFVTTTTHKTLR 
ObaG    179 QSFKLRWQPLAEIRSVLPDS-CTLTYDMSHDGGLIMGGVFDSPLSCGADIVHGNTHKTIP 
 
 
PaGlyA1 234 GPRGGLILAR-ANEEIEKKLNSAVFPGAQGGPLMHVIAAKAVCFKEALEPGFKDYQAQVI 
PfGlyA  233 GPRGGLILAR-ANAEIEKKLNSAVFPGAQGGPLEHVIAAKAICFKEALQPEFKTYQQQVV 
1EQB_B  233 GPRGGLILAKGGSEELYKKLNSAVFPGGQGGPLMHVIAGKAVALKEAMEPEFKTYQQQVA 
2VMV_A  230 GPRGGMILCQ---EQFAKQIDKAIFPGIQGGPLMHVIAAKAVAFGEALQDDFKAYAKRVV 
ObaG    238 GPQKGYIGFKSAQHPLLVDTSLWVCPHLQSNCHAEQLPPMWVAFKEMELFG-RDYAAQIV 
 
 
PaGlyA1 293 RNAKAMAEVFIGRGYDVVSGG---TDNHLMLISLVRQGLTGKEADAALGRVGITVNKNAV 
PfGlyA  292 KNAQTMASVFIERGFDVVSGG---TENHLFLLSLIKQDISGKDADAALGKAFITVNKNSV 
1EQB_B  293 KNAKAMVEVFLERGYKVVSGG---TDNHLFLVDLVDKNLTGKEADAALGRANITVNKNSV 
2VMV_A  287 DNAKRLASALQNEGFTLVSGG---TDNHLLLVDLRPQQLTGKTAEKVLDEVGITVNKNTI 
ObaG    297 SNAKTLARHLHELGLDVTGESFGFTQTHQVHFAVGDLQKALDLCVNSLHAGGIRSTNIEI 
 
 
PaGlyA1 350 PNDPQSPFVTSGIRIGTPAITTRGLQEAQSRELAGWICDILDHLGDADVEAKVATQVAGL 
PfGlyA  349 PNDPRSPFVTSGLRFGTPAVTTRGFKEAECKELAGWICDILADLNNEAVIDAVREKVKAI 
1EQB_B  350 PNDPKSPFVTSGIRVGTPAITRRGFKEAEAKELAGWMCDVLDSINDEAVIERIKGKVLDI 
2VMV_A  344 PYDPESPGVTSGIRIGTAAVTTRGFGLEEMDEIAAIIGLVLKNVGSEQALEEARQRVAAL 
ObaG    357 PGKPG----VHGIRLGVQAMTRRGMKEKDFEVVARFIADLYFKKTEPAKVAQQIKEFLQA 
 
 
PaGlyA1 410 CADFPVYR-------------------- 
PfGlyA  409 CKKLPVYGA------------------- 
1EQB_B  410 CARYPVYA-------------------- 
2VMV_A  404 TD-------------------------- 
ObaG    413 FPLAPLAYSFDNYLDEELLAAVYQGAQR 
 
 
Supplementary Figure 1. Sequence alignment of authentic and putative SHMT amino acid 
sequences. ObaG from the oba BGC is aligned (ClustalX2) with predicted SHMTs from P. 
aeruginosa PA01 (PaGlyA1, NP_254102.1) and P. fluorescens SBW25 (PfGlyA, WP_015885982.1) 
whole-genome sequences, and validated SHMTs with solved structures from E. coli (EcGlyA, 
1EQB_B) and B. stearothermophilus (BsGlyA, 2VMV_A). ▼ indicates the conserved lysine residue 




LipK     1 ---------MTVGAGGKTSADADPLMLVRAIADADRRAAHALNLVPSENRISPLASLPLA 
FTase    1 MPSSVNRTSRTEPAGHHREFPLSLAAIDELVAEEEAEDARVLHLTANETVLSPRARAVLA 
ObaG     1 ------------MSNVKQQTAQIVDWLSSTLGKDHQYREDSLSLTANENYPSALVRLTSG 
 
 
LipK    52 SDFYNRYFFN-------TDGDPLFWEFRGGEDIAHIEALGAAALRRMASARYCNVRPISG 
FTase   61 SPLTSRYLLEHLDMRGPSPARLGNLLLRGLDRIGTIEESATEVCRRLFGARYAEFRCLSG 
ObaG    49 STAGAFYHCS-----FPFEVPAGEWHFPEPGHMNAIADQVRDLGKTLIGAQAFDWRPNGG 
 
 
LipK   105 MSAMILTVAALSPPGSTVVSVDQNSGGHYATPALLGRLGRRSRLLNCK-DGE-VDESELA 
FTase  121 LHAMQTTFAALSRPGDTVMRVATKDGGHFLTELICRSFGRRSCTYVFD-DTMTIDLERTR 
ObaG   104 STAEQALMLAACKPGEGFVHFAHRDGGHFALESLAQKMGIEIFHLPVNPTSLLIDVAKLD 
 
 
LipK   163 EVLAPG-DVALVYVDVQNCVRVPDFRRMSDVIREVSPGTRLYVDASHYLGLVLGGLLANP 
FTase  180 EVVEKE-RPSLLFVDAMNYLFPFPIAELKAIAGDVP----LVFDASHTLGLIAGGRFQDP 
ObaG   164 EMVRRNPHIRIVILDQSFKLRWQPLAEIRSVLPDSCT---LTYDMSHDGGLIMGGVFDSP 
 
 
LipK   222 LDCGADAFGGSTHKSFPGPHKGVIFTN--AEDVDESLR-SAQFDLVSSHHFAETLALSLA 
FTase  235 LREGADLLQANTHKTFFGPQKGIILGN--DRSLMEELGYTLSTGMVSSQHTASTVALLIA 
ObaG   221 LSCGADIVHGNTHKTIPGPQKGYIGFKSAQHPLLVDTSLWVCPHLQSNCHAEQLPPMWVA 
 
 
LipK   279 ALEVEDRMGDYARATNDNARRLAGALADAGFRVYGDSATGYTDTHQVWVELDGVAAAYAL 
FTase  293 LHEMWYDGREYAAQVIDNARRLAGALRDRGVPVVAE-ERGFTANHMFFVDTRPLGSGPAV 
ObaG   281 FKEMELFGRDYAAQIVSNAKTLARHLHELGLDVTGE-SFGFTQTHQVHFAVGDLQKALDL 
 
 
LipK   339 SNR-LAEGGIRVNLQSSMPGMSGVHLRLGSNEVTFEGAGPQAIEELAGALVTARER---- 
FTase  352 IQR-LVRAGVSANRAVAFNHLD--TIRFGVQEITRRGYDHDDLDEAADLVAAVLLERQEP 
ObaG   340 CVNSLHAGGIRSTNIEIPGKPGVHGIRLGVQAMTRRGMKEKDFEVVARFIADLYFKKTEP 
 
 
LipK   394 -ALGPRTVHEIRGRFGAPFYTDPEKLKVEAGL---------------------------- 
FTase  409 ERIRPRVAELVGRRRTVRYTGDPASAAGPPARERYAPPTAPAGHPARPRWIGVRLTPLPE 
ObaG   400 AKVAQQIKEFLQAFPLAPLAYSFDNYLDEELLAAVYQGAQR------------------- 
 
 
LipK       ------------------------------------------------------------ 
FTase  469 PVTEAECAGAQRLGRLAGAFPHQIDSSGNVSFTSTDGRLFVTGSGTYIKDLAPGDFVELT 
ObaG       ------------------------------------------------------------ 
 
 
LipK       ------------------------------------------------------------ 
FTase  529 GAEGWTLHCRGDGPPSAEAYLHHLLRERVGARYVVHNHCIPGRALETSGALVIPPKEYGS 
ObaG       ------------------------------------------------------------ 
 
 
LipK       ---------------------------------------------- 
FTase  589 VALAEAVADACQDSQVMYVRRHGLVFWAHSYDECLALIEDVRRITG 
ObaG       ---------------------------------------------- 
 
 
Supplementary Figure 2. Sequence alignment of biochemically characterised L-TTAs. ObaG 
from the oba BGC is aligned (ClustalX2) with 4-FTase from Streptomyces cattleya 
(WP_014151017.1)7 and LipK from S. sp. SANK 60405 (BAJ05887.1). FTase comprises an N-
terminal SHMT-like domain and a C-terminal phosphate binding domain similar to those of bacterial 
aldolases and empimerases. ObaG shares 29% identity (88% query cover) to the N-terminal domain 
of FTase, and 33% identity (67% query cover) with LipK. ▼ indicates the conserved lysine residue 






Supplementary Figure 3. Maximum likelihood tree of SHMTs, L-TAs and L-TTAs version 2. A 
set of 3-amino-5-hydroxybenzoate synthase (AHBAS) amino acid sequences serve as the outgroup. 
RAxML likelihood values at the root nodes for SHMT and L-TA cluster clades are annotated. The 
clade comprising the L-TTA ObaG characterised in this work has been expanded and annotated 
with RAxML likelihood values and the identity of amino acid sequences represented. Initial 







Supplementary Figure 4. Maximum likelihood tree of SHMTs, L-TAs and L-TTAs version 3. A 
set of 3-amino-5-hydroxybenzoate synthase (AHBAS) amino acid sequences serve as the outgroup. 
RAxML likelihood values at the root nodes for SHMT and L-TA cluster clades are annotated. The 
clade comprising the L-TTA ObaG characterised in this work has been expanded and annotated 
with RAxML likelihood values and the identity of amino acid sequences represented. Initial trimming 




TycC      1 RNVFCFTPIGAQSVYYQK-LAAEIQ-GVSLYSFDFIQD-----------DNRMEQYIAAI 
GrsB      1 RNVFLFAPIGAQGVFYKK-LAEQIP-TASLYGFDFIED-----------DDRIQQYIESM 
SrfA-C    1 QIIFAFPPVLGYGLMYQN-LSSRLP-SYKLCAFDFIEE-----------EDRLDRYADLI 
EntF      1 PTLFCFHPASGFAWQFSV-LSRYLDPQWSIIGIQSPRPNGPMQTA-ANLDEVCEAHLATL 
VcmC      1 PPLFCVHASGGLSWNYEP-LLRYLPANQPVYGVQARGLARTEPLP-GSVEEMAADYLAQI 
NocB      1 GALVLVHPGEGLALPYHG-LAPLLP-DVRLHVLSDPRFGQSDNRF-ATLAEMATRYVEWV 
PcbAB     1 RTLFVLPPGEGGAESYLSNLARQLP-DLRLVLFNNVHLHTPMG----SFEELGRYYVEHI 
PvdD      1 SPLFMFHPSFGSVHCYKT-LAMALRDRHPVKGVVCRALLGAGREV-PEWDDMVAEYAEQL 
ObaI      1 LNLVCVPFAGGNAFAYRN-LVNQLSSVFNCVSVNLPGHDIMRPDEGMQALEVVADAATQE 
 
 
TycC     48 TAIDPSGPYTLMGYSSGGNLAFEVAKELEERGYGVTDIILFDSYWKDKAIERTVAETEND 
GrsB     48 IQTQSDGQYVLIGYSSGGNLAFEVAKEMERQGYSVSDLVLFDVYWKGKVFEQTKEEEEEN 
SrfA-C   48 QKLQPEGPLTLFGYSAGCSLAFEAAKKLEEQGRIVQRIIMVDSYKKQGVSDLDGRTVESD 
EntF     59 LEQQPHGPYYLLGYSLGGTLAQGIAARLRARGEQVAFLGLLDTWPPETQNWQEKEANGLD 
VcmC     59 RAVQPSGPYHLLGWSLGGRIAQAMARLLEQEGEKVGLLALLDAYP--VYMGRKTTGAASE 
NocB     58 RTTEPEGPYRLGGWSFGGVVALEMASQMTAHGDEVSDLLLVDSHNLNAAPRTGDPREGVR 
PcbAB    56 RRLQPSGPYHLLGWSFGGVLSLEISRQLARAGERIDDLLLIDPYFGMRQASANIGLPGVE 
PvdD     59 LQEHPEGVFNLAGWSLGGNLAMDVAARLEQRGRQVAFVGWIDAPAPVRVEAFWNEIGPTP 
ObaI     60 ILATLSGPIIVYGHCAGNATAIEIARRLEQAGADLKALVIGGMLLDQDPVDVQARVADQS 
 
 
TycC    108 IAQLFAEIGENTEMFNMTQEDFQLYAANEFVKQSFVRKTVSYVMFHNNLVNTGMTTAAIH 
GrsB    108 IKIIMEELRENPGMFNMTREDFELYFANEFVKQSFTRKMRKYMSFYTQLVNYGEVEATIH 
SrfA-C  108 VEALMNVNRDNEALN------------SEAVKHGLKQKTHAFYSYYVNLISTGQVKADID 
EntF    119 PEVLAEINREREAFLAAQQ--------GSTSTELFTTIEGNYADAVRLLTTAHSVPFDGK 
VcmC    117 EAALSKRNQADLDLAGQLVK-------SEAARARLEAVMRNLWDIGPRHVSS-PFAGDIL 
NocB    118 QRLVELGVDPD----------------SPEGVDVVEELLHNGALAAQYAPPAYRGRVSLL 
PcbAB   116 DILDPINYHYRP---------------DEADLARLAGRLGNLVLFKAGEPNDVVNGPHQP 
PvdD    119 EAVPNLSVGEMR---------------VELLGVMFPERAEHIERAWSSICSATTDDEQRW 
ObaI    120 GENIIDFLQQIGGFKEVLDDAS----MASIARMTKHDATQTARFFAEEALNRQTLQAPIH 
 
 
TycC    168 LIQSELE---------ADEEAP--VAAKWNESAWANATQRLLTYSGHGIHSRMLAGDYAS 
GrsB    168 LIQAEFEEEKIDENEKADEEEKTYLEEKWNEKAWNKAAKRFVKYNGYGAHSNMLGGDGLE 
SrfA-C  156 LLTSGAD----------------FDIPEWLASWEEATTGVYRMKRGFGTHAEMLQGETLD 
EntF    171 ATLFVAER--------------TLQEGMSPERAWSPWIAELDIYRQDCAHVDIISPGTFE 
VcmC    169 LFVATVDR------------PEHLPVSVAKASWKEFTTGTIEAHDIPSNHYDMVQTAALG 
NocB    162 VTPTDGDR-----------------DAVRARGWDRALLPDLVVEPVPGAHERLFDEEHLS 
PcbAB   161 RLFEYYHG----------------TRFNHLDLLLPAAAIEVCDLAGETHHSWVRNEKLVR 
PvdD    164 TRMSDWAE---------------------AEIGAEFATLRSEIAQSNELEVSWELKQILD 
ObaI    176 VIVGDMDP------------LTPDYEERYKDWQMYSSDVTLSVIEGGGHYFVTDLAEPLA 
 
 
TycC    217 QNASILQNILQEL- 
GrsB    228 RNSSILKQILQGT- 
SrfA-C  200 RNAEILLEFLNTQT 
EntF    217 KIGPII-------- 
VcmC    217 QIGSIVAEKL---- 
NocB    205 DTADAIRRAL---- 
PcbAB   205 LMCERISTSL---- 
PvdD    203 ERLKAM-------- 
ObaI    224 QVLLANYKHL---- 
 
 
Supplementary Figure 5. Amino acid sequence alignment of NRPS TE domains. Amino acid 
sequences for TE-containing NRPS domains from biosynthetic pathways described and characterised 
in the literature were first submitted to the PKS/NRPS Analysis website to identify the TE domains 
(Bachmann and Ravel, 2009). Sequences were subsequently aligned using ClustalX2. TE domains 
used are from: EntF (TROQ_A) – Enterobactin, VcmC (AAL90875.1) – Vancomycin, TycC (O30409.1) 
– Tyrocidine, NocB = Nocardicin AAT09805.1 (O30409.1), PcbAB = Penicillin (P27743.1), PvdD = 
Pyoverdine (CDM45811.1), GrsB = Gramicidin (CAA43838.1), SrfA-C = Surfactin (2VSQ_A), and ObaI 
= 1 (AQZ26587.1). ▼ indicate the serine-histidine-aspartate catalytic triad residues, characteristic of α/β 
hydrolase fold enzymes (Nardini and Dijkstra, 1999; Hur et al., 2012). The ObaI active site cysteine is 








1QF6        1 --MPVITLPDGSQRHYDHAVSPMDVALDIGPGLAKACIAGRVNGELVDACDLIENDAQLS 
1NYQ        1 MEQINIQFPDGNKKAFDKGTTTEDIAQSISPGLRKKAVAGKFNGQLVDLTKPLETDGSIE 
4P3N        1 ------------------------------------------------------------ 
39502'S'    1 --MPTITLPDGSQRSFDHPVSVAEVAASIGAGLAKATVAGKVDGQLVDASDLITSDASLQ 
obaO        1 --MVTIALPDGSRRDFPEALTVQQLAQSIGAGLAAATIGGKVDGTLVDASYLLETDATVE 
Cshin'S'    1 --MPVITLPDGSQRQFDAPVTVAGVAASIGAGLARAALAGKVDGKLVDTSYLIDRDVQLA 
Cshin'R'    1 --MITISLPDGSKREFAEPISVHELACAIGPGLGAAALAGKVDGKLVDTAHLLRHDATVE 
Bdiff'S'    1 --MVSIRLPDGSVRQYEHPVTVAEVAASIGPGLAKAALGGKLDGELVDTSTVIDRDASLA 
Bdiff'R'    1 --MISIALPDGSRRAYDHPVTVAALAADIGPGLAKAALAGKIDGKLVDLDYLIDIDATAE 
Pf'S'       1 --MPTITLPDGSQRSFDHPVSVAEVAASIGAGLAKATVAGKVDGLLVDASDLITSDASLQ 
Pf'R'       1 --MVTIALPDGSRRDFPEALTVQQLAQSIGAGLAAATIGGKVDGTLVDASYLLETDATVE 
 
 
1QF6       59 IITAKDEEGLEIIRHSCAHLLGHAIKQLWPHTKMAIGPVIDNGFYYDVDLDRTLTQEDVE 
1NYQ       61 IVTPGSEEALEVLRHSTAHLMAHAIKRLYGNVKFGVGPVIEGGFYYDFDIDQNISSDDFE 
4P3N        1 ------------------------------------------------------------ 
39502'S'   59 IITPKDQEGLEIIRHSCAHLIGHAVKQLYPTAKMVIGPVIEEGFYYDIAYERPFTPDDLA 
obaO       59 IVTTKSPQALELIRHSTAHLMAQAVQRLYPGTQVTIGPVIDNGFYYDFVAPRPFTMDDLP 
Cshin'S'   59 IVTERDADGLDVIRHSTAHLLAYAVKELFSSAQVTIGPVIEDGFYYDFSYERPFTPEDLD 
Cshin'R'   59 IVTDRHPDALEVVRHSTAHLLAQAVQRLYPGTQVTIGPVIDNGFYYDFAGERPFTVEDLP 
Bdiff'S'   59 IVTDKDADGLDIIRHSTAHLLAYAVKDLYPDAQVTIGPVIDNGFYYDFSYNRPFTPEDLE 
Bdiff'R'   59 IVTEKHPDALSIIRHSCAHLLAQAVQRLYPAAQFSIGPVIENGFYYDISISPPLSEDDLP 
Pf'S'      59 IITPKDQEGLEIIRHSCAHLIGHAVKQLYPTAKMVIGPVIEEGFYYDIAYERPFTPDDLA 
Pf'R'      59 IVTTKSPQALELIRHSTAHLMAQAVQRLYPGTQVTIGPVIDNGFYYDFVAPRPFTMDDLP 
 
 
1QF6      119 ALEKRMHELAEKNYDVIKKKVSWHEARETFANRGESYKVSILDENIAHDDKPGLYFHEEY 
1NYQ      121 QIEKTMKQIVNENMKIERKVVSRDEAKELFSN--DEYKLELIDA-IPEDENVTLYSQGDF 
4P3N        1 ------------------------------------------------------------ 
39502'S'  119 AIEQRMHALIEKDYDVIKKVTPRAEVIDVFTARGEDYKLRLVED-MPDEQAMGLYYHEEY 
obaO      119 LIEAEMTRIVKEQLPVTRTQLPRDEALAFFEQLGESYKTQIIDA-IPAGETLSLYTQGEF 
Cshin'S'  119 AIEKKMFELSKKDIPVERYELSRDDAVAYFKGIGEAYKAEIIES-IPQNEVLSLYREGDF 
Cshin'R'  119 AIEAEMARIAKEALPVTRSEKTREQAAQFFEGLGEHYKVEILRD-IADDQPLSLYTQGEF 
Bdiff'S'  119 KIEKRMQELAKKDEPVTRRVVSRDEAAGYFRSLGEKYKAEIIES-IPQSDEIKLYSHGGF 
Bdiff'R'  119 RIEAEMRAIVAEAVPVSRAVLSRDDAIRFFSDRGQTYKAEIVAS-IPEHEQLTIYTQGEF 
Pf'S'     119 AIEQRMHALIEKDYDVIKKVTPRAEVIDVFSARGEDYKLRLVED-MPDEQAMGLYYHEEY 
Pf'R'     119 LIEAEMTRIVKEQLPVTRTQLPRDEALAFFEQLGESYKTQIIDA-IPAGETLSLYTQGEF 
 
 
1QF6      179 VDMCRGPHVPNMRFCHHFKLMKTAGAYWRGDSNNKMLQRIYGTAWADKKALNAYLQRLEE 
1NYQ      178 TDLCRGVHVPSTAKIKEFKLLSTAGAYWRGDSNNKMLQRIYGTAFFDKKELKAHLQMLEE 
4P3N        1 ----------------------------MGSS-----------------------HHHHH 
39502'S'  178 VDMCRGPHVPNTRFLKSFKLTKLSGAYWRGDAKNEQLQRIYGTAWADKKQLAAYIQRIEE 
obaO      178 TDLCRGPHVPNTAKLGAFKLMKVAGAYWRGDSNNIMLSRIYGTAWGNEKELKAYLNQLQE 
Cshin'S'  178 TDLCRGPHVPSTGKLKVFKLMKVAGAYWRGDSRNEMLTRVYGTAWAKKEDLDAYLHRLEE 
Cshin'R'  178 TDLCRGPHVPNTGKLRAFKLMKVAGAYWRGNSDNAMLSRIYGTAWLNDKDLKAYLLQLEE 
Bdiff'S'  178 TDLCRGPHVPSTGKLKVFKLMKVAGAYWRGDSKNEQLQRIYGTAWTKKEDQDQYLHMLEE 
Bdiff'R'  178 SDLCRGPHVPNTRALRAFKLMKTAGAYWRGDSNNEMLCRVYGTAWLNDADLQAYLHQLAE 
Pf'S'     178 VDMCRGPHVPNTRFLKSFKLTKLSGAYWRGDAKNEQLQRIYGTAWADKKQLAAYIQRIEE 
Pf'R'     178 TDLCRGPHVPNTAKLGAFKLMKVAGAYWRGDSNNIMLSRIYGTAWGNEKELKAYLNQLQE 
 
 
1QF6      239 AAKRDHRKIGKQLDLYHM-QEEAPGMVFWHNDGWTIFRELEVFVRSKLKEYQYQEVKGPF 
1NYQ      238 RKERDHRKIGKELELFTNSQLVGAGLPLWLPNGATIRREIERYIVDKEVSMGYDHVYTPV 
4P3N       10 HSSGDHRKIGRDQELYFF-HELSPGSCFFLPKGAYIYNALIEFIRSEYRKRGFQEVVTPN 
39502'S'  238 AEKRDHRKIGKRLNLFHL-QEEAPGMVFWHPNGWTLYQVLEQYMRKVQRENGYLEIKTPQ 
obaO      238 AEKRDHRKLAKQFDLFHQ-QEEAPGMVFWHPKGWSLWQTVEQYMRRVYRDGGYREVKSPQ 
Cshin'S'  238 AEKRDHRKIGKALDLFHM-QDEAPGMVFWHPKGWSLWQSVEQYIRRRLAKAGYQEVRTPM 
Cshin'R'  238 AEKRDHRKIAKLLDLFHQ-QEEAPGMVFWHYKGWALWQAVEQYMRRVYRDSGYREVKAPQ 
Bdiff'S'  238 AEKRDHRKLGKQLDLFHM-QEESPGMVFWHPKGWALWQQVEQYMRRRVSEAGYLEIKTPM 
Bdiff'R'  238 AERRDHRKLGKQLDLFHI-QEEAPGMVFWHPKGWSVWQVVEQYMRRVYVECGYQEVKAPQ 
Pf'S'     238 AEKRDHRKIGKRLNLFHL-QEEAPGMVFWHPNGWTLYQVLEQYMRKVQRENGYLEIKTPQ 
Pf'R'     238 AEKRDHRKLAKQFDLFHQ-QEEAPGMVFWHPKGWSLWQTVEQYMRRVYRDGGYREVKSPQ 
275 
 
1QF6      298 MMDRVLWEKTGHWDNYKDAMFTTS--SENREYCIKPMNCPGHVQIFNQGLKSYRDLPLRM 
1NYQ      298 LANVDLYKTSGHWDHYQEDMFPPMQLDETESMVLRPMNCPHHMMIYANKPHSYRELPIRI 
4P3N       69 IFNSRLWMTSGHWQHYSENMFSFE--VEKELFALKPMNCPGHCLMFDHRPRSWRELPLRL 
39502'S'  297 VVDRSLWEKSGHWANYADNMFTTQ--SENRDYAIKPMNCPCHVQVFNQGLKSYRELPMRL 
obaO      297 VLDSTLWKKSGHWDNYKENMFVTE--SENRQYALKPMNCPGHIQIFKHGLRSHRELPIRY 
Cshin'S'  297 MMDRSLWEKSGHWENYQENMFITE--SEKRTYAVKPMNCPGHIQIFSSDLRSYRDLPLRL 
Cshin'R'  297 VLDVSLWQRSGHWQNYQENMFLTE--SEKRQYALKPMNCPGHIQIFKQGLRSYRELPIRY 
Bdiff'S'  297 IMDRSLWEASGHWQNYRENMFTTE--SEKRDYAIKPMNCPGHVQVFKHGLRSYRDLPLRY 
Bdiff'R'  297 VVDVSLWKRSGHWDNYKENMFFTE--SEKREYALKPMNCPGHIQIFKHGLRSYRDLPLRY 
Pf'S'     297 VVDRSLWEKSGHWANYADNMFTTQ--SENRDYAIKPMNCPCHVQVFNQGLKSYRELPMRL 
Pf'R'     297 VLDSTLWKKSGHWDNYKENMFVTE--SENRQYALKPMNCPGHIQIFKHGLRSHRELPIRY 
 
 
1QF6      356 AEFGSCHRNEPSGSLHGLMRVRGFTQDDAHIFCTEEQIRDEVNGCIRLVYDMYSTFGFEK 
1NYQ      358 AELGTMHRYEASGAVSGLQRVRGMTLNDSHIFVRPDQIKEEFKRVVNMIIDVYKDFGFED 
4P3N      127 ADFGVLHRNELSGALTGLTRVRRFQQDDAHIFCAMEQIEDEIKGCLDFLRTVYSVFGFSF 
39502'S'  355 AEFGACHRNEPSGALHGIMRVRGFTQDDAHIFCTEEQMQAESAAFIKLTMDVYRDFGFTE 
obaO      355 GEFGGCHRNEPSGALHGIMRVRAFTQDDGHIFCTEEQIAAEIKAFHYQAVKVYADFGFTD 
Cshin'S'  355 AEFGACHRNEPSGALHGLMRVRGFTQDDAHIFCTENQLIDEARIFHALAMSVYDDFGFEG 
Cshin'R'  355 GEFGGCHRNEPSGALHGIMRVRAFTQDDGHVFCTEEQIADEVQAFHRQALKVYADFGFDN 
Bdiff'S'  355 AEFGSCHRNEASGALHGLMRVRGFVQDDAHIFCTEEQFIAESIAFNTLAMSVYKDFGFEH 
Bdiff'R'  355 GEFGGCHRNEASGALHGIMRVRAFTQDDGHIFCTEAQIEDEVAAFHRQAMKVYRDFGFGD 
Pf'S'     355 AEFGACHRNEPSGALHGIMRVRGFTQDDAHIFCTEEQMQAESAAFIKLTMDVYRDFGFTE 
Pf'R'     355 GEFGGCHRNEPSGALHGIMRVRAFTQDDGHIFCTEEQIAAEIKAFHYQAVKVYADFGFTD 
 
 
1QF6      416 --IVVKLSTR--PEK--RIGSDEMWDRAEADLAVALEENNIPFEYQLGEGAFYGPKIEFT 
1NYQ      418 --YSFRLSYRDPEDKEKYFDDDDMWNKAENMLKEAADELGLSYEEAIGEAAFYGPKLDVQ 
4P3N      187 ---KLNLSTR--PEK--FLGDIEVWDQAEKQLENSLNEFGEKWELNSGDGAFYGPKIDIQ 
39502'S'  415 --VEMKLSTR--PEK--RVGSDELWDRAEAALAAALDSAGLAYDLQPGEGAFYGPKIEFS 
obaO      415 --IAVKIALR--PEPGKRLGSDEVWDKAENLLREALSECDVEWEELPGEGAFYSPKIEYH 
Cshin'S'  415 --IAIKLALR--PDK--RAGSDEGWDKAEHGLREALRACGVEWEELPGEGAFYGPKIEYH 
Cshin'R'  415 --IAVKIALR--PEAGKRLGSDEVWDKAEALLRSALSACGVTWEELPGEGAFYSPKIEYH 
Bdiff'S'  415 --IDIKLSLR--PDQ--RAGTDETWDRAEQGLRDALTACGLSWEELPGEGAFYGPKIEYH 
Bdiff'R'  415 DSIAVKIALR--PEL--RLGSDEVWDRAENTLRDALRKCGVEWEELPGEGAFYSPKVEYH 
Pf'S'     415 --VEMKLSTR--PEK--RVGSDELWDRAEAALAAALDSAGLAYDLQPGEGAFYGPKIEFS 
Pf'R'     415 --IAVKIALR--PEPGKRLGSDEVWDKAENLLREALSECDVEWEELPGEGAFYSPKIEYH 
 
 
1QF6      470 LYDCLDRAWQCGTVQLDFSLPSRLSASYVGEDNE-RKVPVMIHRAILGSMERFIGILTEE 
1NYQ      476 VKTAMGKEETLSTAQLDFLLPERFDLTYIGQDGE-HHRPVVIHRGVVSTMERFVAFLTEE 
4P3N      240 IKDAIGRYHQCATIQLDFQLPIRFNLTYVSHDGDDKKRPVIVHRAILGSVERMIAILTEN 
39502'S'  469 LKDCLGRVWQCGTLQLDFNLPIRLGAEYVCEDNS-RKHPVMLHRAILGSFERFVGILIEH 
obaO      471 LRDAIGREWQVGTMQVDYHMPDRLGAEYVDEHSQ-RRKPVMLHRAIVGSLERFLGILIEH 
Cshin'S'  469 IKDAIGRSWQCGTLQLDFVLPERFGPEYVAEDNS-RQRPVMLHRAIVGSMERFLGILIEN 
Cshin'R'  471 LKDAIGREWQVGTMQVDYLMPERLGAEYIDEHSQ-RRSPVMLHRAIVGSLERFIGILIEH 
Bdiff'S'  469 IKDALGRSWQCGTLQLDMVLPERLGAEYVAEDNS-RRRPVMLHRAIVGSMERFLGILIEH 
Bdiff'R'  471 LKDAIGREWQVGTIQADYLMPEKLGAEYIDDRSE-RRTPVMLHRAIVGSMERFIGILIEH 
Pf'S'     469 LKDCLGRVWQCGTLQLDFNLPIRLGAEYVCEDNS-RKHPVMLHRAILGSFERFVGILIEH 
Pf'R'     471 LRDAIGREWQVGTMQVDYHMPDRLGAEYVDEHSQ-RRKPVMLHRAIVGSLERFLGILIEH 
 
 
1QF6      529 FAGFFPTWLAPVQVVIMNI-TDSQSEYVNELTQKLSNAGIRVKADLR-NEKIGFKIREHT 
1NYQ      535 TKGAFPTWLAPKQVQIIPVNVDLHYDYARQLQDELKSQGVRVSIDDR-NEKMGYKIREAQ 
4P3N      300 YGGKWPFWLSPRQVMVVPV-GPTCDEYAQKVRQQFHDAKFMADIDLDPGCTLNKKIRNAQ 
39502'S'  528 YEGAFPAWLAPTQAVIMNI-TDKQADFAAEVEKTLNESGFRAKSDLR-NEKIGFKIREHT 
obaO      530 HAGQFPLWLAPVQAIVVTV-TDAQNDYADQTRNDLVQLGFRVEADLR-NEKIGYKIREST 
Cshin'S'  528 FAGSFPTWLAPVQAVVMNI-SESQREYTDQVAQTLRQGGLRVDADLR-NEKITYKIREHS 
Cshin'R'  530 HAGYFPTWLAPVQAMLMNV-TDAQADYVEAVRTALTREGFRVESDLR-NEKIGYKIRENT 
Bdiff'S'  528 HAGAMPVWLAPFQAIVLNI-AESQAEYAQSLAQTLQKQGVRVAADLR-NEKISYKIREHT 
Bdiff'R'  530 HAGQLPVWLAPIQAMVLNV-TDAQREYVHDVRRALIGHGVRVDVDVR-NEKIGYKVREHV 
Pf'S'     528 YEGAFPAWLAPTQAVIMNI-TDKQADFAAEVEKTLNESGFRAKSDLR-NEKIGFKIREHT 
Pf'R'     530 HAGQFPLWLAPVQAIVVTV-TDAQNDYADQTRNDLVQLGFRVEADLR-NEKIGYKIREST 
▼ ▼ 
▼ ▼ ▼ ▼ ▼ 
▼ 




1QF6      587 LRRVPYMLVCGDKEVESGKVAVRTRRGKDLGSMDVNEVIEKLQQEIRSRSLKQLEE- 
1NYQ      594 MQKIPYQIVVGDKEVENNQVNVRQYGSQDQETVEKDEFIWNLVDEIRLKKHR----- 
4P3N      359 LAQYNFILVVGEKEKISGTVNIRTRDNKVHGERTISETIERLQQLKEFRSKQAEEEF 
39502'S'  586 LLKVPYLLVIGDREVEMQTVAVRTREGADLGSMPVAQFAEFLAQAVSRRGRPDSE-- 
obaO      588 LQRVPYLLVVGEREKENGTVTVRSRAGEDLGSMTMEALHAFLLNEQSAGG------- 
Cshin'S'  586 LQRLPYQLIVGEKEKAAGLVAVRSRSGEDLGQMTVQAFLERVQAEHPGT-------- 
Cshin'R'  588 LQRIPYLLVIGDREKEHGTVTVRSRAGDDLGTMTPAEFAARLREETAIG-------- 
Bdiff'S'  586 LEKVPYLLVVGDKERDAQTVAVRARGGVDLGVMPVEAFVERLQEDLRSFK------- 
Bdiff'R'  588 LQKVPYLLVAGEREREAGVVSVRAHSGEDLGTMTLEAFAAHVRRERPA--------- 
Pf'S'     586 LLKVPYLLVIGDREVEMQTVAVRTREGADLGSMPVAQFAEFLAQAVSRRGRPDSE-- 




Supplementary Figure 6. Amino acid sequence alignment of authentic and putative ThrRSs with 
putative obafluorin (1) resistance proteins. The ThrRS of E. coli ThrRS (1QF6) was aligned 
(ClustalX2) with that of Staphylococcus aureus (1NYQ), Homo sapiens (4P3N), P. fluorescens ATCC 
39502 (non-1 BGC copy – 39502‘S’), ObaO, the Chitiniphilus shinanonensis DSM 23277 putative 1-
‘sensitive’ ThrRS (Cshin ‘S’ - WP_026263085.1) and ObaO homologue (Cshin‘R’ - WP_026263187.1), 
the Burkholderia diffusa INT4-BP16 putatitve 1-‘sensitive’ ThrRS (Bdiff‘S’ - WP_059467658.1) and 
ObaO homologue (Bdiff‘R’ - WP_059467191.1), and the P. fluorescens sp. 34 E 7 putatitve 1-‘sensitive’ 
ThrRS (Pf‘S’ - WP_065952948) and ObaO homologue (Pf‘R’ - WP_065936865.1). ▼ indicates the key 
active site residues for substrate binding identified in E. coli (Figure 8.5) and ▼ represents the active 















































1QF6      1 ---MPVITLPDGSQRHYDHAVSPMDVALDIGP---GLAKACIAGRVNGELVDACDLIEND 
ObaO      1 ---MVTIALPDGSRRDFPEALTVQQLAQSIGA---GLAAATIGGKVDGTLVDASYLLETD 
BorO      1 MSVIRPTAETERAVVVVPAGTTCADAVTAAKLPRNGPNAIVVVRDPSGALRDLDWTPDSD 
OzmT      1 ------------------------------------------------------------ 
ThrS      1 MSDMVKITFPDGAVKEFAKGTTTEDIAASISP---GLKKKSLAGKLNGKEIDLRTPINED 
ThrZ      1 MSKHVHIQLPDGQIQEYPKGITIKEAAGSISS---SLQKKAAAGQVNGKLVDLSFKLEED 
 
 
1QF6     55 AQLSIITAKDEEGLEIIRHSCAHLLGHAIKQLWPHTKMAIGPVIDNGFYYDVDLDRTLTQ 
ObaO     55 ATVEIVTTKSPQALELIRHSTAHLMAQAVQRLYPGTQVTIGPVIDNGFYYDFVAPRPFTM 
BorO     61 VEVEAVALSSEDGLTVLRHSTAHVLAQAVQQLWPEARLGIGPPIENGFYYDFDVERPFQP 
OzmT      1 -------------------------------------------------MSRRAERCLEP 
ThrS     58 GTVEIITEGSEEGLQIMRHSAAHLLAQAIKRIYKDVKFGVGPVIENGFYYDVEMDEAITP 
ThrZ     58 AELSIVTLDSQEGLQVLRHTTAHVLAQAVKRLYGEVSLGVGPVILDGFYYDMKLGKSLAS 
 
 
1QF6    115 EDVEALEKRMHELAEKNYDVIKKKVS-WHEARETFANRGESYKVSILDEN---------I 
ObaO    115 DDLPLIEAEMTRIVKEQLPVTRTQLP-RDEALAFFEQLGESYKTQIIDA----------I 
BorO    121 EDLERVEQRMKEIIKSGQRFCRREFPDREAARAELAK--EPYKLELVDLKGDVDAAEAME 
OzmT     12 K----------------------------------------------------PRGE--- 
ThrS    118 EDLPKIEKEMKKIVNANLPIVRKEVS-REEAKARFAEIGDDLKLELLDA----------I 
ThrZ    118 GDLEAIEKEMKNIINENLEIKRIEVS-YEEAEELFAQKDERLKLEILKD----------I 
 
 
1QF6    165 AHDDKPGLYFHEE-------YVDMCRGPHVPNMRFCHHFKLMKTAGAYWRGDSNNKMLQR 
ObaO    164 PAGETLSLYTQGE-------FTDLCRGPHVPNTAKLGAFKLMKVAGAYWRGDSNNIMLSR 
BorO    179 VGGSDLTIYDNLDARTGDVCWSDLCRGPHLPSTRLIPAFKLLRNAAAYWRGSEKNPQLQR 
OzmT     17 -----------------------------CPGASSCAHSPLVR----------------- 
ThrS    167 PEGETVSIYEQGE-------FFDLCRGVHVPSTGKIKEFKLLSLAGAYWRGDSKNQMLQR 
ThrZ    167 PRGEDITLYQQGE-------FVDLCRGPHLPSTGMIKAFKLTRVSGAYWRGDSKNEVLQR 
 
 
1QF6    218 IYGTAWADKKALNAYLQRLEEAAKRDHRKIGKQLDLYHM-QEEAPGMVFWHNDGWTIFRE 
ObaO    217 IYGTAWGNEKELKAYLNQLQEAEKRDHRKLAKQFDLFHQ-QEEAPGMVFWHPKGWSLWQT 
BorO    239 IYGTAWPTRDELKSHLAALEEAAKRDHRRIGEELDLFAFNKEIGRGLPLWLPNGAIIRDE 
OzmT     31 -------------------KETTMHDHRRLGRELELFDTDPLIGAGLPYWLPDGAAVRHA 
ThrS    220 VYGTAFFKKADLEEHLRMLEEAKERDHRKLGKELKLFANSQKVGQGLPLWLPKGATIRRV 
ThrZ    220 VYGVAFQKKKDLDAHLHMLEEAAKRDHRKLGKQLGLFMF-SEEAPGMPFYLPKGQIVRNE 
 
 
1QF6    277 LEVFVRSKLKEYQYQEVKGPFMMDRVLWEKTGHWDNYKDAMFT-TSSENREYCIKPMNCP 
ObaO    276 VEQYMRRVYRDGGYREVKSPQVLDSTLWKKSGHWDNYKENMFV-TESENRQYALKPMNCP 
BorO    299 LEDWARKTERKLGYKRVVTPHITQEDLYYLSGHLPYYAEDLYAPIDIDGEKYYLKPMNCP 
OzmT     72 LEEYVRAAERRAGYRHVYSPVLGKRELYEISGHWSHYSEDMFPPMEVGGEQMLLRPSLCP 
ThrS    280 IERYIVDKEISLGYEHVYTPVLGSKELYETSGHWDHYQEGMFPPMEMDNETLVLRPMNCP 
ThrZ    279 LERFSRELQTNAGYDEVRTPFMMNQRLWEQSGHWDHYRDNMYF-SEVDDTRFAMKPMNCP 
 
 
1QF6    336 GHVQIFNQGLKSYRDLPLRMAEFGSCHRNEPSGSLHGLMRVRGFTQDDAHIFCTEEQIRD 
ObaO    335 GHIQIFKHGLRSHRELPIRYGEFGGCHRNEPSGALHGIMRVRAFTQDDGHIFCTEEQIAA 
BorO    359 HHHMVYKARPHSYRDLPYKVAEYGTVYRFERSGQLHGMMRTRGFSQNDAHIYCTADQAKD 
OzmT    132 HHALIYRSRPRSHRELPLRMAELGGMYRAELSGVLGGLSRVRSIHLNDAHVFCTLDQAAG 
ThrS    340 HHMMIYKQDIHSYRELPIRIAELGTMHRYEMSGALSGLQRVRGMTLNDAHIFVRPDQIKD 
ThrZ    338 GHMLIFKNSLYSYRDLPIRMAEFGQVHRHEYSGALNGMLRVRTFCQDDAHIFVREDQIES 
 
 
1QF6    396 EVNGCIRLVYDMYSTFGFEKIVVKLSTRPE----KRIGSDEMWDRAEADLAVALEENNIP 
ObaO    395 EIKAFHYQAVKVYADFGFTDIAVKIALRPEP--GKRLGSDEVWDKAENLLREALSECDVE 
BorO    419 QFLEVMRMHADYYRTLGISDFYMVLALRDSANKDKYHDDEQMWEDAERITREAMEESDIP 
OzmT    192 EARAALEMIGRAYEALGIRPARFRLSLPGPG--GKYVADPEKWRRSTALLTEVLDASGVA 
ThrS    400 EFIRTVRLIQDVYEDFGLSDYTFRLSYRDPEDTEKYFDDDEMWNKAQSMLKEAMDEIGHD 













1QF6    452 FEYQLGEGAFYGPKIEFTLYDCLDRAWQCGTVQLDFSLPSRLSASYVGEDNERKVPVMIH 
ObaO    453 WEELPGEGAFYSPKIEYHLRDAIGREWQVGTMQVDYHMPDRLGAEYVDEHSQRRKPVMLH 
BorO    479 FQIDLGGAAHYGPKVDFMIRAVTGKEFAASTNQVDLYTPQRFGLTYHDSDGTEKPVVVIH 
OzmT    250 YEAVEGEAAFYGPKIDVQIADGQGRESTLSTVQVDFHQPERFGLRYIGADGAGHRPVMIH 
ThrS    460 YYEAEGEAAFYGPKLDVQVKTAIGKEETLSTVQLDFLLPERFDLTYIGEDGKQHRPVVIH 
ThrZ    453 YEINEGDGAFYGPKIDFHIKDALKRSHQCATIQLDFQMPEKFDLTYINELNEKVRPVVIH 
 
 
1QF6    512 RAILGSMERFIGILTEEFAGFFPTWLAPVQVVIMNIT-DSQSEYVNELTQKLSNAGIRVK 
ObaO    513 RAIVGSLERFLGILIEHHAGQFPLWLAPVQAIVVTVT-DAQNDYADQTRNDLVQLGFRVE 
BorO    539 RAPLGSHERFTAYLTEHFAGAFPVWLAPEQVRIIPIV-EELTDYAEEVRDMLLDADVRAD 
OzmT    310 RSVIGSVERAVAHLVEEHGGAFPAWLAPVQIAVLPVT-GAQVPDGEAFLRRCAALGLRAE 
ThrS    520 RGVVSTMERFVAFLIEEHKGALPTWLAPVQFQVIPVSPAVHLDYAKKVQERLQCEGLRVE 
ThrZ    513 RAVFGSIDRFFGILIEHYGGAFPVWLAPIQVQIIPVS-HVHLDYCRKVQAELKQAGIRAG 
 
 
1QF6    571 -ADLRNEKIGFKIREHTLRRVPYMLVCGDKEVESGKVAVRTRRGKDLGSMDVNEVIEKLQ 
ObaO    572 -ADLRNEKIGYKIRESTLQRVPYLLVVGEREKENGTVTVRSRAGEDLGSMTMEALHAFLL 
BorO    598 -VDAGDGRLNAKVRAAVTRKIPLVVVVGRREAEQRTVTVRDRSGEE-TPMSLEKFVAHVT 
OzmT    369 QADPGRGSLGARIR--AARLVPYQVVIGEEEAADGRVALRLRDGRRVGPLPADEALARID 
ThrS    580 -VDSRDEKIGYKIREAQMQKIPYMLVVGDQEAENGAVNVRKYGEQNSETISLDEFVKKAV 
ThrZ    572 -IDERNEKLGYKIRESQVQKIPYVLVLGDHEEQENAVNVRRFGHQQNEHVPFQTFKDKLV 
 
 
1QF6    630 QEIRSRSLKQLEE------- 
ObaO    631 NEQSAGG------------- 
BorO    656 GLIRTKSLDGAGHIRPLSKA 
OzmT    427 ALVSAYGTGLWDR------- 
ThrS    639 AEAKK--------------- 
ThrZ    631 KQVENRGM------------ 
 
Supplementary Figure 7. Sequence alignment of putative NP-resistant and B. subtilis ThrRS 
amino acid sequences. E. coli ThrRS (1QF6) (used as a reference sequence – 1QF6_A) was aligned 
(ClustalX2) with ObaO, BorO (Borrelidin resistance - CAE45679.1), OzmT (Putative oxazolomycin 
resistance - ABS90481.1), ThrS (CAA99608.1) and ThrZ (KIX83533.1), the two B. subtilis ThrRSs. ▼ 
indicates the key active site residues for substrate binding identified in E. coli (Figure 8.5) and ▼ 




































Primer Sequence 5'-3' Function 
F27 (16S FW) AGAGTTTGATCMTGGCTCAG FW primer for 
amplifying 
bacterial 16S pcr 
product 
R1492 (16S RV) TACGGYTACCTTGTTACGACTT RV primer for 
amplifying 
bacterial 16S pcr 
product 





for cloning an 
expanded MCS 
into pME3087. 
pTS1 MCS RV AGCTCATATGATGCCTCGAGAGGTGCTAGCCAACCAT
GGTGACCAATTGACTACCTAGGA 
sacB FW AGTCCGGAATTCGGAATACGGTTAGCCATTTG Primers for 
amplifying sacB 
from pFLP2, for 
cloning into 
pTS1. 
sacB RV AGTCCGGAATTCGGATCGATCCTTTTTAACCC 





for cloning an 
expanded MCS 
into pJH10. 
pJH10TS MCS RV AATTTGCCATATGATGCCTCGAGAGGTGCTAGCGCAG
TTAATTAATGACCAATTGACTAG 
orf2345 KOF1 FW TCGCGGTACCGCATAGTCTAGAGCGAAGTGAAGGTC
AATGTGCGC 











N- and C- 
termini of each 
oba gene coding 
sequence. KOF1 
is cloned as an 
XbaI-AvrII 
fragment, and 
KOF2 as an 
AvrII-BmtI, into 
the suicide 
vector pTS1.  
orf2345 KOF1 RV TCGGGGATCCCCGACTCCTAGGCACGAAAACCACAT
CACCCAGCG 
orf2345 KOF2 FW TGACGGATCCCCGTCACCTAGGGCACTGGATACCGA
AGTGTCTGC 
orf2345 KOF2 RV CATGAAGCTTCTGGACGCTAGCCGGTAAGTGTGCGC
ATCTTCGC 
obaC KOF1 FW TCGCGGTACCGCATAGTCTAGACTGTCGAGAGCCATC
ACCCATCG 
obaC KOF1 RV TCGGGGATCCCCGACTCCTAGGCACGAGAATGCGTG
GGGTTGAGC 
obaC KOF2 FW TGACGGATCCCCGTCACCTAGGCGACTGCTCAACCA
GATCGGC 
obaC KOF2 RV CATGAAGCTTCTGGACGCTAGCGGCTGCTCGCAGTG
GTAATGG 
obaF KOF1 FW TCGCGGTACCGCATAGTCTAGAGGTTGAACATGACGA
AGACCGGC 
obaF KOF1 RV TCGGGGATCCCCGACTCCTAGGCAGTTGATTGGCCA
GTAGCTGGC 
obaF KOF2 FW TGACGGATCCCCGTCACCTAGGGCCTGCCAGATCGA
ATACGACG 
obaF KOF2 RV CATGAAGCTTCTGGACGCTAGCGAACGACTCACCGG
TCACATCC 
obaG KOF1 FW TCGCGAGCTCGCATAGTCTAGAGACACCCTGTCGATC
AAGAGCG 
obaG KOF1 RV TCGGGGTACCCCGACTCCTAGGGCTCAACCAATCGA
CGATCTGGG 
obaG KOF2 FW TCGCGAGCTCCCGTCACCTAGGCTGGACGAGGAGTT
ACTGGCG 
obaG KOF2 RV CATGAAGCTTCTGGACGCTAGCGCGATATGACTGGC
GATGCCC 
obaH KOF1 FW CATCGGGATCCCCTAGGCTCCTCGGAGGTCAGGTTG
ATGT 
obaH KOF1 RV CCATGAAGCTTGCTAGCCATCGATGAAGCCTGCCAGA
TC 
obaH KOF2 FW CATGGGGTACCTCTAGACTGATAGGTGAGGTGTTCGC
CG 
obaH KOF2 RV CATCGGGATCCCCTAGGGTGAAAGGCCAGCAGCACT
TGC 
obaI KOF1 FW CGGCGGTACCGATCGACCTAGGCTGCAGGGCGTGCT
GAA 




obaI KOF2 FW GCCGGGTACCGCATGATCTAGAGACGTAGTGGCAAT
GCTCTTGGCC 
obaI KOF2 RV CGGCGGTACCGCATGACCTAGGGATCAGGTTCATCT
GGTCCCGTCG 
obaJ KOF1 FW TCGCGGTACCGCATAGTCTAGACAACTTCACGCTCAG
TTCGCCG 
obaJ KOF1 RV TCGGGGATCCCCGACTCCTAGGCCAGTCCAACGGTT
TGCGTTGC 
obaJ KOF2 FW TGACGGATCCCCGTCACCTAGGCATATGGCCAGTTGC
TCCAGC 
obaJ KOF2 RV CATGAAGCTTCTGGACGCTAGCGACAGCAGAAAGGC
CACTACC 
obaK KOF1 FW TCGCGGTACCGCATAGTCTAGACTCAAGTCGTTCGTT
CGCCAGC 
obaK KOF1 RV TCGGGGATCCCCGACTCCTAGGCTCTTGAGGCGACT
CGAGTTCG 
obaK KOF2 FW TGACGGATCCCCGTCACCTAGGGTGAGCTTCATGGA
GCTTGCC 
obaK KOF2 RV CATGAAGCTTCTGGACGCTAGCCTACCGCAGCAATAT
CCTGCGG 
obaL KOF1 FW TCGCGGTACCGCATAGTCTAGAGGCTTAACTGGCACC
TGAACC 
obaL KOF1 RV TCGGGGATCCCCGACTCCTAGGCAATGCCTGGGCGT
TGTTGTCC 
obaL KOF2 FW TGACGGATCCCCGTCACCTAGGCAGGATATTGCTGC
GGTAGTGGC 
obaL KOF2 RV CATGAAGCTTCTGGACGCTAGCCTGCGGTATTGGCAA
TCAGGAGG 
obaM KOF1 FW CGTCGGTCTAGACAGACGAACAACGCTCACCC 
obaM KOF1 RV CGTCGGCCTAGGGTCGTCTTCACTGACCAGCC 
obaM KOF2 FW GCTAGTTCTAGACGTCGGCCTAGGGAAGACGCAGTG
CCCTTCTTCG 
obaM KOF2 RV GCTAGTAAGCTTCGTCGGGCTAGCGCAGGTCGTTGT
CCTTGCG 
obaO KOF1 FW CGTCGGTCTAGACGCATTACGAGTTCGTCTTCCG 
obaO KOF1 RV CGTCGGCCTAGGCTGTTGCACAGTCAAAGCTTCTGG 
obaO KOF2 FW GCTAGTTCTAGACGTCGGCCTAGGGACTTGGGAAGC
ATGACGATGG 
obaO KOF2 RV GCTAGTAAGCTTCGTCGGGCTAGCCTGCAACTTAAGC
AGGTACCCG 




clone the entire 
coding 
sequence of 
each oba gene 




pJH10TS-obaC RV GAGTCCGGTACCTCAAGTCGTGACATAGTTGCG 





pJH10TS-obaG RV GAGTCCGGTACCTCATCGTTGGGCTCCCTGATACACC 
pJH10TS-obaH FW CCTGAAGCTAGCATGACCAACCTCCCCTCCACG 
pJH10TS-obaH RV GAGTCCTCTAGAGAGGTCATGCCTTGGGCAAGTG  
pJH10TS-obaI FW CCTACGGCTAGCATGTCAGCCTCATTCACCACTGC 
pJH10TS-obaI RV GAGTCCTCTAGATTATTGGCCCAGTTGTACTCGC 
pJH10TS-obaJ FW CCTGAAGCTAGCATGGCAATCCCGAAAATCATGG 
pJH10TS-obaJ RV GAGTCCGGTACCTCATCGTGCCTTCCCCAG 
pJH10TS-obaK FW CCTGAAGCTAGCATGACCCAGGGCAAGCTGATCTACG 
pJH10TS-obaK RV GAGTCCGGTACCTCATGGCTGCTCGCACTCCGTC 
pJH10TS-obaL FW CCTGAAGCTAGCATGAACCGTTTCGAACATCAGTCGA
TTGTCG 
pJH10TS-obaL RV GAGTCCTCTAGAGTCACTCAAAGGTGGCCCCACCG 
pJH10TS-obaM FW CCTGAAGCTAGCGTGAGTCGCCTATCGCC 
pJH10TS-obaM RV GAGTCCGGTACCTCATCGAGACTCCCGATAGGC 
pJH10TS-obaO FW CCTGAAGCTAGCATGGTCACTATCGCTCTACCGG 
pJH10TS-obaO RV GAGTCCGGTACCTCAGCCGCCTGCTGATTGC 




clone the entire 
coding 
pET28a(+)-obaC RV GAGTCCCTCGAGTCAAGTCGTGACATAGTTGCG 
pET28a(+)-obaG FW CGTAACCATATGAGCAATGTCAAACAACAAACCG 
pET28a(+)-obaG RV GAGTCCCTCGAGTCATCGTTGGGCTCCCTGATACAC 
pET28a(+)-obaH FW GTCAGCCATATGACCAACCTCCCCTCCACG 
pET28a(+)-obaH RV CACCGCCTCGAGTCATGCCTTGGGCAAGTGCTGC 
281 
 
pET28a(+)-obaI FW CGTAACCATATGTCAGCCTCATTCACCACTGC sequence of 






cloned in two 
steps using an 
internal BamHI 
site due to an 
internal NdeI site 
between the 
BamHI site and 
XhoI in the obaH 
PCS. 
pET28a(+)-obaI RV GAGTCCCTCGAGTTATTGGCCCAGTTGTACTCGC 
pET28a(+)-obaK FW CGTAACCATATGACCCAGGGCAAGCTGATCTACG 
pET28a(+)-obaK RV CCGAGTCCGCGGCCGCTCATGGCTGCTCGCACTCCG 
ObaI C1141A GA 
fragment 1 FW 
CGGCCTGGTGCCGCGCGGCAGCCATATGTCAGCCTC
ATTCACC 




the assembly of 
the obaI gene 
with a two base 
pair substitution 
to replace the 
active site Cys 
to Ala in 
pET28a(+) 
ObaI C1141A GA 
fragment 1 RV 
GCGTTACCGGCGGCGTGCCCGTAGACGATAATC 
ObaI C1141A GA 
fragment 2 FW 
GTCTACGGGCACGCCGCCGGTAACGCCACCG 
ObaI C1141A GA 
fragment 2 RV 
AGTGGTGGTGGTGGTGGTGCTCGAGTTATTGGCCCA
GTTGTACTCGCAGTAATTTCTTG 
ObaI C1141A GA 
fragment 3 FW 
CTCGAGCACCACCACCACCACCAC 
ObaI C1141A GA 
fragment 3 RV 
ATGGCTGCCGCGCGGCAC 








the assembly of 
both WT and 
C480V copies of 
the E. coli thrRS 
gene with a 
three base pair 
substitution to 
replace the 
active site Cys 
to Val in 
pET28a(+) 




ThrS C480V GA 
fragment 1 FW 
TGGTGCCGCGCGGCAGCCATATGGTCACTATCGCTCT
ACCG 
ThrS C480V GA 
fragment 1 RV 
GCATCGTGCCGCACTGCCATTCACGCCC 
ThrS C480V GA 
fragment 2 FW 
ATGGCAGTGCGGCACGATGCAGGTCGAC 
ThrS C480V GA 
fragment 2 RV 
CAGTGGTGGTGGTGGTGGTGCTCGAGTCAGCCGCC 
ThrS pET28a (+) GA 
fragment FW 
CTCGAGCACCACCACCAC 
ThrS pET28a (+) GA 
fragment RV 
ATGGCTGCCGCGCGGCAC 
pME3087 new MCS 
FW screen 
GCATAGAATTCGAGCTCGGTACCC Primers to 
screen for pTS1 
new MCS 
cloning success 
pME3087 new MCS 
RV screen 
CCATGAGTGACGACTGAATCCG 
sacB screen FW GGTCCTAGCAATCCCATTTGG Primers to 
screen for 
correct cloning 
of the sacB gene 
in pTS1 
sacB screen RV CTGCAGGTCGACTCTAGAGGATC 
NdeI screen CGTTTGCGCCTAGCTTCCTGC Primer designed 
to screen for 
successful 
removal of the 
NdeI site in 
pTS1 outside 
the new MCS 
pTS1 FW CGGCAGGTATATGTGATGGG Vector-specific 
screening primer 
pair for pTS1 
pTS1 RV CCATGAGTGACGACTGAATCCG 
pJH10TS FW GCCGACATCATAACGGTTCTGGC Vector-specific 









pET RV GCTAGTTATTGCTCAGCGGTGG 
orf2345 screen FW CTTATCTCTCACTGACCCACCGC Primers for 
screening 
across the 
region of oba 
gene deletions 
orf2345 screen RV CGACCCATGCAAACACAGTGGG 
obaC screen FW CACCGTCTATGTGGTTGCTCGG 
obaC screen RV GGGAGTGATAACGAACCACCGG 
obaF screen FW CAACTGGTCTCGACCATCAGC 
obaF screen RV GTTTGGCGACGTCAATCAGCAGG 
obaG screen FW GATCAACTGGTGGACTTGCTCGG 
obaG screen RV CACGCGCTCTACATAGGCTTGGG 
obaH screen FW CTGCTGGCCTTTCACCCTAGG 
obaH screen RV GGAGATGGAACTCTTCGGTCGGG 
obaI screen FW CCAGATGAACCTGATCCCTAGG 
obaI screen RV CCGTTATTCCTGCACCACACG 
obaJ screen FW CACGCCAGATGGTTTCTACCGC 
obaJ screen RV GGGTGATATCGACCACCTTCGG 
obaK screen FW CTGGTCAAGCATCGCTACAGCG 
obaK screen RV CCTGGAGACGAAGAAGGTACCG 
obaL screen FW CCATATGGCCAGTTGCTCCAGC 
obaL screen RV GAAGCGTTGATCGAACGTGGCG 
obaM screen FW GATATTGCTGCGGTAGTGGC 
obaM screen RV CATGGAACAATCGCGAAGCG 
obaO screen FW GAATCGCACATTCATGTCTACGCC 
obaO screen RV GACCTGGACCATCATTGGTCAGC 
Supplementary Table 1. Oligonucleotides and primers used in this work. Restriction sites are 



















NA Proteobacteria L-TA 3 
Pseudomonas 
aeruginosa PA01 
NP_254100.1 Proteobacteria L-TA 4 
Pseudomonas 
aeruginosa PA01 
NP_249593.1 Proteobacteria L-TA 5 
Pseudomonas 
fluorescens SBW25 
WP_015886246.1 Proteobacteria L-TA 6 
Pseudomonas 
fluorescens SBW25 
WP_015885469.1 Proteobacteria L-TA 7 
Pseudomonas putida 
KT2440 
NP_742488.1 Proteobacteria L-TA 8 
Pseudomonas 
protegens Pf-5 
WP_011063906.1 Proteobacteria L-TA 9 
Pseudomonas 
protegens Pf-5 
WP_011062763.1 Proteobacteria L-TA 10 
Pseudomonas 
syringae pv. tomato 
str. DC3000 
NP_790259.1 Proteobacteria L-TA 11 
Pseudomonas 
syringae pv. tomato 
str. DC3000 
NP_791665.1 Proteobacteria L-TA 12 
283 
 
Escherichia coli K12 
substr. MG1655 
P75823.1 Proteobacteria L-TA 13 
Pseudomonas sp. 
NCIMB 10558 
O50584.1 Proteobacteria L-TA 14 
Ruegeria pomeroyi 
DSS-3 
AAV96391.1 Proteobacteria L-TA 15 
Bordetella 
parapertussis12822 
CAE38557.1 Proteobacteria L-TA 16 
Bordetella 
bronchiseptica RB50 
CAE35697.1 Proteobacteria L-TA 17 
Caulobacter 
crescentus CB15 
NP_421887.1 Proteobacteria L-TA 18 
Pseudomonas stutzeri WP_003292028.1 Proteobacteria L-TA 19 
Desulfobulbus 
japonicus 
WP_028581067.1 Proteobacteria L-TA 20 
Shewanella pealeana WP_012155441.1 Proteobacteria L-TA 21 
Yersinia enterocolitica WP_005171133.1 Proteobacteria L-TA 22 
Azorhizobium 
caulinodans ORS 571 
WP_012170545.1 Proteobacteria L-TA 23 
Bosea sp. 117 WP_029351492.1 Proteobacteria L-TA 24 
Methylobacterium sp. 
GXF4 
WP_007566405.1 Proteobacteria L-TA 25 
Burkholderia sp. H160 WP_008921553.1 Proteobacteria L-TA 26 
Geobacter bremensis WP_026841789.1 Proteobacteria L-TA 27 
Aeromonas jandaei 
DK-39 
O07051.1 Proteobacteria L-TA 28 
Mycobacterium liflandii WP_015356249.1 Actinobacteria L-TA 29 
Brevibacterium linens WP_009882170.1 Actinobacteria L-TA 30 
Streptomyces 
hygroscopicus 
WP_014669227.1 Actinobacteria L-TA 31 
Frankia sp. CN3 WP_027140959.1 Actinobacteria L-TA 32 
Micromonospora sp. 
M42 
EWM68484.1 Actinobacteria L-TA 33 
Actinomadura 
oligospora 
WP_026414616.1 Actinobacteria L-TA 34 
Sciscionella marina WP_020495043.1 Actinobacteria L-TA 35 
Streptomyces sp. 
SPB78 
WP_009070954.1 Actinobacteria L-TA 36 
Glutamicibacter 
arilaitensis 
WP_013349325.1 Actinobacteria L-TA 37 




ADN26256.1 Actinobacteria L-TA 39 
Streptomyces sp. DSM 
5940 




EFE75624.1 Actinobacteria L-TA 41 




3PJ0_A Firmicutes L-TA 43 
Exiguobacterium 
sibiricum 255-15 
3LWS_A Firmicutes L-TA 44 
Bacillus thuringiensis WP_000854011.1 Firmicutes L-TA 45 
Bacillus cereus WP_002014149.1 Firmicutes L-TA 46 
Virgibacillus 
halodenitrificans 





WP_019119750.1 Firmicutes L-TA 48 
Planomicrobium glaciei 
CHR43 
ETP70229.1 Firmicutes L-TA 49 
Thermincola potens WP_013121253.1 Firmicutes L-TA 50 
Robinsoniella sp. 
KNHs210 
WP_027294918.1 Firmicutes L-TA 51 
Caloramator 
australicus 
WP_008908414.1 Firmicutes L-TA 52 
Desulfotomaculum 
nigrificans 
WP_051410853.1 Firmicutes L-TA 53 
Caldisalinibacter 
kiritimatiensis 
EOD01392.1 Firmicutes L-TA 54 
Thermotoga maritima 
MSB8 








XP_002184057.1 Heterokontophyta L-TA 57 
Calothrix sp. PCC 
7507 
WP_015127083.1 Cyanobacteria L-TA 58 
Nostoc sp. PCC 7107 WP_015112230.1 Cyanobacteria L-TA 59 
Scytonema hofmanni 
PCC 7110 
WP_017742536.1 Cyanobacteria L-TA 60 
Halothece sp. PCC 
7418 
WP_015227610.1 Cyanobacteria L-TA 61 
Spirulina subsalsa WP_017307090.1 Cyanobacteria L-TA 62 
Microcoleus sp. PCC 
7113 
WP_015182894.1 Cyanobacteria L-TA 63 
Trichodesmium 
erythraeum 
WP_011611295.1 Cyanobacteria L-TA 64 
Rubidibacter lacunae WP_022605981.1 Cyanobacteria L-TA 65 
Synechococcus sp. 
PCC 7335 
EDX85769.1 Cyanobacteria L-TA 66 
Synechococcus sp. 
PCC 7336 
WP_017325528.1 Cyanobacteria L-TA 67 
Leptolyngbya sp. PCC 
7375 
WP_006513919.1 Cyanobacteria L-TA 68 
Pleurocapsa sp. PCC 
7327 
AFY78919.1 Cyanobacteria L-TA 69 
Nodosilinea nodulosa WP_017302462.1 Cyanobacteria L-TA 70 
Gloeobacter violaceus WP_011142473.1 Cyanobacteria L-TA 71 
Leishmania major 
Friedlin 
XP_003721570.1 Euglenozoa L-TA 72 
Naumovozyma 
dairenensis CBS 421 
XP_003668398.1 Ascomycota L-TA 73 
Kazachstania 
naganishii CBS 8797 
CCK71098.1 Ascomycota L-TA 74 
Fusarium verticillioides 
7600 
EWG42458.1 Ascomycota L-TA 75 
Talaromyces marneffei 
ATCC 18224 
XP_002151879.1 Ascomycota L-TA 76 
Candida albicans O13427.1 Ascomycota L-TA 77 
Saccharomyces 
cerevisiae S288C 
NP_010868.1 Ascomycota L-TA 78 
Eremothecium 
gossypii ATCC 10985 
NP_985913.2 Ascomycota L-TA 79 
Saccharomyces 
cerevisiae W3031B 




aethiopicum IBT 5753 
D7PHZ0.1 Ascomycota L-TA 81 
Rhodotorula toruloides 
NP11 
EMS19212.1 Basidiomycota L-TA 82 
Phytophthora 
parasitica 
ETM34049.1 Heterokontophyta L-TA 83 
Phytophthora infestans 
T30-4 
XP_002907740.1 Heterokontophyta L-TA 84 
Halalkalicoccus 
jeotgali 
WP_008418842.1 Euryarchaeota L-TA 85 




EMR73220.1 Euryarchaeota L-TA 87 
Natronolimnobius 
innermongolicus 
WP_007259344.1 Euryarchaeota L-TA 88 
Haloferax sp. WP_004065464.1 Euryarchaeota L-TA 89 
Haloferax volcanii DS2 WP_004045358.1 Euryarchaeota L-TA 90 
Salinarchaeum sp. 
Harcht-Bsk1 
WP_020446474.1 Euryarchaeota L-TA 91 




WP_004556422.1 Euryarchaeota L-TA 93 
Arabidopsis thaliana 
CoL-0 
OAP13027.1 Plantae L-TA 94 
Arabidopsis thaliana 
CoL-0 
OAP06494.1 Plantae L-TA 95 
Mus musculus NP_082195.2 Mammalia L-TA 96 
Pseudomonas putida 
24-1 















































NA Proteobacteria SHMT 105 
Pseudomonas 
aeruginosa PA01 
NP_254102.1 Proteobacteria SHMT 106 
Pseudomonas 
aeruginosa PA01 
NP_251134.1 Proteobacteria SHMT 107 
Pseudomonas 
aeruginosa PA01 





WP_015886244.1 Proteobacteria SHMT 109 
Pseudomonas 
fluorescens SBW25 
WP_015885982.1 Proteobacteria SHMT 110 
Pseudomonas putida 
KT2440 
NP_742832.1 Proteobacteria SHMT 111 
Pseudomonas putida 
KT2440 
NP_742489.1 Proteobacteria SHMT 112 
Pseudomonas 
protegens Pf5 
WP_011063571.1 Proteobacteria SHMT 113 
Pseudomonas 
protegens Pf5 
WP_011063904.1 Proteobacteria SHMT 114 
Pseudomonas 
syringae pv. tomato 
str. DC3000 
NP_792241.1 Proteobacteria SHMT 115 
Pseudomonas 
syringae pv. tomato 
str. DC3000 
NP_794383.1 Proteobacteria SHMT 116 
Pseudomonas 
syringae pv. tomato 
str. DC3000 
NP_790310.1 Proteobacteria SHMT 117 
Escherichia coli K12 
substr. MG1655 
NP_417046.1 Proteobacteria SHMT 118 
Pseudomonas 
plecoglossicida 
WP_013970518.1 Proteobacteria SHMT 119 
Psychromonas 
ingrahamii 
WP_011769815.1 Proteobacteria SHMT 120 
Methylobacterium 
extorquens AM1 
AAA64456.1 Proteobacteria SHMT 121 
Burkholderia 
pseudomallei 
3ECD_A Proteobacteria SHMT 122 
Salmonella 
typhimurium 
3GBX_A Proteobacteria SHMT 123 
Campylobacter jejuni 3N0L_A Proteobacteria SHMT 124 
Rickettsia rickettsii str. 
Sheila Smith 
4J5U_A Proteobacteria SHMT 125 
Burkholderia 
cenocepacia J2315 
4N0W_A Proteobacteria SHMT 126 
Escherichia coli SE11 B6I5C4.1 Proteobacteria SHMT 127 
Xanthomonas 
campestris pv. 
vesicatoria str. 85-10 
Q3BXI8.1 Proteobacteria SHMT 128 
Lactobacillus 
acidophilus NCFM 
Q5FMC0.1 Proteobacteria SHMT 129 
Streptomyces 
clavuligerus 
ACJ04032.1 Actinobacteria SHMT 130 
Mycobacterium leprae 
TN 
NP_302318.1 Actinobacteria SHMT 131 
Mycobacterium 
tuberculosis H37Rv 
CCP43846.1 Actinobacteria SHMT 132 
Mycobacterium 
tuberculosis H37Rv 
CCP42793.1 Actinobacteria SHMT 133 
Mycobacterium 
tuberculosis 




NP_600221.1 Actinobacteria SHMT 135 
Streptomyces 
coelicolor A3(2) 
NP_629503.1 Actinobacteria SHMT 136 
Bacillus subtilis subsp. 
subtilis str. 168 
NP_391571.1 Firmicutes SHMT 137 
Geobacillus 
stearothermophilus 
1KKJ_A Firmicutes SHMT 138 
Streptococcus 
thermophilus 




subsp. lactis Il1403 




B1I6M4.1 Firmicutes SHMT 141 
Thermoanaerobacter 
sp. X514 
B0K631.1 Firmicutes SHMT 142 
Hydrogenobacter 
thermophilus TK-6 
BAI70276.1 Aquificales SHMT 143 
Thermus thermophilus WP_011228734.1 Deinococcus-Thermus SHMT 144 
Synechococcus 
elongatus PCC 6301 
Q5N2P9.2 Cyanobacteria SHMT 145 
Thermosynechococcus 
elongatus BP-1 
Q8DH33.1 Cyanobacteria SHMT 146 
Plasmodium 
falciparum 3D7 
4O6Z_A Apicomplexa SHMT 147 
Plasmodium vivax SaL-
1 
XP_001613892.1 Apicomplexa SHMT 148 
Saccharomyces 
cerevisiae S288C 
P37291.2 Ascomycota SHMT 149 
Talaromyces marneffei 
ATCC 18224 
XP_002151718.1 Ascomycota SHMT 150 
Aspergillus niger CAK48606.1 Ascomycota SHMT 151 
Homo sapiens 3OU5_A Mammalia SHMT 152 
Oryctolagus cuniculus 1LS3_A Mammalia SHMT 153 
Mus musculus AAK15040.1 Mammalia SHMT 154 
Homo sapiens 1BJ4_A Mammalia SHMT 155 
Paracoccus sp. 
AJ110402 
BAG31000.1 Proteobacteria MSHMT 156 
Aminobacter sp. 
AJ110403 




AEF16058.1 Actinobacteria G/SHMT 158 
Streptomyces sp. 
Sp080513GE-23 
BAP16701.1 Actinobacteria A/MSHMT 159 
Streptomyces sp. 
Sp080513GE-23 
BAP16692.1 Actinobacteria A/MSHMT 160 
Streptomyces sp. 
SANK 60405 
BAJ05887.1 Actinobacteria SHMT 161 
Streptomyces sp. 
NRRL 30471 
ADZ45329.1 Actinobacteria SHMT 162 
Streptomyces sp. SN-
1061M 
ADC96660.1 Actinobacteria SHMT 163 
Streptomyces sp. 
MK730-62F2 
ACQ63622.1 Actinobacteria GHMT 164 
Amycolatopsis 
mediterranei U32 





AAC13997.1 Actinobacteria AHABS B 
Streptomyces 
leeuwenhoekii C34 
WP_029387788.1 Actinobacteria AHABS C 
Streptomyces sp. 
FXJ7.023 











Actinobacteria AHABS F 
Streptomyces collinus 
Tü1892 














Actinobacteria AHABS J 
Supplementary Table 2. Source organisms and GenBank Accession numbers for SHMT, L-TA, L-
TTA and AHBAS amino acid sequences used in phylogenetic analyses. Seq ref. numbers refer to 





























Appendix 2: Supplementary Sequence Data 
Supplementary Sequence Data 1. Trimmed sequences used in the Maximum Likelihood 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.2. NPs form Streptomyces coelicolor A3(2). The colour-based 
phenotypes associated the production of some S. coelicolor NPs made it an ideal 
model organism for biosynthetic studies. (a) Clockwise from top: WT S. coelicolor, S. 
coelicolor ΔactΔred (actinorhodin and prodigiosin BGCs knocked out), and S. 
coelicolor Δact. The WT strain is producing actinorhodin (blue) and the Δact strain 
can be seen to be producing prodigiosin (pink/red). (b) S. coelicolor ΔactΔcdaΔred 
(Δcda = calcium-dependent antibiotic BGC knocked out). The yellow metabolite 
diffusing from the streaked strain is coelimycin. (c) Diversity of NPs encoded in the S. 
coelicolor A3(2) genome (coelibactin is a predicted structure). Many were only 
characterised after their BGCs had been identified as they were not 
produced/detectable using standard culture conditions. Plate images are courtesy of 


























Figure 1.5. Illustration of NRPS assembly line biosynthetic logic. (a) Chain 
elongation on a hypothetical NRPS assembly line. (b) The condensation catalysed 
during NRPS biosynthesis. Nucleophilic attack of the downstream aminoacyl-S-PCP 
amine on the upstream peptidyl-S-PCP leads to the formation of an amide bond. (c) 
Reaction catalysed by NRPS epimerisation (E) domains. The E domain epimerises 
the upstream L-peptidyl-S-PCP donor to a D-peptidyl-S-PCP prior to condensation. 
These two steps can be catalysed by the sequential action of independent E and C 
domains, or both reactions can be catalysed by C/E didomains. (d) Following 
condensation, cyclisation (Cy) domains catalyse the attack of nucleophilic cysteine, 
serine or threonine side chains on the ‘upstream’ carbonyl before catalysing 



























Figure 3.5. BGC architecture and proposed biosynthetic pathway for the 
biosynthesis of obafluorin (1). This pathway is based on the hypothetical pathway 
for 1 proposed by Herbert and Knaggs (1988; 1990; 1992a; 1992b) and in silico 
analysis described in this Chapter. PCSs obaA-N (~19 kb) are labelled and coloured 
according to anticipated functions during the biosynthesis of 1, with putative operons 
indicated with black arrows beneath the gene cluster. Orfs12345678 represent PCSs 
that could contribute to 1 production, but which are not considered essential. The 
domain architectures of the ArCP ObaK and NRPS ObaI are represented, and the 
anticipated mechanism of TE-catalysed peptide release and β-lactone ring closure is 



























Figure 4.4. BGC architecture and revised pathway for the biosynthesis of 
obafluorin (1) based on mutagenetic data. This pathway is based on mutagenetic 
data described in this Chapter. PCSs obaA-N are labelled and coloured according to 
related biosynthetic functions, with putative operons indicated with black arrows 
beneath the gene cluster. The domain architectures of the ArCP ObaK and NRPS 
ObaI are represented, and the anticipated mechanism of TE-catalysed peptide 
release and β-lactone ring closure is also illustrated (described further in Chapter 7). 
4 and 5 are derived from some element of the biosynthesis of 2, and were ultimately 
identified as breakdown products of (4-NPA; 11). 4 and 5 accumulate when either the 
biosynthesis of 6, or the assembly of 1, was disrupted. Compounds 3 and 9 were 
used in chemical feeding experiments in this work, but were shown not to be 

























Figure 5.8. Experimental confirmation that ObaG binds PLP. (a) UV/Vis spectrum 
of 20 µM His6-ObaG (blue) showing peaks at 340 nm and 390 nm, representing the 
enolimine and ketoenamine forms of the PLP cofactor respectively. Addition of 10 
mM L-penicillamine (red) led to formation of a thiazolidine adduct (340 nm peak) and 
concomitant loss of the 390 nm peak following 30 min incubation. (b) UV/Vis spectrum 
of 20 µM His6-ObaG (blue). Addition of 1 mM NaBH4 (red) led to formation of a 
covalent His6-ObaG-PLP adduct (330 nm peak) and concomitant loss of the 390 nm 
ketoenamine peak following 15 min on ice. (c) The enzyme is pink in solution (right), 
but following boiling (left), the pink colour is lost and instead a faint green/yellow 
colour can be seen, indicating release of the PLP cofactor. (d) L-penicillamine reacts 
with PLP via an external aldimine intermediate to form a thiazolidine adduct. (e) 
Reduction of the internal aldimine formed between the enzyme catalytic lysine residue 

























Figure 6.2. Maximum likelihood tree of L-TAs, SHMTs and L-TTAs. A set of 3-
amino-5-hydroxybenzoate synthase (AHBAS) amino acid sequences serve as the 
outgroup. RAxML likelihood values at the root nodes for SHMT and L-TA cluster 
clades are annotated. The clade comprising the L-TTA ObaG characterised in this 
work has been expanded and annotated with RAxML likelihood values and the 
identity of amino acid sequences represented. Initial trimming was performed 
following alignment with ClustalX2, before final alignment with T-Coffee. Circles 





























Figure 6.3. Proposed biosynthetic pathways to alanylclavam, the clavamycins 
and valclavam. Purple – biosynthesis of alanylclavam in S. clavuligerus NRRL 3585; 
turquoise – biosynthesis of clavamycin A in S. hygroscopicus NRRL 15879; and dark 
blue – biosynthesis of valclavam in S. antibioticus Tü1718. The proposed reactions 
catalysed by OrfA-like GHMT homologues are highlighted in orange. We hypothesise 
that these enzymes are in fact L-TTAs that use L-threonine rather than glycine (as 
depicted) as a co-substrate with aldehydes X (alanylclavam and clavamycin 
biosynthesis) or Y (valclavam biosynthesis). The products of these reactions are 8-
hydroxyalanylclavam and a 9-hydroxyalanylclavam intermediate, Z, respectively. All 
pathways share the same conserved steps to clavaminic acid. Jensen (2012) - 



























Figure 8.1. Illustration of the diverse bacterial targets for microbial NPs. A 
comprehensive review of the antibacterial NPs identified 54 distinct molecular targets 
of known antibacterials, including:  
 
Membrane-associated targets - 1) lipid II; 2) undecaprenyl phosphate; 3) 
phosphatidylethanolamine; 4) Na-dependent NADH-quinone reductase; 5) 
translocase 1; 6) SecA–YEG complex; 7) type 1 signal peptidase; 8) type 2 signal 
peptidase; 9) WalK-WalRtwo-component system; 10) NADH oxidase; 11) 
menaquinone; 12) cytochrome bd; 13) membrane stability; 14) LPS 
 
Cell wall–associated enzymes - 15) peptidoglycan transglycosylase; 16) penicillin-
binding proteins; 17) D-alanine-D-alanine dipeptide; 18) UDP-N-acetylglucosamine-3-
enolpyruvyl transferase 
 
Targets associated with amino acid biosynthesis and metabolism - 19) L-
histidinol phosphate aminotransferase; 20) N-acetylornithine transaminase; 21, 
isoleucyl-tRNA synthetase; 22, leucyl-tRNA synthetase; 23, tryptophanyl-tRNA 
synthetase; 24) prolyl-tRNA synthetase; 25) tyrosyl-tRNA synthetase; 26) threonyl-
tRNA synthetase; 27) phenylalanyl-tRNA synthetase; 28) aspartyl-tRNA synthetase; 
29) seryl-tRNA synthetase; 30) aspartate semialdehyde dehydrogenase; 31) alanine 
racemase; 32) glutamine synthase; 33) pyruvate dehydrogenase; 34) threonine 
synthase; 35) biotin aminotransferase; 36) homoserine-O-succinyltransferase; 37) 
pyruvate carboxylase; 38) peptide deformylase 
 
Fatty acid biosynthesis - 39) FabF; 40) FabB; 41) acyl-CoA carboxylase; 42) FabD; 
43) FabG; 44) FabI), individual metabolic enzymes (45) glucosamine-6-phosphate 
synthase; 46) deoxyxylulose phosphate reductoisomerase; 47) ADC synthase 
 
Components of macromolecular machinery - 48) ClpP protease; 49) elongation 
factors; 50) ribosome; 51) transcription termination factor Rho; 52) RNA polymerase; 
53) DNA gyrase; 54) DNA polymerase 
 




Figure 8.10. Illustration of the mutasynthetic strategy to generate novel 
congeners of obafluorin (1) in the ΔobaL strain. 6 should no longer be produced 
in the ΔobaL strain, allowing the exogenous introduction of alternative benzyl 
carboxylic acids (coloured in burgundy). If the ObaI A1 domain is sufficiently 
promiscuous, it may accept these alternative substrates and assemble them together 
with 2 to create novel 1-like metabolites. Downstream-acting domains must also be 
able to tolerate these alternative substrates. 
